n n u l r e p r march shareholders alex gorsky chairman chief executive officer iiii hhhhaaaavvvveeee tttthhhheeee pppprrrriiiivvvviiiilllleeeeggggeeee ooooffff bbbbeeeeiiiinnnngggg tttthhhheeee cccceeeeoooo ooooffff aaaannnndddd mmmmaaaarrrrkkkkeeeetttt sssshhhhaaaarrrreeee nnnnuuuummmmbbbbeeeerrrrssss tttthhhhiiiissss pppphhhhiiiilllloooossssoooopppphhhhyyyy jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn dddduuuurrrriiiinnnngggg aaaa rrrreeeemmmmaaaarrrrkkkkaaaabbbblllleeee ttttiiiimmmmeeee aaaalllllllloooowwwwssss uuuussss ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy eeeevvvveeeennnn iiiinnnn tttthhhheeee iiiinnnn hhhhiiiissssttttoooorrrryyyy tttthhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy sssseeeevvvveeeennnn yyyyeeeeaaaarrrrssss iiiinnnn tttthhhhiiiissss mmmmoooosssstttt cccchhhhaaaalllllllleeeennnnggggiiiinnnngggg ttttiiiimmmmeeeessss ttttoooo ddddrrrriiiivvvveeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee rrrroooolllleeee tttthhhheeeerrrreeee hhhhaaaavvvveeee bbbbeeeeeeeennnn mmmmaaaannnnyyyy ddddrrrraaaammmmaaaattttiiiicccc cccchhhhaaaannnnggggeeeessss aaaannnndddd ppppuuuurrrrppppoooosssseeee wwwwiiiitttthhhh eeeeqqqquuuuaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt aaaannnndddd iiiinnnn gggglllloooobbbbaaaallll ppppoooolllliiiittttiiiiccccssss tttthhhheeee wwwwoooorrrrlllldddd eeeeccccoooonnnnoooommmmyyyy sssscccciiiieeeennnncccceeee eeeennnnaaaabbbblllleeeessss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa lllleeeeaaaaddddiiiinnnngggg rrrroooolllleeee iiiinnnn tttteeeecccchhhhnnnnoooollllooooggggyyyy aaaannnndddd ccccuuuullllttttuuuurrrreeee aaaatttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee tttthhhheeeerrrreeee ddddeeeefifififinnnniiiinnnngggg tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee wwwwoooorrrrllllddddwwwwiiiiddddeeee hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ppppaaaacccceeee ooooffff pppprrrrooooggggrrrreeeessssssss iiiinnnn hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh uuuunnnnlllloooocccckkkkiiiinnnngggg tttthhhheeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ooooffff tttthhhheeee hhhhuuuummmmaaaannnn ggggeeeennnnoooommmmeeee eeeevvvvoooollllvvvviiiinnnngggg aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg tttthhhheeee honor lead innovationdriven uuuusssseeee ooooffff rrrroooobbbboooottttiiiiccccssss aaaannnndddd mmmmiiiiccccrrrroooo ssssuuuurrrrggggeeeerrrryyyy eeeexxxxtttteeeennnnddddiiiinnnngggg culture continues demonstrate tttthhhheeee lllliiiiffffeeee eeeexxxxppppeeeeccccttttaaaannnnccccyyyy ffffoooorrrr ppppeeeeoooopppplllleeee wwwwiiiitttthhhh hhhhiiiivvvv aaaannnndddd energy drive passion startup ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo wwwwaaaaggggeeee aaaannnndddd wwwwiiiinnnn tttthhhheeee fifififigggghhhhtttt aaaaggggaaaaiiiinnnnsssstttt ccccaaaannnncccceeeerrrr aaaannnndddd ooootttthhhheeeerrrr ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeeessss tttthhhhaaaatttt iiiinnnn tttthhhhiiiissss lllleeeetttttttteeeerrrr iiii sssshhhhaaaarrrreeee tttthhhheeee hhhhiiiigggghhhhlllliiiigggghhhhttttssss ooooffff oooouuuurrrr hhhhaaaavvvveeee rrrreeeessssiiiisssstttteeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee oooouuuurrrr nnnnoooottttaaaabbbblllleeee aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnnttttssss aaaannnndddd oooouuuurrrr aaaassssppppiiiirrrraaaattttiiiioooonnnnssss ffffoooorrrr tttthhhheeee yyyyeeeeaaaarrrrssss ttttoooo ccccoooommmmeeee mmmmyyyy ggggooooaaaallll iiiissss ttttoooo wwwwhhhhaaaattttssss mmmmoooosssstttt eeeexxxxcccciiiittttiiiinnnngggg aaaabbbboooouuuutttt tttthhhhiiiissss pppprrrrooooggggrrrreeeessssssss pppprrrroooovvvviiiiddddeeee aaaannnn aaaaeeeerrrriiiiaaaallll vvvviiiieeeewwww ooooffff jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiissss tttthhhhaaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn hhhhaaaassss bbbbeeeeeeeennnn aaaatttt tttthhhheeee ttttooooddddaaaayyyyaaaa ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt ssssppppaaaannnnssss ssssiiiixxxx ccccoooonnnnttttiiiinnnneeeennnnttttssss vvvveeeerrrryyyy ffffoooorrrreeeeffffrrrroooonnnntttt ooooffff mmmmaaaannnnyyyy ooooffff tttthhhheeeesssseeee rrrreeeevvvvoooolllluuuuttttiiiioooonnnnaaaarrrryyyy aaaannnndddd ccccoooouuuunnnnttttrrrriiiieeeessss ddddeeeevvvveeeellllooooppppssss nnnnuuuummmmeeeerrrroooouuuussss iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeee cccchhhhaaaannnnggggeeeessss aaaannnndddd eeeexxxxppppaaaannnnddddiiiinnnngggg hhhhoooorrrriiiizzzzoooonnnnssssttttiiiimmmmeeee pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss aaaannnndddd ttttoooouuuucccchhhheeeessss tttthhhheeee lllliiiivvvveeeessss aaaannnndddd ttttiiiimmmmeeee aaaaggggaaaaiiiinnnn ddddeeeelllliiiivvvveeeerrrriiiinnnngggg lllliiiiffffeeee ssssaaaavvvviiiinnnngggg ooooffff ppppeeeeoooopppplllleeee aaaallllllll aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy ddddaaaayyyy mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd lllliiiiffffeeeecccchhhhaaaannnnggggiiiinnnngggg ssssoooolllluuuuttttiiiioooonnnnssss mmmmoooosssstttt iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy iiii wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee mmmmyyyy iiiitttt iiiissss aaaannnn hhhhoooonnnnoooorrrr ttttoooo lllleeeeaaaadddd aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnnddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee ccccoooonnnnfifififiddddeeeennnncccceeee iiiinnnn oooouuuurrrr eeeexxxxppppaaaannnnssssiiiivvvveeee ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss eeeexxxxpppprrrreeeessssssss tttthhhhaaaatttt ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeee tttthhhheeee eeeennnneeeerrrrggggyyyy ddddrrrriiiivvvveeee mmmmyyyy rrrreeeeaaaalllliiiissssttttiiiicccc ooooppppttttiiiimmmmiiiissssmmmm aaaabbbboooouuuutttt oooouuuurrrr ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss aaaannnndddd aaaannnndddd ppppaaaassssssssiiiioooonnnn ooooffff aaaa ssssttttaaaarrrrttttuuuupppp hhhhoooowwwweeeevvvveeeerrrr wwwweeee aaaallllssssoooo cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooffffffffeeeerrrr mmmmyyyy iiiinnnnssssiiiigggghhhhttttssss oooonnnn hhhhoooowwww wwwweeee wwwwiiiillllllll hhhhaaaavvvveeee tttthhhheeee ddddiiiissssttttiiiinnnncccctttt aaaaddddvvvvaaaannnnttttaaaaggggeeee ooooffff oooouuuurrrr ttttiiiimmmmeeeelllleeeessssssss ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo sssshhhhaaaappppeeee tttthhhheeee ffffuuuuttttuuuurrrreeee ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ttttooooddddaaaayyyy vvvvaaaalllluuuueeeessss ssssuuuucccchhhh aaaassss tttthhhheeee ssssttttrrrroooonnnngggg iiiinnnnflflflfluuuueeeennnncccceeee ooooffff oooouuuurrrr lllloooonnnnggggtttteeeerrrrmmmm ssssttttrrrraaaatttteeeeggggiiiicccc vvvviiiieeeewwww tttthhhheeee uuuunnnnwwwwaaaavvvveeeerrrriiiinnnngggg cccceeeelllleeeebbbbrrrraaaattttiiiinnnngggg oooouuuurrrr ccccrrrreeeeddddoooo gggguuuuiiiiddddaaaannnncccceeee ooooffff oooouuuurrrr ccccrrrreeeeddddoooo aaaannnndddd tttthhhheeee pppprrrrooooffffoooouuuunnnndddd wwwwaaaayyyy iiiinnnn wwwweeee cccceeeelllleeeebbbbrrrraaaatttteeeedddd tttthhhheeee tttthhhh aaaannnnnnnniiiivvvveeeerrrrssssaaaarrrryyyy iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee mmmmeeeeaaaassssuuuurrrreeee pppprrrrooooggggrrrreeeessssssss aaaannnndddd ssssuuuucccccccceeeessssssss ooooffff oooouuuurrrr ccccrrrreeeeddddoooo wwwwrrrriiiitttttttteeeennnn aaaannnndddd iiiinnnnttttrrrroooodddduuuucccceeeedddd iiiinnnn oooouuuurrrr ccccrrrreeeeddddoooo cccchhhhaaaalllllllleeeennnnggggeeeessss uuuussss ttttoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg bbbbyyyy ggggeeeennnneeeerrrraaaallll rrrroooobbbbeeeerrrrtttt wwwwoooooooodddd jjjjoooohhhhnnnnssssoooonnnn oooouuuurrrr ccccrrrreeeeddddoooo oooouuuuttttccccoooommmmeeeessss ffffoooorrrr ppppaaaattttiiiieeeennnnttttssss aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee bbbblllluuuueeeepppprrrriiiinnnntttt ffffoooorrrr sssshhhhaaaappppiiiinnnngggg tttthhhheeee rrrroooolllleeee wwwwhhhhiiiilllleeee wwwweeee aaaallllssssoooo ffffooooccccuuuussss oooonnnn iiiimmmmpppprrrroooovvvviiiinnnngggg rrrreeeevvvveeeennnnuuuueeee tttthhhhaaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ppppllllaaaayyyyssss iiiinnnn ssssoooocccciiiieeeettttyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidaaaalllltttthhhhoooouuuugggghhhh oooouuuurrrr ccccrrrreeeeddddoooo iiiissss lllliiiitttteeeerrrraaaallllllllyyyy eeeettttcccchhhheeeedddd iiiinnnn ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss eeeexxxxppppeeeerrrriiiieeeennnncccceeeessss ooooppppiiiinnnniiiioooonnnnssss aaaannnndddd ssssttttoooonnnneeee iiiitttt iiiissss aaaa lllliiiivvvviiiinnnngggg ddddooooccccuuuummmmeeeennnntttt tttthhhhaaaatttt oooonnnn aaaa vvvveeeerrrryyyy aaaapppppppprrrrooooaaaacccchhhheeeessss eeeennnnrrrriiiicccchhhheeeessss oooouuuurrrr ccccoooollllllllaaaabbbboooorrrraaaattttiiiivvvveeee ffffeeeewwww sssseeeelllleeeecccctttt ooooccccccccaaaassssiiiioooonnnnssss wwwweeee hhhhaaaavvvveeee eeeevvvvoooollllvvvveeeedddd ttttoooo iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn pppprrrroooocccceeeessssssss aaaannnndddd tttthhhhiiiissss ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn kkkkeeeeeeeepppp ppppaaaacccceeee wwwwiiiitttthhhh tttthhhheeee wwwwoooorrrrlllldddd iiiinnnn wwwwhhhhiiiicccchhhh wwwweeee lllliiiivvvveeee rrrreeeeaaaacccchhhheeeessss ffffaaaarrrr bbbbeeeeyyyyoooonnnndddd tttthhhheeee wwwwaaaallllllllssss ooooffff jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ffffoooorrrr iiiinnnnssssttttaaaannnncccceeee wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh iiiinnnn ffffaaaacccctttt llllaaaatttteeee llllaaaasssstttt yyyyeeeeaaaarrrr wwwweeee ddddiiiidddd eeeexxxxaaaaccccttttllllyyyy tttthhhhiiiissss bbbbyyyy ssssoooommmmeeee ooooffff tttthhhheeee wwwwoooorrrrllllddddssss mmmmoooosssstttt rrrreeeessssppppeeeecccctttteeeedddd uuuunnnniiiivvvveeeerrrrssssiiiittttiiiieeeessss iiiinnnnttttrrrroooodddduuuucccciiiinnnngggg ssssoooommmmeeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss ttttoooo oooouuuurrrr rrrreeeesssseeeeaaaarrrrcccchhhh iiiinnnnssssttttiiiittttuuuuttttiiiioooonnnnssss tttteeeecccchhhhnnnnoooollllooooggggyyyy ggggiiiiaaaannnnttttssss aaaannnndddd ccccrrrreeeeddddoooo rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt wwwweeeerrrreeee iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy ttttrrrraaaaddddiiiittttiiiioooonnnnaaaallll ssssttttaaaarrrrttttuuuuppppssss aaaassss wwwweeee ssssuuuuppppppppoooorrrrtttt tttthhhhoooosssseeee wwwwhhhhoooo ffffeeeeeeeeddddbbbbaaaacccckkkk ffffrrrroooommmm mmmmoooorrrreeee tttthhhhaaaannnn ooooffff oooouuuurrrr ddddiiiivvvveeeerrrrsssseeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn eeeemmmmppppllllooooyyyyeeeeeeeessss rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiinnnnccccuuuubbbbaaaattttoooorrrrssss aaaallllllll rrrreeeeggggiiiioooonnnnssss sssseeeeggggmmmmeeeennnnttttssss aaaannnndddd ffffuuuunnnnccccttttiiiioooonnnnssss aaaa kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee iiiissss hhhhoooowwww wwwweeee aaaarrrreeee hhhhaaaarrrrnnnneeeessssssssiiiinnnngggg tttthhhheeee tttthhhheeeesssseeee eeeennnnhhhhaaaannnncccceeeemmmmeeeennnnttttssss ssssttttrrrreeeennnnggggtttthhhh ooooffff aaaallllllll tttthhhhrrrreeeeeeee ooooffff oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaatttt tttthhhheeee cccceeeennnntttteeeerrrr ooooffff oooouuuurrrr ffffooooccccuuuussss sssscccciiiieeeennnnttttiiiissssttttssss ttttoooo iiiiddddeeeennnnttttiiiiffffyyyy wwwwaaaayyyyssss ttttoooo bbbbeeeetttttttteeeerrrr ddddeeeetttteeeecccctttt aaaannnndddd ttttrrrreeeeaaaatttt tttthhhheeee eeeennnnttttiiiirrrreeee ccccyyyycccclllleeee ooooffff lllluuuunnnngggg ccccaaaannnncccceeeerrrr tttthhhhiiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnndddd aaaa nnnneeeewwww ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff eeeemmmmppppllllooooyyyyeeeeeeeessss ddddiiiisssseeeeaaaasssseeee iiiissss tttthhhheeee lllleeeeaaaaddddiiiinnnngggg ccccaaaauuuusssseeee ooooffff ccccaaaannnncccceeeerrrr mmmmoooorrrrttttaaaalllliiiittttyyyy aaaarrrroooouuuunnnndddd tttthhhheeee gggglllloooobbbbeeeewwwweeee rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee nnnneeeeeeeedddd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnndddd uuuurrrrggggeeeennnnccccyyyy aaaannnndddd wwwweeee aaaarrrreeee rrrreeeessssppppoooonnnnddddiiiinnnngggg ttttoooo tttthhhhiiiissss ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn aaaannnndddd ccccaaaallllllll ttttoooo aaaaccccttttiiiioooonnnn wwwwiiiitttthhhh tttthhhhiiiissss eeeexxxxcccciiiittttiiiinnnngggg ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tttthhhheeee hhhheeeeaaaalllltttthhhh ooooffff hhhhuuuummmmaaaannnniiiittttyyyy ppppoooowwwweeeerrrrffffuuuullll iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn hhhhaaaassss aaaallllssssoooo bbbbeeeeeeeennnn mmmmaaaaddddeeee ppppoooossssssssiiiibbbblllleeee bbbbyyyy tttthhhheeee fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh wwwweeeevvvveeee bbbbuuuuiiiilllltttt oooovvvveeeerrrr tttthhhheeee oooouuuurrrr ccccrrrreeeeddddoooo rrrreeeemmmmaaaaiiiinnnnssss aaaassss rrrreeeelllleeeevvvvaaaannnntttt ttttooooddddaaaayyyy aaaassss wwwwhhhheeeennnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid iiiitttt wwwwaaaassss fifififirrrrsssstttt iiiinnnnttttrrrroooodddduuuucccceeeedddd yyyyeeeeaaaarrrrssss aaaaggggoooo aaaannnndddd iiiimmmm iiiissss cccceeeennnnttttrrrraaaallll ttttoooo oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo ccccrrrreeeeaaaatttteeee mmmmeeeeaaaannnniiiinnnnggggffffuuuullll ccccoooonnnnfifififiddddeeeennnntttt tttthhhhaaaatttt iiiitttt wwwwiiiillllllll pppprrrrooooppppeeeellll jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn cccchhhhaaaannnnggggeeee aaaannnndddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee ddddiiiiffffffffeeeerrrreeeennnnttttiiiiaaaattttiiiioooonnnn iiiinnnn ffffoooorrrrwwwwaaaarrrrdddd ffffoooorrrr tttthhhheeee nnnneeeexxxxtttt yyyyeeeeaaaarrrrssss aaaannnndddd bbbbeeeeyyyyoooonnnndddd wwwweeee aaaacccchhhhiiiieeeevvvveeeedddd aaaa rrrreeeeccccoooorrrrddddlllleeeevvvveeeellll ooooffff rrrreeeesssseeeeaaaarrrrcccchhhh aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss oooouuuurrrr ccccaaaalllllllliiiinnnngggg ccccaaaarrrrdddd ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt rrrrdddd iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ooooffff aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy wwwwhhhheeeennnn wwwweeee hhhheeeeaaaarrrr tttthhhheeee tttteeeerrrrmmmm ssssttttaaaarrrrttttuuuupppp wwwweeee tttthhhhiiiinnnnkkkk ooooffff aaaannnn bbbbiiiilllllllliiiioooonnnn iiiinnnn ffffaaaacccctttt aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss wwwweeee oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn wwwwiiiitttthhhh hhhhiiiigggghhhh eeeennnneeeerrrrggggyyyy aaaannnndddd ccccrrrreeeeaaaattttiiiivvvviiiittttyyyy oooonnnneeee aaaarrrreeee oooonnnneeee ooooffff tttthhhheeee ttttoooopppp ccccoooommmmppppaaaannnniiiieeeessss tttthhhhaaaatttt iiiinnnnvvvveeeesssstttteeeedddd tttthhhhaaaatttt vvvvaaaalllluuuueeeessss aaaaggggiiiilllliiiittttyyyy aaaannnndddd hhhhaaaassss aaaa bbbboooolllldddd vvvviiiissssiiiioooonnnn ttttoooo cccchhhhaaaannnnggggeeee aaaatttt tttthhhheeee hhhhiiiigggghhhheeeesssstttt lllleeeevvvveeeellllssss iiiinnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaannnndddd rrrrdddd tttthhhheeee wwwwoooorrrrlllldddd aaaassss iiii llllooooooookkkk aaaatttt tttthhhheeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss wwwweeee aaaarrrreeee llllaaaasssstttt yyyyeeeeaaaarrrr tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ffffaaaammmmiiiillllyyyy ooooffff iiiinnnnvvvveeeessssttttiiiinnnngggg iiiinnnn tttthhhheeee ccccoooommmmppppaaaannnniiiieeeessss wwwweeee aaaarrrreeee ppppaaaarrrrttttnnnneeeerrrriiiinnnngggg wwwwiiiitttthhhh ccccoooommmmppppaaaannnniiiieeeessss iiiinnnnvvvveeeesssstttteeeedddd iiiinnnn aaaa nnnnuuuummmmbbbbeeeerrrr ooooffff vvvvaaaalllluuuueeeeccccrrrreeeeaaaattttiiiinnnngggg aaaannnndddd tttthhhheeee ppppeeeeoooopppplllleeee wwwwhhhhoooo ccccoooommmmeeee ttttoooo wwwwoooorrrrkkkk ffffoooorrrr uuuussss eeeevvvveeeerrrryyyy aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnnssss wwwwhhhhiiiicccchhhh iiiinnnncccclllluuuuddddeeeedddd ddddaaaayyyy iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhoooosssseeee ssssttttaaaarrrrttttuuuupppp aaaattttttttrrrriiiibbbbuuuutttteeeessss ddddeeeefifififinnnneeee oooouuuurrrr zzzzaaaarrrrbbbbeeeeeeeessss iiiinnnncccc aaaa lllleeeeaaaaddddeeeerrrr iiiinnnn nnnnaaaattttuuuurrrraaaallllllllyyyy bbbbaaaasssseeeedddd oooovvvveeeerrrrtttthhhheeee ccccoooommmmppppaaaannnnyyyy ttttooooooooddddrrrriiiivvvviiiinnnngggg aaaa vvvviiiissssiiiioooonnnn ooooffff cccchhhhaaaannnnggggeeee tttthhhhaaaatttt wwwwiiiillllllll ccccoooouuuunnnntttteeeerrrr oooottttcccc rrrreeeemmmmeeeeddddiiiieeeessss oooorrrrtttthhhhoooottttaaaaxxxxyyyy aaaa ddddeeeevvvveeeellllooooppppeeeerrrr hhhhaaaavvvveeee lllloooonnnnggggllllaaaassssttttiiiinnnngggg iiiimmmmppppaaaacccctttt ffffoooorrrr ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee ooooffff ssssooooffffttttwwwwaaaarrrreeeeeeeennnnaaaabbbblllleeeedddd oooorrrrtttthhhhooooppppaaaaeeeeddddiiiicccc ssssuuuurrrrggggeeeerrrryyyy tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss aaaannnndddd aaaarrrrrrrroooowwwwhhhheeeeaaaadddd pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallllssss iiiinnnncccc wwwwhhhheeeerrrreeee wwwweeee aaaarrrreeee wwwwoooorrrrkkkkiiiinnnngggg ttttoooo bbbbrrrriiiinnnngggg aaaa ffffuuuunnnnccccttttiiiioooonnnnaaaallll sustaining investment innovation ccccuuuurrrreeee ttttoooo ppppaaaattttiiiieeeennnnttttssss wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeppppaaaattttiiiittttiiiissss bbbb iiiinnnn central ability create meaningful ttttoooottttaaaallll wwwweeee eeeexxxxeeeeccccuuuutttteeeedddd aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnsssseeeessss change competitive differentiation ooooffff vvvvaaaarrrriiiioooouuuussss ssssiiiizzzzeeeessss iiiinnnncccclllluuuuddddiiiinnnngggg oooouuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff tttthhhheeee ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt mmmmaaaarrrrkkkkeeeettttssss tttthhhheeee ddddrrrr cccciiii llllaaaabbbboooo lllliiiinnnneeee ooooffff hhhhoooowwwweeeevvvveeeerrrr tttthhhheeee ttttiiiimmmmeeeelllleeeessssssss vvvvaaaalllluuuueeeessss tttthhhhaaaatttt ssssuuuuppppppppoooorrrrtttt sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuuccccttttssss wwwwhhhhiiiicccchhhh ooooffiffiffifficccciiiiaaaallllllllyyyy cccclllloooosssseeeedddd iiiinnnn tttthhhheeeesssseeee ssssttttrrrraaaatttteeeeggggiiiieeeessss aaaallllssssoooo mmmmaaaakkkkeeee uuuussss ddddiiiiffffffffeeeerrrreeeennnntttt aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy wwwweeee ssssiiiiggggnnnneeeedddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ddddeeeeaaaallllssss aaaassss wwwweeeellllllll ffffrrrroooommmm tttthhhheeee ttttyyyyppppiiiiccccaaaallll ssssttttaaaarrrrttttuuuupppp oooouuuurrrr yyyyeeeeaaaarrrrssss ooooffff aaaassss nnnneeeewwww ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt ddddeeeeaaaallllssss aaaannnndddd wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee ssssuuuucccccccceeeessssssss aaaannnndddd aaaacccchhhhiiiieeeevvvveeeemmmmeeeennnntttt mmmmoooottttiiiivvvvaaaatttteeee uuuussss eeeevvvveeeennnn ttttoooo mmmmaaaakkkkeeee iiiinnnnvvvveeeessssttttmmmmeeeennnnttttssss aaaaccccrrrroooossssssss aaaallllllll iiiinnnndddduuuussssttttrrrriiiieeeessss tttthhhhrrrroooouuuugggghhhh mmmmoooorrrreeee ttttoooo bbbbrrrriiiinnnngggg nnnneeeewwww iiiiddddeeeeaaaassss aaaannnndddd aaaapppppppprrrrooooaaaacccchhhheeeessss ttttoooo jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnnjjjjjjjjddddcccc iiiinnnncccc jjjjjjjjddddcccc mmmmaaaarrrrkkkkeeeetttt ttttooooddddaaaayyyy aaaannnndddd wwwweeeellllllll iiiinnnnttttoooo tttthhhheeee ffffuuuuttttuuuurrrreeee aaaassss iiii jjjjuuuusssstttt mmmmeeeennnnttttiiiioooonnnneeeedddd wwwweeee ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo iiiinnnnnnnnoooovvvvaaaatttteeee tttthhhheeee ddddiiiivvvveeeerrrrssssiiiittttyyyy ooooffff oooouuuurrrr oooorrrrggggaaaannnniiiizzzzaaaattttiiiioooonnnn wwwwhhhhiiiicccchhhh iiiinnnn ssssuuuurrrrggggeeeerrrryyyy oooovvvveeeerrrr yyyyeeeeaaaarrrrssss aaaaggggoooo wwwweeee wwwweeeerrrreeee tttthhhheeee ccccoooommmmpppprrrriiiisssseeeessss aaaa wwwwiiiiddddeeee aaaarrrrrrrraaaayyyy ooooffff bbbbaaaacccckkkkggggrrrroooouuuunnnnddddssss ppppiiiioooonnnneeeeeeeerrrrssss ooooffff sssstttteeeerrrriiiilllleeee ssssuuuurrrrggggeeeerrrryyyy eeeessssttttaaaabbbblllliiiisssshhhhiiiinnnngggg aaaannnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidiiiinnnnccccrrrreeeeddddiiiibbbblllleeee hhhheeeerrrriiiittttaaaaggggeeee tttthhhhaaaatttt ttttooooddddaaaayyyy iiiinnnncccclllluuuuddddeeeessss oooouuuurrrr ddddrrrriiiivvvviiiinnnngggg lllloooonnnnggggtttteeeerrrrmmmm sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrr vvvvaaaalllluuuueeee lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp iiiinnnn mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy aaaannnndddd oooouuuurrrr ffffrrrreeeeeeee ccccaaaasssshhhh flflflfloooowwww ffffoooorrrr iiiimmmmpppprrrroooovvvveeeedddd ttttoooo iiiinnnnnnnnoooovvvvaaaattttiiiivvvveeeellllyyyy ccccoooonnnnttttrrrroooolllllllliiiinnnngggg ssssuuuurrrrggggiiiiccccaaaallll bbbblllleeeeeeeeddddiiiinnnngggg aaaannnndddd bbbbiiiilllllllliiiioooonnnn aaaannnndddd eeeemmmmppppllllooooyyyyiiiinnnngggg oooouuuurrrr pppprrrroooovvvveeeennnn ccccaaaappppiiiittttaaaallll iiiinnnnffffeeeeccccttttiiiioooonnnn gggglllloooobbbbaaaallllllllyyyy oooouuuurrrr ggggooooaaaallll aaaannnndddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt iiiissss aaaallllllllooooccccaaaattttiiiioooonnnn ssssttttrrrraaaatttteeeeggggyyyy wwwweeee aaaarrrreeee aaaabbbblllleeee ttttoooo eeeeffffffffeeeeccccttttiiiivvvveeeellllyyyy ttttoooo nnnnoooowwww ccccrrrreeeeaaaatttteeee tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ssssuuuurrrrggggeeeerrrryyyy tttthhhhaaaattttssss iiiinnnnvvvveeeesssstttt iiiinnnn oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo ddddrrrriiiivvvveeee wwwwhhhhyyyy iiiimmmm eeeexxxxcccciiiitttteeeedddd tttthhhhaaaatttt wwwweeee eeeennnntttteeeerrrreeeedddd iiiinnnnttttoooo aaaa ddddeeeefifififinnnniiiittttiiiivvvveeee ggggrrrroooowwwwtttthhhh ffffoooorrrr lllloooonnnnggggtttteeeerrrrmmmm vvvvaaaalllluuuueeee wwwwhhhhiiiilllleeee aaaallllssssoooo rrrreeeettttuuuurrrrnnnniiiinnnngggg aaaaggggrrrreeeeeeeemmmmeeeennnntttt ttttoooo aaaaccccqqqquuuuiiiirrrreeee aaaauuuurrrriiiissss hhhheeeeaaaalllltttthhhh iiiinnnncccc aaaauuuurrrriiiissss vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss oooouuuurrrr ccccaaaappppiiiittttaaaallll aaaallllllllooooccccaaaattttiiiioooonnnn hhhheeeeaaaalllltttthhhh iiiissss aaaa ddddeeeevvvveeeellllooooppppeeeerrrr ooooffff rrrroooobbbboooottttiiiicccc tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss ssssttttrrrraaaatttteeeeggggyyyy iiiinnnncccclllluuuuddddeeeessss ffffoooouuuurrrr kkkkeeeeyyyy pppprrrriiiioooorrrriiiittttiiiieeeessss tttthhhhaaaatttt ccccuuuurrrrrrrreeeennnnttttllllyyyy ffffooooccccuuuusssseeeessss oooonnnn lllluuuunnnngggg ccccaaaannnncccceeeerrrr tttthhhhiiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn wwwwiiiillllllll aaaacccccccceeeelllleeeerrrraaaatttteeee oooouuuurrrr eeeennnnttttrrrryyyy iiiinnnnttttoooo ddddiiiiggggiiiittttaaaallllllllyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid eeeennnnaaaabbbblllleeeedddd rrrroooobbbboooottttiiiiccccssss pppprrrroooocccceeeedddduuuurrrreeeessss wwwwiiiitttthhhh tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd aaaaddddmmmmiiiinnnniiiissssttttrrrraaaattttiiiivvvveeee iiiinnnniiiittttiiiiaaaattttiiiivvvveeeessss ffffoooorrrr ggggrrrroooowwwwtttthhhh aaaannnndddd eeeexxxxppppaaaannnnssssiiiioooonnnn iiiinnnnttttoooo ooootttthhhheeeerrrr iiiinnnntttteeeerrrrvvvveeeennnnttttiiiioooonnnnaaaallll aaaapppppppplllliiiiccccaaaattttiiiioooonnnnssss iiiinnnn tttthhhhiiiissss nnnneeeewwww eeeerrrraaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee wwwweeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaarrrreeee aaaaiiiimmmmiiiinnnngggg ttttoooo ssssiiiimmmmpppplllliiiiffffyyyy ssssuuuurrrrggggeeeerrrryyyy ddddrrrriiiivvvveeee eeeeffiffiffifficccciiiieeeennnnccccyyyy ddddiiiivvvviiiiddddeeeennnndddd ttttoooo oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss aaaannnndddd iiiinnnn rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss iiiimmmmpppprrrroooovvvveeee oooouuuuttttccccoooommmmeeeessss ffffoooorrrr wwwweeee ppppaaaaiiiidddd bbbbiiiilllllllliiiioooonnnn iiiinnnn ddddiiiivvvviiiiddddeeeennnnddddssss wwwweeee aaaarrrreeee ppppaaaattttiiiieeeennnnttttssss aaaannnndddd mmmmaaaakkkkeeee ssssuuuurrrrggggeeeerrrryyyy eeeevvvveeeennnn ssssaaaaffffeeeerrrr tttthhhhiiiissss vvvveeeerrrryyyy pppprrrroooouuuudddd tttthhhhaaaatttt oooouuuurrrr ddddiiiivvvviiiiddddeeeennnndddd hhhhaaaassss iiiinnnnccccrrrreeeeaaaasssseeeedddd ccccoooonnnnttttiiiinnnnuuuueeeessss oooouuuurrrr ssssuuuurrrrggggiiiiccccaaaallll lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttthhhhaaaatttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr tttthhhheeee llllaaaasssstttt ccccoooonnnnsssseeeeccccuuuuttttiiiivvvveeee yyyyeeeeaaaarrrrssss iiiinnnn mmmmoooottttiiiioooonnnn ssssiiiinnnncccceeee tttthhhheeee bbbbeeeeggggiiiinnnnnnnniiiinnnngggg ooooffff oooouuuurrrr ccccoooommmmppppaaaannnnyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttaaaarrrrggggeeeetttt mmmmeeeerrrrggggeeeerrrrssss aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd lllliiiicccceeeennnnssssiiiinnnngggg llllooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd iiii aaaammmm aaaallllssssoooo vvvveeeerrrryyyy eeeexxxxcccciiiitttteeeedddd aaaabbbboooouuuutttt oooouuuurrrr aaaaggggrrrreeeeeeeemmmmeeeennnnttttssss tttthhhhaaaatttt wwwweeee bbbbeeeelllliiiieeeevvvveeee wwwwiiiillllllll aaaadddddddd ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn wwwwiiiitttthhhh aaaapppppppplllleeee iiiinnnncccc tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd ssssiiiiggggnnnniiiifififificcccaaaannnntttt lllloooonnnnggggtttteeeerrrrmmmm vvvvaaaalllluuuueeee ccccrrrreeeeaaaattttiiiioooonnnn ffffoooorrrr oooouuuurrrr eeeeaaaarrrrllllyyyy iiiinnnn ttttooooggggeeeetttthhhheeeerrrr wwwweeee wwwwiiiillllllll bbbbeeee ccccoooonnnndddduuuuccccttttiiiinnnngggg aaaa sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss aaaannnndddd aaaallllllll ooootttthhhheeeerrrr ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss rrrreeeesssseeeeaaaarrrrcccchhhh ssssttttuuuuddddyyyy tttthhhhaaaatttt aaaannnnaaaallllyyyyzzzzeeeessss wwwwhhhheeeetttthhhheeeerrrr aaaa nnnneeeewwww hhhheeeeaaaarrrrtttt hhhheeeeaaaalllltttthhhh pppprrrrooooggggrrrraaaammmm uuuussssiiiinnnngggg aaaannnn aaaapppppppp ffffrrrroooommmm tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid jjjjoooohhhhnnnnssssoooonnnn ffffaaaammmmiiiillllyyyy ooooffff ccccoooommmmppppaaaannnniiiieeeessss iiiinnnn ccccoooommmmbbbbiiiinnnnaaaattttiiiioooonnnn ttttoooo rrrreeeettttuuuurrrrnnnn vvvvaaaalllluuuueeee ttttoooo sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss ssssuuuucccchhhh aaaassss sssshhhhaaaarrrreeee wwwiiiittthhhh aaapppppplllleee wwwaaatttccchhhhsss iiiirrrrrreeeggguuullllaaarrr rrrhhhhyyyttthhhhmmm nnnoootttiiiifififificccaaatttiiiiooonnnsss rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee pppprrrrooooggggrrrraaaammmmssss aaaannnndddd wwwweeee aaaarrrreeee ccccuuuurrrrrrrreeeennnnttttllllyyyy aaaannnndddd eeeelllleeeeccccttttrrrroooo ccccaaaarrrrddddiiiiooooggggrrrraaaammmm eeeeccccgggg aaaapppppppp ccccaaaannnn eeeexxxxeeeeccccuuuuttttiiiinnnngggg aaaaggggaaaaiiiinnnnsssstttt aaaa bbbbiiiilllllllliiiioooonnnn sssshhhhaaaarrrreeee rrrreeeeppppuuuurrrrcccchhhhaaaasssseeee aaaacccccccceeeelllleeeerrrraaaatttteeee aaaattttrrrriiiiaaaallll fifififibbbbrrrriiiillllllllaaaattttiiiioooonnnn aaaaffffiiiibbbb ddddiiiiaaaaggggnnnnoooossssiiiissss aaaannnndddd tttthhhhaaaatttt wwwweeee aaaannnnnnnnoooouuuunnnncccceeeedddd llllaaaasssstttt ddddeeeecccceeeemmmmbbbbeeeerrrr iiiimmmmpppprrrroooovvvveeee hhhheeeeaaaalllltttthhhh oooouuuuttttccccoooommmmeeeessss iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeee pppprrrreeeevvvveeeennnnttttiiiioooonnnn ggggiiiivvvveeeennnn oooouuuurrrr fifififinnnnaaaannnncccciiiiaaaallll ssssttttrrrreeeennnnggggtttthhhh wwwweeee ccccaaaannnn ppppuuuurrrrssssuuuueeee aaaallllllll ooooffff ssssttttrrrrooookkkkeeee ffffoooorrrr tttthhhheeee mmmmiiiilllllllliiiioooonnnn ppppeeeeoooopppplllleeee wwwwoooorrrrllllddddwwwwiiiiddddeeee ooooffff tttthhhheeeesssseeee pppprrrriiiioooorrrriiiittttiiiieeeessss ssssiiiimmmmuuuullllttttaaaannnneeeeoooouuuussssllllyyyy aaaassss wwwweeee ddddiiiidddd iiiinnnn lllliiiivvvviiiinnnngggg wwwwiiiitttthhhh aaaaffffiiiibbbb tttthhhhiiiissss iiiissss aaaa ccccoooonnnnddddiiiittttiiiioooonnnn tttthhhhaaaatttt ccccaaaannnn tttthhhhrrrroooouuuugggghhhhoooouuuutttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnnssss hhhhiiiissssttttoooorrrryyyy lllleeeeaaaadddd ttttoooo ssssttttrrrrooookkkkeeee aaaannnndddd ooootttthhhheeeerrrr ppppooootttteeeennnnttttiiiiaaaallllllllyyyy ddddeeeevvvvaaaassssttttaaaattttiiiinnnngggg wwwweeee hhhhaaaavvvveeee mmmmaaaaiiiinnnnttttaaaaiiiinnnneeeedddd aaaa ssssttttrrrroooonnnngggg ccccoooonnnnssssiiiisssstttteeeennnntttt aaaannnndddd cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ssssuuuussssttttaaaaiiiinnnnaaaabbbblllleeee bbbbuuuussssiiiinnnneeeessssssss tttthhhhiiiissss iiiissss iiiilllllllluuuussssttttrrrraaaatttteeeedddd bbbbyyyy rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ffffoooorrrr aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy ddddeeeeaaaatttthhhhssss aaaannnndddd hhhhoooossssppppiiiittttaaaalllliiiizzzzaaaattttiiiioooonnnnssss eeeevvvveeeerrrryyyy yyyyeeeeaaaarrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll eeeeaaaarrrrnnnniiiinnnnggggssss ggggrrrroooowwwwtttthhhh wwwweeee aaaarrrreeee vvvveeeerrrryyyy ooooppppttttiiiimmmmiiiissssttttiiiicccc aaaabbbboooouuuutttt tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll ooooffff tttthhhhiiiissss wwwweeeeaaaarrrraaaabbbblllleeee tttteeeecccchhhhnnnnoooollllooooggggyyyy aaaannnndddd bbbbaaaasssseeeedddd oooonnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tttthhhheeee iiiinnnnssssiiiigggghhhhttttssss ggggeeeennnneeeerrrraaaatttteeeedddd tttthhhhrrrroooouuuugggghhhh tttthhhhiiiissss rrrreeeesssseeeeaaaarrrrcccchhhh hhhhoooolllldddd aaaa ttttrrrriiiipppplllleeee aaaa ccccrrrreeeeddddiiiitttt rrrraaaattttiiiinnnngggg aaaannnndddd pppprrrrooooggggrrrraaaammmm iiiinnnn tttthhhheeee ffffuuuuttttuuuurrrreeee wwwweeee mmmmaaaayyyy aaaallllssssoooo bbbbeeee aaaabbbblllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttoooo ddddeeeevvvveeeelllloooopppp nnnneeeewwww wwwwaaaayyyyssss ttttoooo ddddeeeetttteeeecccctttt ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhh ttttoooopppp mmmmaaaarrrrkkkkeeeetttt ccccaaaapppp ccccoooommmmppppaaaannnniiiieeeessss ccccoooonnnnddddiiiittttiiiioooonnnnssss ssssoooooooonnnneeeerrrr eeeeaaaarrrrllllyyyy ddddiiiiaaaaggggnnnnoooossssiiiissss nnnnooootttt oooonnnnllllyyyy tttthhhheeee ssssttttrrrraaaatttteeeeggggiiiiccccaaaaddddvvvvaaaannnnttttaaaaggggeeee ooooffff oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee hhhhaaaassss tttthhhheeee ppppooootttteeeennnnttttiiiiaaaallll ttttoooo ssssaaaavvvveeee lllliiiivvvveeeessss bbbbuuuutttt iiiitttt mmmmaaaayyyy aaaallllssssoooo ppppoooossssiiiittttiiiioooonnnneeeedddd aaaaccccrrrroooossssssss tttthhhhrrrreeeeeeee vvvviiiittttaaaallll aaaassssppppeeeeccccttttssss ooooffff lllloooowwwweeeerrrr ccccoooossssttttssss aaaaccccrrrroooossssssss tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssyyyysssstttteeeemmmm hhhheeeeaaaalllltttthhhhccccaaaarrrreeeepppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll ccccoooonnnnssssuuuummmmeeeerrrr aaaannnndddd iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn iiiissss oooouuuurrrr ccccaaaalllllllliiiinnnngggg ccccaaaarrrrdddd ttttoooo tttthhhheeee wwwwoooorrrrlllldddd ooooffff mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeesssswwwweeee hhhhaaaavvvveeee uuuunnnniiiiqqqquuuueeee iiiinnnnssssiiiigggghhhhtttt iiiinnnnttttoooo sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy wwwweeee rrrreeeemmmmaaaaiiiinnnn ooooppppeeeennnn ttttoooo tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss wwwwhhhheeeennnneeeevvvveeeerrrr aaaannnndddd bbbbeeeesssstttt iiiiddddeeeeaaaassss nnnnoooo mmmmaaaatttttttteeeerrrr wwwwhhhheeeerrrreeee tttthhhheeeeyyyy ccccoooommmmeeee ffffrrrroooommmm wwwwhhhheeeerrrreeeevvvveeeerrrr tttthhhheeeeyyyy eeeemmmmeeeerrrrggggeeee wwwweeee aaaarrrreeee ssssttttrrrruuuuccccttttuuuurrrreeeedddd ttttoooo aaaassss wwwweeee rrrreeeelllleeeennnnttttlllleeeessssssssllllyyyy ppppuuuurrrrssssuuuueeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll mmmmeeeeeeeetttt tttthhhheeee ccccuuuurrrrrrrreeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee nnnneeeeeeeeddddssss ooooffff ppppaaaattttiiiieeeennnnttttssss iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ttttoooo bbbbeeeennnneeeefifififitttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh iiiinnnntttteeeerrrrnnnnaaaallllllllyyyy aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy aaaannnndddd ttttoooo aaaaddddddddrrrreeeessssssss tttthhhheeee aaaannnndddd tttthhhhrrrroooouuuugggghhhhoooouuuutttt oooouuuurrrr iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn eeeeccccoooossssyyyysssstttteeeemmmm cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttiiiieeeessss tttthhhhaaaatttt tttthhhheeee wwwwoooorrrrlllldddd aaaaccccrrrroooossssssss oooouuuurrrr iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn cccceeeennnntttteeeerrrrssss jjjjllllaaaabbbbssss ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrreeeesssseeeennnnttttssss wwwweeee rrrreeeemmmmaaaaiiiinnnn ffffooooccccuuuusssseeeedddd oooonnnn jjjjjjjjddddcccc aaaannnndddd mmmmaaaannnnyyyy ssssttttrrrraaaatttteeeeggggiiiicccc ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiippppssss lllleeeevvvveeeerrrraaaaggggiiiinnnngggg oooouuuurrrr bbbbrrrrooooaaaaddddbbbbaaaasssseeeedddd ccccaaaappppaaaabbbbiiiilllliiiittttiiiieeeessss ttttoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddrrrriiiivvvveeee tttthhhheeee nnnneeeexxxxtttt ggggeeeennnneeeerrrraaaattttiiiioooonnnn ooooffff ggggrrrroooowwwwtttthhhh bbbbuuuussssiiiinnnneeeessssssss ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd oooouuuuttttllllooooooookkkk aaaaccccrrrroooossssssss oooouuuurrrr eeeennnnttttiiiirrrreeee ppppoooorrrrttttffffoooolllliiiioooo bbbbooootttthhhh iiiinnnn mmmmaaaarrrrkkkkeeeettttssss pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll wwwwhhhheeeerrrreeee wwwweeee hhhhaaaavvvveeee ggggrrrreeeeaaaatttteeeerrrr ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo ccccoooommmmppppeeeetttteeee wwwiiiittthhhh aaannn iiiinnndddduuussstttrrryyylllleeeaaaddddiiiinnnggg pppiiiipppeeelllliiiinnneee aaannndddd eeessstttaaabbbblllliiiissshhhheeedddd aaaassss wwwweeeellllllll aaaassss iiiinnnn tttthhhheeee mmmmaaaarrrrkkkkeeeettttssss wwwwhhhheeeerrrreeee wwwweeee lllleeeeaaaadddd wwwwhhhhiiiicccchhhh ccccoooommmmmmmmeeeerrrrcccciiiiaaaallll eeeexxxxcccceeeelllllllleeeennnncccceeee oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll iiiinnnncccclllluuuuddddeeee oooouuuurrrr ppppllllaaaattttffffoooorrrrmmmmssss tttthhhhaaaatttt eeeeaaaacccchhhh ddddeeeelllliiiivvvveeeerrrreeeedddd bbbbuuusssiiiinnneeessssss hhhhaaasss ddddeeelllliiiivvveeerrreeedddd ooouuutttssstttaaannnddddiiiinnnggg pppeeerrrffffooorrrmmmaaannnccceee aaaa bbbbiiiilllllllliiiioooonnnn ddddoooollllllllaaaarrrrssss oooorrrr mmmmoooorrrreeee iiiinnnn ssssaaaalllleeeessss llllaaaasssstttt yyyyeeeeaaaarrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee iiiissss nnnnooootttt jjjjuuuusssstttt oooouuuurrrr hhhheeeerrrriiiittttaaaaggggeeee iiiitttt llllaaaauuuunnnncccchhhheeeessss aaaannnndddd ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh iiiinnnn sssseeeevvvveeeerrrraaaallll ooooffff iiiissss aaaa ssssttttrrrraaaatttteeeeggggiiiicccc cccchhhhooooiiiicccceeee ggggrrrroooouuuunnnnddddeeeedddd aaaannnndddd pppprrrroooovvvveeeennnn oooouuuurrrr bbbblllloooocccckkkkbbbbuuuusssstttteeeerrrr mmmmeeeeddddiiiicccciiiinnnneeeessss ccccrrrreeeeaaaatttteeeedddd iiiinnnn lllloooonnnnggggtttteeeerrrrmmmm ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee aaaannnndddd oooouuuurrrr bbbbrrrrooooaaaadddd ooopppeeerrraaatttiiiiooonnnaaallll gggrrrooowwwttthhhh aaannndddd ooouuurrr ppphhhhaaarrrmmmaaaccceeeuuutttiiiicccaaallll aaaannnndddd ddddeeeeeeeepppp uuuunnnnddddeeeerrrrssssttttaaaannnnddddiiiinnnngggg ooooffff tttthhhheeee iiiinnnndddduuuussssttttrrrryyyyssss bbbbuuuussssiiiinnnneeeessssssss ccccoooonnnnttttiiiinnnnuuuueeeessss ttttoooo bbbbeeee aaaannnn iiiinnnndddduuuussssttttrrrryyyy lllleeeeaaaaddddeeeerrrr iiiinnnn pppprrrreeeesssseeeennnntttt aaaannnndddd ffffuuuuttttuuuurrrreeee wwwweeee cccclllleeeeaaaarrrrllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee tttthhhheeee aaaallllllll ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee mmmmeeeeaaaassssuuuurrrreeeessss iiiinnnncccclllluuuuddddiiiinnnngggg rrrrdddd iiiimmmmppppoooorrrrttttaaaannnntttt rrrroooolllleeee wwwweeee ppppllllaaaayyyy iiiinnnn lllleeeeaaaaddddiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy aaaannnndddd rrrreeeepppprrrreeeesssseeeennnnttttiiiinnnngggg oooouuuurrrr iiiinnnndddduuuussssttttrrrryyyy wwwwiiiitttthhhh iiiinnnntttteeeeggggrrrriiiittttyyyy aaaassss wwwweeee llllooooooookkkk ttttoooowwwwaaaarrrrdddd aaaannnndddd bbbbeeeeyyyyoooonnnndddd wwwweeee rrrreeeemmmmaaaaiiiinnnn fffooocccuuussseeeddd ooonnn bbbrrriiinnnggggiiinnngggg iiinnnnnnooovvvaaatttiiivvveee sssooollluuutttiiiooonnnsss tttooo oooouuuurrrr hhhheeeeaaaalllltttthhhh ffffoooorrrr hhhhuuuummmmaaaannnniiiittttyyyy rrrreeeeppppoooorrrrtttt uuuunnnnddddeeeerrrrssssccccoooorrrreeeessss ppppaaaattttiiiieeeennnnttttssss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy oooouuuurrrr ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo hhhheeeellllpppp eeeennnnssssuuuurrrreeee tttthhhhaaaatttt eeeeaaaacccchhhh nnnneeeewwww wwwwhhhhiiiilllleeee ddddrrrriiiivvvviiiinnnngggg ssssttttrrrroooonnnngggg ggggrrrroooowwwwtttthhhh aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ggggeeeennnneeeerrrraaaattttiiiioooonnnn iiiissss hhhheeeeaaaalllltttthhhhiiiieeeerrrr tttthhhhaaaannnn tttthhhheeee llllaaaasssstttt wwwweeee bbbbeeeelllliiiieeeevvvveeee ttttoooo aaaaddddvvvvaaaannnncccceeee oooouuuurrrr ppppiiiippppeeeelllliiiinnnneeee ppppaaaatttteeeennnntttt pppprrrreeeessssssssuuuurrrreeee iiiissss aaaa oooouuuurrrr bbbbrrrrooooaaaadddd bbbbaaaasssseeee hhhheeeellllppppssss uuuussss bbbbeeeetttttttteeeerrrr uuuunnnnddddeeeerrrrssssttttaaaannnndddd aaaannnndddd fffeeeaaatttuuurrreee ooofff tttooodddaaayyyysss pppphhhaaarrrmmmaaaccceeeuuutttiiicccaaalll iiinnnddduuussstttrrryyyy aaannnddd ppppoooossssiiiittttiiiivvvveeeellllyyyy iiiimmmmppppaaaacccctttt hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaatttt eeeevvvveeeerrrryyyy aaaaggggeeee aaaannnndddd wwweee hhhhaaavvveee ddddeeelllliiiibbbbeeerrraaattteeellllyyy aaannndddd aaaccctttiiiivvveeellllyyy mmmaaannnaaagggeeedddd ooouuurrr aaaatttt eeeevvvveeeerrrryyyy ssssttttaaaaggggeeee iiiinnnn wwwweeee wwwweeeerrrreeee rrrreeeeccccooooggggnnnniiiizzzzeeeedddd aaaassss oooonnnneeee ppppoooorrrrttttffffoooolllliiiioooo oooovvvveeeerrrr tttthhhheeee llllaaaasssstttt ffffeeeewwww yyyyeeeeaaaarrrrssss ttttoooo eeeennnnaaaabbbblllleeee uuuussss ooooffff tttthhhheeee ttttoooopppp tttteeeennnn ccccoooorrrrppppoooorrrraaaattttiiiioooonnnnssss ffffoooorrrr oooouuuurrrr eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll tttooo mmmaaakkkeee ttthhheee iiinnnvvveeessstttmmmeeennntttsss nnneeeccceeessssssaaarrryyyy tttooo nnnooottt ooonnnlllyyyy ssssoooocccciiiiaaaallll aaaannnndddd ggggoooovvvveeeerrrrnnnnaaaannnncccceeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee bbbbyyyy wwwiiiittthhhhssstttaaannndddd ttthhhhiiiisss iiiimmmpppaaacccttt bbbbuuuttt tttooo gggrrrooowww aaattt cccooommmpppeeetttiiiitttiiiivvveee ccccoooorrrrppppoooorrrraaaatttteeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy mmmmaaaaggggaaaazzzziiiinnnneeee rrraaattteeesss iiiinnn wwweee rrreeemmmaaaiiiinnn ffffooocccuuussseeedddd ooonnn ddddeeevvveeellllooopppiiiinnnggg mmmmeeeeddddiiiicccciiiinnnneeeessss aaaannnndddd ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt ddddeeeelllliiiivvvveeeerrrr ggggrrrreeeeaaaatttt vvvvaaaalllluuuueeee tttooo ttthhheee ppppaaatttiiieeennntttsss aaannnddd cccooonnnsssuuummmeeerrrsss wwwhhhooo dddeeeppppeeennnddd broad base heritage oooonnnn oooouuuurrrr pppprrrroooodddduuuuccccttttssss ttttoooo mmmmaaaakkkkeeee tttthhhheeeeiiiirrrr lllliiiivvvveeeessss bbbbeeeetttttttteeeerrrr oooouuuurrrr strategic choice grounded ggggooooaaaallll aaaannnndddd eeeexxxxppppeeeeccccttttaaaattttiiiioooonnnn ffffoooorrrr aaaannnndddd bbbbeeeeyyyyoooonnnndddd iiiissss proven longterm performance ssssuuuussssttttaaaaiiiinnnneeeedddd lllloooonnnnggggtttteeeerrrrmmmm aaaabbbboooovvvveeeemmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh broad deep understanding wwweee kkkknnnooowww ttthhhhaaattt iiiinnnnnnooovvvaaatttiiiiooonnn ddddrrriiiivvveeesss ooouuurrr industrys present future ppphhhaaarrrmmmaaaccceeeuuutttiiicccaaalll bbbuuusssiiinnneeesssssssss sssuuucccccceeessssss aaannnddd wwweee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ccccoooollllllllaaaabbbboooorrrraaaattttiiiioooonnnn iiiissss ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll ttttoooo tttthhhheeee wwwwoooorrrrkkkk wwwweeee ddddoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid eeeevvvveeeerrrryyyy ddddaaaayyyy aaaannnndddd oooouuuurrrr pppprrrreeeesssseeeennnncccceeee iiiinnnn jjjjuuuusssstttt aaaabbbboooouuuutttt eeeevvvveeeerrrryyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaarrrreeeeaaaa ooooffff hhhheeeeaaaalllltttthhhhccccaaaarrrreeee tttthhhhiiiissss lllleeeevvvveeeellll ooooffff eeeennnnggggaaaaggggeeeemmmmeeeennnntttt ttttrrrreeeeaaaattttmmmmeeeennnntttt rrrreeeessssiiiissssttttaaaannnntttt ddddeeeepppprrrreeeessssssssiiiioooonnnn ttttrrrrdddd wwwwhhhhoooo aaaalllllllloooowwwwssss uuuussss ttttoooo mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ccccoooonnnnttttiiiinnnnuuuuoooouuuussss ddddiiiiaaaalllloooogggguuuueeee hhhhaaaavvvveeee ccccyyyycccclllleeeedddd tttthhhhrrrroooouuuugggghhhh mmmmuuuullllttttiiiipppplllleeee ttttrrrreeeeaaaattttmmmmeeeennnnttttssss wwwwiiiitttthhhh hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss bbbbuuuussssiiiinnnneeeessssssss lllleeeeaaaaddddeeeerrrrssss wwwwiiiitttthhhhoooouuuutttt rrrreeeelllliiiieeeeffff ttttrrrrdddd iiiissss aaaa ddddeeeebbbbiiiilllliiiittttaaaattttiiiinnnngggg ddddiiiisssseeeeaaaasssseeee tttthhhhaaaatttt aaaaccccaaaaddddeeeemmmmiiiiccccssss ggggoooovvvveeeerrrrnnnnmmmmeeeennnntttt ooooffiffiffifficccciiiiaaaallllssss sssscccciiiieeeennnnttttiiiissssttttssss iiiissss aaaassssssssoooocccciiiiaaaatttteeeedddd wwwwiiiitttthhhh cccchhhhrrrroooonnnniiiicccc hhhheeeeaaaalllltttthhhh pppprrrroooobbbblllleeeemmmmssss aaaannnndddd pppprrrroooovvvviiiiddddeeeerrrr ssssyyyysssstttteeeemmmmssss ccccuuuussssttttoooommmmeeeerrrrssss ppppaaaattttiiiieeeennnnttttssss aaaannnndddd qqqquuuuiiiitttteeee ttttrrrraaaaggggiiiiccccaaaallllllllyyyy ccccaaaannnn lllleeeeaaaadddd ttttoooo ssssuuuuiiiicccciiiiddddeeee iiiiffff nnnnooootttt ttttrrrreeeeaaaatttteeeedddd ccccoooonnnnssssuuuummmmeeeerrrrssss wwwweeee rrrreeeemmmmaaaaiiiinnnn ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo bbbbeeeeiiiinnnngggg aaaa cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid lllleeeeaaaaddddeeeerrrr iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ssssppppaaaacccceeee ttttoooo hhhheeeellllpppp ddddrrrriiiivvvveeee bbbbrrrreeeeaaaakkkktttthhhhrrrroooouuuugggghhhh mmmmeeeeddddiiiicccciiiinnnneeee iiiinnnn oooouuuurrrr pppprrrroooodddduuuucccctttt ppppoooorrrrttttffffoooolllliiiioooo tttthhhheeee cccchhhhaaaannnnggggeeee tttthhhhaaaatttt ppppeeeeoooopppplllleeee aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd wwwwaaaannnntttt bbbbuuuutttt aaaallllssssoooo aaaa nnnneeeewwww hhhhooooppppeeee ffffoooorrrr aaaadddduuuullllttttssss wwwwhhhhoooo ssssuuuuffffffffeeeerrrr ffffrrrroooommmm aaaannnndddd nnnneeeeeeeedddd ttttoooo sssseeeeeeee ttttrrrrdddd iiiitttt aaaallllssssoooo ooooffffffffeeeerrrrssss tttthhhheeee fifififirrrrsssstttt nnnneeeewwww mmmmeeeecccchhhhaaaannnniiiissssmmmm wwwweeee sssseeeeeeee aaaa vvvviiiittttaaaallll aaaannnndddd vvvviiiibbbbrrrraaaannnntttt ffffuuuuttttuuuurrrreeee ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ooooffff aaaaccccttttiiiioooonnnn ttttoooo aaaaddddddddrrrreeeessssssss ttttrrrrdddd aaaannnndddd iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy iiiinnnn aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd tttthhhhaaaatttt iiiissss bbbbeeeeiiiinnnngggg ddddrrrriiiivvvveeeennnn bbbbyyyy tttthhhheeee aaaaccccccccoooorrrrddddaaaannnncccceeee wwwwiiiitttthhhh rrrriiiisssskkkk mmmmiiiittttiiiiggggaaaattttiiiioooonnnn gggguuuuiiiiddddaaaannnncccceeee ffffrrrroooommmm ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg eeeexxxxppppaaaannnnssssiiiioooonnnn ooooffff tttthhhheeee gggglllloooobbbbaaaallll mmmmiiiiddddddddlllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ccccllllaaaassssssss iiiitttt iiiissss tttthhhheeee mmmmiiiiddddddddlllleeee ccccllllaaaassssssss tttthhhhaaaatttt ddddrrrriiiivvvveeeessss gggglllloooobbbbaaaallll bbbbyyyy cccceeeerrrrttttiiiififififieeeedddd ttttrrrreeeeaaaattttmmmmeeeennnntttt cccceeeennnntttteeeerrrrssss aaaannnndddd wwwwiiiillllllll nnnnooootttt bbbbeeee eeeeccccoooonnnnoooommmmiiiicccc ggggrrrroooowwwwtttthhhh aaaannnndddd wwwwiiiitttthhhh iiiitttt tttthhhheeee ddddeeeemmmmaaaannnndddd ffffoooorrrr ddddiiiissssppppeeeennnnsssseeeedddd ddddiiiirrrreeeeccccttttllllyyyy ttttoooo ppppaaaattttiiiieeeennnnttttssss ttttoooo ttttaaaakkkkeeee aaaatttt hhhhoooommmmeeee ggggrrrreeeeaaaatttteeeerrrr aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhaaaatttt nnnnoooo ccccoooommmmppppaaaannnnyyyy oooonnnn eeeeaaaarrrrtttthhhh iiiissss bbbbeeeetttttttteeeerrrr ppppoooossssiiiittttiiiioooonnnneeeedddd wwwweeee hhhhaaaavvvveeee lllliiiisssstttteeeennnneeeedddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttt iiiinnnntttteeeennnntttt ttttoooo tttthhhheeee ccccoooonnnncccceeeerrrrnnnnssss tttthhhhaaaannnn jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ttttoooo ccccaaaappppttttuuuurrrreeee tttthhhhiiiissss vvvvooooiiiicccceeeedddd bbbbyyyy mmmmaaaannnnyyyy ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssss oooovvvveeeerrrr tttthhhheeee pppprrrriiiicccciiiinnnngggg aaaannnndddd ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd lllleeeeaaaadddd tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ooooffff pppprrrroooodddduuuuccccttttssss aaaannnndddd oooouuuurrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ffffrrrraaaaggggrrrraaaannnncccceeee iiiinnnnggggrrrreeeeddddiiiieeeennnnttttssss aaaabbbboooovvvveeee ppppaaaarrrrttttssss ppppeeeerrrr mmmmiiiilllllllliiiioooonnnn wwwwoooorrrrlllldddd wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ttttaaaakkkkiiiinnnngggg tttthhhheeee lllleeeeaaaadddd ppppppppmmmm iiiinnnn oooouuuurrrr sssshhhhaaaammmmppppoooooooossss wwwwaaaasssshhhheeeessss aaaannnndddd lllloooottttiiiioooonnnnssss bbbbeeeeiiiinnnngggg rrrreeeessssppppoooonnnnssssiiiibbbblllleeee ppppaaaarrrrttttnnnneeeerrrrssss aaaannnndddd ddddooooiiiinnnngggg oooouuuurrrr ppppaaaarrrrtttt ttttoooo aaaannnndddd wwwweeeevvvveeee bbbbeeeeeeeennnn rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr tttthhhhiiiissss ggggrrrreeeeaaaatttteeeerrrr nnnnooootttt oooonnnnllllyyyy ttttrrrreeeeaaaatttt ppppaaaattttiiiieeeennnnttttssss bbbbuuuutttt aaaallllssssoooo eeeennnnssssuuuurrrreeee tttthhhheeeeyyyy ccccaaaannnn ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy bbbbyyyy tttthhhheeee eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnnttttaaaallll wwwwoooorrrrkkkkiiiinnnngggg ggggeeeetttt aaaacccccccceeeessssssss iiiinnnn aaaannnn ooooppppeeeennnn aaaannnndddd aaaaffffffffoooorrrrddddaaaabbbblllleeee mmmmaaaannnnnnnneeeerrrr ggggrrrroooouuuupppp oooouuuurrrr rrrreeeellllaaaauuuunnnncccchhhh aaaallllssssoooo iiiinnnncccclllluuuuddddeeeessss nnnneeeewwww ppppaaaacccckkkkaaaaggggiiiinnnngggg aaaannnndddd iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnnaaaallll ssssoooocccciiiiaaaallll mmmmeeeeddddiiiiaaaa ccccoooommmmmmmmuuuunnnniiiiccccaaaattttiiiioooonnnnssss aaaassss aaaa rrrreeeessssuuuulllltttt ooooffff ddddiiiirrrreeeecccctttt iiiinnnntttteeeerrrraaaaccccttttiiiioooonnnn wwwwiiiitttthhhh ppppaaaattttiiiieeeennnnttttssss ttttaaaaiiiilllloooorrrreeeedddd ttttoooo tttthhhheeee nnnneeeeeeeeddddssss aaaannnndddd wwwwaaaannnnttttssss ooooffff mmmmiiiilllllllleeeennnnnnnniiiiaaaallll tttthhhheeeeiiiirrrr ffffaaaammmmiiiilllliiiieeeessss aaaannnndddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallllssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid rrrreeeellllaaaauuuunnnncccchhhh iiiissss ooooffffffff ttttoooo aaaa ssssoooolllliiiidddd ssssttttaaaarrrrtttt aaaannnndddd wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ttttoooo llllaaaauuuunnnncccchhhh aaaaccccrrrroooossssssss gggglllloooobbbbaaaallll mmmmaaaarrrrkkkkeeeettttssss tttthhhhrrrroooouuuugggghhhhoooouuuutttt cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt mmmmeeeeaaaassssuuuurrrreeee ttttoooo hhhheeeellllpppp ccccoooonnnnssssuuuummmmeeeerrrrssss ggggaaaaiiiinnnn aaaa aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy iiiinnnn rrrreeeessssppppoooonnnnsssseeee ttttoooo oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss aaaasssskkkkiiiinnnngggg bbbbeeeetttttttteeeerrrr ppppiiiiccccttttuuuurrrreeee ooooffff wwwwhhhhaaaatttt tttthhhheeeeyyyy sssshhhhoooouuuulllldddd eeeexxxxppppeeeecccctttt ttttoooo ppppaaaayyyy ffffoooorrrr ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss tttthhhhaaaatttt aaaaddddddddrrrreeeessssssss ffffoooorrrr tttthhhheeeeiiiirrrr mmmmeeeeddddiiiicccciiiinnnneeeessss wwwweeee hhhhaaaavvvveeee pppprrrrooooppppoooosssseeeedddd iiiinnnncccclllluuuuddddiiiinnnngggg tttthhhheeeeiiiirrrr sssskkkkiiiinnnnssss uuuunnnniiiiqqqquuuueeee nnnneeeeeeeeddddssss wwwweeee aaaarrrreeee ddddeeeevvvveeeellllooooppppiiiinnnngggg lllliiiissssttttpppprrrriiiicccceeee iiiinnnnffffoooorrrrmmmmaaaattttiiiioooonnnn iiiinnnn ddddiiiirrrreeeeccccttttttttooooccccoooonnnnssssuuuummmmeeeerrrr ttttvvvv oooouuuurrrr mmmmoooosssstttt ppppeeeerrrrssssoooonnnnaaaalllliiiizzzzeeeedddd sssskkkkiiiinnnnccccaaaarrrreeee pppprrrroooodddduuuucccctttt ttttoooo aaaaddddssss ssssttttaaaarrrrttttiiiinnnngggg wwwwiiiitttthhhh oooouuuurrrr mmmmoooossssttttpppprrrreeeessssccccrrrriiiibbbbeeeedddd mmmmeeeeddddiiiicccciiiinnnneeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid xxxxaaaarrrreeeellllttttoooo rrrriiiivvvvaaaarrrrooooxxxxaaaabbbbaaaannnn aaaannnn oooorrrraaaallll aaaannnnttttiiiiccccooooaaaagggguuuullllaaaannnntttt ddddpppprrrriiiinnnntttteeeedddd sssshhhheeeeeeeetttt mmmmaaaasssskkkk iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy uuuusssseeeerrrr ddddaaaattttaaaa ttttoooo eeeennnnssssuuuurrrreeee ppppaaaattttiiiieeeennnnttttssss hhhhaaaavvvveeee ccccllllaaaarrrriiiittttyyyy wwwweeee ppppllllaaaannnn ttttoooo aaaannnndddd wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr tttthhhheeee cccclllliiiinnnniiiiccccaaaallll eeeeffiffiffifficcccaaaaccccyyyy eeeexxxxppppeeeecccctttteeeedddd iiiinnnncccclllluuuuddddeeee bbbbooootttthhhh tttthhhheeee lllliiiisssstttt pppprrrriiiicccceeee aaaannnndddd ppppooootttteeeennnnttttiiiiaaaallll ppppaaaattttiiiieeeennnntttt ffffrrrroooommmm tttthhhheeee ddddeeeerrrrmmmmaaaattttoooollllooooggggiiiissssttttrrrreeeeccccoooommmmmmmmeeeennnnddddeeeedddd oooouuuuttttooooffffppppoooocccckkkkeeeetttt ccccoooossssttttssss wwwweeee bbbbeeeelllliiiieeeevvvveeee ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy iiiissss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaa ffffuuuunnnnddddaaaammmmeeeennnnttttaaaallll rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy ooooffff tttthhhhiiiissss ccccoooommmmppppaaaannnnyyyy iiiissss aaaallllrrrreeeeaaaaddddyyyy gggglllloooobbbbaaaallllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeeedddd ffffoooorrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg iiiittttssss aaaallllssssoooo aaaannnnooootttthhhheeeerrrr ssssttttrrrroooonnnngggg ddddeeeemmmmoooonnnnssssttttrrrraaaattttiiiioooonnnn tttthhhhaaaatttt ttttooooppppiiiiccccaaaallll sssskkkkiiiinnnnccccaaaarrrreeee ssssoooolllluuuuttttiiiioooonnnnssss aaaatttt tttthhhheeee iiiinnnntttteeeerrrrsssseeeeccccttttiiiioooonnnn oooouuuurrrr ppppuuuurrrrppppoooosssseeee ffffooooccccuuuusssseeeedddd oooonnnn hhhheeeellllppppiiiinnnngggg ppppaaaattttiiiieeeennnnttttssss iiiissss ooooffff sssscccciiiieeeennnncccceeee aaaannnndddd tttteeeecccchhhhnnnnoooollllooooggggyyyy tttthhhhiiiissss nnnneeeewwww pppprrrroooodddduuuucccctttt ddddrrrriiiivvvviiiinnnngggg oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss jjjjuuuusssstttt aaaassss iiiitttt sssshhhhoooouuuulllldddd bbbbeeee wwwwiiiillllllll rrrreeeepppprrrreeeesssseeeennnntttt oooonnnneeee ffffuuuurrrrtttthhhheeeerrrr sssstttteeeepppp ttttoooowwwwaaaarrrrdddd aaaa nnnneeeewwww mmmmooooddddeeeellll ooooffff pppprrrroooodddduuuucccctttt ddddeeeevvvveeeellllooooppppmmmmeeeennnntttt wwwwhhhheeeerrrreeee wwwweeee fifififinnnndddd oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss hhhhaaaassss ttttaaaakkkkeeeennnn aaaa ssssttttrrrroooonnnngggg ccccrrrreeeeaaaattttiiiivvvveeee uuuusssseeeessss ffffoooorrrr tttthhhheeee llllaaaatttteeeesssstttt tttteeeecccchhhhnnnnoooollllooooggggyyyy ssssuuuucccchhhh aaaassss lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp ssssttttaaaannnncccceeee oooonnnn iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy ddddiiiiggggiiiittttaaaallll iiiimmmmaaaaggggiiiinnnngggg sssskkkkiiiinnnn aaaannnnaaaallllyyyyssssiiiissss aaaannnndddd dddd pppprrrriiiinnnnttttiiiinnnngggg iiiinnnn tttthhhheeee iiiinnnndddduuuussssttttrrrryyyy iiii aaaammmm pppplllleeeeaaaasssseeeedddd ttttoooo sssshhhhaaaarrrreeee wwwweeee ttttoooo ggggiiiivvvveeee ccccoooonnnnssssuuuummmmeeeerrrrssss nnnneeeewwww wwwwaaaayyyyssss ttttoooo aaaacccchhhhiiiieeeevvvveeee tttthhhheeeeiiiirrrr cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid bbbbeeeesssstttt sssskkkkiiiinnnnccccaaaarrrreeee ppppoooossssssssiiiibbbblllleeee iiiitttt iiiissss aaaallllssssoooo aaaa ggggrrrreeeeaaaatttt eeeexxxxaaaammmmpppplllleeee ttttrrrraaaannnnssssppppaaaarrrreeeennnnccccyyyy rrrreeeeppppoooorrrrtttt iiiinnnn llllaaaatttteeee mmmmaaaarrrrcccchhhh tttthhhhiiiissss rrrreeeeppppoooorrrrtttt ooooffff hhhhoooowwww wwwweeee aaaarrrreeee lllleeeevvvveeeerrrraaaaggggiiiinnnngggg iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn aaaaccccrrrroooossssssss rrrreeeeflflflfleeeeccccttttiiiivvvveeee ooooffff oooouuuurrrr aaaaccccttttiiiioooonnnnssss iiiinnnn sssshhhhoooowwwwssss tttthhhhaaaatttt oooouuuurrrr oooouuuurrrr bbbbuuuussssiiiinnnneeeessssssss sssseeeeggggmmmmeeeennnnttttssss aaaassss oooouuuurrrr dddd pppprrrriiiinnnnttttiiiinnnngggg nnnneeeetttt pppprrrriiiicccceeeessss hhhhaaaavvvveeee ddddeeeeccccrrrreeeeaaaasssseeeedddd aaaaggggaaaaiiiinnnn bbbbyyyy ccccaaaappppaaaabbbbiiiilllliiiittttyyyy oooorrrriiiiggggiiiinnnnaaaatttteeeedddd wwwwiiiitttthhhhiiiinnnn mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss ccccoooonnnnssssuuuummmmeeeerrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss iiiinnnn ffffuuuueeeelllleeeedddd bbbbyyyy oooouuuurrrr iiiiccccoooonnnniiiicccc bbbbrrrraaaannnnddddssss aaaannnndddd ddddeeeeeeeepppp oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaarrrreeee aaaammmmoooonnnngggg tttthhhheeee ccccoooonnnnssssuuuummmmeeeerrrr iiiinnnnssssiiiigggghhhhttttssss oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss mmmmoooosssstttt ddddiiiivvvveeeerrrrsssseeee aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll iiiinnnn tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee aaaacccchhhhiiiieeeevvvveeeedddd aaaabbbboooovvvveeeemmmmaaaarrrrkkkkeeeetttt ggggrrrroooowwwwtttthhhh aaaassss wwwweeee llllooooooookkkk iiiinnnndddduuuussssttttrrrryyyy aaaatttt tttthhhheeee ssssaaaammmmeeee ttttiiiimmmmeeee wwwweeee ffffuuuullllllllyyyy rrrreeeeccccooooggggnnnniiiizzzzeeee aaaahhhheeeeaaaadddd wwwweeee wwwwiiiillllllll wwwwoooorrrrkkkk ttttoooo eeeennnnhhhhaaaannnncccceeee oooouuuurrrr lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttthhhhaaaatttt oooouuuurrrr pppprrrrooooggggrrrreeeessssssss hhhhaaaassss nnnnooootttt bbbbeeeeeeeennnn uuuunnnniiiiffffoooorrrrmmmm aaaaccccrrrroooossssssss iiiinnnn pppprrrriiiioooorrrriiiittttyyyy ccccaaaatttteeeeggggoooorrrriiiieeeessss bbbbyyyy ffffooooccccuuuussssiiiinnnngggg oooonnnn ccccrrrriiiittttiiiiccccaaaallll tttthhhheeee mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss ppppoooorrrrttttffffoooolllliiiioooo wwwweeee hhhhaaaavvvveeee mmmmaaaannnnyyyy ggggeeeeooooggggrrrraaaapppphhhhiiiieeeessss aaaannnndddd oooouuuurrrr mmmmeeeeggggaaaabbbbrrrraaaannnnddddssss wwwwhhhhiiiilllleeee aaaallllssssoooo aaaarrrreeeeaaaassss ooooffff ppppaaaarrrrttttiiiiccccuuuullllaaaarrrrllllyyyy ssssttttrrrroooonnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ssssuuuucccchhhh ccccoooonnnnttttiiiinnnnuuuuiiiinnnngggg ttttoooo eeeexxxxppppaaaannnndddd iiiinnnnttttoooo tttthhhheeee ffffaaaassssttttggggrrrroooowwwwiiiinnnngggg aaaassss eeeelllleeeeccccttttrrrroooopppphhhhyyyyssssiiiioooollllooooggggyyyy vvvviiiissssiiiioooonnnn ccccaaaarrrreeee wwwwoooouuuunnnndddd nnnnaaaattttuuuurrrraaaallllssss ccccaaaatttteeeeggggoooorrrryyyy oooouuuurrrr aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnn ooooffff zzzzaaaarrrrbbbbeeeeeeeessss iiiinnnncccc cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid iiiinnnn oooottttcccc iiiissss aaaa kkkkeeeeyyyy eeeexxxxaaaammmmpppplllleeee ooooffff tttthhhhiiiissss eeeexxxxppppaaaannnnddddiiiinnnngggg ffffooooccccuuuussss aaaallllssssoooo aaaarrrreeeeaaaassss wwwwhhhheeeerrrreeee wwwweeee mmmmuuuusssstttt iiiimmmmpppprrrroooovvvveeee ssssppppeeeecccciiiifififificcccaaaallllllllyyyy wwwwiiiitttthhhhiiiinnnn oooorrrrtttthhhhooooppppaaaaeeeeddddiiiiccccssss wwwweeee ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd pppprrrrooooggggrrrreeeessssssss wwwweeee hhhhaaaavvvveeee tttthhhheeee ssssttttrrrraaaatttteeeeggggiiiieeeessss iiiinnnn ppppllllaaaacccceeee ttttoooo mmmmoooovvvveeee wwwwiiiitttthhhh tttthhhheeee tttthhhhrrrroooouuuugggghhhhoooouuuutttt wwwwiiiitttthhhh tttthhhheeee ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ooooffff oooouuuurrrr aaaaggggiiiilllliiiittttyyyy rrrreeeeqqqquuuuiiiirrrreeeedddd ttttoooo aaaaddddddddrrrreeeessssssss eeeevvvvoooollllvvvviiiinnnngggg mmmmaaaarrrrkkkkeeeetttt nnnneeeeeeeeddddssss kkkknnnneeeeeeee aaaannnndddd ssssppppiiiinnnneeee bbbbuuuussssiiiinnnneeeesssssssseeeessss aaaannnndddd wwwweeee bbbbeeeelllliiiieeeevvvveeee wwwweeee hhhhaaaavvvveeee aaaaddddoooopppptttteeeedddd aaaa mmmmuuuullllttttiiiicccchhhhaaaannnnnnnneeeellll aaaapppppppprrrrooooaaaacccchhhh tttthhhhiiiissss ppppoooossssiiiittttiiiioooonnnnssss uuuussss wwwweeeellllllll ffffoooorrrr aaaannnndddd bbbbeeeeyyyyoooonnnndddd ffffrrrroooommmm tttthhhheeee bbbbiiiiggggbbbbooooxxxx rrrreeeettttaaaaiiiilllleeeerrrrssss ttttoooo eeeeccccoooommmmmmmmeeeerrrrcccceeee cccchhhhaaaannnnnnnneeeellllssss ttttoooo bbbbeeeetttttttteeeerrrr sssseeeerrrrvvvveeee oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrrssss iiiinnnn wwwweeee iiiimmmmpppprrrroooovvvveeeedddd ooooppppeeeerrrraaaattttiiiioooonnnnaaaallll ggggrrrroooowwwwtttthhhh tttthhhheeee rrrreeeessssuuuullllttttssss ooooffff oooouuuurrrr ccccoooonnnnttttiiiinnnnuuuuaaaallll ccccoooonnnnnnnneeeeccccttttiiiioooonnnn wwwwiiiitttthhhh eeeexxxxcccclllluuuuddddiiiinnnngggg aaaaccccqqqquuuuiiiissssiiiittttiiiioooonnnnssss aaaannnndddd ddddiiiivvvveeeessssttttiiiittttuuuurrrreeeessss bbbbyyyy ccccoooonnnnssssuuuummmmeeeerrrrssss ccccaaaannnn bbbbeeee sssseeeeeeeennnn iiiinnnn tttthhhheeee gggglllloooobbbbaaaallll rrrreeeellllaaaauuuunnnncccchhhh ooooffff aaaassss ccccoooommmmppppaaaarrrreeeedddd ttttoooo aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid wwwweeee iiiimmmmpppprrrroooovvvveeeedddd oooouuuurrrr ccccaaaaddddeeeennnncccceeee ooooffff iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn bbbbyyyy wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo ddddiiiisssscccclllloooossssiiiinnnngggg ooooffff oooouuuurrrr ddddeeeelllliiiivvvveeeerrrriiiinnnngggg mmmmaaaajjjjoooorrrr pppprrrroooodddduuuucccctttt llllaaaauuuunnnncccchhhheeeessss iiiinnnn cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidoooonnnneeee eeeexxxxaaaammmmpppplllleeee iiiissss tttthhhheeee llllaaaauuuunnnncccchhhh ooooffff tttthhhheeee eeeemmmmbbbboooottttrrrraaaapppp nnnnaaaammmmeeee jjjjuuuusssstttt aaaa ffffeeeewwww aaaannnndddd lllliiiittttiiiiggggaaaattttiiiioooonnnn uuuunnnnffffoooorrrrttttuuuunnnnaaaatttteeeellllyyyy iiiissss iiiiiiii rrrreeeevvvvaaaassssccccuuuullllaaaarrrriiiizzzzaaaattttiiiioooonnnn ddddeeeevvvviiiicccceeee aaaa nnnneeeexxxxttttggggeeeennnneeeerrrraaaattttiiiioooonnnn pppprrrreeeevvvvaaaalllleeeennnntttt tttthhhhrrrroooouuuugggghhhhoooouuuutttt tttthhhheeee hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnndddduuuussssttttrrrryyyy sssstttteeeennnntttt rrrreeeettttrrrriiiieeeevvvveeeerrrr uuuusssseeeedddd ttttoooo ccccaaaappppttttuuuurrrreeee aaaannnndddd rrrreeeemmmmoooovvvveeee tttthhhheeeesssseeee kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll ffffaaaaccccttttoooorrrrssss ccccaaaannnn iiiimmmmppppaaaacccctttt aaaannnnyyyy lllliiiiffffeeeetttthhhhrrrreeeeaaaatttteeeennnniiiinnnngggg bbbblllloooooooodddd cccclllloooottttssss ffffrrrroooommmm tttthhhheeee bbbbrrrraaaaiiiinnnn bbbbuuuussssiiiinnnneeeessssssss bbbbrrrraaaannnndddd rrrreeeeppppuuuuttttaaaattttiiiioooonnnn aaaannnndddd bbbbuuuussssiiiinnnneeeessssssss mmmmooooddddeeeellll ffffoooolllllllloooowwwwiiiinnnngggg aaaannnn iiiisssscccchhhheeeemmmmiiiicccc ssssttttrrrrooookkkkeeee wwwweeee rrrreeeecccceeeeiiiivvvveeeedddd ssssoooo iiiinnnn ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr bbbbooooaaaarrrrdddd ooooffff ddddiiiirrrreeeeccccttttoooorrrrssss ffffddddaaaa cccclllleeeeaaaarrrraaaannnncccceeee ttttoooo mmmmaaaarrrrkkkkeeeetttt tttthhhheeee mmmmeeeecccchhhhaaaannnniiiiccccaaaallll ccccllllooootttt eeeexxxxeeeeccccuuuuttttiiiivvvveeee ccccoooommmmmmmmiiiitttttttteeeeeeee aaaannnndddd lllleeeeaaaaddddeeeerrrrsssshhhhiiiipppp tttteeeeaaaammmmssss rrrreeeemmmmoooovvvvaaaallll oooorrrr tttthhhhrrrroooommmmbbbbeeeeccccttttoooommmmyyyy ddddeeeevvvviiiicccceeee llllaaaasssstttt mmmmaaaayyyy aaaaccccrrrroooossssssss tttthhhheeee ccccoooommmmppppaaaannnnyyyy wwwweeee llllooooooookkkk ttttoooo mmmmiiiittttiiiiggggaaaatttteeee tttthhhheeeesssseeee iiiinnnn wwwweeee ppppllllaaaannnn ttttoooo llllaaaauuuunnnncccchhhh ttttoooo mmmmaaaajjjjoooorrrr kkkkiiiinnnnddddssss ooooffff eeeexxxxtttteeeerrrrnnnnaaaallll rrrriiiisssskkkk ffffaaaaccccttttoooorrrrssss wwwwhhhheeeerrrreeeevvvveeeerrrr ppppoooossssssssiiiibbbblllleeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaddddddddiiiittttiiiioooonnnnaaaallllllllyyyy iiii wwwwaaaannnntttt ttttoooo eeeemmmmpppphhhhaaaassssiiiizzzzeeee tttthhhhaaaatttt pppprrrroooodddduuuucccctttt aaaa fifififirrrrssssttttooooffffiiiittttsssskkkkiiiinnnndddd ccccoooonnnnttttaaaacccctttt lllleeeennnnssss tttthhhhaaaatttt wwwwaaaassss nnnnaaaammmmeeeedddd qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeeettttyyyy aaaarrrreeee nnnnooootttt oooonnnnllllyyyy ttttoooopppp bbbbuuuussssiiiinnnneeeessssssss oooonnnneeee ooooffff ttttiiiimmmmeeee mmmmaaaaggggaaaazzzziiiinnnneeeessss bbbbeeeesssstttt iiiinnnnvvvveeeennnnttttiiiioooonnnnssss ooooffff pppprrrriiiioooorrrriiiittttiiiieeeessss ffffoooorrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn tttthhhheeeeyyyy aaaarrrreeee cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaallllssssoooo ccccoooorrrreeee oooobbbblllliiiiggggaaaattttiiiioooonnnnssss eeeemmmmbbbbooooddddiiiieeeedddd iiiinnnn oooouuuurrrr ccccrrrreeeeddddoooo cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid aaaaccccrrrroooossssssss eeeevvvveeeerrrryyyy jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn bbbbuuuussssiiiinnnneeeessssssss wwwweeee ttttoooo rrrreeeedddduuuucccceeee ccccoooommmmpppplllliiiiccccaaaattttiiiioooonnnnssss iiiinnnn ccccoooolllloooorrrreeeeccccttttaaaallll ggggaaaassssttttrrrriiiicccc aaaappppppppllllyyyy aaaa sssscccciiiieeeennnnttttiiiifififificccc eeeevvvviiiiddddeeeennnncccceeeebbbbaaaasssseeeedddd aaaapppppppprrrrooooaaaacccchhhh iiiinnnn aaaannnndddd tttthhhhoooorrrraaaacccciiiicccc ccccaaaannnncccceeeerrrr ssssuuuurrrrggggeeeerrrriiiieeeessss cccclllleeeeaaaarrrrllllyyyy ddddeeeecccciiiissssiiiioooonnnnssss aaaabbbboooouuuutttt tttthhhheeee rrrreeeesssseeeeaaaarrrrcccchhhh mmmmaaaarrrrkkkkeeeettttiiiinnnngggg aaaannnndddd aaaaddddvvvvaaaannnncccciiiinnnngggg oooouuuurrrr ssssttttrrrraaaatttteeeeggggyyyy iiiinnnn ddddiiiiggggiiiittttaaaallll ssssuuuurrrrggggeeeerrrryyyy iiiissss aaaa uuuusssseeee ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss mmmmaaaannnnyyyy ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss aaaannnndddd mmmmaaaajjjjoooorrrr iiiinnnnvvvveeeessssttttmmmmeeeennnntttt ffffoooorrrr oooouuuurrrr ffffuuuuttttuuuurrrreeee oooouuuurrrr ddddiiiiggggiiiittttaaaallll pppprrrroooodddduuuuccccttttssss hhhhaaaavvvveeee bbbbeeeeeeeennnn ttttrrrruuuusssstttteeeedddd bbbbyyyy ccccoooonnnnssssuuuummmmeeeerrrrssss ffffoooorrrr ssssuuuurrrrggggeeeerrrryyyy ppppllllaaaattttffffoooorrrrmmmm iiiissss bbbbeeeeiiiinnnngggg ddddeeeessssiiiiggggnnnneeeedddd ttttoooo ccccoooommmmbbbbiiiinnnneeee ddddeeeeccccaaaaddddeeeessss aaaannnndddd wwwwhhhheeeennnn tttthhhheeee ssssaaaaffffeeeettttyyyy ooooffff oooouuuurrrr pppprrrroooodddduuuuccccttttssss rrrroooobbbboooottttiiiiccccssss aaaaddddvvvvaaaannnncccceeeedddd iiiinnnnssssttttrrrruuuummmmeeeennnnttttaaaattttiiiioooonnnn aaaannnndddd ddddaaaattttaaaa iiiissss cccchhhhaaaalllllllleeeennnnggggeeeedddd wwwweeee wwwwiiiillllllll ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ddddeeeeffffeeeennnndddd tttthhhheeeemmmm aaaannnnaaaallllyyyyttttiiiiccccssss ttttoooo eeeennnnaaaabbbblllleeee bbbbeeeetttttttteeeerrrr ppppaaaattttiiiieeeennnntttt oooouuuuttttccccoooommmmeeeessss bbbbyyyy wwwweeee hhhhaaaavvvveeee aaaa lllleeeeggggaaaaccccyyyy ooooffff wwwwoooorrrrkkkkiiiinnnngggg hhhhaaaarrrrdddd ttttoooo eeeeaaaarrrrnnnn oooouuuurrrr iiiimmmmpppprrrroooovvvviiiinnnngggg aaaacccccccceeeessssssss ttttoooo mmmmiiiinnnniiiimmmmaaaallllllllyyyy iiiinnnnvvvvaaaassssiiiivvvveeee ssssuuuurrrrggggeeeerrrryyyy ccccuuuussssttttoooommmmeeeerrrrssss ttttrrrruuuusssstttt aaaannnndddd wwwwoooorrrrkkkkiiiinnnngggg eeeeqqqquuuuaaaallllllllyyyy hhhhaaaarrrrdddd ttttoooo kkkkeeeeeeeepppp aaaannnndddd hhhheeeellllppppiiiinnnngggg ttttoooo rrrreeeedddduuuucccceeee tttthhhheeee ccccoooosssstttt ooooffff ccccaaaarrrreeee iiiitttttttthhhhiiiissss ccccoooommmmmmmmiiiittttmmmmeeeennnntttt wwwwiiiillllllll aaaallllwwwwaaaayyyyssss rrrreeeemmmmaaaaiiiinnnn iiiinnnnttttaaaacccctttt aaaassss wwwweeee ccccaaaappppiiiittttaaaalllliiiizzzzeeee oooonnnn oooouuuurrrr ccccoooommmmpppprrrreeeehhhheeeennnnssssiiiivvvveeee wwwweeee aaaarrrreeee ccccoooonnnnfifififiddddeeeennnntttt iiiinnnn oooouuuurrrr aaaabbbbiiiilllliiiittttyyyy ttttoooo lllleeeeaaaadddd wwwwiiiitttthhhh ppppoooorrrrttttffffoooolllliiiioooo aaaannnndddd aaaannnn aaaacccccccceeeelllleeeerrrraaaatttteeeedddd ggggrrrroooowwwwtttthhhh ssssttttrrrraaaatttteeeeggggyyyy cccceeeerrrrttttaaaaiiiinnnnttttyyyy aaaannnndddd ttttoooo rrrreeeessssppppoooonnnnssssiiiibbbbllllyyyy nnnnaaaavvvviiiiggggaaaatttteeee oooouuuurrrr wwwwaaaayyyy wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo iiiimmmmpppprrrroooovvvviiiinnnngggg ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee tttthhhhrrrroooouuuugggghhhh tttthhhheeeesssseeee ppppooootttteeeennnnttttiiiiaaaallll cccchhhhaaaalllllllleeeennnnggggeeeessss aaaannnndddd bbbbeeeeccccaaaauuuusssseeee aaaaccccrrrroooossssssss oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss wwwweeee aaaarrrreeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo tttthhhhrrrriiiivvvviiiinnnngggg iiiinnnn tttthhhhiiiissss cccchhhhaaaannnnggggeeee eeeennnnvvvviiiirrrroooonnnnmmmmeeeennnntttt oooouuuurrrr ggggooooaaaallll iiiissss nnnnooootttt mmmmeeeerrrreeeellllyyyy ttttoooo aaaaddddaaaapppptttt wwwwhhhhiiiilllleeee wwwweeee aaaarrrreeee pppplllleeeeaaaasssseeeedddd wwwwiiiitttthhhh oooouuuurrrr ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ttttoooo cccchhhhaaaannnnggggeeee bbbbuuuutttt ttttoooo bbbbeeee tttthhhheeee ccccaaaattttaaaallllyyyysssstttt ffffoooorrrr nnnneeeeeeeeddddeeeedddd wwwweeee aaaarrrreeee nnnneeeevvvveeeerrrr ssssaaaattttiiiissssfifififieeeedddd llllooooooookkkkiiiinnnngggg aaaahhhheeeeaaaadddd wwwweeee aaaarrrreeee cccchhhhaaaannnnggggeeee wwwweeee aaaallllssssoooo lllleeeeaaaadddd wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy bbbbeeeeccccaaaauuuusssseeee ccccoooommmmmmmmiiiitttttttteeeedddd ttttoooo aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn ppppiiiippppeeeelllliiiinnnneeee wwwweeee aaaarrrreeee iiiinnnn tttthhhheeee bbbbuuuussssiiiinnnneeeessssssss ooooffff ccccaaaarrrriiiinnnngggg ffffoooorrrr tttthhhheeee wwwwoooorrrrlllldddd aaaallllllll iiiinnnn oooouuuurrrr pppphhhhaaaarrrrmmmmaaaacccceeeeuuuuttttiiiiccccaaaallll bbbbuuuussssiiiinnnneeeessssssss bbbbrrrrooooaaaaddddeeeennnniiiinnnngggg tttthhhheeee ddddaaaayyyy eeeevvvveeeerrrryyyy ddddaaaayyyy gggguuuuiiiiddddeeeedddd bbbbyyyy oooouuuurrrr ccccrrrreeeeddddoooo wwwweeee hhhhaaaavvvveeee rrrreeeeaaaacccchhhh ooooffff oooouuuurrrr ccccoooonnnnssssuuuummmmeeeerrrr bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd mmmmeeeeeeeettttiiiinnnngggg tttthhhheeee aaaa ssssoooolllliiiidddd fifififinnnnaaaannnncccciiiiaaaallll ffffoooouuuunnnnddddaaaattttiiiioooonnnn aaaa ssssttttrrrroooonnnngggg ssssttttrrrraaaatttteeeeggggiiiicccc ffffuuuullllllll ppppooootttteeeennnnttttiiiiaaaallll ooooffff oooouuuurrrr mmmmeeeeddddiiiiccccaaaallll ddddeeeevvvviiiicccceeeessss bbbbuuuussssiiiinnnneeeessssssss ffffrrrraaaammmmeeeewwwwoooorrrrkkkk aaaannnn iiiinnnnnnnnoooovvvvaaaattttiiiioooonnnn mmmmiiiinnnnddddsssseeeetttt aaaa ppppeeeerrrrffffoooorrrrmmmmaaaannnncccceeee ddddrrrriiiivvvveeeennnn ccccuuuullllttttuuuurrrreeee aaaannnndddd aaaa vvvveeeerrrryyyy bbbbrrrriiiigggghhhhtttt ffffuuuuttttuuuurrrreeee ffffooooccccuuuusssseeeedddd oooonnnn aaaaddddvvvvaaaannnncccciiiinnnngggg tttthhhheeee hhhheeeeaaaalllltttthhhh aaaannnndddd wwwweeeellllllllbbbbeeeeiiiinnnngggg ooooffff aaaallllllll oooouuuurrrr want emphasize product quality ssssttttaaaakkkkeeeehhhhoooollllddddeeeerrrrssssttttooooddddaaaayyyy aaaannnndddd ffffoooorrrr ggggeeeennnneeeerrrraaaattttiiiioooonnnnssss ttttoooo ccccoooommmmeeee safety top business priorities oooouuuurrrr ppppeeeeoooopppplllleeee ppppaaaassssssssiiiioooonnnn aaaannnndddd ppppuuuurrrrppppoooosssseeee johnson johnson also core iiiivvvveeee oooofffftttteeeennnn nnnnooootttteeeedddd hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss aaaannnn iiiinnnndddduuuussssttttrrrryyyy tttthhhhaaaatttt obligations embodied credo aaaattttttttrrrraaaaccccttttssss vvvveeeerrrryyyy ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee wwwwhhhhiiiilllleeee tttthhhheeeeyyyy wwwwaaaannnntttt tttthhhheeee ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy ttttoooo bbbbuuuuiiiilllldddd aaaa mmmmeeeeaaaannnniiiinnnnggggffffuuuullll ccccaaaarrrreeeeeeeerrrr lllleeeeaaaaddddiiiinnnngggg wwwwiiiitttthhhh cccceeeerrrrttttaaaaiiiinnnnttttyyyy tttthhhheeeeyyyy aaaallllssssoooo wwwwaaaannnntttt ttttoooo bbbbeeee aaaa ppppaaaarrrrtttt ooooffff ssssoooommmmeeeetttthhhhiiiinnnngggg ttttrrrruuuullllyyyy tttthhhheeee vvvvoooolllluuuummmmeeee aaaannnndddd ssssppppeeeeeeeedddd ooooffff cccchhhhaaaannnnggggeeee aaaarrrroooouuuunnnndddd tttthhhheeee ssssiiiiggggnnnniiiifififificcccaaaannnntttt tttthhhhaaaatttt mmmmaaaakkkkeeeessss aaaannnn iiiimmmmppppoooorrrrttttaaaannnntttt ddddiiiiffffffffeeeerrrreeeennnncccceeee iiiinnnn wwwwoooorrrrlllldddd aaaannnndddd aaaaccccrrrroooossssssss aaaallllllll bbbbuuuussssiiiinnnneeeessssssss iiiinnnndddduuuussssttttrrrriiiieeeessss iiiissss ppppeeeeoooopppplllleeeessss lllliiiivvvveeeessss ffffoooorrrrttttuuuunnnnaaaatttteeeellllyyyy wwwweeee hhhhaaaavvvveeee tttthhhheeee vvvveeeerrrryyyy bbbbeeeesssstttt tttthhhheeee nnnneeeewwww nnnnoooorrrrmmmmaaaallll tttthhhheeee vvvveeeelllloooocccciiiittttyyyy ooooffff tttthhhhiiiissss cccchhhhaaaannnnggggeeee ooooffff tttthhhheeeesssseeee ssssppppeeeecccciiiiaaaallll ppppeeeeoooopppplllleeee aaaatttt tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiiissss aaaappppppppaaaarrrreeeennnntttt wwwwiiiitttthhhh cccciiiirrrrccccuuuummmmssssttttaaaannnncccceeeessss lllliiiikkkkeeee tttthhhheeee ffffaaaammmmiiiillllyyyy ooooffff ccccoooommmmppppaaaannnniiiieeeessss aaaannnndddd iiii bbbbeeeelllliiiieeeevvvveeee oooouuuurrrr ccccuuuullllttttuuuurrrreeee eeeevvvvoooollllvvvviiiinnnngggg ggggeeeeooooppppoooolllliiiittttiiiiccccaaaallll llllaaaannnnddddssssccccaaaappppeeee oooonnnnggggooooiiiinnnngggg ooooffff ddddiiiivvvveeeerrrrssssiiiittttyyyy aaaannnndddd iiiinnnncccclllluuuussssiiiioooonnnn bbbbrrrriiiinnnnggggssss oooouuuutttt tttthhhheeee bbbbeeeesssstttt tttthhhhaaaatttt mmmmaaaarrrrkkkkeeeetttt vvvvoooollllaaaattttiiiilllliiiittttyyyy rrrriiiissssiiiinnnngggg pppprrrreeeessssssssuuuurrrreeee ttttoooo rrrreeeedddduuuucccceeee oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss hhhhaaaavvvveeee ttttoooo ooooffffffffeeeerrrr pppprrrriiiicccciiiinnnngggg rrrraaaappppiiiidddd eeeennnnttttrrrryyyy ooooffff ddddiiiissssrrrruuuuppppttttiiiivvvveeee tttteeeecccchhhhnnnnoooollllooooggggiiiieeeessss aaaa ccccrrrroooowwwwddddeeeedddd ccccoooommmmppppeeeettttiiiittttiiiivvvveeee mmmmaaaarrrrkkkkeeeettttppppllllaaaacccceeee aaaannnndddd aaaannnn ttttooooddddaaaayyyy wwwweeee hhhhaaaavvvveeee aaaapppppppprrrrooooxxxxiiiimmmmaaaatttteeeellllyyyy gggglllloooobbbbaaaallll eeeexxxxppppaaaannnnddddiiiinnnngggg rrrraaaannnnggggeeee ooooffff ccccuuuussssttttoooommmmeeeerrrr pppprrrreeeeffffeeeerrrreeeennnncccceeeessss ttttoooo eeeemmmmppppllllooooyyyyeeeeeeeessss uuuunnnniiiitttteeeedddd bbbbyyyy aaaa sssshhhhaaaarrrreeeedddd ccccoooommmmmmmmiiiittttmmmmeeeennnntttt cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidaaaannnndddd aaaa ccccoooommmmmmmmoooonnnn ppppuuuurrrrppppoooosssseeee tttthhhhaaaatttt aaaassssppppiiiirrrreeeessss ttttoooo ccccrrrreeeeaaaatttteeee gggguuuuiiiiddddiiiinnnngggg ssssuuuuppppppppoooorrrrtttt ooooffff oooouuuurrrr hhhhiiiigggghhhhllllyyyy aaaaccccccccoooommmmpppplllliiiisssshhhheeeedddd aaaa wwwwoooorrrrlllldddd wwwwiiiitttthhhhoooouuuutttt ddddiiiisssseeeeaaaasssseeee aaaannnndddd wwwwiiiitttthhhh ggggrrrreeeeaaaatttteeeerrrr bbbbooooaaaarrrrdddd ooooffff ddddiiiirrrreeeeccccttttoooorrrrssss aaaannnndddd ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo bbbbeeee pppprrrroooouuuudddd aaaannnndddd aaaacccccccceeeessssssss ttttoooo qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeeelllliiiiffffeeeessssaaaavvvviiiinnnngggg hhhhuuuummmmbbbblllleeeedddd aaaassss iiii wwwwoooorrrrkkkk ssssiiiiddddeeee bbbbyyyy ssssiiiiddddeeee wwwwiiiitttthhhh tttthhhhiiiissss tttteeeeaaaammmm ooooffff mmmmeeeeddddiiiicccciiiinnnneeeessss lllliiiiffffeeeecccchhhhaaaannnnggggiiiinnnngggg mmmmeeeeddddiiiiccccaaaallll ssssoooolllluuuuttttiiiioooonnnnssss aaaannnndddd iiiimmmmpppprrrreeeessssssssiiiivvvveeee eeeexxxxeeeeccccuuuuttttiiiivvvveeee lllleeeeaaaaddddeeeerrrrssss wwwwhhhhoooosssseeee ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp lllliiiiffffeeeeeeeennnnhhhhaaaannnncccciiiinnnngggg ccccoooonnnnssssuuuummmmeeeerrrr pppprrrroooodddduuuuccccttttssss aaaallllllll ooooffff uuuussss aaaannnndddd eeeexxxxppppeeeerrrrttttiiiisssseeee mmmmoooottttiiiivvvvaaaatttteeee mmmmeeee aaaannnndddd aaaallllllll oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn mmmmaaaaiiiinnnnttttaaaaiiiinnnn aaaa ppppeeeerrrrssssiiiisssstttteeeennnntttt ffffooooccccuuuussss oooonnnn ddddeeeevvvveeeellllooooppppiiiinnnngggg aaaannnndddd jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss eeeevvvveeeerrrryyyy ddddaaaayyyy iiiinnnn oooouuuurrrr sssshhhhaaaarrrreeeedddd ddddeeeelllliiiivvvveeeerrrriiiinnnngggg qqqquuuuaaaalllliiiittttyyyy aaaannnndddd ssssaaaaffffeeee pppprrrroooodddduuuuccccttttssss aaaannnndddd sssseeeerrrrvvvviiiicccceeeessss ccccoooommmmmmmmiiiittttmmmmeeeennnntttt ttttoooo aaaaddddvvvvaaaannnncccceeee hhhheeeeaaaalllltttthhhh ffffoooorrrr hhhhuuuummmmaaaannnniiiittttyyyy ddddeeeelllliiiivvvveeeerrrriiiinnnngggg oooonnnn tttthhhheeee pppprrrroooommmmiiiisssseeeessss ooooffff oooouuuurrrr bbbbrrrraaaannnnddddssss iiiissss bbbbooootttthhhh aaaa ppppeeeerrrrssssoooonnnnaaaallll aaaannnndddd pppprrrrooooffffeeeessssssssiiiioooonnnnaaaallll ccccoooommmmmmmmiiiittttmmmmeeeennnntttt approximately global tttthhhhiiiissss iiiissss ddddeeeemmmmoooonnnnssssttttrrrraaaatttteeeedddd iiiinnnn tttthhhheeee ttttiiiirrrreeeelllleeeessssssss eeeeffffffffoooorrrrttttssss employees united shared commitment aaaannnndddd rrrreeeelllleeeennnnttttlllleeeessssssss ppppaaaassssssssiiiioooonnnn tttthhhhaaaatttt ddddrrrriiiivvvveeee oooouuuurrrr aaaammmmbbbbiiiittttiiiioooonnnn common purpose aspires ttttoooo rrrreeeeaaaacccchhhh tttthhhheeee nnnneeeexxxxtttt ffffrrrroooonnnnttttiiiieeeerrrr ooooffff ccccaaaannnncccceeeerrrr ccccaaaarrrreeee ccccoooonnnnttttiiiinnnnuuuueeee ttttoooo ccccoooommmmbbbbaaaatttt eeeebbbboooollllaaaa aaaannnndddd hhhhiiiivvvv bbbbrrrriiiinnnngggg hhhheeeeaaaalllltttthhhhyyyy create world without disease vvvviiiissssiiiioooonnnn ttttoooo ppppeeeeoooopppplllleeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee ccccrrrreeeeaaaatttteeee aaaa wwwwoooorrrrlllldddd greater access quality healthcare ffffrrrreeeeeeee ffffrrrroooommmm ttttuuuubbbbeeeerrrrccccuuuulllloooossssiiiissss rrrreeeedddduuuucccceeee oooouuuurrrr ccccaaaarrrrbbbboooonnnn ffffoooooooottttpppprrrriiiinnnntttt iiiimmmmpppprrrroooovvvveeee oooouuuurrrr pppprrrroooodddduuuucccctttt ssssuuuussssttttaaaaiiiinnnnaaaabbbbiiiilllliiiittttyyyy mmmmyyyy ooooppppttttiiiimmmmiiiissssmmmm ffffoooorrrr tttthhhheeee ffffuuuuttttuuuurrrreeee iiiissss iiiinnnnssssppppiiiirrrreeeedddd bbbbyyyy tttthhhheeee aaaannnndddd rrrreeeeiiiimmmmaaaaggggiiiinnnneeee tttthhhheeee wwwwaaaayyyy tttthhhhaaaatttt ccccaaaarrrreeee iiiissss ddddeeeelllliiiivvvveeeerrrreeeedddd rrrraaaappppiiiidddd aaaannnndddd ccccoooonnnnttttiiiinnnnuuuuoooouuuussss iiiimmmmpppprrrroooovvvveeeemmmmeeeennnnttttssss iiiinnnn tttthhhheeee wwwwhhhhiiiilllleeee aaaallllssssoooo eeeexxxxppppaaaannnnddddiiiinnnngggg aaaacccccccceeeessssssss ffffoooorrrr tttthhhheeee wwwwoooorrrrllllddddssss mmmmoooosssstttt ccccoooonnnnddddiiiittttiiiioooonnnn ooooffff hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaannnndddd tttthhhheeee iiiinnnnccccrrrreeeeaaaassssiiiinnnngggg vvvvuuuullllnnnneeeerrrraaaabbbblllleeee ppppooooppppuuuullllaaaattttiiiioooonnnnssss jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ffffoooorrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiinnnn tttthhhheeee wwwwoooorrrrlllldddd mmmmoooosssstttt mmmmaaaaddddeeee ffffoooorrrrttttuuuunnnneeeessss cccchhhhaaaannnnggggeeee tttthhhheeee wwwwoooorrrrlllldddd lllliiiisssstttt aaaaggggaaaaiiiinnnn iiiimmmmppppoooorrrrttttaaaannnnttttllllyyyy wwwweeee hhhhaaaavvvveeee tttthhhheeee aaaammmmaaaazzzziiiinnnngggg pppprrrriiiivvvviiiilllleeeeggggeeee iiiinnnn iiiinnnn rrrreeeeccccooooggggnnnniiiittttiiiioooonnnn ooooffff oooouuuurrrr eeeeffffffffoooorrrrttttssss ttttoooo hhhheeeellllpppp ttttrrrraaaaiiiinnnn ooooffff ttttoooouuuucccchhhhiiiinnnngggg lllliiiivvvveeeessss aaaarrrroooouuuunnnndddd tttthhhheeee wwwwoooorrrrlllldddd eeeevvvveeeerrrryyyy ssssuuuurrrrggggeeeeoooonnnnssss ppppaaaarrrraaaammmmeeeeddddiiiiccccssss aaaannnndddd ooootttthhhheeeerrrr hhhheeeeaaaalllltttthhhhccccaaaarrrreeee ddddaaaayyyyffffrrrroooommmm bbbbaaaabbbbiiiieeeessss ttttaaaakkkkiiiinnnngggg tttthhhheeeeiiiirrrr fifififirrrrsssstttt bbbbrrrreeeeaaaatttthhhh ttttoooo pppprrrroooovvvviiiiddddeeeerrrrssss gggglllloooobbbbaaaallllllllyyyy tttthhhhrrrroooouuuugggghhhh oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn bbbbaaaabbbbyyyy bbbboooooooommmmeeeerrrrssss ttttaaaakkkkiiiinnnngggg aaaa bbbbrrrreeeeaaaatttthhhh aaaafffftttteeeerrrr ddddooooiiiinnnngggg tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn iiiinnnnssssttttiiiittttuuuutttteeee aaaannnndddd ooootttthhhheeeerrrr ccccaaaarrrreeee pppprrrrooooggggrrrraaaammmmssss jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ooooffiffiffifficccciiiiaaaallll mmmmiiiinnnnuuuutttteeee wwwwoooorrrrkkkkoooouuuutttt oooouuuurrrr ggggooooaaaallll iiiissss ttttoooo lllleeeeaaaadddd bbbbyyyy eeeexxxxaaaammmmpppplllleeee bbbbyyyy ccccuuuullllttttiiiivvvvaaaattttiiiinnnngggg wwwweeee aaaallllssssoooo hhhhaaaavvvveeee tttthhhheeee pppplllleeeeaaaassssuuuurrrreeee ooooffff sssseeeerrrrvvvviiiinnnngggg ppppaaaattttiiiieeeennnnttttssss tttthhhheeee wwwwoooorrrrllllddddssss hhhheeeeaaaalllltttthhhhiiiieeeesssstttt mmmmoooosssstttt pppprrrroooodddduuuuccccttttiiiivvvveeee aaaannnndddd mmmmoooosssstttt aaaannnndddd ccccoooonnnnssssuuuummmmeeeerrrrssss eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee oooonnnn eeeeaaaarrrrtttthhhhppppeeeeoooopppplllleeee eeeennnnggggaaaaggggeeeedddd wwwwoooorrrrkkkkffffoooorrrrcccceeee iiii bbbbeeeelllliiiieeeevvvveeee tttthhhhiiiissss iiiissss ccccrrrriiiittttiiiiccccaaaallll ffffoooorrrr wwwwhhhhoooo ppppuuuutttt tttthhhheeeeiiiirrrr ttttrrrruuuusssstttt iiiinnnn oooouuuurrrr jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn ooooppppeeeerrrraaaattttiiiinnnngggg aaaa hhhheeeeaaaalllltttthhhhyyyy aaaannnndddd ssssuuuucccccccceeeessssssssffffuuuullll bbbbuuuussssiiiinnnneeeessssssss aaaannnndddd bbbbrrrraaaannnnddddssss wwwweeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttyyyy tttthhhhaaaatttt tttthhhhiiiissss iiiissss hhhhoooowwww wwwweeee wwwwiiiillllllll ddddeeeelllliiiivvvveeeerrrr aaaannnndddd eeeennnnssssuuuurrrreeee tttthhhhaaaatttt aaaannnnooootttthhhheeeerrrr ccccoooommmmeeeessss wwwwiiiitttthhhh tttthhhhiiiissss ttttrrrruuuusssstttt aaaannnndddd wwwweeee nnnneeeevvvveeeerrrr ffffoooorrrrggggeeeetttt oooouuuurrrr yyyyeeeeaaaarrrrssss ooooffff qqqquuuuaaaalllliiiittttyyyy hhhheeeeaaaalllltttthhhhccccaaaarrrreeee iiiissss wwwwiiiitttthhhhiiiinnnn rrrreeeeaaaacccchhhh ooooffff eeeesssssssseeeennnnttttiiiiaaaallll ppppaaaarrrrttttnnnneeeerrrrsssshhhhiiiipppp wwwwiiiitttthhhh oooouuuurrrr sssshhhhaaaarrrreeeehhhhoooollllddddeeeerrrrssss eeeevvvveeeerrrryyyyoooonnnneeee eeeevvvveeeerrrryyyywwwwhhhheeeerrrreeee wwwwhhhhoooo ssssuuuuppppppppoooorrrrtttt oooouuuurrrr mmmmiiiissssssssiiiioooonnnn aaaannnndddd hhhheeeellllpppp uuuussss ppppuuuurrrrssssuuuueeee aaaa nnnnoooobbbblllleeee ppppuuuurrrrppppoooosssseeee wwwwhhhhiiiilllleeee tttthhhheeee cccchhhhaaaalllllllleeeennnnggggeeeessss aaaarrrreeee aaaannnn eeeedddduuuuccccaaaattttiiiioooonnnn iiiinnnnhhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh ggggrrrreeeeaaaatttt tttthhhheeee rrrreeeewwwwaaaarrrrddddssss aaaarrrreeee eeeevvvveeeennnn ggggrrrreeeeaaaatttteeeerrrr iiii ccccaaaannnntttt iiii aaaammmm aaaassss eeeexxxxcccciiiitttteeeedddd aaaannnndddd eeeennnnccccoooouuuurrrraaaaggggeeeedddd ttttooooddddaaaayyyy aaaassss iiii wwwwaaaassss iiiimmmmaaaaggggiiiinnnneeee aaaa bbbbeeeetttttttteeeerrrr oooorrrr mmmmoooorrrreeee ffffuuuullllfifififilllllllliiiinnnngggg ccccaaaalllllllliiiinnnngggg oooonnnn tttthhhheeee ddddaaaayyyy iiii ssssttttaaaarrrrtttteeeedddd aaaassss cccceeeeoooo ooooffff tttthhhhiiiissss ccccoooommmmppppaaaannnnyyyy aaaannnndddd aaaacccccccceeeepppptttteeeedddd tttthhhheeee rrrreeeessssppppoooonnnnssssiiiibbbbiiiilllliiiittttiiiieeeessss tttthhhhaaaatttt ccccoooommmmeeee wwwwiiiitttthhhh iiiitttt iiii ooooffffffffeeeerrrr mmmmyyyy ssssiiiinnnncccceeeerrrreeee tttthhhhaaaannnnkkkkssss ttttoooo aaaallllllll ooooffff yyyyoooouuuu ffffoooorrrr tttthhhhiiiissss ggggrrrreeeeaaaatttt pppprrrriiiivvvviiiilllleeeeggggeeee ooooppppppppoooorrrrttttuuuunnnniiiittttyyyy aaaannnndddd eeeexxxxppppeeeerrrriiiieeeennnncccceeee tttthhhhrrrroooouuuugggghhhhoooouuuutttt mmmmyyyy ccccaaaarrrreeeeeeeerrrr aaaatttt jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn iiii hhhhaaaavvvveeee bbbbeeeeeeeennnn vvvveeeerrrryyyy ffffoooorrrrttttuuuunnnnaaaatttteeee ttttoooo lllleeeeaaaarrrrnnnn tttthhhhiiiissss bbbbuuuussssiiiinnnneeeessssssss cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid ffffrrrroooommmm tttthhhheeee ppppeeeerrrrssssppppeeeeccccttttiiiivvvveeee ooooffff aaaa ccccoooommmmppppaaaannnnyyyy tttthhhhaaaatttt iiiissss bbbbuuuuiiiilllltttt oooonnnn tttthhhheeee bbbbeeeelllliiiieeeeffff iiiinnnn tttthhhheeee ttttrrrraaaannnnssssffffoooorrrrmmmmaaaattttiiiivvvveeee ppppoooossssssssiiiibbbbiiiilllliiiittttiiiieeeessss ooooffff hhhhuuuummmmaaaannnn iiiinnnnggggeeeennnnuuuuiiiittttyyyy aaaannnndddd ppppeeeerrrrssssoooonnnnaaaallll ccccaaaarrrriiiinnnngggg tttthhhheeee wwwwoooorrrrlllldddd hhhhaaaassss bbbbeeeeeeeennnn tttthhhheeee ccccaaaammmmppppuuuussss ffffoooorrrr mmmmyyyy eeeedddduuuuccccaaaattttiiiioooonnnn iiiinnnn aaaalllleeeexxxx ggggoooorrrrsssskkkkyyyy hhhhuuuummmmaaaannnn hhhheeeeaaaalllltttthhhh aaaassss iiiitttt hhhhaaaassss bbbbeeeeeeeennnn ffffoooorrrr mmmmyyyy jjjjoooohhhhnnnnssssoooonnnn cccchhhhaaaaiiiirrrrmmmmaaaannnn aaaannnndddd cccchhhhiiiieeeeffff eeeexxxxeeeeccccuuuuttttiiiivvvveeee ooooffiffiffifficccceeeerrrr jjjjoooohhhhnnnnssssoooonnnn ccccoooolllllllleeeeaaaagggguuuueeeessss iiii ddddeeeeeeeeppppllllyyyy aaaapppppppprrrreeeecccciiiiaaaatttteeee tttthhhheeee jjjjoooohhhhnnnnssssoooonnnn jjjjoooohhhhnnnnssssoooonnnn nongaap measures free cash flow defined operating cash flow less capital spending adjusted operational earnings growth excludes special items intangible cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid tions free cash flow operational sales growth excluding acquisitions divestitures medical devices segment annual report cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid letter contains forwardlooking statements relating among things future operating financial performance product development market position business strategy reader cautioned rely statements based current expectations future events important information statements including risks uncertainties factors could cause actual results vary materially assumptions expectations projections expressed forwardlooking statements readers review enclosed annual report fiscal year ended december cidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcidcid update forwardlooking statement result new information future events developmentsunited states securities exchange commission washington dc annual report pursuant section securities exchange act forthefiscalyearendeddecember commissionfilenumber johnson johnson exactnameofregistrantasspecifiedinitscharter newjersey stateofincorporation irsemployeridentificationno onejohnsonjohnsonplaza newbrunswicknewjersey addressofprincipalexecutiveoffices zipcode registrantstelephonenumberincludingareacode securitiesregisteredpursuanttosectionboftheact titleofeachclass nameofeachexchangeonwhichregistered commonstockparvalue newyorkstockexchange notesduenovember newyorkstockexchange notesduejanuary newyorkstockexchange notesduemay newyorkstockexchange notesduenovember newyorkstockexchange notesduenovember newyorkstockexchange notesduemay newyorkstockexchange indicatebycheckmarkiftheregistrantisawellknownseasonedissuerasdefinedinruleofthesecurities act yes indicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttosectionorsectiondoftheexchange act yes indicatebycheckmarkwhethertheregistranthasfiledallreportsrequiredtobefiledbysectionordofthe exchangeactduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwasrequiredtofilesuch reportsandhasbeensubjecttosuchfilingrequirementsforthepastdays yes indicatebycheckmarkwhethertheregistranthassubmittedelectronicallyeveryinteractivedatafilerequiredtobesubmitted pursuanttoruleofregulationstduringtheprecedingmonthsorforsuchshorterperiodthattheregistrantwas requiredtosubmitsuchfiles yes indicatebycheckmarkifdisclosureofdelinquentfilerspursuanttoitemofregulationskisnotcontainedhereinand willnotbecontainedtothebestofregistrantsknowledgeindefinitiveproxyorinformationstatementsincorporatedby referenceinpartiiiofthisformkoranyamendmenttothisformk indicatebycheckmarkwhethertheregistrantisalargeacceleratedfileranacceleratedfileranonacceleratedfilerasmaller reportingcompanyoremerginggrowthcompanyseethedefinitionsoflargeacceleratedfileracceleratedfilersmaller reportingcompanyandemerginggrowthcompanyinruleboftheexchangeact largeacceleratedfiler acceleratedfiler nonacceleratedfiler smallerreportingcompany emerginggrowthcompany ifanemerginggrowthcompanyindicatebycheckmarkiftheregistranthaselectednottousetheextendedtransitionperiod forcomplyingwithanyneworrevisedfinancialaccountingstandardsprovidedpursuanttosectionaoftheexchange act indicatebycheckmarkwhethertheregistrantisashellcompanyasdefinedinruleboftheexchange act yes theaggregatemarketvalueofthecommonstockheldbynonaffiliatescomputedbyreferencetothepriceatwhichthe commonstockwaslastsoldasofthelastbusinessdayoftheregistrantsmostrecentlycompletedsecondfiscalquarter wasapproximatelybillion onfebruarythereweresharesofcommonstockoutstanding documentsincorporatedbyreference partsiandiii portionsofregistrantsproxystatementforitsannualmeetingofshareholdersfiledwithin daysafterthecloseoftheregistrantsfiscalyeartheproxystatementareincorporatedby referencetothisreportonformkthisreportitem parti business general segmentsofbusiness geographicareas rawmaterials patents trademarks seasonality competition environment regulation availableinformation riskfactors b unresolvedstaffcomments properties legalproceedings minesafetydisclosures executiveofficersoftheregistrant partii marketforregistrantscommonequityrelatedstockholdermattersandissuerpurchasesof equitysecurities selectedfinancialdata managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition quantitativeandqualitativedisclosuresaboutmarketrisk financialstatementsandsupplementarydata changesinanddisagreementswithaccountantsonaccountingandfinancialdisclosure controlsandprocedures b otherinformation partiii directorsexecutiveofficersandcorporategovernance executivecompensation securityownershipofcertainbeneficialownersandmanagementandrelatedstockholder matters certainrelationshipsandrelatedtransactionsanddirectorindependence principalaccountantfeesandservices partiv exhibitsandfinancialstatementschedules formksummary signatures exhibitindex cautionary note regarding forwardlooking statements thisannualreportonformkandjohnsonjohnsonsotherpubliclyavailabledocumentscontainforwardlooking statementswithinthemeaningofthesafeharborprovisionsoftheusprivatesecuritieslitigationreformactof managementandrepresentativesofjohnsonjohnsonanditssubsidiariesthecompanyalsomayfromtimeto timemakeforwardlookingstatementsforwardlookingstatementsdonotrelatestrictlytohistoricalorcurrentfactsand reflectmanagementsassumptionsviewsplansobjectivesandprojectionsaboutthefutureforwardlookingstatements maybeidentifiedbytheuseofwordssuchasplansexpectswillanticipatesestimatesandotherwordsof similarmeaninginconjunctionwithamongotherthingsdiscussionsoffutureoperationsexpectedoperatingresultsand financialperformanceimpactofplannedacquisitionsanddispositionsthecompanysstrategyforgrowthproduct developmentregulatoryapprovalsmarketpositionandexpenditures becauseforwardlookingstatementsarebasedoncurrentbeliefsexpectationsandassumptionsregardingfutureevents theyaresubjecttouncertaintiesrisksandchangesthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinvestorsshouldrealizethatifunderlyingassumptionsproveinaccurateorknownorunknownrisksor uncertaintiesmaterializethecompanysactualresultsandfinancialconditioncouldvarymateriallyfromexpectationsand projectionsexpressedorimpliedinitsforwardlookingstatementsinvestorsarethereforecautionednottorelyonthese forwardlookingstatementsrisksanduncertaintiesincludebutarenotlimitedto risksrelatedtoproductdevelopmentmarketsuccessandcompetition challengesanduncertaintiesinherentininnovationanddevelopmentofnewandimprovedproductsandtechnologies onwhichthecompanyscontinuedgrowthandsuccessdependincludinguncertaintyofclinicaloutcomesadditional analysisofexistingclinicaldataobtainingregulatoryapprovalshealthplancoverageandcustomeraccessandinitial andcontinuedcommercialsuccess challengestothecompanysabilitytoobtainandprotectadequatepatentandotherintellectualpropertyrightsfornew andexistingproductsandtechnologiesintheunitedstatesandotherimportantmarkets theimpactofpatentexpirationstypicallyfollowedbytheintroductionofcompetingbiosimilarsandgenericsand resultingrevenueandmarketsharelosses increasinglyaggressiveandfrequentchallengestothecompanyspatentsbycompetitorsandothersseekingtolaunch competinggenericbiosimilarorotherproductsandincreasedreceptivityofcourtstheunitedstatespatentand trademarkofficeandotherdecisionmakerstosuchchallengespotentiallyresultinginlossofmarketexclusivityand rapiddeclineinsalesfortherelevantproductsoonerthanexpected competitioninresearchanddevelopmentofnewandimprovedproductsprocessesandtechnologieswhichcanresult inproductandprocessobsolescence competitiontoreachagreementwiththirdpartiesforcollaborationlicensingdevelopmentandmarketingagreements forproductsandtechnologies competitionbasedoncosteffectivenessproductperformancetechnologicaladvancesandpatentsattainedby competitorsand allegationsthatthecompanysproductsinfringethepatentsandotherintellectualpropertyrightsofthirdpartieswhich couldadverselyaffectthecompanysabilitytoselltheproductsinquestionandrequirethepaymentofmoneydamages andfutureroyalties risksrelatedtoproductliabilitylitigationandregulatoryactivity productefficacyorsafetyconcernswhetherornotbasedonscientificevidencepotentiallyresultinginproduct withdrawalsrecallsregulatoryactiononthepartoftheunitedstatesfoodanddrugadministrationorinternational counterpartsdecliningsalesreputationaldamageincreasedlitigationexpenseandsharepriceimpact impactincludingdecliningsalesandreputationaldamageofsignificantlitigationorgovernmentactionadversetothe companyincludingproductliabilityclaimsandallegationsrelatedtopharmaceuticalmarketingpracticesand contractingstrategies impactofanadversejudgmentorsettlementandtheadequacyofreservesrelatedtolegalproceedingsincluding patentlitigationproductliabilitypersonalinjuryclaimssecuritiesclassactionsgovernmentinvestigationsemployment andotherlegalproceedings increasedscrutinyofthehealthcareindustrybygovernmentagenciesandstateattorneysgeneralresultingin investigationsandprosecutionswhichcarrytheriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimited todebarmentfromgovernmentbusiness johnsonjohnsonannualreport failuretomeetcomplianceobligationsinthemcneilppcincconsentdecreeoranyothercomplianceagreements withgovernmentsorgovernmentagencieswhichcouldresultinsignificantsanctions potentialchangestoapplicablelawsandregulationsaffectingunitedstatesandinternationaloperationsincluding relatingtoapprovalofnewproductslicensingandpatentrightssalesandpromotionofhealthcareproductsaccess toandreimbursementandpricingforhealthcareproductsandservicesenvironmentalprotectionandsourcingofraw materials compliancewithlocalregulationsandlawsthatmayrestrictthecompanysabilitytomanufactureorsellitsproductsin relevantmarketsincludingrequirementstocomplywithmedicaldevicereportingregulationsandotherrequirements suchastheeuropeanunionsmedicaldevicesregulation changesindomesticandinternationaltaxlawsandregulationsincludingchangesrelatedtothetaxcutsandjobs actintheunitedstatesthefederalactontaxreformandahvfinancinginswitzerlandincreasingauditscrutinyby taxauthoritiesaroundtheworldandexposurestoadditionaltaxliabilitiespotentiallyinexcessofexistingreservesand issuanceofneworrevisedaccountingstandardsbythefinancialaccountingstandardsboardandregulationsbythe securitiesandexchangecommission risksrelatedtothecompanysstrategicinitiativesandhealthcaremarkettrends pricingpressuresresultingfromtrendstowardhealthcarecostcontainmentincludingthecontinuedconsolidation amonghealthcareprovidersandothermarketparticipantstrendstowardmanagedcaretheshifttowardgovernments increasinglybecomingtheprimarypayersofhealthcareexpensessignificantnewentrantstothehealthcaremarkets seekingtoreducecostsandgovernmentpressureoncompaniestovoluntarilyreducecostsandpriceincreases restrictedspendingpatternsofindividualinstitutionalandgovernmentalpurchasersofhealthcareproductsand servicesduetoeconomichardshipandbudgetaryconstraints challengestothecompanysabilitytorealizeitsstrategyforgrowthincludingthroughexternallysourcedinnovations suchasdevelopmentcollaborationsstrategicacquisitionslicensingandmarketingagreementsandthepotential heightenedcostsofanysuchexternalarrangementsduetocompetitivepressures thepotentialthattheexpectedstrategicbenefitsandopportunitiesfromanyplannedorcompletedacquisitionor divestiturebythecompanymaynotberealizedormaytakelongertorealizethanexpectedand thepotentialthattheexpectedbenefitsandopportunitiesrelatedtopastandongoingrestructuringactionsmaynotbe realizedormaytakelongertorealizethanexpected risksrelatedtoeconomicconditionsfinancialmarketsandoperatinginternationally marketconditionsandthepossibilitythatthecompanyssharerepurchaseprogrammaybedelayedsuspendedor discontinued impactofinflationandfluctuationsininterestratesandcurrencyexchangeratesandthepotentialeffectofsuch fluctuationsonrevenuesexpensesandresultingmargins potentialchangesinexportimportandtradelawsregulationsandpoliciesoftheunitedstatesandothercountries includinganyincreasedtraderestrictionsortariffsandpotentialdrugreimportationlegislation theimpactoninternationaloperationsfromfinancialinstabilityininternationaleconomiessovereignriskpossible impositionofgovernmentalcontrolsandrestrictiveeconomicpoliciesandunstableinternationalgovernmentsandlegal systems changestoglobalclimateextremeweatherandnaturaldisastersthatcouldaffectdemandforthecompanysproducts andservicescausedisruptionsinmanufacturinganddistributionnetworksaltertheavailabilityofgoodsandservices withinthesupplychainandaffecttheoveralldesignandintegrityofthecompanysproductsandoperationsand theimpactofarmedconflictsandterroristattacksintheunitedstatesandotherpartsoftheworldincludingsocialand economicdisruptionsandinstabilityoffinancialandothermarkets risksrelatedtosupplychainandoperations difficultiesanddelaysinmanufacturinginternallythroughthirdpartyprovidersorotherwisewithinthesupplychainthat mayleadtovoluntaryorinvoluntarybusinessinterruptionsorshutdownsproductshortageswithdrawalsor suspensionsofproductsfromthemarketandpotentialregulatoryaction interruptionsandbreachesofthecompanysinformationtechnologysystemsorthoseofthecompanysvendors whichcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryaction relianceonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexandsubjecttoincreasing regulatoryrequirementsthatmayadverselyaffectsupplysourcingandpricingofmaterialsusedinthecompanys productsand johnsonjohnsonannualreport thepotentialthattheexpectedbenefitsandopportunitiesrelatedtorestructuringactionscontemplatedfortheglobal supplychainmaynotberealizedormaytakelongertorealizethanexpectedincludingduetoanyrequiredapprovals fromapplicableregulatoryauthoritiesdisruptionsassociatedwiththeannouncedglobalsupplychainactionsmay adverselyaffectsupplyandsourcingofmaterialsusedinthecompanysproducts investorsalsoshouldcarefullyreadtheriskfactorsdescribedinitemaofthisannualreportonformkfora descriptionofcertainrisksthatcouldamongotherthingscausethecompanysactualresultstodiffermateriallyfrom thoseexpressedinitsforwardlookingstatementsinvestorsshouldunderstandthatitisnotpossibletopredictoridentify allsuchfactorsandshouldnotconsidertherisksdescribedaboveandinitematobeacompletestatementofall potentialrisksanduncertaintiesthecompanydoesnotundertaketopubliclyupdateanyforwardlookingstatementthat maybemadefromtimetotimewhetherasaresultofnewinformationorfutureeventsordevelopments johnsonjohnsonannualreport part item business general johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldjohnsonjohnson isaholdingcompanywhichhasmorethanoperatingcompaniesconductingbusinessinvirtuallyallcountriesofthe worldthecompanysprimaryfocusisproductsrelatedtohumanhealthandwellbeingjohnsonjohnsonwas incorporatedinthestateofnewjerseyin theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe companysthreebusinesssegmentsconsumerpharmaceuticalandmedicaldeviceswithinthestrategicparameters providedbythecommitteeseniormanagementgroupsatusandinternationaloperatingcompaniesareeach responsiblefortheirownstrategicplansandthedaytodayoperationsofthosecompanieseachsubsidiarywithinthe businesssegmentsiswithlimitedexceptionsmanagedbyresidentsofthecountrywherelocated segments business thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesadditional informationrequiredbythisitemisincorporatedhereinbyreferencetothenarrativeandtabulardescriptionsofsegments andoperatingresultsunderitemmanagementsdiscussionandanalysisofresultsofoperationsandfinancial conditionofthisreportandnotesegmentsofbusinessandgeographicareasofthenotestoconsolidated financialstatementsincludedinitemofthisreport consumer theconsumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketsbabycareincludesthejohnsonslineofproductsoral careincludesthelisterineproductlinemajorbrandsinbeautyincludetheaveenocleanclear dabaojohnsonsadultlepetitemarseillaisneutrogenaandogxproductlines overthecountermedicinesincludethebroadfamilyoftylenolacetaminophenproductssudafedcoldfluand allergyproductsbenadrylandzyrtecallergyproductsmotrinibibuprofenproductsandthepepcidline ofacidrefluxproductsmajorbrandsinwomenshealthoutsideofnorthamericaarestayfreeandcarefree sanitarypadsandobtamponbrandswoundcarebrandsincludethebandaidbrandadhesivebandagesand neosporinfirstaidproductlinestheseproductsaremarketedtothegeneralpublicandsoldbothtoretailoutlets anddistributorsthroughouttheworld pharmaceutical thepharmaceuticalsegmentisfocusedonsixtherapeuticareasimmunologyegrheumatoidarthritisinflammatory boweldiseaseandpsoriasisinfectiousdiseasesandvaccineseghivaidsneuroscienceegmooddisorders neurodegenerativedisordersandschizophreniaoncologyegprostatecancerandhematologicmalignancies cardiovascularandmetabolismegthrombosisanddiabetesandpulmonaryhypertensionegpulmonaryarterial hypertensionmedicinesinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealthcare professionalsforprescriptionusekeyproductsinthepharmaceuticalsegmentincluderemicadeinfliximaba treatmentforanumberofimmunemediatedinflammatorydiseasessimponigolimumabasubcutaneoustreatment foradultswithmoderatetosevererheumatoidarthritisactivepsoriaticarthritisactiveankylosingspondylitisand moderatelyactivetoseverelyactiveulcerativecolitissimponiariagolimumabanintravenoustreatmentforadults withmoderatetosevererheumatoidarthritisactivepsoriaticarthritisandactiveankylosingspondylitisstelara ustekinumabatreatmentforadultsandchildrenwithmoderatetosevereplaquepsoriasisforadultswithactivepsoriatic arthritisandforadultswithmoderatelytoseverelyactivecrohnsdiseasetremfyaguselkumabatreatmentfor adultswithmoderatetosevereplaquepsoriasisedurantrilpivirineintelenceetravirineprezista johnsonjohnsonannualreport darunavirandprezcobixrezolstadarunavircobicistatantiretroviralmedicinesforthetreatmentofhuman immunodeficiencyvirushivincombinationwithotherantiretroviralproductsandsymtuzadarunavircobicistat emtricitabinetenofoviralafenamideaoncedailysingletabletregimenforthetreatmentofhivconcerta methylphenidatehclextendedreleasetabletsciiatreatmentforattentiondeficithyperactivitydisorderinvega sustennaxeplionpaliperidonepalmitateforthetreatmentofschizophreniaandschizoaffectivedisorderin adultsinvegatrinzatrevictapaliperidonepalmitateforthetreatmentofschizophreniainpatientsafterthey havebeenadequatelytreatedwithinvegasustennaforatleastfourmonthsrisperdalconstarisperidone longactinginjectionforthetreatmentofschizophreniaandthemaintenancetreatmentofbipolardisorderinadults zytigaabirateroneacetateatreatmentformetastaticcastrationresistantprostatecancercrpcandmetastatic highriskcastrationsensitiveprostatecancerimbruvicaibrutinibatreatmentforcertainbcellmalignanciesor bloodcancerschronicgraftversushostdiseaseandwaldenstrmsmacroglobulinemiadarzalexdaratumumaba treatmentforrelapsedrefractorymultiplemyelomavelcadebortezomibatreatmentformultiplemyelomamantlecell lymphomaprocriteprexepoetinalfaatreatmentforchemotherapyinducedanemiaandpatientswithchronic kidneydiseasexareltorivaroxabananoralanticoagulantforthepreventionofdeepveinthrombosisdvtwhich mayleadtopulmonaryembolismpeinpatientsundergoinghiporkneereplacementsurgerytoreducetheriskofstroke andsystemicembolisminpatientswithnonvalvularatrialfibrillationandforthetreatmentandreductionofriskof recurrenceofdvtandpeinvokanacanagliflozinforthetreatmentofadultswithtypediabetesinvokamet vokanametcanagliflozinmetforminhclacombinationtherapyoffixeddosesofcanagliflozinandmetformin hydrochlorideforthetreatmentofadultswithtypediabetesandinvokametxrcanagliflozinmetformin hydrochlorideextendedreleaseaoncedailyfixeddosecombinationtherapyofcanagliflozinandmetformin hydrochlorideextendedreleaseforthetreatmentofadultswithtypediabetesopsumitmacitentanas monotherapyorincombinationindicatedforthelongtermtreatmentofpulmonaryarterialhypertensionpahuptravi selexipagtheonlyapprovedoralselectiveipreceptoragonisttargetingaprostacyclinpathwayinpahmanyofthese medicinesweredevelopedincollaborationwithstrategicpartnersorarelicensedfromothercompaniesandmaintain activelifecycledevelopmentprograms medicaldevices themedicaldevicessegmentincludesabroadrangeofproductsusedintheorthopaedicsurgeryinterventional solutionscardiovascularandneurovasculardiabetescaredivestedinthefiscalfourthquarterofandeyehealth fieldstheseproductsaredistributedtowholesalershospitalsandretailersandusedprincipallyintheprofessionalfields byphysiciansnurseshospitalseyecareprofessionalsandclinicstheyincludeorthopaedicproductsgeneralsurgery biosurgicalendomechanicalandenergyproductselectrophysiologyproductstotreatcardiovasculardiseasesterilization anddisinfectionproductstoreducesurgicalinfectionandvisionproductssuchasdisposablecontactlensesand ophthalmicproductsrelatedtocataractandlaserrefractivesurgery geographic areas thebusinessofjohnsonjohnsonisconductedbymorethanoperatingcompanieslocatedinmorethan countriesincludingtheuswhichsellproductsinvirtuallyallcountriesthroughouttheworldtheproductsmadeand soldintheinternationalbusinessincludemanyofthosedescribedaboveundersegmentsofbusinessconsumer pharmaceuticalandmedicaldeviceshowevertheprincipalmarketsproductsandmethodsofdistributionin theinternationalbusinessvarywiththecountryandtheculturetheproductssoldininternationalbusinessincludethose developedintheusandbysubsidiariesabroad investmentsandactivitiesinsomecountriesoutsidetheusaresubjecttohigherrisksthancomparableusactivities becausetheinvestmentandcommercialclimatemaybeinfluencedbyfinancialinstabilityininternationaleconomies restrictiveeconomicpoliciesandpoliticalandlegalsystemuncertainties raw materials rawmaterialsessentialtothecompanysbusinessaregenerallyreadilyavailablefrommultiplesourceswherethereare exceptionsthetemporaryunavailabilityofthoserawmaterialswouldnotlikelyhaveamaterialadverseeffectonthe financialresultsofthecompany patents thecompanyssubsidiarieshavemadeapracticeofobtainingpatentprotectionontheirproductsandprocesseswhere possibletheyownorarelicensedunderasignificantnumberofpatentsintheusandothercountriesrelatingtotheir johnsonjohnsonannualreportproductsproductusesformulationsandmanufacturingprocesseswhichintheaggregatearebelievedtobeofmaterial importancetothecompanyintheoperationofitsbusinessesthecompanyssubsidiariesfacepatentchallengesfrom thirdpartiesincludingchallengesseekingtomanufactureandmarketgenericandbiosimilarversionsofthecompanys keypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductssignificantlegal proceedingsandclaimsinvolvingthecompanyspatentandotherintellectualpropertyaredescribedinnotelegal proceedingsintellectualpropertyofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport salesofthecompanysndlargestproductstelaraustekinumabaccountedforapproximatelyofthe companystotalrevenuesforfiscalaccordinglythepatentsrelatedtothisproductarebelievedtobematerialto thecompany thereisonesetofgrantedpatentsrelatedspecificallytostelarathissetofpatentsisownedbyjanssenbiotech incawhollyownedsubsidiaryofjohnsonjohnsonthesepatentsareinforceintheusandmanycountriesoutside theunitedstatesintheusthelatestprojectedexpirationdateforpatentsinthissetisduetoapatentterm extensionineuropethelatestprojectedexpirationdateforpatentsinthissetisduetoasupplementalpatent certificatepatenttermextensioninmostothercountriesthelatestprojectedexpirationdateis inadditiontocompetingintheimmunologymarketwithstelarathecompanyiscurrentlymarketingsimponi golimumabandsimponiariagolimumabnextgenerationimmunologyproductswithremainingpatentlivesofupto sixyearsthecompanyalsomarketsremicadeinfliximabintheimmunologymarketwhichisthecompanyslargest productpatentsonthisproducthaveexpiredandthefoodanddrugadministrationapprovedthefirstinfliximabbiosimilar forsaleintheusinandanumberofsuchproductshavebeenlaunchedsincethenforamoreextensive descriptionoflegalmattersregardingthepatentsrelatedtoremicadeseenotelegalproceedingsintellectual propertypharmaceuticalremicaderelatedcasesofthenotestoconsolidatedfinancialstatementsincluded initemofthisreport trademarks thecompanyssubsidiarieshavemadeapracticeofsellingtheirproductsundertrademarksandofobtainingprotection forthesetrademarksbyallavailablemeansthesetrademarksareprotectedbyregistrationintheusandothercountries wheresuchproductsaremarketedthecompanyconsidersthesetrademarksintheaggregatetobeofmaterial importanceintheoperationofitsbusinesses seasonality worldwidesalesdonotreflectanysignificantdegreeofseasonalityhoweverspendinghasbeenheavierinthefourth quarterofeachyearthaninotherquartersthisreflectsincreasedspendingdecisionsprincipallyforadvertisingand researchanddevelopmentactivity competition inalloftheirproductlinesthecompanyssubsidiariescompetewithcompaniesbothlocallyandgloballycompetition existsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolvedcompetitionin researchbothinternallyandexternallysourcedinvolvingthedevelopmentandtheimprovementofnewandexisting productsandprocessesisparticularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotecting theunderlyingintellectualpropertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareas ofitsbusinessthecompetitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthe developmentandmaintenanceofcustomerdemandforthecompanysconsumerproductsinvolvesignificant expendituresforadvertisingandpromotion environment thecompanyissubjecttoavarietyofusandinternationalenvironmentalprotectionmeasuresthecompanybelieves thatitsoperationscomplyinallmaterialrespectswithapplicableenvironmentallawsandregulationsthecompanys compliancewiththeserequirementsdidnotchangeduringthepastyearandisnotexpectedtohaveamaterialeffect uponitscapitalexpenditurescashflowsearningsorcompetitiveposition regulation thecompanysbusinessesaresubjecttovaryingdegreesofgovernmentalregulationinthecountriesinwhichoperations areconductedandthegeneraltrendistowardincreasinglystringentregulationintheusthedrugdeviceandcosmetic johnsonjohnsonannualreport industrieshavelongbeensubjecttoregulationbyvariousfederalandstateagenciesprimarilyastoproductsafety efficacymanufacturingadvertisinglabelingandsafetyreportingtheexerciseofbroadregulatorypowersbytheus foodanddrugadministrationthefdacontinuestoresultinincreasesintheamountsoftestinganddocumentation requiredforfdaapprovalofnewdrugsanddevicesandacorrespondingincreaseintheexpenseofproductintroduction similartrendsarealsoevidentinmajormarketsoutsideoftheusthenewmedicaldeviceregulatoryframeworkandthe newprivacyregulationsineuropeareexamplesofsuchincreasedregulation thecostsofhumanhealthcarehavebeenandcontinuetobeasubjectofstudyinvestigationandregulationby governmentalagenciesandlegislativebodiesaroundtheworldintheusattentionhasbeenfocusedondrugprices andprofitsandprogramsthatencouragedoctorstowriteprescriptionsforparticulardrugsortorecommenduseor purchaseparticularmedicaldevicespayershavebecomeamorepotentforceinthemarketplaceandincreasedattention isbeingpaidtodrugandmedicaldevicepricingappropriatedrugandmedicaldeviceutilizationandthequalityandcosts ofhealthcaregenerally usgovernmentagenciescontinuetoimplementtheextensiverequirementsofthepatientprotectionandaffordablecare acttheacathesehavebothpositiveandnegativeimpactsontheushealthcareindustrywithmuchremaining uncertainastohowvariousprovisionsoftheacaandpotentialmodificationorrepealofacaprovisionswillultimately affecttheindustry theregulatoryagenciesunderwhosepurviewthecompanyoperateshaveadministrativepowersthatmaysubjectitto actionssuchasproductwithdrawalsrecallsseizureofproductsandothercivilandcriminalsanctionsinsomecasesthe companyssubsidiariesmaydeemitadvisabletoinitiateproductrecalls inadditionbusinesspracticesinthehealthcareindustryhavecomeunderincreasedscrutinyparticularlyintheusby governmentagenciesandstateattorneysgeneralandresultinginvestigationsandprosecutionscarrytheriskofsignificant civilandcriminalpenalties furtherthecompanyreliesonglobalsupplychainsandproductionanddistributionprocessesthatarecomplexare subjecttoincreasingregulatoryrequirementsandmaybefacedwithunexpectedchangessuchasthoseresultingfrom brexitthatmayaffectsourcingsupplyandpricingofmaterialsusedinthecompanysproductstheseprocessesalso aresubjecttolengthyregulatoryapprovals available information thecompanysmaincorporatewebsiteaddressiswwwjnjcomallofthecompanyssecfilingsarealsoavailableonthe companyswebsiteatwwwinvestorjnjcomseccfmassoonasreasonablypracticableafterhavingbeenelectronically filedorfurnishedtothesecallsecfilingsarealsoavailableatthesecswebsiteatwwwsecgovinadditionthe writtenchartersoftheauditcommitteethecompensationbenefitscommitteethenominatingcorporate governancecommitteetheregulatorycompliancecommitteeandthesciencetechnologysustainabilitycommittee oftheboardofdirectorsandthecompanysprinciplesofcorporategovernancecodeofbusinessconductfor employeescodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficersandother corporategovernancematerialsareavailableatwwwinvestorjnjcomgovcfmonthecompanyswebsiteandwillbe providedwithoutchargetoanyshareholdersubmittingawrittenrequestasprovidedabovetheinformationonthe companyswebsiteisnotandwillnotbedeemedapartofthisreportorincorporatedintoanyotherfilingsthecompany makeswiththesec item risk factors thecompanyfacesanumberofuncertaintiesandrisksthataredifficulttopredictandmanyofwhichareoutsideofthe companyscontrolinadditiontotheotherinformationinthisreportandthecompanysotherfilingswiththesec investorsshouldconsidercarefullythefactorssetforthbelowinvestorsshouldbeawarethatitisnotpossibletopredict oridentifyallsuchfactorsandthatthefollowingisnotmeanttobeacompletediscussionofallpotentialrisksor uncertaintiesifknownorunknownrisksoruncertaintiesmaterializethecompanysbusinessresultsofoperationsor financialconditioncouldbeadverselyaffectedpotentiallyinamaterialway globalsalesinthecompanyspharmaceuticalandmedicaldevicessegmentsmaybenegativelyimpacted byhealthcarereformsandincreasingpricingpressures salesofthecompanyspharmaceuticalandmedicaldeviceproductsaresignificantlyaffectedbyreimbursementsby thirdpartypayerssuchasgovernmenthealthcareprogramsprivateinsuranceplansandmanagedcareorganizationsas johnsonjohnsonannualreportpartofvariouseffortstocontainhealthcarecoststhesepayersareputtingdownwardpressureonpricesatwhich productswillbereimbursedintheusincreasedpurchasingpowerofentitiesthatnegotiateonbehalfofmedicare medicaidandprivatesectorbeneficiariesinpartduetocontinuedconsolidationamonghealthcareproviderscould resultinfurtherpricingpressuresinadditionincreasedpoliticalscrutinycouldresultinadditionalpricingpressures outsidetheusnumerousmajormarketsincludingtheeuandjapanhavepervasivegovernmentinvolvementinfunding healthcareandinthatregarddirectlyorindirectlyimposepricecontrolslimitaccesstoorreimbursementforthe companysproductsorreducethevalueofitsintellectualpropertyprotection thecompanyissubjecttosignificantlegalproceedingsthatcanresultinsignificantexpensesfinesand reputationaldamage intheordinarycourseofbusinessjohnsonjohnsonanditssubsidiariesaresubjecttonumerousclaimsandlawsuits involvingvariousissuessuchaspatentdisputesproductliabilityandclaimsthattheirproductsalesmarketingandpricing practicesviolatevariousantitrustunfairtradepracticesandorconsumerprotectionlawsthemostsignificantofthese proceedingsaredescribedinnotelegalproceedingsundernotestotheconsolidatedfinancialstatements includedinitemofthisreportwhilethecompanybelievesithassubstantialdefensesinthesemattersitisnot feasibletopredicttheultimateoutcomeoflitigationthecompanycouldinthefutureberequiredtopaysignificant amountsasaresultofsettlementsorjudgmentsinthesematterspotentiallyinexcessofaccrualsincludingmatterswhere thecompanycouldbeheldjointlyandseverallyliableamongotherdefendantstheresolutionoforincreaseinaccruals foroneormoreofthesemattersinanyreportingperiodcouldhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiodfurthermoreasaresultofcostandavailabilityfactorseffectivenovember thecompanyceasedpurchasingthirdpartyproductliabilityinsurance productreliabilitysafetyandeffectivenessconcernscanhavesignificantnegativeimpactsonsalesand resultsofoperationsleadtolitigationandcausereputationaldamage concernsaboutproductsafetywhetherraisedinternallyorbylitigantsregulatorsorconsumeradvocatesandwhetheror notbasedonscientificevidencecanresultinsafetyalertsproductrecallsgovernmentalinvestigationsregulatoryaction onthepartofthefdaoritscounterpartinothercountriesprivateclaimsandlawsuitspaymentoffinesandsettlements decliningsalesandreputationaldamagethesecircumstancescanalsoresultindamagetobrandimagebrandequity andconsumertrustinthecompanysproductsproductrecallshaveinthepastandcouldinthefutureprompt governmentinvestigationsandinspectionstheshutdownofmanufacturingfacilitiescontinuedproductshortagesand relatedsalesdeclinessignificantremediationcostsreputationaldamagepossiblecivilpenaltiesandcriminalprosecution changesintaxlawsorexposurestoadditionaltaxliabilitiescouldnegativelyimpactthecompanys operatingresults changesintaxlawsorregulationsaroundtheworldcouldnegativelyimpactthecompanyseffectivetaxrateandresults ofoperationsachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthecompanysdeferredtax assetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawisenactedthischange wouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementofearningsthecompany closelymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothestatutorytaxratemay occuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarterandyearinwhichthe lawchangeisenacted ondecembertheusenactedthetaxcutsandjobsactthetcjawhichintroducedsignificantchangesto uscorporateincometaxlawthatwillhaveameaningfulimpactonthecompanysprovisionforincometaxesaccounting fortheincometaxeffectsofthetcjarequiressignificantjudgmentstobemadeininterpretingitsprovisionsanticipated guidancefromtheustreasuryaboutimplementingthetcjawhichshouldbefinalbyjunemonthsafter enactmentmayresultinadjustmentsthatcouldmateriallyaffectthecompanysfinancialpositionandresultsof operationsaswellastheeffectivetaxrateintheperiodinwhichtheadjustmentsaremade onseptembertheswissparliamentapprovedthefederalactontaxreformandahvfinancingswisstax reformhoweverareferendumhasbeencalledandasaresultapublicvoteontheswisstaxreformwilltakeplaceon maythiftheswisstaxreformpassesthenthemeasuresareexpectedtocomeintoforceineitherjanuary orjanuarypriortoapprovalinthereferendumanditssubsequentcantonalimplementationtheproposed swisstaxreformisnotenactedandthereforethecompanyhasnotreflectedanyofthepotentialimpactsinitsfiscal resultsthecompanyiscurrentlyassessingtheimpactoftheproposedswisstaxreformandwhenenactedthelaw mayhaveamaterialimpactonthecompanysoperatingresults thecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandisaddressingtaxauditsanddisputes withmanytaxauthoritiesinconnectionwiththeorganizationforeconomiccooperationanddevelopmentbaseerosion johnsonjohnsonannualreport andprofitshiftingbepsprojectcompaniesarerequiredtodisclosemoreinformationtotaxauthoritiesonoperations aroundtheworldwhichmayleadtogreaterauditscrutinyofprofitsearnedinothercountriesthecompanyregularly assessesthelikelyoutcomesofitstaxauditsanddisputestodeterminetheappropriatenessofitstaxreserveshowever anytaxauthoritycouldtakeapositionontaxtreatmentthatiscontrarytothecompanysexpectationswhichcouldresult intaxliabilitiesinexcessofreserves thecompanymaynotbeabletosuccessfullysecureanddefendintellectualpropertyrightsessentialto thecompanysbusinesses thecompanyownsorlicensesasignificantnumberofpatentsandotherproprietaryrightsdeterminedbypatentoffices courtsandlawmakersinvariouscountriesrelatingtoitsproductsandmanufacturingprocessestheserightsareessential tothecompanysbusinessesandmateriallyimportanttothecompanysresultsofoperationspublicpolicybothwithin andoutsidetheushasbecomeincreasinglyunfavorabletowardintellectualpropertyrightsthecompanycannotbe certainthatitwillobtainadequatepatentprotectionfornewproductsandtechnologiesintheusandotherimportant marketsorthatsuchprotectionsoncegrantedwilllastaslongasoriginallyanticipated competitorsroutinelychallengethevalidityorextentofthecompanysownedorlicensedpatentsandproprietaryrights throughlitigationinterferencesoppositionsandotherproceedingstheseproceedingsabsorbresourcesandcanbe protractedaswellasunpredictableinadditionchallengesthatthecompanysproductsinfringethepatentsofthird partiescouldresultintheneedtopaypastdamagesandfutureroyaltiesandadverselyaffectthecompetitivepositionand salesoftheproductsinquestion thecompanyhasfacedincreasingpatentchallengesfromthirdpartiesseekingtomanufactureandmarketgenericand biosimilarversionsofthecompanyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscovering thoseproductsintheusmanufacturersofgenericversionsofinnovativehumanpharmaceuticalproductsmay challengethevalidityorclaimnoninfringementofinnovatorproductsthroughtheabbreviatednewdrugapplicationor andaprocesswiththefdathebiologicspricecompetitionandinnovationactbpciaenactedinwhich createdanewregulatorypathwayfortheapprovalbythefdaofbiosimilaralternativestoinnovatordevelopedbiological productsalsocreatedmechanismsforbiosimilarapplicantstochallengethepatentsontheinnovatorbiologicstheinter partesreviewiprprocesswiththeusptocreatedundertheamericainventsactisalsobeingusedby competitorstochallengepatentsheldbythecompanyssubsidiaries intheeventthecompanyisnotsuccessfulindefendingitspatentsagainstsuchchallengesorupontheatrisklaunch despitependingpatentinfringementlitigationbythegenericorbiosimilarfirmofitsproductthecompanycanlosea majorportionofrevenuesforthereferencedproductinaveryshortperiodoftimecurrentlegalproceedingsinvolvingthe companyspatentsandotherintellectualpropertyrightsaredescribedinnotelegalproceedingsintellectual propertyofthenotestotheconsolidatedfinancialstatementsincludedinitemofthisreport thecompanysbusinessesoperateinhighlycompetitiveproductmarketsandcompetitivepressurescould adverselyaffectthecompanysearnings thecompanyfacessubstantialcompetitioninallthreeoperatingsegmentsandinallgeographicmarketsthecompanys businessescompetewithcompaniesofallsizesonthebasisofcosteffectivenesstechnologicalinnovationsintellectual propertyrightsproductperformancerealorperceivedproductadvantagespricingandavailabilityandrateof reimbursementthecompanyalsocompeteswithothermarketparticipantsinsecuringrightstoacquisitions collaborationsandlicensingagreementswiththirdpartiescompetitionforrightstoproductcandidatesandtechnologies mayresultinsignificantinvestmentandacquisitioncostsandonerousagreementtermsforthecompanycompetitors developmentofmoreeffectiveorlesscostlyproductsandortheirabilitytosecurepatentandotherintellectualproperty rightsandsuccessfullymarketproductsaheadofthecompanycouldnegativelyimpactsalesofthecompanysexisting productsaswellasitsabilitytobringnewproductstomarketdespitesignificantpriorinvestmentintherelatedproduct development forthecompanyspharmaceuticalbusinesseslossofpatentexclusivityforaproductoftenisfollowedbyasubstantial reductioninsalesascompetitorsgainregulatoryapprovalforgenericandothercompetingproductsandenterthemarket similarcompetitioncanbetriggeredbythelossofexclusivityforabiologicalproductforthecompanysmedicaldevice businessestechnologicalinnovationproductqualityreputationandcustomerserviceareespeciallyimportantto competitivenessdevelopmentbyothercompaniesofneworimprovedproductsprocessesandtechnologiescould threatentomakethecompanysproductsortechnologieslessdesirablelesseconomicalorobsoletethecompanys consumerbusinessesfaceintensecompetitionfromotherbrandedproductsandretailersprivatelabelbrandsifthe companyfailstosufficientlydifferentiateandmarketitsbrandnameconsumerproductsthiscouldadverselyaffect revenuesandprofitabilityofthoseproducts johnsonjohnsonannualreportsignificantchallengesordelaysinthecompanysinnovationanddevelopmentofnewproducts technologiesandindicationscouldhaveanadverseimpactonthecompanyslongtermsuccess thecompanyscontinuedgrowthandsuccessdependsonitsabilitytoinnovateanddevelopnewanddifferentiated productsandservicesthataddresstheevolvinghealthcareneedsofpatientsprovidersandconsumersdevelopmentof successfulproductsandtechnologiesisalsonecessarytooffsetrevenuelosseswhenthecompanysexistingproducts losemarketshareduetovariousfactorssuchascompetitionandlossofpatentexclusivitynewproductsintroduced withinthepastfiveyearsaccountedforapproximatelyofsalesthecompanycannotbecertainwhenor whetheritwillbeabletodeveloplicenseorotherwiseacquirecompaniesproductsandtechnologieswhetherparticular productcandidateswillbegrantedregulatoryapprovalandifapprovedwhethertheproductswillbecommercially successful thecompanypursuesproductdevelopmentthroughinternalresearchanddevelopmentaswellasthroughcollaborations acquisitionsjointventuresandlicensingorotherarrangementswiththirdpartiesinallofthesecontextsdevelopingnew productsparticularlypharmaceuticalandbiotechnologyproductsandmedicaldevicesrequiressignificantinvestmentof resourcesovermanyyearsonlyaveryfewbiopharmaceuticalresearchanddevelopmentprogramsresultincommercially viableproductstheprocessdependsonmanyfactorsincludingtheabilitytodiscernpatientsandhealthcareproviders futureneedsdeveloppromisingnewcompoundsstrategiesandtechnologiesachievesuccessfulclinicaltrialresults secureeffectiveintellectualpropertyprotectionobtainregulatoryapprovalsonatimelybasisandifandwhentheyreach themarketsuccessfullydifferentiatethecompanysproductsfromcompetingproductsandapproachestotreatment newproductsorenhancementstoexistingproductsmaynotbeacceptedquicklyorsignificantlyinthemarketplacedue toproductandpricecompetitionchangesincustomerpreferencesorhealthcarepurchasingpatternsresistanceby healthcareprovidersoruncertaintyoverthirdpartyreimbursementevenfollowinginitialregulatoryapprovalthesuccess ofaproductcanbeadverselyimpactedbysafetyandefficacyfindingsinlargerrealworldpatientpopulationsaswellas marketentryofcompetitiveproducts thecompanyfacesincreasingregulatoryscrutinywhichimposessignificantcompliancecostsandexposes thecompanytogovernmentinvestigationslegalactionsandpenalties likeothercompaniesinthehealthcareindustrythecompanyissubjecttoextensiveregulationinvestigationsandlegal actionbynationalstateandlocalgovernmentagenciesintheusandothercountriesinwhichtheyoperateregulatory issuesregardingcompliancewithgoodmanufacturingpracticescgmpandcomparablequalityregulationsinforeign countriesbymanufacturersofdrugsdevicesandconsumerproductscanleadtofinesandpenaltiesproductrecalls productshortagesinterruptionsinproductiondelaysinnewproductapprovalsandlitigationinadditionthemarketing pricingandsaleofthecompanysproductsaresubjecttoregulationinvestigationsandlegalactionsincludingunderthe federalfooddrugandcosmeticactthemedicaidrebateprogramfederalandstatefalseclaimsactsstateunfair tradepracticesactsandconsumerprotectionlawsincreasedscrutinyofhealthcareindustrybusinesspracticesinrecent yearsbygovernmentagenciesandstateattorneysgeneralintheusandanyresultinginvestigationsandprosecutions carryriskofsignificantcivilandcriminalpenaltiesincludingbutnotlimitedtodebarmentfromparticipationingovernment healthcareprogramsanysuchdebarmentcouldhaveamaterialadverseeffectonthecompanysbusinessandresultsof operationsthemostsignificantcurrentinvestigationsandlitigationbroughtbygovernmentagenciesaredescribedin notelegalproceedingsgovernmentproceedingsundernotestotheconsolidatedfinancialstatementsincluded initemofthisreport thecompanyfacesavarietyofrisksassociatedwithconductingbusinessinternationally thecompanysextensiveoperationsandbusinessactivityoutsidetheusareaccompaniedbycertainfinancial economicandpoliticalrisksincludingthoselistedbelow foreigncurrencyexchangeinfiscalapproximatelyofthecompanyssalesoccurredoutsideoftheuswith approximatelyineuropeinthewesternhemisphereexcludingtheusandintheasiapacificandafrica regionchangesinnonuscurrenciesrelativetotheusdollarimpactthecompanysrevenuesandexpenseswhile thecompanyusesfinancialinstrumentstomitigatetheimpactoffluctuationsincurrencyexchangeratesonitscashflows unhedgedexposurescontinuetobesubjecttocurrencyfluctuationsinadditiontheweakeningorstrengtheningofthe usdollarmayresultinsignificantfavorableorunfavorabletranslationeffectswhentheoperatingresultsofthe companysnonusbusinessactivityaretranslatedintousdollars inflationandcurrencydevaluationrisksthecompanyfaceschallengesinmaintainingprofitabilityofoperationsin economiesexperiencinghighinflationratesthecompanyhasaccountedforoperationsinargentinabeginninginthe fiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyearcumulativeinflationratesurpassed whilethecompanystrivestomaintainprofitmarginsintheseareasthroughcostreductionprogramsproductivity johnsonjohnsonannualreport improvementsandperiodicpriceincreasesitmightexperienceoperatinglossesasaresultofcontinuedinflationin additiontheimpactofcurrencydevaluationsincountriesexperiencinghighinflationratesorsignificantcurrencyexchange fluctuationscouldnegativelyimpactthecompanysoperatingresults illegalimportationofpharmaceuticalproductstheillegalimportationofpharmaceuticalproductsfromcountrieswhere governmentpricecontrolsorothermarketdynamicsresultinlowerpricesmayadverselyaffectthecompanyssalesand profitabilityintheusandothercountriesinwhichthecompanyoperateswiththeexceptionoflimitedquantitiesof prescriptiondrugsforpersonaluseforeignimportsofpharmaceuticalproductsareillegalundercurrentuslaw howeverthevolumeofillegalimportscontinuestoriseastheabilityofpatientsandothercustomerstoobtainthelower pricedimportshasgrownsignificantly antibriberyandotherregulationsthecompanyissubjecttovariousfederalandforeignlawsthatgovernitsinternational businesspracticeswithrespecttopaymentstogovernmentofficialsthoselawsincludetheusforeigncorrupt practicesactfcpawhichprohibitsuspubliclytradedcompaniesfrompromisingofferingorgivinganythingofvalue toforeignofficialswiththecorruptintentofinfluencingtheforeignofficialforthepurposeofhelpingthecompanyobtain orretainbusinessorgainanyimproperadvantagethecompanysbusinessisheavilyregulatedandthereforeinvolves significantinteractionwithforeignofficialsalsoinmanycountriesoutsidetheusthehealthcareproviderswho prescribehumanpharmaceuticalsareemployedbythegovernmentandthepurchasersofhumanpharmaceuticalsare governmententitiesthereforethecompanysinteractionswiththeseprescribersandpurchasersaresubjecttoregulation underthefcpainadditiontotheusapplicationandenforcementofthefcpavariousjurisdictionsinwhichthe companyoperateshavelawsandregulationsincludingtheukbriberyactaimedatpreventingandpenalizing corruptandanticompetitivebehaviorenforcementactivitiesundertheselawscouldsubjectthecompanytoadditional administrativeandlegalproceedingsandactionswhichcouldincludeclaimsforcivilpenaltiescriminalsanctionsand administrativeremediesincludingexclusionfromhealthcareprograms otherlegalsocialandpoliticalrisksotherrisksinherentinconductingbusinessgloballyinclude protectiveeconomicpoliciestakenbygovernmentssuchastradeprotectionmeasuresandimportexportlicensing requirements compliancewithlocalregulationsandlawsincludinginsomecountriesregulatoryrequirementsrestrictingthe companysabilitytomanufactureorsellitsproductsintherelevantmarket diminishedprotectionofintellectualpropertyandcontractualrightsincertainjurisdictions potentialnationalizationorexpropriationofthecompanysforeignassetsand disruptionstomarketsduetowararmedconflictterrorismsocialupheavalsorpandemics interruptionsanddelaysinmanufacturingoperationscouldadverselyaffectthecompanysbusinesssales andreputation thecompanysmanufactureofproductsrequiresthetimelydeliveryofsufficientamountsofcomplexhighquality componentsandmaterialsthecompanyssubsidiariesoperatemanufacturingfacilitiesaswellassourcingfrom hundredsofsuppliersaroundtheworldthecompanyhasinthepastandmayinthefuturefaceunanticipated interruptionsanddelaysinmanufacturingthroughitsinternalorexternalsupplychainmanufacturingdisruptionscanoccur formanyreasonsincludingregulatoryactionproductionqualitydeviationsorsafetyissueslabordisputessitespecific incidentssuchasfiresnaturaldisasterssuchashurricanesandothersevereweathereventsrawmaterialshortages politicalunrestandterroristattackssuchdelaysanddifficultiesinmanufacturingcanresultinproductshortagesdeclines insalesandreputationalimpactaswellassignificantremediationandrelatedcostsassociatedwithaddressingthe shortage thecompanyreliesonthirdpartiestomanufacturecertainofourproductsanyfailurebyorlossofathird partymanufacturercouldresultindelaysandincreasedcostswhichmayadverselyaffectourbusiness thecompanyreliesonthirdpartiestomanufacturecertainofourproductswedependonthesethirdparty manufacturerstoallocatetousaportionoftheirmanufacturingcapacitysufficienttomeetourneedstoproduceproducts ofacceptablequalityandatacceptablemanufacturingyieldsandtodeliverthoseproductstousonatimelybasisandat acceptablepriceshoweverwecannotguaranteethatthesethirdpartymanufacturerswillbeabletomeetournearterm orlongtermmanufacturingrequirementswhichcouldresultinlostsalesandhaveanadverseeffectonourbusiness otherrisksassociatedwithourrelianceonthirdpartiestomanufacturetheseproductsincluderelianceonthethirdparty forregulatorycomplianceandqualityassurancemisappropriationofthecompanysintellectualpropertylimitedabilityto manageourinventorypossiblebreachofthemanufacturingagreementbythethirdpartyandthepossibleterminationor nonrenewalofthemanufacturingagreementbythethirdpartyatatimethatiscostlyorinconvenientforusmoreoverif johnsonjohnsonannualreportanyofourthirdpartymanufacturerssufferanydamagetofacilitieslosebenefitsundermaterialagreementsexperience poweroutagesencounterfinancialdifficultiesareunabletosecurenecessaryrawmaterialsfromtheirsuppliersorsuffer anyotherreductioninefficiencythecompanymayexperiencesignificantbusinessdisruptionintheeventofanysuch disruptionthecompanywouldneedtoseekandsourceotherqualifiedthirdpartymanufacturerslikelyresultinginfurther delaysandincreasedcostswhichcouldaffectourbusinessadversely aninformationsecurityincidentincludingacybersecuritybreachcouldhaveanegativeimpacttothe companysbusinessorreputation tomeetbusinessobjectivesthecompanyreliesonbothinternalinformationtechnologyitsystemsandnetworksand thoseofthirdpartiesandtheirvendorstoprocessandstoresensitivedataincludingconfidentialresearchbusiness plansfinancialinformationintellectualpropertyandpersonaldatathatmaybesubjecttolegalprotectiontheextensive informationsecurityandcybersecuritythreatswhichaffectcompaniesgloballyposearisktothesecurityandavailability oftheseitsystemsandnetworksandtheconfidentialityintegrityandavailabilityofthecompanyssensitivedatathe companycontinuallyassessesthesethreatsandmakesinvestmentstoincreaseinternalprotectiondetectionand responsecapabilitiesaswellasensurethecompanysthirdpartyprovidershaverequiredcapabilitiesandcontrolsto addressthisrisktodatethecompanyhasnotexperiencedanymaterialimpacttothebusinessoroperationsresulting frominformationorcybersecurityattackshoweverbecauseofthefrequentlychangingattacktechniquesalongwiththe increasedvolumeandsophisticationoftheattacksthereisthepotentialforthecompanytobeadverselyimpactedthis impactcouldresultinreputationalcompetitiveoperationalorotherbusinessharmaswellasfinancialcostsand regulatoryactionthecompanymaintainscybersecurityinsuranceintheeventofaninformationsecurityorcyberincident howeverthecoveragemaynotbesufficienttocoverallfinanciallosses item b unresolved staff comments notapplicable item properties thecompanyssubsidiariesoperatemanufacturingfacilitiesoccupyingapproximatelymillionsquarefeetoffloor spacethemanufacturingfacilitiesareusedbytheindustrysegmentsofthecompanysbusinessapproximatelyas follows squarefeet segment inthousands consumer pharmaceutical medicaldevices worldwidetotal withintheusfivefacilitiesareusedbytheconsumersegmentfivebythepharmaceuticalsegmentandbythe medicaldevicessegmentoutsideoftheusfacilitiesareusedbytheconsumersegmentbythepharmaceutical segmentandbythemedicaldevicessegment thelocationsofthemanufacturingfacilitiesbymajorgeographicareasoftheworldareasfollows squarefeet geographicarea numberoffacilities inthousands unitedstates europe westernhemisphereexcludingus africaasiaandpacific worldwidetotal inadditiontothemanufacturingfacilitiesdiscussedabovethecompanymaintainsnumerousofficeandwarehouse facilitiesthroughouttheworldresearchfacilitiesarealsodiscussedinitemmanagementsdiscussionandanalysisof resultsofoperationsandfinancialconditionofthisreport johnsonjohnsonannualreport thecompanyssubsidiariesgenerallyseektoownratherthanleasetheirmanufacturingfacilitiesalthoughsome principallyinnonuslocationsareleasedofficeandwarehousefacilitiesareoftenleasedthecompanyalsoengages contractmanufacturers thecompanyiscommittedtomaintainingallofitspropertiesingoodoperatingcondition mcneilppcincnowjohnsonjohnsonconsumerincmcneilppccontinuestooperateunderaconsentdecree signedinwiththefdawhichgovernscertainmcneilconsumerhealthcaremanufacturingoperationsandrequires mcneilppctoremediatethefacilitiesitoperatesinlancasterpennsylvaniafortwashingtonpennsylvaniaandlas piedraspuertoricotheconsentdecreefollowingfdainspectionsinmcneilppcreceivednotifications fromthefdathatallthreemanufacturingfacilitiesareinconformitywithapplicablelawsandregulationsandcommercial productionhasrestarted undertheconsentdecreeafterreceivingnoticefromthefdaofbeingincompliancewithapplicablelawsand regulationseachofthethreefacilitiesissubjecttoafiveyearauditperiodbyathirdpartycgmpexpertthusathird partyexpertwillcontinuetoreassessthesitesatvarioustimesuntilatleast forinformationregardingleaseobligationsseenoterentalexpenseandleasecommitmentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreportsegmentinformationonadditionstopropertyplant andequipmentiscontainedinnotesegmentsofbusinessandgeographicareasofthenotestoconsolidated financialstatementsincludedinitemofthisreport item legal proceedings theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheinformationsetforthinnotelegal proceedingsofthenotestoconsolidatedfinancialstatementsincludedinitemofthisreport inadditionjohnsonjohnsonanditssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthe comprehensiveenvironmentalresponsecompensationandliabilityactcommonlyknownassuperfundand comparablestatelocalorforeignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation item mine safety disclosures notapplicable johnsonjohnsonannualreportexecutive officers registrant listedbelowaretheexecutiveofficersofthecompanytherearenofamilyrelationshipsbetweenanyoftheexecutive officersandthereisnoarrangementorunderstandingbetweenanyexecutiveofficerandanyotherpersonpursuantto whichtheexecutiveofficerwasselectedattheannualmeetingoftheboardofdirectorstheexecutiveofficersare electedbytheboardtoholdofficeforoneyearanduntiltheirrespectivesuccessorsareelectedandqualifiedoruntil earlierresignationorremoval informationwithregardtothedirectorsofthecompanyincludinginformationforalexgorskywhoisalsoanexecutive officerisincorporatedhereinbyreferencetothematerialcaptioneditemelectionofdirectorsintheproxystatement name age position joaquinduato vicechairmanexecutivecommitteea memberexecutivecommitteeexecutivevicepresidentchiefhuman petermfasolo resourcesofficerb chairmanboardofdirectorschairmanexecutivecommitteechiefexecutive alexgorsky officer memberexecutivecommitteeexecutivevicepresidentworldwidechairman ashleymcevoy medicaldevicesc memberexecutivecommitteeexecutivevicepresidentworldwidechairman jorgemesquita consumerd appointeememberexecutivecommitteeexecutivevicepresidentworldwide thibautmongon chairmanconsumere memberexecutivecommitteeexecutivevicepresidentglobalcorporate michaelesneed affairsandchiefcommunicationofficerf paulusstoffels vicechairmanexecutivecommitteechiefscientificofficerg memberexecutivecommitteeexecutivevicepresidentworldwidechairman jenniferltaubert pharmaceuticalsh michaelhullmann memberexecutivecommitteeexecutivevicepresidentgeneralcounseli memberexecutivecommitteeexecutivevicepresidentchiefglobalsupply kathrynewengel chainofficerj memberexecutivecommitteeexecutivevicepresidentchieffinancial josephjwolk officerk mrjduatojoinedthecompanyinwithjanssenfarmaceuticasaspainasubsidiaryofthecompanyandheldexecutive positionsofincreasingresponsibilityinthepharmaceuticalsectorinhewasnamedcompanygroupchairman pharmaceuticalsandinhewasnamedworldwidechairmanpharmaceuticalsinmrduatobecameamemberofthe executivecommitteeandwasnamedexecutivevicepresidentworldwidechairmanpharmaceuticalsinjulymrduatowas promotedtovicechairmanoftheexecutivecommitteewithresponsibilityforthecompanyspharmaceuticalandconsumersectors supplychaininformationtechnologyglobalservicesandthehealthwellnessgroups b drpmfasolojoinedthecompanyinasvicepresidentworldwidehumanresourcesforcordiscorporationasubsidiary ofthecompanyandwassubsequentlynamedvicepresidentglobaltalentmanagementforthecompanyheleft johnsonjohnsonintojoinkohlbergkravisrobertscoaschieftalentofficerdrfasoloreturnedtothecompanyin asthevicepresidentglobalhumanresourcesandinhebecameamemberoftheexecutivecommitteeinapril hewasnamedexecutivevicepresidentchiefhumanresourcesofficerdrfasolohasresponsibilityforglobaltalent recruitingdiversitycompensationbenefitsemployeerelationsandallaspectsofthehumanresourcesagendaforthecompany c msamcevoyjoinedthecompanyinasassistantbrandmanagerofmcneilconsumerhealthasubsidiaryofthecompany advancingthroughpositionsofincreasingresponsibilitiesuntilshewasappointedcompanygroupchairmanvisioncarein followedbycompanygroupchairmanconsumermedicaldevicesininjulymsmcevoywaspromotedtoexecutive vicepresidentworldwidechairmanmedicaldevicesandbecameamemberoftheexecutivecommitteeshehasresponsibilityfor thesurgeryorthopaedicsinterventionalsolutionsandeyehealthbusinessesacrossethicondepuysynthesbiosensewebsterand johnsonjohnsonvision mrjmesquitajoinedthecompanyinasworldwidechairmanconsumerpriortojoiningthecompanyheservedinvarious marketingandleadershipcapacitiesacrosslatinamericaincludingrolesinoralcareandbeautyattheproctergamble johnsonjohnsonannualreport companyfromtoinaprilmrmesquitabecameamemberoftheexecutivecommitteeandwaspromotedto executivevicepresidentworldwidechairmanconsumermrmesquitaplanstoretirefromthecompanyinmarch e mrtmongonjoinedthecompanyinasdirectorofmarketingforthevisioncaregroupinfranceandsubsequentlyheld generalmanagementpositionsascountrymanagerfrancebelgiumandnorthafricamanagingdirectorlatinamericaand presidentasiapacificmrmongontransitionedtothepharmaceuticalsectorinastheglobalcommercialstrategyleaderfor theneurosciencetherapeuticareabeforejoiningtheconsumersectorascompanygroupchairmanasiapacificthecompanyhas announcedthatmrmongonwillbenamedexecutivevicepresidentandworldwidechairmanconsumerandamemberofthe executivecommitteeupontheretirementofhispredecessormrmesquitaeffectivemarchinadditiontoleadingthe consumerbusinessmrmongonwillhaveresponsibilityforjohnsonjohnsonsoutheastasia f mrmesneedjoinedthecompanyinasproductdirectorforpersonalproductsasubsidiaryofthecompanyandgained increasedresponsibilitiesinexecutivepositionsacrosstheglobalenterpriseinmrsneedwasappointedcompanygroup chairmanconsumernorthamericafollowedbycompanygroupchairmanvisioncarefranchiseininhebecame thevicepresidentglobalcorporateaffairsandchiefcommunicationsofficermrsneedwasappointedexecutivevicepresident globalcorporateaffairsandchiefcommunicationsofficerinjanuaryandbecameamemberoftheexecutivecommitteein julyleadingthecorporationsglobalmarketingcommunicationdesignandphilanthropyfunctions g drpstoffelsjoinedthecompanyinwiththeacquisitionoftibotecvirconvwherehewaschiefexecutiveofficerofvirco nvandchairmanoftibotecnvinhewasappointedcompanygroupchairmanglobalvirologyinheassumedthe roleofcompanygroupchairmanpharmaceuticalsdrstoffelswasappointedglobalheadresearchdevelopment pharmaceuticalsinandinbecameworldwidechairmanpharmaceuticalsindrstoffelswasappointedchief scientificofficerandbecameamemberoftheexecutivecommitteeindrstoffelswasnamedexecutivevicepresident chiefscientificofficerindrstoffelswaspromotedtovicechairmanoftheexecutivecommitteechiefscientificofficerhe isresponsibleforthecompanysinnovationagendaacrossthepharmaceuticalmedicaldevicesandconsumersectorsproduct safetystrategyandthecompanysglobalpublichealthstrategy h msjltaubertjoinedthecompanyinasworldwidevicepresidentatjohnsonjohnsonpharmaceuticalservicesa subsidiaryofthecompanysheheldseveralexecutivepositionsinthepharmaceuticalsectoruntilwhenshewasappointed companygroupchairmannorthamericapharmaceuticalsandinbecamecompanygroupchairmantheamericas pharmaceuticalsinjulymstaubertwaspromotedtoexecutivevicepresidentworldwidechairmanpharmaceuticalsand becameamemberoftheexecutivecommittee mrmhullmannjoinedthecompanyinasacorporateattorneyinthelawdepartmenthewasappointedcorporate secretaryinandservedinthatroleuntilduringthattimehealsoheldvariousmanagementpositionsinthelaw departmentinhewasnamedgeneralcounselmedicaldevicesanddiagnosticsandwasappointedvicepresidentgeneral counselandbecameamemberoftheexecutivecommitteeininaprilmrullmannwasnamedexecutivevice presidentgeneralcounselmrullmannhasworldwideresponsibilityforlegalgovernmentaffairspolicyglobalsecurityaviation andhealthcarecomplianceprivacy j mskewengeljoinedthecompanyinasprojectengineerandengineeringsupervisoratjanssenasubsidiaryofthe companyduringhertenurewiththecompanyshehasheldavarietyofstrategicleadershipandexecutivepositionsacrossthe globalenterpriseinroleswithinoperationsqualityengineeringnewproductsinformationtechnologyandothertechnicaland businessfunctionsinmswengelbecamethefirstchiefqualityofficerofthecompanyinshewaspromotedtovice presidentjohnsonjohnsonsupplychaininjulyshewaspromotedtoexecutivevicepresidentchiefglobalsupplychain officerandbecameamemberoftheexecutivecommittee k mrjjwolkjoinedthecompanyinasfinancemanagerbusinessdevelopmentfororthomcneilasubsidiaryofthe companyandthroughtheyearsheldavarietyofseniorleadershiprolesinseveralsegmentsandfunctionsacrossthecompanys subsidiariesinpharmaceuticalsmedicaldevicesandsupplychainfromtoheservedasvicepresidentfinanceand chieffinancialofficerofthejanssenpharmaceuticalcompaniesofjohnsonjohnsoninmrwolkbecamethevice presidentinvestorrelationsinjulyhewasappointedexecutivevicepresidentchieffinancialofficerandbecameamember oftheexecutivecommitteemrwolkisresponsibleforleadingthedevelopmentandexecutionofthecompanysgloballongterm financialstrategy johnsonjohnsonannualreportpart ii item market registrants common equity related stockholder matters issuer purchases equity securities asoffebruarytherewererecordholdersofcommonstockofthecompanyadditionalinformation calledforbythisitemisincorporatedhereinbyreferencetothefollowingsectionsofthisreportnotecommon stockstockoptionplansandstockcompensationagreementsofthenotestoconsolidatedfinancialstatements includedinitemanditemsecurityownershipofcertainbeneficialownersandmanagementandrelated stockholdermattersequitycompensationplaninformation issuer purchases equity securities ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyscommonstocksharerepurchasestakeplace fromtimetotimeontheopenmarketorthroughprivatelynegotiatedtransactionstherepurchaseprogramhasnotime limitandmaybesuspendedforperiodsordiscontinuedatanytime thefollowingtableprovidesinformationwithrespecttocommonstockpurchasesbythecompanyduringthefiscalfourth quarterofcommonstockpurchasesontheopenmarketaremadeaspartofasystematicplantomeettheneeds ofthecompanyscompensationprogramstherepurchasesbelowalsoincludethestockforstockoptionexercisesthat settledinthefiscalfourthquarter totalnumberof maximumnumberor sharesorunits approximatedollar purchasedaspart valueofsharesorunits totalnumber ofpublicly thatmayyetbe ofshares avgprice announcedplans purchasedunderthe period purchased paidpershare orprograms plansorprograms octoberthroughoctober octoberthroughnovember novemberthrough december total duringthefiscalfourthquarterofthecompanyrepurchasedanaggregateofsharesofjohnsonjohnson commonstockinopenmarkettransactionsofwhichshareswerepurchasedpursuanttotherepurchaseprogramthat waspubliclyannouncedondecemberandofwhichshareswerepurchasedinopenmarkettransactionsas partofasystematicplantomeettheneedsofthecompanyscompensationprograms asofdecemberanaggregateofshareswerepurchasedforatotalofbillionsincetheinceptionofthe repurchaseprogramannouncedondecember asofdecemberthemaximumnumberofsharesthatmayyetbepurchasedundertheplanisbasedonthe closingpriceofjohnsonjohnsoncommonstockonthenewyorkstockexchangeondecemberofpershare johnsonjohnsonannualreport item selected financial data summary operations statistical data dollarsinmillionsexcept pershareamounts salestocustomersus salestocustomers international totalsales costofproductssold sellingmarketingand administrativeexpenses researchanddevelopment expense inprocessresearchand development interestincome interestexpensenetof portioncapitalized otherincomeexpense net restructuring earningsbeforeprovision fortaxesonincome provisionfortaxeson income netearnings addnetlossattributable tononcontrollinginterest netearnings attributableto johnsonjohnson percentofsalesto customers dilutednetearningsper shareofcommonstock percentreturnonaverage shareholdersequity percentincrease decreaseover previousyear salestocustomers dilutednetearningsper share nm supplementarybalance sheetdata propertyplantand equipmentnet additionstopropertyplant andequipment totalassets longtermdebt operatingcashflow commonstock information dividendspaidpershare shareholdersequityper share marketpricepershare yearendclose averagesharesoutstanding millions basic diluted employeesthousands attributabletojohnsonjohnson pertheadoptionofasuprioryearamountsontheconsolidatedstatementofearningshavebeenreclassifiedtoretroactivelyapply classificationoftheservicecostcomponentandtheothercomponentsofnetperiodicbenefitcost nmnotmeaningful johnsonjohnsonannualreportitem managements discussion analysis results operations financial condition organization business segments descriptionofthecompanyandbusinesssegments johnsonjohnsonanditssubsidiariesthecompanyhaveapproximatelyemployeesworldwideengagedinthe researchanddevelopmentmanufactureandsaleofabroadrangeofproductsinthehealthcarefieldthecompany conductsbusinessinvirtuallyallcountriesoftheworldwiththeprimaryfocusonproductsrelatedtohumanhealthand wellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothegeneralpublicandsold bothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentisfocusedonsixtherapeutic areasincludingimmunologyinfectiousdiseasesneuroscienceoncologypulmonaryhypertensionandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgeryinterventionalsolutionscardiovascularandneurovasculardiabetescaredivestedinthefiscal fourthquarterofandvisionfieldswhicharedistributedtowholesalershospitalsandretailersandusedprincipally intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics theexecutivecommitteeofjohnsonjohnsonistheprincipalmanagementgroupresponsibleforthestrategic operationsandallocationoftheresourcesofthecompanythiscommitteeoverseesandcoordinatestheactivitiesofthe consumerpharmaceuticalandmedicaldevicesbusinesssegments inallofitsproductlinesthecompanycompeteswithcompaniesbothlocallyandgloballythroughouttheworld competitionexistsinallproductlineswithoutregardtothenumberandsizeofthecompetingcompaniesinvolved competitioninresearchinvolvingthedevelopmentandtheimprovementofnewandexistingproductsandprocessesis particularlysignificantthedevelopmentofnewandinnovativeproductsaswellasprotectingtheunderlyingintellectual propertyofthecompanysproductportfolioisimportanttothecompanyssuccessinallareasofitsbusinessthe competitiveenvironmentrequiressubstantialinvestmentsincontinuingresearchinadditionthedevelopmentand maintenanceofcustomerdemandforthecompanysconsumerproductsinvolvessignificantexpendituresforadvertising andpromotion johnsonjohnsonannualreport managementsobjectives withourcredoasthefoundationthecompanyspurposeistoblendheartscienceandingenuitytoprofoundly changethetrajectoryofhealthforhumanitythecompanyiscommittedtobringingitsfullbreadthanddepthtoensure healthforpeopletodayandforfuturegenerationsunitedaroundthiscommonambitionthecompanyispoisedtofulfillits purposeandsuccessfullymeetthedemandsoftherapidlyevolvingmarketsinwhichitcompetes thecompanyisbroadlybasedinhumanhealthcareandiscommittedtocreatingvaluebydevelopingaccessiblehigh qualityinnovativeproductsandservicesnewproductsintroducedwithinthepastfiveyearsaccountedforapproximately ofsalesinbillionwasinvestedinresearchanddevelopmentandbillionspenton acquisitionsreflectingmanagementscommitmenttocreatelifeenhancinginnovationsandtocreatevaluethrough partnershipsthatwillprofoundlychangethetrajectoryofhealthforhumanity acriticaldriverofthecompanyssuccessisthediverseemployeesthatworkacrossmorethanoperating companieswhicharelocatedinmorethancountriesemployeesareempoweredandinspiredtoleadwiththe companysourcredoandpurposeasguidesthisallowseveryemployeetousethecompanysreachandsizeto advancethecompanyspurposeandtoalsoleadwithagilityandurgencyleveragingtheextensiveresourcesacrossthe enterpriseenablesthecompanytoinnovateandexecutewithexcellencethisensuresthecompanycanremainfocused onaddressingtheunmetneedsofsocietyeverydayandinvestforanenduringimpactultimatelydeliveringvaluetoits patientsconsumersandhealthcareprofessionalsemployeescommunitiesandshareholders snoillib ni snoillib ni srallod ni research acquisicidons net cash dividends paid per development acquired share results operations analysisofconsolidatedsales inworldwidesalesincreasedtobillioncomparedtoanincreasesofandinand respectivelythesesaleschangesconsistedofthefollowing salesincreasedecreasedueto volume price currency total inthenetimpactofacquisitionsanddivestituresontheworldwidesalesgrowthwasapositiveimpactofin acquisitionsanddivestitureshadapositiveimpactofontheworldwidesalesgrowthinacquisitions anddivestitureshadanegativeimpactofontheworldwidesalesgrowthandcompetitiveproductstothe companyshepatitiscproductsolysiosovriadsimeprevirandincivotelaprevirhadanegativeimpactof ontheworldwidesalesgrowthoperationsinvenezuelanegativelyimpactedtheworldwidesalesgrowth salesbyuscompanieswerebillioninbillioninandbillioninthisrepresents increasesofininandinsalesbyinternationalcompanieswerebillionin billioninandbillioninthisrepresentsanincreaseofininanda decreaseofin johnsonjohnsonannualreportthefiveyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectivelythetenyearcompoundannualgrowthratesforworldwideusandinternationalsaleswereand respectively insalesbycompaniesineuropeachievedgrowthofascomparedtotheprioryearincludingoperational growthofandapositivecurrencyimpactofsalesbycompaniesinthewesternhemisphereexcludingthe usachievedgrowthofascomparedtotheprioryearincludingoperationalgrowthofandanegative currencyimpactofsalesbycompaniesintheasiapacificafricaregionachievedgrowthofascomparedto theprioryearincludingoperationalgrowthofandapositivecurrencyimpactof inthecompanyhadthreewholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenuesinthecompanyhadtwowholesalersdistributing productsforallthreesegmentsthatrepresentedapproximatelyandofthetotalconsolidatedrevenuesin thecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximately andofthetotalconsolidatedrevenues sales geographic region billions sales segment billions europe western hemisphere consumer pharmaceutical asiapacific africa us medical devices analysis sales business segments consumersegment consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandanegativecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandanegative currencyimpactofinacquisitionsanddivestitureshadanetnegativeimpactofontheoperational salesgrowthoftheworldwideconsumersegment majorconsumerfranchisesales change dollarsinmillions vs vs beauty otc babycare oralcare womenshealth woundcareother totalconsumersales johnsonjohnsonannualreport thebeautyfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwasprimarilydrivenby neutrogenaogxandaveenoproductsaswellasstrengthofdrcilaboanddabaoproductsoutside theusgrowthwaspartiallyoffsetbythedivestitureofnizoral theoverthecounterotcfranchisesalesofbillionincreasedascomparedtotheprioryeargrowthwas primarilydrivenbyshareconsumptionandmarketgrowthacrossmultiplebrandsincludingzyrtectylenoland childrensmotrinaswellasdigestivehealthproductsandantismokingaidsadditionallysalesfromtherecentus acquisitionofzarbeesinccontributedapproximatelytogrowth thebabycarefranchisesaleswerebillioninadecreaseofcomparedtotheprioryearprimarilydueto johnsonssharedeclineandincreasedtradepromotionsduetothejohnsonsbabyrelaunchandthenegative impactofcurrencythiswaspartiallyoffsetbystronggrowthofaveenobabydrivenbygeographicexpansion theoralcarefranchisesalesofbillionincreasedascomparedtotheprioryearprimarilydrivenbystrong marketingcampaignsandnewproductlaunches thewomenshealthfranchisesaleswerebillioninadecreaseofascomparedtotheprioryeargrowth inlatinamericawasoffsetbythenegativeimpactofcurrency thewoundcareotherfranchisesaleswerebillioninadecreaseofascomparedtotheprioryear primarilyduetothedivestitureofcompeed consumersegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthandapositivecurrencyimpactofusconsumersegmentsaleswerebillionanincreaseof internationalsaleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrency impactofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowth oftheworldwideconsumersegment johnsonjohnsonannualreportpharmaceutical segment pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandapositivecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpact ofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegment majorpharmaceutical therapeuticareasales change dollarsinmillions vs vs totalimmunology remicade simponisimponiaria stelara tremfya otherimmunology totalinfectiousdiseases edurantrilpivirine prezistaprezcobixrezolstasymtuza otherinfectiousdiseases totalneuroscience concertamethylphenidate invegasustennaxeplioninvegatrinza trevicta risperdalconsta otherneuroscience totaloncology darzalex imbruvica velcade zytigaabirateroneacetate otheroncology pulmonaryhypertension opsumit tracleer uptravi cardiovascularmetabolismother xarelto invokanainvokamet procriteprex totalpharmaceuticalsales prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation percentagegreaterthanornotmeaningful productsacquiredfromacteliononjune johnsonjohnsonannualreport immunologyproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprioryear growthwasdrivenbystronguptakeofstelaraustekinumabincrohnsdiseasestronglaunchuptakeoftremfya guselkumabexpandedindicationsofsimponisimponiariagolimumabandtheusimmunologymarket growthimmunologywasnegativelyimpactedbylowersalesofremicadeinfliximabduetoincreaseddiscounts rebatesandbiosimilarcompetition thepatentsforremicadeinfliximabincertaincountriesineuropeexpiredinfebruarybiosimilarversionsof remicadehavebeenintroducedincertainmarketsoutsidetheusresultinginareductioninsalesofremicadein thosemarketsadditionalbiosimilarcompetitionwilllikelyresultinafurtherreductioninremicadesalesinmarkets outsidetheunitedstatesintheusabiosimilarversionofremicadewasintroducedinandadditional competitorscontinuetoenterthemarketcontinuedinfliximabbiosimilarcompetitionintheusmarketwillresultina furtherreductioninussalesofremicadeseenotetotheconsolidatedfinancialstatementsforadescriptionof legalmattersregardingtheremicadepatents infectiousdiseaseproductssaleswerebillioninrepresentinganincreaseofascomparedtotheprior yearsalesgrowthofprezcobixrezolstadarunavircobicistatedurantrilpivirineandthelaunchof symtuzaandjulucadolutegravirrilpivirinewaspartiallyoffsetbylowersalesofprezistadarunavir neuroscienceproductssaleswerebillionrepresentinganincreaseofascomparedtotheprioryearstrong salesoflongactinginjectablesinvegatrinzatrevictapaliperidonepalmitateandinvegasustenna xeplionwerepartiallyoffsetbycannibalizationofrisperdalconstarisperidoneandgenericcompetitionfor concertamethylphenidate oncologyproductsachievedsalesofbillioninrepresentinganincreaseofascomparedtotheprior yearcontributorstothegrowthwerestrongsalesofdarzalexdaratumumabwithcontinuedmarketgrowthand sharegainimbruvicaibrutinibduetoincreasedpatientuptakegloballyandsalesofzytigaabirateroneacetate drivenbylatitudedataandmarketgrowthadditionallysalesfromthelaunchoferleadaapalutamidecontributed tothegrowthanumberofcompaniesmarketinggenericpharmaceuticalshavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheusseekingtomarketgenericformsof zytigapriortoexpirationofitsapplicablepatentstheseandasincludeallegationsofnoninfringementandinvalidity oftheapplicablepatentsinoctoberthecourtissuedarulinginvalidatingallassertedclaimsoftheapplicable patentjanssenhasappealedthecourtsdecisioninnovembertheuscourtofappealsforthefederalcircuit deniedjanssensrequestforaninjunctionpendingappealasaresultseveralgenericversionsofzytigahaveentered themarketresultinginadeclineinsalesofzytigaintheunitedstatesinthecompanyreportedussalesof billionforzytigaseenotetotheconsolidatedfinancialstatementsforadescriptionoflegalmatters regardingzytiga thepulmonaryhypertensiontherapeuticareawasestablishedwiththeacquisitionofactelionltdonjune salesinrepresentedafullyearascomparedtohalfayearinsalesofopsumitmacitentanand uptraviselexipagwerepositivelyimpactedbymarketgrowthandsharegainswhilesalesoftracleerbosetan werenegativelyimpactedbyincreaseduseofopsumitandgenerics cardiovascularmetabolismotherproductssaleswerebillionadeclineofascomparedtotheprioryear lowersalesofinvokanainvokametcanagliflozinintheuswasprimarilyduetoanincreaseinpricediscounts higherrebatesandmarketsharedeclinedrivenbycompetitivepressurelowersalesofxareltorivaroxabanwere drivenbyanincreaseindiscountsandrebatespartiallyoffsetbyanincreaseinmarketshare johnsonjohnsonannualreportduringthecompanyadvanceditspipelinewithseveralregulatorysubmissionsandapprovalsfornewdrugsand additionalindicationsforexistingdrugsasfollows productnamechemical us eu us eu name indication approval approval filing filing darzalexdaratumumab frontlinemultiplemyelomatransplantineligiblepatientsin combinationwithbortezomibmelphalanandprednisone erdafitinib treatmentoflocallyadvancedormetastaticurothelialcancer erleadaapalutamide treatmentofnonmetastaticcastrationresistantprostate cancer esketamine antidepressantfortreatmentresistantdepressioninadults imbruvicaibrutinib treatmentofwaldenstromsmacroglobulinemiausedin combinationwithrituximab treatmentforpreviouslyuntreatedchroniclymphocytic leukemiaincombinationwithobinutuzumab invokanacanagliflozin reducetheriskofdeathintypediabeteswithestablished orriskforcardiovasculardiseasecanvascanvasr julucarilpivirineand singletabletoncedailytwodrugregimenforthetreatment dolutegravir ofhivinfection opsumitmacitentan treatmentofadultswithinoperablechronicthromboembolic pulmonaryhypertensiontoimproveexercisecapacityand pulmonaryvascularresistance stelaraustekinumab treatmentofadultswithmoderatelytoseverelyactive ulcerativecolitis symtuzadarunavir cobicistatemtricitabinetenofovir acompletedarunavirbasedsingletabletregimenforthe alafenamide treatmentofhivinfection tremfyaguselkumab patientcontrolledinjectorforthetreatmentofadultslivingwith moderatetosevereplaquepsoriasis xareltorivaroxaban treatmenttoreducetheriskofmajorcardiovasculareventsin peoplewithchroniccoronaryorperipheralarterydisease forthepreventionofvenousthromboembolismformedicallyill patients zytigaabirateroneacetate treatmentofhormonenavemetastaticprostatecancer pharmaceuticalsegmentsalesinwerebillionanincreaseoffromwhichincludedoperational growthofandapositivecurrencyimpactofussaleswerebillionanincreaseofinternational saleswerebillionanincreaseofwhichincludedoperationalgrowthandapositivecurrencyimpact ofinacquisitionsanddivestitureshadanetpositiveimpactofontheoperationalsalesgrowthofthe worldwidepharmaceuticalsegmentadjustmentstopreviousreserveestimatesascomparedtotheprioryearnegatively impactedthereportedpharmaceuticalsegmentoperationalgrowthbyapproximatelyprimarilyintheimmunology andcardiovascularmetabolismothertherapeuticareas medicaldevicessegment themedicaldevicessegmentsalesinwerebillionanincreaseoffromwhichincludedan operationalincreaseofandapositivecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionanincreaseofascomparedtotheprioryear withanoperationalincreaseofandapositivecurrencyimpactofinacquisitionsanddivestitureshada netnegativeimpactofontheworldwideoperationalsalesgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreport majormedicaldevicesfranchisesales change dollarsinmillions vs vs surgery advanced general specialty orthopaedics hips knees trauma spineother vision contactlensesother surgical interventionalsolutions diabetescare diagnostics totalmedicaldevicessales previouslyreferredtoascardiovascular onjunethecompanydivestedtheorthoclinicaldiagnosticsbusinessthediagnosticsfranchiseandamounts representtransitionalserviceagreementthatconcludedin prioryearamountshavebeenreclassifiedtoconformtocurrentyearpresentation productsacquiredfromabbottmedicalopticsamoonfebruary percentagegreaterthanornotmeaningful thesurgeryfranchisesaleswerebillioninanincreaseoffromgrowthinadvancedsurgerywas primarilydrivenbyendocutterbiosurgeryandenergyproductsgrowthingeneralsurgerywasprimarilydrivenbywound careproductsgrowthinspecialtysurgerywasprimarilydrivenbyadvancedsterilizationproducts theorthopaedicsfranchisesaleswerebillioninadecreaseoffromthedeclineinspineother wasprimarilyduetothecodmanneurosurgerydivestitureandsharelossinspinepartiallyoffsetbynewproduct launchesthedeclineinkneeswasprimarilyduetocompetitivepressureintheuspartiallyoffsetbygrowthinasia pacificgrowthinhipsandtraumawasduetocontinueduptakeofnewproducts thevisionfranchiseachievedsalesofbillioninanincreaseoffromgrowthwasprimarilydriven bystrengthoftheastigmatismanddailydisposablelensesintheoasyscontactlensescategorysurgicalgrowthwas drivenbycataractperformanceprimarilyoutsidetheus theinterventionalsolutionsfranchiseincludesthecerenovusbusinesspreviouslyincludedinspineandotherin orthopaedicssaleswerebillionanincreaseoffromstronggrowthintheelectrophysiologybusiness wasdrivenbyatrialfibrillationproceduregrowthandcontinueduptakeofthethermocoolsmarttouchcontact forcesensingcatheter thediabetescarefranchisesaleswerebillionadecreaseoffromthedeclinewasprimarilydueto divestitureofitslifescanbusinessinthefiscalfourthquarterofandthecompanysdecisiontoexittheanimas insulinpumpbusinessinthefiscalfourthquarterof themedicaldevicessegmentsalesinwerebillionanincreaseoffromwhichincludedan operationalincreaseofandapositivecurrencyimpactofussaleswerebillionanincreaseof ascomparedtotheprioryearinternationalsaleswerebillionanincreaseofascomparedtotheprioryear withanoperationalincreaseofandapositivecurrencyimpactofinacquisitionsanddivestitureshada netpositiveimpactofontheworldwideoperationalsalesgrowthofthemedicaldevicessegmentascomparedto johnsonjohnsonannualreportanalysis consolidated earnings provision taxes income consolidatedearningsbeforeprovisionfortaxesonincomewasbillionbillionandbillionforthefiscal yearsendedandrespectivelyasapercenttosalesconsolidatedearningsbeforeprovisionfortaxes onincomewasandinandrespectively earnings provision taxes period ending income tax snoillib percent sales costofproductssoldandsellingmarketingandadministrativeexpensescostofproductssoldandselling marketingandadministrativeexpensesasapercenttosaleswereasfollows ofsales costofproductssold percentpointincreasedecreaseovertheprioryear sellingmarketingandadministrativeexpenses percentpointincreasedecreaseovertheprioryear prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu incostofproductssoldasapercenttosalesdecreasedtofromascomparedtothesameperioda yearagoprimarilyduetolowerinventorystepupcostsrelatedtotheactelionacquisitionandfavorableproductand segmentmixdrivenbyahigherpercentageofsalesfromthepharmaceuticalsegmentthiswasmostlyoffsetbyhigher amortizationexpenseprimarilyrelatedtotheactelionacquisitiononjuneintangibleassetamortizationexpense ofbillionwasincludedincostofproductssoldforascomparedtobillionintherewasadecrease inthepercenttosalesofsellingmarketingandadministrativeexpensesinascomparedtotheprioryearprimarily duetolowercostsrelativetosalesgrowthinthepharmaceuticalbusinessandfavorablesegmentmix incostofproductssoldasapercenttosalesincreasedtofromascomparedtothesameperioda yearagotheunfavorableincreasewasprimarilydrivenbybillionofhigheramortizationexpenseandchargesfor inventorystepuprelatedtotherecentacquisitionsprimarilyactelionintangibleassetamortizationexpenseofbillion wasincludedincostofproductssoldforascomparedtobillionintherewasanincreaseinthepercent tosalesofsellingmarketingandadministrativeexpensesinascomparedtotheprioryearprimarilydueto investmentsinnewproductlaunchespartiallyoffsetbyfavorablemix johnsonjohnsonannualreport researchanddevelopmentexpenseresearchanddevelopmentexpensebysegmentofbusinesswasasfollows dollarsinmillions amount ofsales amount ofsales amount ofsales consumer pharmaceutical medicaldevices totalresearchanddevelopmentexpense percentincreasedecreaseovertheprior year prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu asapercenttosegmentsales researchanddevelopmentactivitiesrepresentasignificantpartofthecompanysbusinesstheseexpendituresrelateto theprocessesofdiscoveringtestinganddevelopingnewproductsupfrontpaymentsandmilestonesimprovingexisting productsaswellasensuringproductefficacyandregulatorycompliancepriortolaunchthecompanyremains committedtoinvestinginresearchanddevelopmentwiththeaimofdeliveringhighqualityandinnovativeproductsin worldwidecostsofresearchanddevelopmentactivitiesincreasedbycomparedtobutdecreasedasa percentofsalesthedecreaseasapercentofsalesinthepharmaceuticalsegmentwasattributabletolowercosts relativetosalesgrowththeincreaseddollarspendinthemedicaldevicesandpharmaceuticalsegmentswasfor investmentspendingtoadvancethepipelineinworldwidecostsofresearchanddevelopmentactivitiesincreased bycomparedtotheincreaseasapercentofsaleswasprimarilyinthepharmaceuticalsegmentdueto generalportfolioprogressionaswellascollaborativeagreementsenteredintowithidorsialtdandlegendbiotech researchfacilitiesarelocatedintheusbelgiumbrazilchinafrancegermanyindiaisraelthenetherlandspoland singaporeswedenswitzerlandandtheunitedkingdomwithadditionalrdsupportinoverothercountries inprocessresearchanddevelopmentiprdinthecompanyrecordedaniprdchargeofbillion ofthebillionapartialimpairmentchargeofbillionrelatedtothedevelopmentprogramofalan investigationaldrugforthetreatmentofrespiratorysyncytialvirusrsvandhumanmetapneumovirushmpvacquired withtheacquisitionofaliosbiopharmainctheimpairmentchargewascalculatedbasedonupdatedcashflow projectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephasebclinicaltrial suspensionadecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivitiesthe companycontinuestoevaluateinformationwithrespecttothedevelopmentprogramandwillmonitortheremaining billionintangibleassetforfurtherimpairmentinadditionanimpairmentchargeofbillionwasrecordedforthe discontinuationofthedevelopmentprojectforanantithrombinantibodyassociatedwiththeacquisitionofxo limited inthecompanyrecordedaniprdchargeofbillionprimarilyforthediscontinuationofcertaindevelopment projectsrelatedtonovirawhichwasacquiredintheproductdevelopmentwascanceledduetosafetyconcernsin thecompanyrecordedaniprdchargeofmillionforthediscontinuationofadevelopmentprogramrelatedto crucell otherincomeexpensenetotherincomeexpensenetistheaccountwherethecompanyrecordsgainsand lossesrelatedtothesaleandwritedownofcertaininvestmentsinequitysecuritiesheldbyjohnsonjohnson innovationjjdcincjjdcunrealizedgainsandlossesoninvestmentsgainsandlossesondivestiturescertain transactionalcurrencygainsandlossesacquisitionrelatedcostslitigationaccrualsandsettlementsaswellasroyalty income thechangeinotherincomeexpensenetforthefiscalyearwasanunfavorablechangeofbillionprimarilydue tolitigationexpenseofbillioninascomparedtobillioninadditionallyincludedunrealized lossesonsecuritiesofbillionandlowerrealizedgainsofbillionrelatedtoinvestmentsinequitysecuritiesas comparedtotheprioryearthiswaspartiallyoffsetbyareversalofacontingentliabilityofbillionandlowercostsof billionrelatedtotheactelionandamoacquisitionsinascomparedtothefiscalyearofincluded againofbillionrelatedtomonetizationoffutureroyaltyreceivablesoffsetbyanassetimpairmentchargeof billionprimarilyrelatedtotheinsulinpumpbusinessdivestituregainswereapproximatelybillioninand includedthelifescanbusinessnizoralrocandcertainnonstrategicpharmaceuticalproductsdivestituregains wereapproximatelybillioninandprimarilyincludedthecodmanneurosurgeryandcompeeddivestitures additionallyrestructuringrelatedexpenseinwasbillionascomparedtobillion johnsonjohnsonannualreportthechangeinotherincomeexpensenetforthefiscalyearwasafavorablechangeofbillionduetohigher gainsofbilliononthesaleofassetsbusinessesprimarilythecodmanneurosurgeryandcompeeddivestituresa gainofbillionrelatedtomonetizationoffutureroyaltyreceivablesandahighergainofbillionrelatedtothesale ofcertaininvestmentsinequitysecuritiesascomparedtotheprioryearthiswaspartiallyoffsetbyhigherlitigation expenseofbillionbillionofacquisitioncostsrelatedtoactelionandamoanassetimpairmentchargeof billionprimarilyrelatedtotheinsulinpumpbusinessandahigherrestructuringrelatedchargeofbillionas comparedtothefiscalyear interestincomeexpenseinterestincomewashigherinascomparedtoduetoahigheraverageinterest rateandabenefitfromnetinvestmenthedgingpartiallyoffsetbyaloweraveragecashcashequivalentsandmarketable securitiesbalanceduringtheperiodcashcashequivalentsandmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothecashcashequivalentsandmarketablesecuritiestotalof billionandbillionaveragecashbalanceinthedecreaseintheaveragebalanceofcashcash equivalentsandmarketablesecuritieswasduetotheuseofcashforgeneralcorporatepurposesprimarilytheactelion acquisitionforbillionnetofcashacquiredlateinthefiscalsecondquarterof interestexpenseinwashigherascomparedtoduetoahigheraveragedebtbalancetheaveragedebt balancewasbillioninversusbillioninthetotaldebtbalanceattheendofwas billionascomparedtobillionattheendof interestincomeinincreasedslightlyascomparedtoduetohigheraverageinterestratespartiallyoffsetby lowercashcashequivalentsandmarketablesecuritiesbalancesduringtheperiodcashcashequivalentsand marketablesecuritiestotaledbillionattheendofandaveragedbillionascomparedtothe billionaveragecashbalanceinthedecreaseinthebalanceofcashcashequivalentsandmarketable securitieswasduetotheuseofcashforgeneralcorporatepurposesincludingacquisitionsprimarilytheactelion acquisitionforbillionnetofcashacquired interestexpenseinwashigherascomparedtotheaveragedebtbalancewasbillioninversus billioninthetotaldebtbalanceattheendofwasbillionascomparedtobillionattheend ofthehigherdebtbalanceofapproximatelybillionwasprimarilyduetoincreasedborrowingsthecompany increasedborrowingsinfebruaryandnovemberofcapitalizingonfavorabletermsinthecapitalmarketsthe proceedsoftheborrowingswereusedforgeneralcorporatepurposesincludingthecompletionofthestockrepurchase program incomebeforetaxbysegment incomebeforetaxbysegmentofbusinesswereasfollows percentof incomebeforetax segmentsales segmentsales dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensesnotallocatedtosegments earningsbeforeprovisionfortaxesonincome seenotetotheconsolidatedfinancialstatementsformoredetails amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense consumersegmentintheconsumersegmentincomebeforetaxasapercenttosaleswasversus inthedecreaseintheincomebeforetaxasapercentofsalesinascomparedtowasprimarily attributabletohigherlitigationexpenseofbillioninpartiallyoffsetbyslowerincreasesinexpensesrelativeto theincreaseinsalesdivestituregainsforthefiscalyearofwhichincludedthedivestituresofnizoralandroc werecomparabletofiscalyearofagainofbillionwasrecognizedfromthedivestitureofnizoral intheconsumersegmentincomebeforetaxasapercenttosaleswasversusintheincrease intheincomebeforetaxasapercentofsalesinascomparedtowasattributabletohighergainson johnsonjohnsonannualreport divestituresprimarilythedivestitureofcompeedinthiswaspartiallyoffsetbyhighersellingmarketingand administrativeexpensesascomparedtotheprioryearduetoincreasedadvertisingandpromotionalspendingandslightly higheramortizationexpenseinrelatedtoacquisitionsadditionallythefiscalyearwasnegativelyimpactedby operationsinvenezuela pharmaceuticalsegmentinthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswas versusintheincreaseintheincomebeforetaxasapercentofsaleswasprimarilyduetolowerinventory stepupcostsrelatedtoactelionofbillionfavorableproductmixandslowerincreasesinexpensesrelativetothe increaseinsalesacontingentliabilityreversalofbillionandhigherdivestituregainsofbillionfromdivestituresof certainnonstrategicpharmaceuticalproductsthiswaspartiallyoffsetbyhigheramortizationexpenseofbillion primarilyrelatedtotheactelionacquisitionahigheriprdchargeofbillionandanunrealizedlossonsecuritiesof billionascomparedtotheprioryearadditionallyincludedagainofbillionrelatedtomonetizationof futureroyaltyreceivablesandahighergainofbillionrelatedtothesaleofcertaininvestmentsinequitysecurities inthepharmaceuticalsegmentincomebeforetaxasapercenttosaleswasversusinthe decreaseintheincomebeforetaxasapercentofsaleswasprimarilyduetobillionofhigheramortizationexpense andothercostsrelatedtotheactelionacquisitionhigherresearchanddevelopmentexpenseahigheriprdchargeof billionrelatedtonoviraandlowergainsondivestituresascomparedtotheprioryearadditionallythefiscalyear includedapositiveadjustmentofbilliontopreviousreserveestimatesthiswaspartiallyoffsetbyagainof billionrelatedtomonetizationoffutureroyaltyreceivablesahighergainofbillionrelatedtothesaleofcertain investmentsinequitysecuritiesandfavorableproductmixin medicaldevicessegmentinthemedicaldevicessegmentincomebeforetaxasapercenttosaleswas versusinthedecreaseintheincomebeforetaxasapercenttosaleswasprimarilyduehigherlitigation expenseofbillioninascomparedtobillioninandhigherinvestmentsinthebusinessin additionallyhadlowerdivestituregainsofapproximatelybillionascomparedtodivestituregainsinin thecompanyrecordedagainofbillionrelatedtothelifescandivestiturethiswaspartiallyoffsetbylower restructuringexpenseofbillioninascomparedtoadditionallyincludedanassetimpairment chargeofbillionprimarilyrelatedtotheinsulinpumpbusiness inthemedicaldevicessegmentincomebeforetaxasapercenttosaleswasversusinthe decreaseintheincomebeforetaxasapercenttosaleswasprimarilyduetobillionofhigheramortizationexpense andotheracquisitioncostsrelatedtoamobillionofhigherlitigationanassetimpairmentchargeofbillion primarilyrelatedtotheinsulinpumpbusinessbillionofhigherrestructuringandinvestmentsinnewproductlaunches ascomparedtothefiscalyearthiswaspartiallyoffsetbybillionhighergainsinrelatedtodivestitures primarilythedivestitureofcodmanneurosurgery restructuringinthefirstquarterofthecompanyannouncedrestructuringactionsinitsmedicaldevices segmentthecompanyhasachievedapproximatelybillionofannualizedpretaxcostsavinginandisontrack toachievetheannualizedpretaxcostsavingsofbilliontobillionasoutlinedintherestructuringactionsthe savingswillprovidethecompanywithaddedflexibilityandresourcestofundinvestmentinnewgrowthopportunitiesand innovativesolutionsforcustomersandpatientsinthecompanyrecordedapretaxchargeofmillionof whichmillionisincludedincostofproductssoldandmillionisincludedinotherincomeexpensetotal projectcostsofapproximatelybillionhavebeenrecordedsincetherestructuringwasannouncedthisrestructuring programwascompletedinthefiscalfourthquarterof inthesecondquarterofthecompanyannouncedplanstoimplementactionsacrossitsglobalsupplychainthatare intendedtoenablethecompanytofocusresourcesandincreaseinvestmentsincriticalcapabilitiestechnologiesand solutionsnecessarytomanufactureandsupplyitsproductportfolioofthefutureenhanceagilityanddrivegrowththe companyexpectsthesesupplychainactionswillincludeexpandingitsuseofstrategiccollaborationsandbolsteringits initiativestoreducecomplexityimprovingcostcompetitivenessenhancingcapabilitiesandoptimizingits networkdiscussionsregardingspecificfutureactionsareongoingandaresubjecttoallrelevantconsultation requirementsbeforetheyarefinalizedintotalthecompanyexpectstheseactionstogenerateapproximatelyto billioninannualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecord pretaxrestructuringchargesofapproximatelytobillionthecompanyestimatesthatapproximatelyofthe cumulativepretaxcostswillresultincashoutlaysinthecompanyrecordedapretaxchargeofmillionof whichmillionisincludedincostofproductssoldandmillionisincludedinotherincomeexpense seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtotherestructuringprograms johnsonjohnsonannualreportprovisionfortaxesonincometheworldwideeffectiveincometaxratewasininand intheeffectivetaxratedecreasedbyascomparedtotheeffectivetaxratewas primarilydrivenbyaprovisionaltaxchargeofapproximatelybillionasaresultofthetaxcutsandjobsacttcja recordedinthefourthquarterofandtheimpactofabelgianstatutorytaxratechangewhichincreasedthe effectiveratebythecompanyalsoreceivedabenefitinfromalowerusstatutorytaxratevsaswell asfavorableadjustmentstotheprovisionaltcjataxchargepartiallyoffsetbyunfavorableincometaxmixandthe ustaxonglobalintangiblelowtaxedincomegilti theeffectivetaxrateincreasedbyascomparedtoprimarilydrivenbytheenactmentofthetaxcuts andjobsacttcjaintheunitedstatesindecembertheenactmentofthetcjaresultedinaprovisionaltax chargeinthefourthquarterofofapproximatelybillionorapproximatelypercentagepointincreasetothe effectivetaxrateseenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtothetcja theremainderoftheincreaseinthetaxrateforwasrelatedtotheremeasurementofthecompanysdeferredtax assetsinbelgiumasaresultofchangesinthebelgianstatutorycorporatetaxrateenactedindecemberoffsetby ataxbenefitfortheclosureofthecompanysanimasinsulinpumpbusiness thegovernmentinswitzerlandiscurrentlyconsideringtaxreformlegislationwhichcouldhaveamaterialimpactonthe companyseffectivetaxrateifenactedintolaw seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtothetcjaandincometaxes liquidity capital resources liquiditycashflows cashandcashequivalentswerebillionattheendofascomparedtobillionattheendofthe primarysourcesandusesofcashthatcontributedtothebillionincreasewereapproximatelybillionofcash generatedfromoperatingactivitiesthiswaspartiallyoffsetbybillionnetcashusedbyinvestingactivities billionnetcashusedbyfinancingactivitiesandbillionduetotheeffectonexchangeratechangesoncash andcashequivalentsinadditionthecompanyhadbillioninmarketablesecuritiesattheendofand billionattheendofseenotetotheconsolidatedfinancialstatementsforadditionaldetailsoncashcash equivalentsandmarketablesecurities cashflowfromoperationsofbillionwastheresultofbillionofnetearningsandbillionofnoncash expensesandotheradjustmentsfordepreciationandamortizationstockbasedcompensationandassetswritedowns offsetbybillionfromnetgainsonsaleofassetsbusinessesdeferredtaxprovisionandaccountsreceivable allowancesbillionrelatedtoanincreaseinaccountsreceivableinventoriesandothercurrentandnoncurrentassets andadecreaseinothercurrentandnoncurrentliabilitiesadditionalsourcesofoperatingcashflowofbillion resultedfromanincreaseinaccountspayableandaccruedliabilitiesthedecreaseincurrentandnoncurrentliabilitiesis primarilyduetothetaxpaymentrelatedtotcja investingactivitiesuseofbillionwasforadditionstopropertyplantandequipmentofbillionthenetpurchase ofinvestmentsprimarilymarketablesecuritiesofbillionacquisitionsnetofcashacquiredofbillionprimarilythe acquisitionsofzarbeesandotherusesofbillionthiswaspartiallyoffsetbybillionofproceedsfromthe disposalofassetsbusinessesprimarilythedivestitureoflifescan financingactivitiesuseofbillionwasprimarilyfordividendstoshareholdersofbillionbillionforthe repurchaseofcommonstockbillionforthenetretirementofshortandlongtermdebtandbillionofother financingfinancingactivitiesalsoincludedsourcesofbillionofproceedsfromstockoptionsexercisedemployee withholdingtaxonstockawardsnet ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashasofdecemberbillionhasbeenrepurchasedundertheprogram asofdecemberthecompanysnotespayableandlongtermdebtwasinexcessofcashcashequivalentsand marketablesecuritiesasofdecemberthenetdebtpositionwasbillionascomparedtotheprioryearof billiontherewasadecreaseinthenetdebtpositionduetoretirementofdebtthedebtbalanceattheendof johnsonjohnsonannualreport wasbillionascomparedtobillioninadditionallytherewasahighercashcashequivalentsand marketablesecuritiesbalanceattheendofinthecompanycontinuedtohaveaccesstoliquiditythroughthe commercialpapermarketadditionallyasaresultofthetcjathecompanyhasaccesstoitscashoutsidetheusata significantlyreducedcostthecompanyanticipatesthatoperatingcashflowstheabilitytoraisefundsfromexternal sourcesborrowingcapacityfromexistingcommittedcreditfacilitiesandaccesstothecommercialpapermarketswill continuetoprovidesufficientresourcestofundoperatingneedsforthenexttwelvemonthsthecompanymonitorsthe globalcapitalmarketsonanongoingbasisandfromtimetotimemayraisecapitalwhenmarketconditionsarefavorable thecompanyfiledanewshelfregistrationonfebruarywhichwillenableittoissuedebtsecuritiesonatimely basisforadditionaldetailsonborrowingsseenotetotheconsolidatedfinancialstatements financingandmarketrisk thecompanyusesfinancialinstrumentstomanagetheimpactofforeignexchangeratechangesoncashflows accordinglythecompanyentersintoforwardforeignexchangecontractstoprotectthevalueofcertainforeigncurrency assetsandliabilitiesandtohedgefutureforeigncurrencytransactionsprimarilyrelatedtoproductcostsgainsorlosses onthesecontractsareoffsetbythegainsorlossesontheunderlyingtransactionsaappreciationoftheusdollar fromthedecembermarketrateswouldincreasetheunrealizedvalueofthecompanysforwardcontractsby millionconverselyadepreciationoftheusdollarfromthedecembermarketrateswoulddecrease theunrealizedvalueofthecompanysforwardcontractsbymillionineitherscenariothegainorlossontheforward contractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhavenoimpactonfuture anticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrencyexchangeratesandtheeffectoncertainassetsand liabilitiesinforeigncurrencybyenteringintocurrencyswapcontractsachangeinthespreadbetweenusand foreigninterestratesonthecompanysinterestratesensitivefinancialinstrumentswouldeitherincreaseordecreasethe unrealizedvalueofthecompanysswapcontractsbyapproximatelymillionineitherscenarioatmaturitythegainor lossontheswapcontractwouldbeoffsetbythegainorlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedcashflows thecompanydoesnotenterintofinancialinstrumentsfortradingorspeculativepurposesfurtherthecompanyhasa policyofonlyenteringintocontractswithpartiesthathaveatleastaninvestmentgradecreditratingthecounterparties tothesecontractsaremajorfinancialinstitutionsandthereisnosignificantconcentrationofexposurewithanyone counterpartymanagementbelievestheriskoflossisremoteduringthefiscalsecondquarterofthecompany enteredintocreditsupportagreementscsawithcertainderivativecounterpartiesestablishingcollateralthresholds basedonrespectivecreditratingsandnettingagreements thecompanyinvestsinbothfixedrateandfloatingrateinterestearningsecuritieswhichcarryadegreeofinterestrate riskthefairmarketvalueoffixedratesecuritiesmaybeadverselyimpactedduetoariseininterestrateswhilefloating ratesecuritiesmayproducelessincomethanpredictedifinterestratesfallabasispointschangeinspreadon thecompanysinterestratesensitiveinvestmentswouldeitherincreaseordecreasetheunrealizedvalueofcash equivalentsandcurrentmarketablesecuritiesbyapproximatelymillion thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementarenotmaterial totalborrowingsattheendofandwerebillionandbillionrespectivelythedecreasein borrowingswasduetotheretirementofdebtininnetdebtcashandcurrentmarketablesecuritiesnetof debtwasbillioncomparedtonetdebtofbillionintotaldebtrepresentedoftotalcapital shareholdersequityandtotaldebtinandoftotalcapitalinshareholdersequitypershareattheend ofwascomparedtoatyearend asummaryofborrowingscanbefoundinnotetotheconsolidatedfinancialstatements contractualobligationsandcommitments thecompanyscontractualobligationsareprimarilyfortherecentlyenactedtaxlegislationleasesdebtandunfunded retirementplanstherearenoothersignificantobligationstosatisfytheseobligationsthecompanywillusecashfrom johnsonjohnsonannualreportoperationsthefollowingtablesummarizesthecompanyscontractualobligationsandtheiraggregatematuritiesasof decemberseenotesandtotheconsolidatedfinancialstatementsforfurtherdetails tax intereston unfunded legislation debt debt retirement operating dollarsinmillions tcja obligations obligations plans leases total total fortaxmattersseenotetotheconsolidatedfinancialstatementsforotherretirementplanandpostemployment medicalbenefitinformationseenotetotheconsolidatedfinancialstatementsthetabledoesnotincludeactivity relatedtobusinesscombinations dividends thecompanyincreaseditsdividendinforthethconsecutiveyearcashdividendspaidwerepersharein comparedwithdividendsofpershareinandpersharein information criticalaccountingpoliciesandestimates managementsdiscussionandanalysisofresultsofoperationsandfinancialconditionarebasedonthecompanys consolidatedfinancialstatementsthathavebeenpreparedinaccordancewithaccountingprinciplesgenerallyacceptedin theusgaapthepreparationofthesefinancialstatementsrequiresthatmanagementmakeestimatesand assumptionsthataffecttheamountsreportedforrevenuesexpensesassetsliabilitiesandotherrelateddisclosures actualresultsmayormaynotdifferfromtheseestimatesthecompanybelievesthattheunderstandingofcertainkey accountingpoliciesandestimatesareessentialinachievingmoreinsightintothecompanysoperatingresultsand financialconditionthesekeyaccountingpoliciesincluderevenuerecognitionincometaxeslegalandselfinsurance contingenciesvaluationoflonglivedassetsassumptionsusedtodeterminetheamountsrecordedforpensionsandother employeebenefitplansandaccountingforstockbasedawards revenuerecognitionthecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofa contractwiththecustomeraresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthe companysglobalpaymenttermsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentives tradepromotionscouponsproductreturnsanddiscountstocustomersareaccountedforasvariableconsiderationand recordedasareductioninsalesseenotetotheconsolidatedfinancialstatementsfortheaccountingstandards updaterelatedtorevenuewhichwasadoptedin productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual termshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit johnsonjohnsonannualreport tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsofcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomers inadditionthecompanyentersintocollaborationarrangementsthatcontainmultiplerevenuegeneratingactivities amountsduefromcollaborativepartnersforthesearrangementsarerecognizedaseachactivityisperformedordelivered basedontherelativesellingpriceupfrontfeesreceivedaspartofthesearrangementsaredeferredandrecognizedover theperformanceperiodseenotetotheconsolidatedfinancialstatementsforadditionaldisclosuresoncollaborations reasonablylikelychangestoassumptionsusedtocalculatetheaccrualsforrebatesreturnsandpromotionsarenot anticipatedtohaveamaterialeffectonthefinancialstatementsthecompanycurrentlydisclosestheimpactofchanges toassumptionsinthequarterlyorannualfilinginwhichthereisamaterialfinancialstatementimpact belowaretablesthatshowtheprogressionofaccruedrebatesreturnspromotionsreservefordoubtfulaccountsand reserveforcashdiscountsbysegmentofbusinessforthefiscalyearsendeddecemberanddecember consumersegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreportpharmaceutical segment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset includesadjustments medicaldevicessegment balanceat balanceat beginning payments endof dollarsinmillions ofperiod accruals credits period accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total accruedrebates accruedreturns accruedpromotions subtotal reservefordoubtfulaccounts reserveforcashdiscounts total includesreserveforcustomerrebatesofmillionatdecemberandmillionatdecemberrecordedasa contraasset johnsonjohnsonannualreport incometaxesincometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludethe resultsofanydifferencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilities thecompanyestimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesin taxlawsandratesmayaffectrecordeddeferredtaxassetsandliabilities thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardingincometaxes legalandselfinsurancecontingenciesthecompanyrecordsaccrualsforvariouscontingenciesincludinglegal proceedingsandproductliabilityclaimsastheseariseinthenormalcourseofbusinesstheaccrualsarebasedon managementsjudgmentastotheprobabilityoflossesandwhereapplicableactuariallydeterminedestimatesthe companyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyinadditiontoaccrualsintheself insuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesareprobableandamountscanbe reasonablyestimated thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued seenotesandtotheconsolidatedfinancialstatementsforfurtherinformationregardingproductliabilityandlegal proceedings longlivedandintangibleassetsthecompanyassesseschangesineconomicconditionsandmakesassumptions regardingestimatedfuturecashflowsinevaluatingthevalueofthecompanyspropertyplantandequipmentgoodwill andintangibleassetsastheseassumptionsandestimatesmaychangeovertimeitmayormaynotbenecessaryforthe companytorecordimpairmentcharges employeebenefitplansthecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefit definedcontributionandterminationindemnityplanswhichcovermostemployeesworldwidetheseplansarebasedon assumptionsforthediscountrateexpectedreturnonplanassetsmortalityratesexpectedsalaryincreaseshealthcare costtrendratesandattritionratesseenotetotheconsolidatedfinancialstatementsforfurtherdetailsontheserates andtheeffectaratechangetothehealthcarecosttrendwouldhaveonthecompanysresultsofoperations stockbasedcompensationthecompanyrecognizescompensationexpenseassociatedwiththeissuanceofequity instrumentstoemployeesfortheirservicesbasedonthetypeofequityinstrumentthefairvalueisestimatedonthedate ofgrantusingeithertheblackscholesoptionvaluationmodeloracombinationofboththeblackscholesoption valuationmodelandmontecarlovaluationmodelandisexpensedinthefinancialstatementsovertheserviceperiodthe inputassumptionsusedindeterminingfairvaluearetheexpectedlifeexpectedvolatilityriskfreerateandexpected dividendyieldforperformanceshareunitsthefairmarketvalueiscalculatedforeachofthethreecomponentgoalsatthe dateofgrantthefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedon thedateofgrantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenot paidontheperformanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalof eachperformanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelseenoteto theconsolidatedfinancialstatementsforadditionalinformation newaccountingpronouncements refertonotetotheconsolidatedfinancialstatementsforrecentlyadoptedaccountingpronouncementsandrecently issuedaccountingpronouncementsnotyetadoptedasofdecember johnsonjohnsonannualreporteconomicandmarketfactors thecompanyisawarethatitsproductsareusedinanenvironmentwhereformorethanadecadepolicymakers consumersandbusinesseshaveexpressedconcernsabouttherisingcostofhealthcareinresponsetotheseconcerns thecompanyhasalongstandingpolicyofpricingproductsresponsiblyfortheperiodintheusthe weightedaveragecompoundannualgrowthrateofthecompanysnetpriceincreasesforhealthcareproducts prescriptionandoverthecounterdrugshospitalandprofessionalproductswasbelowtheusconsumerpriceindex cpi thecompanyoperatesincertaincountrieswheretheeconomicconditionscontinuetopresentsignificantchallengesthe companycontinuestomonitorthesesituationsandtakeappropriateactionsinflationratescontinuetohaveaneffecton worldwideeconomiesandconsequentlyonthewaycompaniesoperatethecompanyhasaccountedforoperationsin argentinabeginninginthefiscalthirdquarterofandvenezuelaashighlyinflationaryasthepriorthreeyear cumulativeinflationratesurpassedthisdidnothaveamaterialimpacttothecompanysresultsintheperiodin thefaceofincreasingcoststhecompanystrivestomaintainitsprofitmarginsthroughcostreductionprograms productivityimprovementsandperiodicpriceincreases injunetheunitedkingdomukheldareferenduminwhichvotersapprovedanexitfromtheeuropeanunion eucommonlyreferredtoasbrexitandinmarchtheukformallystartedtheprocessfortheuktoleavethe eugiventhelackofcomparableprecedentitisunclearwhatfinancialtraderegulatoryandlegalimplicationsthe withdrawaloftheukfromtheeuwillhavebrexitcreatesglobalpoliticalandeconomicuncertaintywhichmaycause amongotherconsequencesvolatilityinexchangeratesandinterestratesadditionalcostcontainmentbythirdparty payorsandchangesinregulationshoweverthecompanycurrentlydoesnotbelievethattheseandotherrelatedeffects willhaveamaterialimpactonthecompanysconsolidatedfinancialpositionoroperatingresultsasofdecember thebusinessofthecompanysuksubsidiariesrepresentedlessthanofboththecompanysconsolidated assetsandfiscaltwelvemonthsrevenuesrespectively thecompanyisexposedtofluctuationsincurrencyexchangeratesachangeinthevalueoftheusdollaras comparedtoallforeigncurrenciesinwhichthecompanyhadsalesincomeorexpenseinwouldhaveincreasedor decreasedthetranslationofforeignsalesbyapproximatelymillionandnetincomebyapproximatelymillion governmentsaroundtheworldconsidervariousproposalstomakechangestotaxlawswhichmayincludeincreasingor decreasingexistingstatutorytaxratesachangeinstatutorytaxrateinanycountrywouldresultintherevaluationofthe companysdeferredtaxassetsandliabilitiesrelatedtothatparticularjurisdictionintheperiodinwhichthenewtaxlawis enactedthischangewouldresultinanexpenseorbenefitrecordedtothecompanysconsolidatedstatementof earningsthecompanycloselymonitorstheseproposalsastheyariseinthecountrieswhereitoperateschangestothe statutorytaxratemayoccuratanytimeandanyrelatedexpenseorbenefitrecordedmaybematerialtothefiscalquarter andyearinwhichthelawchangeisenactedonseptembertheswissparliamentapprovedthefederalacton taxreformandahvfinancingswisstaxreformhoweverareferendumhasbeencalledandasaresultapublicvote ontheswisstaxreformwilltakeplaceonmaythiftheswisstaxreformpassesthenthemeasuresare expectedtocomeintoforceineitherjanuaryorjanuarypriortoapprovalinthereferendumandits subsequentcantonalimplementationtheproposedswisstaxreformisnotenactedandthereforethecompanyhasnot reflectedanyofthepotentialimpactsinitsfiscalresultsthecompanyiscurrentlyassessingtheimpactoftheproposed swisstaxreformandwhenenactedthelawmayhaveamaterialimpactonthecompanysoperatingresults thecompanyfacesvariousworldwidehealthcarechangesthatmaycontinuetoresultinpricingpressuresthatinclude healthcarecostcontainmentandgovernmentlegislationrelatingtosalespromotionsandreimbursementofhealthcare products changesinthebehaviorandspendingpatternsofpurchasersofhealthcareproductsandservicesincludingdelaying medicalproceduresrationingprescriptionmedicationsreducingthefrequencyofphysicianvisitsandforegoinghealth careinsurancecoverageasaresultofthecurrentglobaleconomicdownturnmaycontinuetoimpactthecompanys businesses thecompanyalsooperatesinanenvironmentincreasinglyhostiletointellectualpropertyrightsfirmshavefiled abbreviatednewdrugapplicationsorbiosimilarbiologicalproductapplicationswiththefdaorotherwisechallenged thecoverageandorvalidityofthecompanyspatentsseekingtomarketgenericorbiosimilarformsofmanyofthe companyskeypharmaceuticalproductspriortoexpirationoftheapplicablepatentscoveringthoseproductsintheevent thecompanyisnotsuccessfulindefendingthepatentclaimschallengedintheresultinglawsuitsgenericorbiosimilar versionsoftheproductsatissuewillbeintroducedtothemarketresultinginthepotentialforsubstantialmarketshareand johnsonjohnsonannualreport revenuelossesforthoseproductsandwhichmayresultinanoncashimpairmentchargeinanyassociatedintangible assetthereisalsoariskthatoneormorecompetitorscouldlaunchagenericorbiosimilarversionoftheproductatissue followingregulatoryapprovaleventhoughoneormorevalidpatentsareinplaceforfurtherinformationseethe discussiononremicaderelatedcasesandlitigationagainstfilersofabbreviatednewdrugapplicationsin notetotheconsolidatedfinancialstatements legalproceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialandothermattersgovernmentalinvestigationsandotherlegalproceedingsthatarise fromtimetotimeintheordinarycourseofbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedthecompanyhasaccruedforcertain litigationmattersandcontinuestomonitoreachrelatedlegalissueandadjustaccrualsfornewinformationandfurther developmentsinaccordancewithaccountingstandardscodificationascfortheseandotherlitigation andregulatorymatterscurrentlydisclosedforwhichalossisprobableorreasonablypossiblethecompanyisunableto estimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccruedforlegalcontingencies oftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrelyheavilyonestimatesand assumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvariousfactorsincludingwhether damagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegaldiscoveryhasnot commencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertaintiestherearesignificant factsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod seenotetotheconsolidatedfinancialstatementsforfurtherinformationregardinglegalproceedings commonstock thecompanyscommonstockislistedonthenewyorkstockexchangeunderthesymboljnjasoffebruary therewererecordholdersofcommonstockofthecompany johnsonjohnsonannualreportitem quantitative qualitative disclosures market risk theinformationcalledforbythisitemisincorporatedhereinbyreferencetoitemmanagementsdiscussionand analysisofresultsofoperationsandfinancialconditionliquidityandcapitalresourcesfinancingandmarketrisk ofthisreportandnotesummaryofsignificantaccountingpoliciesfinancialinstrumentsofthenotesto consolidatedfinancialstatementsincludedinitemofthisreport item financial statements supplementary data indextoauditedconsolidatedfinancialstatements consolidatedbalancesheets consolidatedstatementsofearnings consolidatedstatementsofcomprehensiveincome consolidatedstatementsofequity consolidatedstatementsofcashflows notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm managementsreportoninternalcontroloverfinancialreporting johnsonjohnsonannualreport johnson johnson subsidiaries consolidated balance sheets atdecemberanddecember dollarsinmillionsexceptshareandpershareamountsnote assets currentassets cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccounts inventoriesnotesand prepaidexpensesandotherreceivables assetsheldforsalenote totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherassets totalassets liabilitiesandshareholdersequity currentliabilities loansandnotespayablenote accountspayable accruedliabilities accruedrebatesreturnsandpromotions accruedcompensationandemployeerelatedobligations accruedtaxesonincomenote totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand longtermtaxespayablenote otherliabilities totalliabilities shareholdersequity preferredstockwithoutparvalueauthorizedandunissuedshares commonstockparvaluepersharenoteauthorizedsharesissued shares accumulatedothercomprehensiveincomelossnote retainedearnings lesscommonstockheldintreasuryatcostnotesharesandshares totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements earnings dollarsandsharesinmillionsexceptpershareamountsnote salestocustomers costofproductssold grossprofit sellingmarketingandadministrativeexpenses researchanddevelopmentexpense inprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearnings netearningspersharenotesand basic diluted averagesharesoutstandingnotesand basic diluted prioryearsamountswerereclassifiedtoconformtocurrentyearpresentationadoptionofasu seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements comprehensive income dollarsinmillionsnote netearnings othercomprehensiveincomelossnetoftax foreigncurrencytranslation securities unrealizedholdinggainlossarisingduringperiod reclassificationstoearnings netchange employeebenefitplans priorservicecreditcostnetofamortization gainlossnetofamortization effectofexchangerates netchange derivativeshedges unrealizedgainlossarisingduringperiod reclassificationstoearnings netchange othercomprehensiveincomeloss comprehensiveincome includestheimpactfromadoptionofasuforfurtherdetailsseenotetotheconsolidatedfinancialstatements thetaxeffectsinothercomprehensiveincomeforthefiscalyearsendedandrespectivelyforeign currencytranslationmillioninduetotheenactmentoftheustaxcutsandjobsactsecuritiesmillion millionandmillionemployeebenefitplansmillionmillionandmillionderivativeshedges millionmillionandmillion seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportjohnson johnson subsidiaries consolidated statements equity dollarsinmillionsnote accumulated common stock treasury retained comprehensive issued stock total earnings income amount amount balancejanuary netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancejanuary netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember cumulativeadjustment netearnings cashdividendspaidpershare employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomelossnetoftax balancedecember seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheeffectofcumulativeadjustmentstoretainedearnings seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreport johnson johnson subsidiaries consolidated statements cash flows dollarsinmillionsnote cashflowsfromoperatingactivities netearnings adjustmentstoreconcilenetearningstocashflowsfromoperatingactivities depreciationandamortizationofpropertyandintangibles stockbasedcompensation assetwritedowns gainonsaleofassetsbusinesses deferredtaxprovision accountsreceivableallowances changesinassetsandliabilitiesnetofeffectsfromacquisitionsanddivestitures increaseinaccountsreceivable increasedecreaseininventories increaseinaccountspayableandaccruedliabilities increaseinothercurrentandnoncurrentassets decreaseincreaseinothercurrentandnoncurrentliabilities netcashflowsfromoperatingactivities cashflowsfrominvestingactivities additionstopropertyplantandequipment proceedsfromthedisposalofassetsbusinessesnet acquisitionsnetofcashacquirednote purchasesofinvestments salesofinvestments otherprimarilyintangibles netcashusedbyinvestingactivities cashflowsfromfinancingactivities dividendstoshareholders repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebtnetofissuancecosts retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsemployeewithholdingtaxonstockawardsnet netcashusedbyfinancingactivities effectofexchangeratechangesoncashandcashequivalents increasedecreaseincashandcashequivalents cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest interestnetofamountcapitalized incometaxes supplementalscheduleofnoncashinvestingandfinancingactivities treasurystockissuedforemployeecompensationandstockoptionplansnetofcashproceedsemployee withholdingtaxonstockawards conversionofdebt acquisitions fairvalueofassetsacquired fairvalueofliabilitiesassumedandnoncontrollinginterests netcashpaidforacquisitions seenotestoconsolidatedfinancialstatements johnsonjohnsonannualreportnotes consolidated financial statements summary significant accounting policies principlesofconsolidation theconsolidatedfinancialstatementsincludetheaccountsofjohnsonjohnsonanditssubsidiariesthecompany intercompanyaccountsandtransactionsareeliminated descriptionofthecompanyandbusinesssegments thecompanyhasapproximatelyemployeesworldwideengagedintheresearchanddevelopmentmanufacture andsaleofabroadrangeofproductsinthehealthcarefieldthecompanyconductsbusinessinvirtuallyallcountriesof theworldanditsprimaryfocusisonproductsrelatedtohumanhealthandwellbeing thecompanyisorganizedintothreebusinesssegmentsconsumerpharmaceuticalandmedicaldevicesthe consumersegmentincludesabroadrangeofproductsusedinthebabycareoralcarebeautyoverthecounter pharmaceuticalwomenshealthandwoundcaremarketstheseproductsaremarketedtothegeneralpublicandsold bothtoretailoutletsanddistributorsthroughouttheworldthepharmaceuticalsegmentisfocusedonsixtherapeutic areasincludingimmunologyinfectiousdiseasesneuroscienceoncologypulmonaryhypertensionandcardiovascular andmetabolicdiseasesproductsinthissegmentaredistributeddirectlytoretailerswholesalershospitalsandhealth careprofessionalsforprescriptionusethemedicaldevicessegmentincludesabroadrangeofproductsusedinthe orthopaedicsurgeryinterventionalsolutionscardiovascularandneurovasculardiabetescaredivestedinthefiscal fourthquarterofandvisionfieldswhicharedistributedtowholesalershospitalsandretailersandusedprincipally intheprofessionalfieldsbyphysiciansnurseshospitalseyecareprofessionalsandclinics newaccountingstandards recentlyadoptedaccountingstandards asurevenuefromcontractswithcustomers onjanuarythecompanyadoptedthenewaccountingstandardascrevenuefromcontractswith customersandalltherelatedamendmentsnewrevenuestandardtoallcontractsusingthemodifiedretrospective methodthecumulativeeffectofinitiallyapplyingthenewrevenuestandardwasrecognizedasanadjustmenttothe openingbalanceofretainedearningsthecomparativeinformationhasnotbeenrestatedandcontinuestobereported undertheaccountingstandardsineffectforthoseperiodstheadoptionofthenewrevenuestandardhasnothada materialimpacttoeitherreportedsalestocustomersornetearningsadditionallythecompanywillcontinueto recognizerevenuefromproductsalesasgoodsareshippedordeliveredtothecustomerascontrolofgoodstransfersat thesametime inaccordancewiththenewrevenuestandardrequirementsthedisclosureoftheimpactofadoptiononthecompanys consolidatedstatementofearningsandbalancesheetwasasfollows statementofearningsforthefiscalyearendeddecember balancewithoutadoption dollarsinmillions asreported effectofchange ofasc salestocustomers netearnings balancesheetasofdecember balancewithoutadoption asreported effectofchange ofasc assets liabilities equity thecompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionof asuwhichdecreasedbeginningretainedearningsbymillion johnsonjohnsonannualreport aspartoftheadoptionofascseenotetotheconsolidatedfinancialstatementsforfurtherdisaggregationof revenue asufinancialinstrumentsrecognitionandmeasurementoffinancialassetsandfinancialliabilities thecompanyadoptedthisstandardasofthebeginningofthefiscalyearonamodifiedretrospectivebasisthe amendmentsinthisupdatesupersedetheguidancetoclassifyequitysecuritieswithreadilydeterminablefairvaluesinto differentcategoriesthatistradingoravailableforsaleandrequireequitysecuritiestobemeasuredatfairvaluewith changesinthefairvaluerecognizedthroughnetearningsthestandardamendsfinancialreportingbyprovidingrelevant informationaboutanentitysequityinvestmentsandreducingthenumberofitemsthatarerecognizedinother comprehensiveincome thecompanymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofasu thatincreasedretainedearningsbymillionnetoftaxanddecreasedaccumulatedothercomprehensive incomeforpreviouslyunrealizedgainsfromequityinvestmentsforadditionaldetailsseenotetotheconsolidated financialstatements asuincometaxesintraentitytransfersofassetsotherthaninventory thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdateremovesthecurrent exceptioninusgaapprohibitingentitiesfromrecognizingcurrentanddeferredincometaxexpensesorbenefitsrelated totransferofassetsotherthaninventorywithintheconsolidatedentitythecurrentexceptiontodefertherecognitionof anytaximpactonthetransferofinventorywithintheconsolidatedentityuntilitissoldtoathirdpartyremainsunaffected asdiscussedfurtherinnotetotheconsolidatedfinancialstatementsinthefourthfiscalquarterofthecompany electedanaccountingpolicytotreatthetaxonglobalintangiblelowtaxedincomegiltiunderthedeferredtax accountingmodelasaresultthecompanyisrequiredtorecordanadditionaldeferredtaxliabilityrelatedtothebasis differenceoftheseintraentityassettransfersthecompanyrecordednetadjustmentsincludinganincreasetodeferred taxassetsofapproximatelybillionanincreasetodeferredtaxliabilitiesofapproximatelybillionrelatedtothe giltiaccountingpolicyelectioninthefourthfiscalquarterofadecreasetootherassetsofapproximately billionandadecreasetoretainedearningsofapproximatelybilliontheadoptionofthisstandarddidnothavea materialimpactonthecompanysconsolidatedfinancialstatements asuclarifyingthedefinitionofabusiness thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdatenarrowsthedefinitionofa businessbyprovidingascreentodeterminewhenanintegratedsetofassetsandactivitiesisnotabusinessthescreen specifiesthatanintegratedsetofassetsandactivitiesisnotabusinessifsubstantiallyallofthefairvalueofthegross assetsacquiredordisposedofisconcentratedinasingleoragroupofsimilaridentifiableassetsthisupdatewasapplied prospectivelytheadoptionofthisstandarddidnothaveamaterialimpactonthecompanysconsolidatedfinancial statements asuimprovingthepresentationofnetperiodicpensioncostandnetperiodicpostretirementbenefitcost thecompanyadoptedthisstandardasofthebeginningofthefiscalyearthisupdaterequiresthatanemployer disaggregatetheservicecostcomponentfromtheothercomponentsofnetperiodicbenefitcostnpbcinadditiononly theservicecostcomponentwillbeeligibleforcapitalizationtheamendmentsinthisupdatearerequiredtobeapplied retrospectivelyforthepresentationoftheservicecostcomponentandtheothercomponentsofnpbcinthe consolidatedstatementofearningsandprospectivelyonandaftertheadoptiondateforthecapitalizationoftheservice costcomponentofnpbcinassetsasrequiredbythetransitionprovisionsofthisupdatethefollowingtableshowsthe impactoftheadoptionontherespectivelineitemsintheconsolidatedstatementofearningsforandthe reclassificationstotheandfiscalyearconsolidatedstatementofearningstoretroactivelyapplyclassification oftheservicecostcomponentandtheothercomponentsofnpbc increasedecrease tonetexpense dollarsinmillions costofproductssold sellingmarketingandadministrativeexpenses researchanddevelopmentexpense otherincomeexpensenet earningsbeforeprovisionfortaxesonincome johnsonjohnsonannualreportthefollowingtablesummarizesthecumulativeeffectadjustmentsmadetotheopeningbalanceofretainedearnings uponadoptionofthenewaccountingstandardsmentionedabove cumulativeeffect adjustmentincrease decreaseto dollarsinmillions retainedearnings asurevenuefromcontractswithcustomers asufinancialinstruments asuincometaxesintraentitytransfers total asutargetedimprovementstoaccountingforhedgingactivities thecompanyelectedtoearlyadoptthisstandardasofthebeginningofthefiscalsecondquarterofthisupdate makesmorefinancialandnonfinancialhedgingstrategieseligibleforhedgeaccountingitalsoamendsthepresentation anddisclosurerequirementsandchangeshowcompaniesassesseffectivenesstheadoptionofthisstandarddidnot haveamaterialimpactonthecompanysconsolidatedfinancialstatementsforadditionalrequireddisclosuresseenote totheconsolidatedfinancialstatements recentlyissuedaccountingstandards notadoptedasofdecember asucollaborativearrangements thisupdateclarifiestheinteractionbetweenasccollaborativearrangementsandascrevenuefrom contractswithcustomerstheupdateclarifiesthatcertaintransactionsbetweenparticipantsinacollaborative arrangementshouldbeaccountedforunderascwhenthecounterpartyisacustomerinadditiontheupdate precludesanentityfrompresentingconsiderationfromatransactioninacollaborativearrangementasrevenueifthe counterpartyisnotacustomerforthattransactionthisupdatewillbeeffectiveforthecompanyforfiscalyearsbeginning afterdecemberandinterimperiodswithinthosefiscalyearsasushouldbeappliedretrospectivelyto thedateofinitialapplicationofascandearlyadoptionispermittedthecompanyiscurrentlyassessingtheimpact ofthisupdateonthecompanysconsolidatedfinancialstatementsandrelateddisclosures asuderivativesandhedgingtopicasc thisupdateaddstheovernightindexswapoisratebasedonthesecuredovernightfinancingratesofrasan eligiblebenchmarkinterestratepermittedintheapplicationofhedgeaccountingthisupdatewillbeeffectiveforthe companyforfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyearsearlyadoption ispermittedifanentityhasadoptedasuthecompanyiscurrentlyassessingtheimpactofthisupdateonthe companysconsolidatedfinancialstatementsandrelateddisclosures asureclassificationofcertaintaxeffectsfromaccumulatedothercomprehensiveincome thisupdateallowsareclassificationfromaccumulatedothercomprehensiveincometoretainedearningsforstrandedtax effectsresultingfromthetaxcutsandjobactenactedindecemberthisupdatewillbeeffectiveforthecompany forfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyearsthecompanydoesnot expectthisstandardtohaveamaterialimpactonthecompanysconsolidatedfinancialstatements asufinancialinstrumentscreditlosses thisupdateintroducesthecurrentexpectedcreditlossceclmodelwhichwillrequireanentitytomeasurecredit lossesforcertainfinancialinstrumentsandfinancialassetsincludingtradereceivablesunderthisupdateoninitial recognitionandateachreportingperiodanentitywillberequiredtorecognizeanallowancethatreflectstheentitys currentestimateofcreditlossesexpectedtobeincurredoverthelifeofthefinancialinstrumentthisupdatewillbe effectiveforthecompanyforfiscalyearsbeginningafterdecemberandinterimperiodswithinthosefiscalyears earlyadoptionispermittedthecompanyiscurrentlyassessingtheimpactofthisupdateonthecompanysconsolidated financialstatementsandrelateddisclosures asuleases thisupdaterequirestherecognitionofleaseassetsandleaseliabilitiesonthebalancesheetforallleaseobligationsand disclosingkeyinformationaboutleasingarrangementsthisupdaterequirestherecognitionofleaseassetsandlease liabilitiesbylesseesforthoseleasesclassifiedasoperatingleasesundercurrentgenerallyacceptedaccounting johnsonjohnsonannualreport principlesthisupdatewillbeeffectiveforthecompanyforallannualperiodsbeginningafterdecember includinginterimperiodswithinthosefiscalyearsthecompanywillapplythenewstandardatitsadoptiondaterather thanattheearliestcomparativeperiodpresentedinthefinancialstatementsthecompanysoperatingleaseswillresultin therecognitionofadditionalassetsandthecorrespondingliabilitiesonitsconsolidatedbalancesheetstheadoptionof thisstandardwillnothaveamaterialimpactonthecompanysconsolidatedfinancialstatements cashequivalents thecompanyclassifiesallhighlyliquidinvestmentswithstatedmaturitiesofthreemonthsorlessfromdateofpurchase ascashequivalentsandallhighlyliquidinvestmentswithstatedmaturitiesofgreaterthanthreemonthsfromthedateof purchaseascurrentmarketablesecuritiesthecompanyhasapolicyofmakinginvestmentsonlywithcommercial institutionsthathaveatleastaninvestmentgradecreditratingthecompanyinvestsitscashprimarilyingovernment securitiesandobligationscorporatedebtsecuritiesmoneymarketfundsandreverserepurchaseagreementsrras rrasarecollateralizedbydepositsintheformofgovernmentsecuritiesandobligationsforanamountnotlessthan oftheirvaluethecompanydoesnotrecordanassetorliabilityasthecompanyisnotpermittedtosellor repledgetheassociatedcollateralthecompanyhasapolicythatthecollateralhasatleastanaorequivalentcredit ratingthecompanyutilizesathirdpartycustodiantomanagetheexchangeoffundsandensurethatcollateralreceivedis maintainedatofthevalueoftherrasonadailybasisrraswithstatedmaturitiesofgreaterthanthreemonths fromthedateofpurchaseareclassifiedasmarketablesecurities investments investmentsclassifiedasheldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesare reportedinearningsinvestmentsclassifiedasavailableforsalearecarriedatestimatedfairvaluewithunrealizedgains andlossesrecordedasacomponentofaccumulatedothercomprehensiveincomeavailableforsalesecuritiesavailable forcurrentoperationsareclassifiedascurrentassetsotherwisetheyareclassifiedaslongtermmanagementdetermines theappropriateclassificationofitsinvestmentindebtandequitysecuritiesatthetimeofpurchaseandreevaluatessuch determinationateachbalancesheetdatethecompanyreviewsitsinvestmentsinequitysecuritiesforimpairmentand adjuststheseinvestmentstofairvaluethroughearningsasrequired propertyplantandequipmentanddepreciation propertyplantandequipmentarestatedatcostthecompanyutilizesthestraightlinemethodofdepreciationoverthe estimatedusefullivesoftheassets buildingandbuildingequipment years landandleaseholdimprovements years machineryandequipment years thecompanycapitalizescertaincomputersoftwareanddevelopmentcostsincludedinmachineryandequipmentwhen incurredinconnectionwithdevelopingorobtainingcomputersoftwareforinternalusecapitalizedsoftwarecostsare amortizedovertheestimatedusefullivesofthesoftwarewhichgenerallyrangefromtoyears thecompanyreviewslonglivedassetstoassessrecoverabilityusingundiscountedcashflowswhencertaineventsor changesinoperatingoreconomicconditionsoccuranimpairmentassessmentmaybeperformedontherecoverabilityof thecarryingvalueoftheseassetsiftheassetisdeterminedtobeimpairedthelossismeasuredbasedonthedifference betweentheassetsfairvalueanditscarryingvalueifquotedmarketpricesarenotavailablethecompanywillestimate fairvalueusingadiscountedvalueofestimatedfuturecashflows revenue recognition thecompanyrecognizesrevenuefromproductsaleswhenobligationsunderthetermsofacontractwiththecustomer aresatisfiedgenerallythisoccurswiththetransferofcontrolofthegoodstocustomersthecompanysglobalpayment termsaretypicallybetweentodaysprovisionsforcertainrebatessalesincentivestradepromotionscoupons productreturnsanddiscountstocustomersareaccountedforasvariableconsiderationandrecordedasareductionin sales productdiscountsgrantedarebasedonthetermsofarrangementswithdirectindirectandothermarketparticipantsas wellasmarketconditionsincludingconsiderationofcompetitorpricingrebatesareestimatedbasedoncontractual johnsonjohnsonannualreporttermshistoricalexperiencepatientoutcomestrendanalysisandprojectedmarketconditionsinthevariousmarkets servedthecompanyevaluatesmarketconditionsforproductsorgroupsofproductsprimarilythroughtheanalysisof wholesalerandotherthirdpartysellthroughandmarketresearchdataaswellasinternallygeneratedinformation salesreturnsareestimatedandrecordedbasedonhistoricalsalesandreturnsinformationproductsthatexhibitunusual salesorreturnpatternsduetodatingcompetitionorothermarketingmattersarespecificallyinvestigatedandanalyzedas partoftheaccountingforsalesreturnaccruals salesreturnsallowancesrepresentareserveforproductsthatmaybereturnedduetoexpirationdestructioninthefield orinspecificareasproductrecallthesalesreturnsreserveisbasedonhistoricalreturntrendsbyproductandbymarket asapercenttogrosssalesinaccordancewiththecompanysaccountingpoliciesthecompanygenerallyissuescredit tocustomersforreturnedgoodsthecompanyssalesreturnsreservesareaccountedforinaccordancewiththe usgaapguidanceforrevenuerecognitionwhenrightofreturnexistssalesreturnsreservesarerecordedatfullsales valuesalesreturnsintheconsumerandpharmaceuticalsegmentsarealmostexclusivelynotresalablesalesreturnsfor certainfranchisesinthemedicaldevicessegmentaretypicallyresalablebutarenotmaterialthecompanyinfrequently exchangesproductsfrominventoryforreturnedproductsthesalesreturnsreserveforthetotalcompanyhasbeen approximatelyofannualnettradesalesduringthefiscalreportingyearsand promotionalprogramssuchasproductlistingallowancesandcooperativeadvertisingarrangementsarerecordedinthe sameperiodasrelatedsalescontinuingpromotionalprogramsincludecouponsandvolumebasedsalesincentive programstheredemptioncostofconsumercouponsisbasedonhistoricalredemptionexperiencebyproductandvalue volumebasedincentiveprogramsarebasedontheestimatedsalesvolumesfortheincentiveperiodandarerecordedas productsaresoldthesearrangementsareevaluatedtodeterminetheappropriateamountstobedeferredorrecordedas areductionofrevenuethecompanyalsoearnsprofitsharepaymentsthroughcollaborativearrangementsforcertain productswhichareincludedinsalestocustomersforallyearspresentedprofitsharepaymentswerelessthanof thetotalrevenuesandareincludedinsalestocustomers shippingandhandling shippingandhandlingcostsincurredweremillionmillionandmillioninand respectivelyandareincludedinsellingmarketingandadministrativeexpensetheamountofrevenuereceivedfor shippingandhandlingislessthanofsalestocustomersforallperiodspresented inventories inventoriesarestatedatthelowerofcostornetrealizablevaluedeterminedbythefirstinfirstoutmethod intangibleassetsandgoodwill theauthoritativeliteratureonusgaaprequiresthatgoodwillandintangibleassetswithindefinitelivesbeassessed annuallyforimpairmentthecompanycompletedtheannualimpairmenttestforinthefiscalfourthquarterfuture impairmenttestswillbeperformedannuallyinthefiscalfourthquarterorsoonerifwarrantedpurchasedinprocess researchanddevelopmentisaccountedforasanindefinitelivedintangibleassetuntiltheunderlyingprojectiscompleted atwhichpointtheintangibleassetwillbeaccountedforasadefinitelivedintangibleassetorabandonedatwhichpoint theintangibleassetwillbewrittenofforpartiallyimpaired intangibleassetsthathavefiniteusefullivescontinuetobeamortizedovertheirusefullivesandarereviewedfor impairmentwhenwarrantedbyeconomicconditionsseenoteforfurtherdetailsonintangibleassetsandgoodwill financialinstruments asrequiredbyusgaapallderivativeinstrumentsarerecordedonthebalancesheetatfairvaluefairvalueistheexit pricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbasedmeasurement determinedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitytheauthoritativeliterature establishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluewithlevelhavingthehighest priorityandlevelhavingthelowestchangesinthefairvalueofderivativesarerecordedeachperiodincurrentearnings orothercomprehensiveincomedependingonwhetherthederivativeisdesignatedaspartofahedgetransactionandif sothetypeofhedgetransaction johnsonjohnsonannualreport thecompanydocumentsallrelationshipsbetweenhedgeditemsandderivativestheoverallriskmanagementstrategy includesreasonsforundertakinghedgetransactionsandenteringintoderivativestheobjectivesofthisstrategyare minimizeforeigncurrencyexposuresimpactonthecompanysfinancialperformanceprotectthecompanyscash flowfromadversemovementsinforeignexchangeratesensuretheappropriatenessoffinancialinstrumentsand managetheenterpriseriskassociatedwithfinancialinstitutionsseenoteforadditionalinformationonfinancial instruments productliability accrualsforproductliabilityclaimsarerecordedonanundiscountedbasiswhenitisprobablethataliabilityhasbeen incurredandtheamountoftheliabilitycanbereasonablyestimatedbasedonexistinginformationandactuarially determinedestimateswhereapplicabletheaccrualsareadjustedperiodicallyasadditionalinformationbecomes availablethecompanyaccruesanestimateofthelegaldefensecostsneededtodefendeachmatterwhenthosecosts areprobableandcanbereasonablyestimatedtotheextentadverseverdictshavebeenrenderedagainstthecompany thecompanydoesnotrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimated asaresultofcostandavailabilityfactorseffectivenovemberthecompanyceasedpurchasingthirdparty productliabilityinsurancethecompanyhasselfinsurancethroughawhollyownedcaptiveinsurancecompanyin additiontoaccrualsintheselfinsuranceprogramclaimsthatexceedtheinsurancecoverageareaccruedwhenlossesare probableandamountscanbereasonablyestimated researchanddevelopment researchanddevelopmentexpensesareexpensedasincurredinaccordancewithascresearchand developmentupfrontandmilestonepaymentsmadetothirdpartiesinconnectionwithresearchanddevelopment collaborationsareexpensedasincurreduptothepointofregulatoryapprovalpaymentsmadetothirdpartiessubsequent toregulatoryapprovalarecapitalizedandamortizedovertheremainingusefullifeoftherelatedproductamounts capitalizedforsuchpaymentsareincludedinotherintangiblesnetofaccumulatedamortization thecompanyentersintocollaborativearrangementstypicallywithotherpharmaceuticalorbiotechnologycompaniesto developandcommercializedrugcandidatesorintellectualpropertythesearrangementstypicallyinvolvetwoormore partieswhoareactiveparticipantsinthecollaborationandareexposedtosignificantrisksandrewardsdependentonthe commercialsuccessoftheactivitiesthesecollaborationsusuallyinvolvevariousactivitiesbyoneormoreparties includingresearchanddevelopmentmarketingandsellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentupontheoccurrenceofcertainfutureeventslinkedtothe successoftheassetindevelopmentamountsduefromcollaborativepartnersrelatedtodevelopmentactivitiesare generallyreflectedasareductionofresearchanddevelopmentexpensebecausetheperformanceofcontract developmentservicesisnotcentraltothecompanysoperationsingeneraltheincomestatementpresentationforthese collaborationsisasfollows naturetypeofcollaboration statementofearningspresentation thirdpartysaleofproductprofitsharepaymentsreceived salestocustomers royaltiesmilestonespaidtocollaborativepartnerpost costofproductssold regulatoryapproval royaltiesreceivedfromcollaborativepartner otherincomeexpensenet upfrontpaymentsmilestonespaidtocollaborativepartner researchanddevelopmentexpense preregulatoryapproval researchanddevelopmentpaymentstocollaborative researchanddevelopmentexpense partner researchanddevelopmentpaymentsreceivedfrom reductionofresearchanddevelopmentexpense collaborativepartner milestonesarecapitalizedasintangibleassetsandamortizedtocostofproductssoldovertheusefullife forallyearspresentedtherewasnoindividualprojectthatrepresentedgreaterthanofthetotalannualconsolidated researchanddevelopmentexpense johnsonjohnsonannualreportthecompanyhasanumberofproductsandcompoundsdevelopedincollaborationwithstrategicpartnersincluding xareltocodevelopedwithbayerhealthcareagandimbruvicadevelopedincollaborationandcomarketed withpharmacyclicsllcanabbviecompany thecompanyhasanumberoflicensingarrangementsforproductsandcompoundsincludingdarzalexlicensed fromgenmabas advertising costsassociatedwithadvertisingareexpensedintheyearincurredandareincludedinsellingmarketingand administrativeexpensesadvertisingexpensesworldwidewhichcomprisedtelevisionradioprintmediaandinternet advertisingwerebillionbillionandbillioninandrespectively incometaxes incometaxesarerecordedbasedonamountsrefundableorpayableforthecurrentyearandincludetheresultsofany differencebetweenusgaapaccountingandtaxreportingrecordedasdeferredtaxassetsorliabilitiesthecompany estimatesdeferredtaxassetsandliabilitiesbasedonenactedtaxregulationsandratesfuturechangesintaxlawsand ratesmayaffectrecordeddeferredtaxassetsandliabilitiesinthefuture thecompanyhasunrecognizedtaxbenefitsforuncertaintaxpositionsthecompanyfollowsusgaapwhich prescribesarecognitionthresholdandmeasurementattributeforthefinancialstatementrecognitionandmeasurementof ataxpositiontakenorexpectedtobetakeninataxreturnmanagementbelievesthatchangesintheseestimateswould nothaveamaterialeffectonthecompanysresultsofoperationscashflowsorfinancialposition inthefourthfiscalquarterofthecompanyhaselectedtoaccountforthegiltitaxunderthedeferredmethodthe deferredtaxamountsrecordedarebasedontheevaluationoftemporarydifferencesthatareexpectedtoreverseasgilti isincurred thecompanyhasrecordeddeferredtaxliabilitiesonallundistributedearningspriortodecemberfromits internationalsubsidiariesthecompanyhasnotprovideddeferredtaxesontheundistributedearningssubsequentto januaryfromcertaininternationalsubsidiarieswheretheearningsareconsideredtobeindefinitelyreinvestedthe companyintendstocontinuetoreinvesttheseearningsinthoseinternationaloperationsifthecompanydecidesata laterdatetorepatriatetheseearningstotheusthecompanywouldberequiredtoprovideforthenettaxeffectson theseamountsthecompanyestimatesthatthetotaltaxeffectofthisrepatriationwouldbeapproximatelybillion undercurrentenactedtaxlawsandregulationsandatcurrentcurrencyexchangerates seenoteforfurtherinformationregardingincometaxes netearningspershare basicearningspershareiscomputedbydividingnetearningsavailabletocommonshareholdersbytheweightedaverage numberofcommonsharesoutstandingfortheperioddilutedearningspersharereflectsthepotentialdilutionthatcould occurifsecuritieswereexercisedorconvertedintocommonstockusingthetreasurystockmethod useofestimates thepreparationofconsolidatedfinancialstatementsinconformitywithaccountingprinciplesgenerallyacceptedinthe usrequiresmanagementtomakeestimatesandassumptionsthataffecttheamountsreportedestimatesareusedwhen accountingforsalesdiscountsrebatesallowancesandincentivesproductliabilitiesincometaxeswithholdingtaxes depreciationamortizationemployeebenefitscontingenciesandintangibleassetandliabilityvaluationsactualresults mayormaynotdifferfromthoseestimates thecompanyfollowstheprovisionsofusgaapwhenrecordinglitigationrelatedcontingenciesaliabilityisrecorded whenalossisprobableandcanbereasonablyestimatedthebestestimateofalosswithinarangeisaccruedhowever ifnoestimateintherangeisbetterthananyothertheminimumamountisaccrued annualclosingdate thecompanyfollowstheconceptofafiscalyearwhichendsonthesundaynearesttotheendofthemonthof decembernormallyeachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthefiscalyearconsistsofweeks andthereforeincludesadditionalshippingdaysaswasthecaseinandwillbethecaseagainin reclassification certainpriorperiodamountshavebeenreclassifiedtoconformtocurrentyearpresentation johnsonjohnsonannualreport cash cash equivalents current marketable securities attheendofandcashcashequivalentsandcurrentmarketablesecuritieswerecomprisedof cash current carrying estimated cash marketable dollarsinmillions amount fairvalue equivalents securities cash usreverserepurchaseagreements otherreverserepurchaseagreements moneymarketfunds timedeposits subtotal govtsecurities corporatedebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecurities inthecarryingamountwasthesameastheestimatedfairvalue inthecarryingamountwasthesameastheestimatedfairvalue estimated cash current carrying fair cash marketable dollarsinmillions amount value equivalents securities cash othersovereignsecurities usreverserepurchaseagreements corporatedebtsecurities moneymarketfunds timedeposits subtotal govtsecurities othersovereignsecurities corporatedebtsecurities subtotalavailableforsale totalcashcashequivalentsandcurrentmarketablesecurities heldtomaturityinvestmentsarereportedatamortizedcostandrealizedgainsorlossesarereportedinearnings availableforsaledebtsecuritiesarereportedatfairvaluewithunrealizedgainsandlossesreportednetoftaxesinother comprehensiveincome fairvalueofgovernmentsecuritiesandobligationsandcorporatedebtsecuritieswereestimatedusingquotedbroker pricesandsignificantotherobservableinputs johnsonjohnsonannualreportthecontractualmaturitiesoftheavailableforsaledebtsecuritiesatdecemberareasfollows cost fair dollarsinmillions basis value duewithinoneyear dueafteroneyearthroughfiveyears dueafterfiveyearsthroughtenyears totaldebtsecurities thecompanyinvestsitsexcesscashinbothdepositswithmajorbanksthroughouttheworldandotherhighquality moneymarketinstrumentsthecompanyhasapolicyofmakinginvestmentsonlywithcommercialinstitutionsthathaveat leastaninvestmentgradecreditrating inventories attheendofandinventorieswerecomprisedof dollarsinmillions rawmaterialsandsupplies goodsinprocess finishedgoods totalinventories netofassetsheldforsaleontheconsolidatedbalancesheetforapproximatelybillionrelatedtothedivestitureofthe advancedsterilizationproductsbusinessandbillionrelatedtothestrategiccollaborationwithjabilincbothofwhichwere pendingasofdecember property plant equipment attheendofandpropertyplantandequipmentatcostandaccumulateddepreciationwere dollarsinmillions landandlandimprovements buildingsandbuildingequipment machineryandequipment constructioninprogress totalpropertyplantandequipmentgross lessaccumulateddepreciation totalpropertyplantandequipmentnet netofassetsheldforsaleontheconsolidatedbalancesheetforapproximatelybillionrelatedtothedivestitureofthe advancedsterilizationproductsbusinessandbillionrelatedtothestrategiccollaborationwithjabilincbothofwhichwere pendingasofdecember thecompanycapitalizesinterestexpenseaspartofthecostofconstructionoffacilitiesandequipmentinterestexpense capitalizedinandwasmillionmillionandmillionrespectively depreciationexpenseincludingtheamortizationofcapitalizedinterestinandwasbillion billionandbillionrespectively uponretirementorotherdisposalofpropertyplantandequipmentthecostsandrelatedamountsofaccumulated depreciationoramortizationareeliminatedfromtheassetandaccumulateddepreciationaccountsrespectivelythe differenceifanybetweenthenetassetvalueandtheproceedsarerecordedinearnings johnsonjohnsonannualreport intangible assets goodwill attheendofandthegrossandnetamountsofintangibleassetswere dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarksgross lessaccumulatedamortization patentsandtrademarksnet customerrelationshipsandotherintangiblesgross lessaccumulatedamortization customerrelationshipsandotherintangiblesnet intangibleassetswithindefinitelives trademarks purchasedinprocessresearchanddevelopment totalintangibleassetswithindefinitelives totalintangibleassetsnet thedecreasewasprimarilyattributabletothewritedownofbillionrelatedtotheassetsacquiredintheacquisitionsofalios biopharmaincaliosandxolimitedxoofthebillionthecompanyrecordedapartialimpairmentchargeofbillion relatedtothedevelopmentprogramofalaninvestigationaldrugforthetreatmentofrespiratorysyncytialvirusrsvand humanmetapneumovirushmpvacquiredwiththeacquisitionofaliostheimpairmentchargewascalculatedbasedon updatedcashflowprojectionsdiscountedfortheinherentriskintheassetdevelopmentandreflectstheimpactofthephaseb clinicaltrialsuspensionadecreaseintheprobabilityofsuccessfactorsandtheongoinganalysisofassetdevelopmentactivitiesin additionanimpairmentchargeofbillionwasrecordedforthediscontinuationofthedevelopmentprojectforanantithrombin antibodyassociatedwiththeacquisitionofxoadditionallybillionofiprdrelatedtoerleadawasreclassifiedto definitelivedintangibleassetsuponcommercialization goodwillasofdecemberanddecemberasallocatedbysegmentofbusinesswasasfollows dollarsinmillions consumer pharmaceutical medicaldevices total goodwillatjanuary goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatdecember goodwillrelatedtoacquisitions goodwillrelatedtodivestitures currencytranslationother goodwillatdecember goodwillofbillionrelatedtotheactelionacquisitionacquiredinthefiscalsecondquarterofwithinthepharmaceutical segmentandbillionrelatedtotheamoacquisitionacquiredinthefiscalfirstquarterofwithinthemedicaldevices segment goodwillofbillionisrelatedtothedivestitureofthelifescanbusinessgoodwillofbillionisrelatedtothedivestitureof theadvancedsterilizationproductsbusinesswhichwaspendingandclassifiedasassetsheldforsaleontheconsolidatedbalance sheetasofdecember theweightedaverageamortizationperiodsforpatentsandtrademarksandcustomerrelationshipsandotherintangible assetsareyearsandyearsrespectivelytheamortizationexpenseofamortizableassetsincludedincostof productssoldwasbillionbillionandbillionbeforetaxforthefiscalyearsendeddecember decemberandjanuaryrespectivelytheestimatedamortizationexpenseforthefivesucceedingyears approximatesbillionbeforetaxperyearintangibleassetwritedownsareincludedinotherincomeexpensenet seenotetotheconsolidatedfinancialstatementsforadditionaldetailsrelatedtoacquisitionsanddivestitures johnsonjohnsonannualreport fair value measurements thecompanyusesforwardforeignexchangecontractstomanageitsexposuretothevariabilityofcashflowsprimarily relatedtotheforeignexchangeratechangesoffutureintercompanyproductsandthirdpartypurchasesofmaterials denominatedinaforeigncurrencythecompanyusescrosscurrencyinterestrateswapstomanagecurrencyrisk primarilyrelatedtoborrowingsbothtypesofderivativesaredesignatedascashflowhedges additionallythecompanyusesinterestrateswapsasaninstrumenttomanageinterestrateriskrelatedtofixedrate borrowingsthesederivativesaredesignatedasfairvaluehedgesthecompanyusescrosscurrencyinterestrateswaps andforwardforeignexchangecontractsdesignatedasnetinvestmenthedgesadditionallythecompanyusesforward foreignexchangecontractstooffsetitsexposuretocertainforeigncurrencyassetsandliabilitiestheseforwardforeign exchangecontractsarenotdesignatedashedgesandthereforechangesinthefairvaluesofthesederivativesare recognizedinearningstherebyoffsettingthecurrentearningseffectoftherelatedforeigncurrencyassetsandliabilities thecompanyearlyadoptedasutargetedimprovementstoaccountingforhedgeactivitieseffectiveasofthe beginningoffiscalsecondquarterof thecompanydoesnotenterintoderivativefinancialinstrumentsfortradingorspeculativepurposesorthatcontaincredit riskrelatedcontingentfeaturesduringthefiscalsecondquarterofthecompanyenteredintocreditsupport agreementscsawithcertainderivativecounterpartiesestablishingcollateralthresholdsbasedonrespectivecredit ratingsandnettingagreementsasofdecemberthetotalamountofcollateralpaidunderthecreditsupport agreementscsaamountedtomillionnetonanongoingbasisthecompanymonitorscounterpartycredit ratingsthecompanyconsiderscreditnonperformancerisktobelowbecausethecompanyprimarilyentersinto agreementswithcommercialinstitutionsthathaveatleastaninvestmentgradecreditratingrefertothetableon significantfinancialassetsandliabilitiesmeasuredatfairvaluecontainedinthisfootnoteforreceivablesandpayableswith thesecommercialinstitutionsasofdecemberthecompanyhadnotionalamountsoutstandingforforward foreignexchangecontractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionand billionrespectivelyasofdecemberthecompanyhadnotionalamountsoutstandingforforwardforeign exchangecontractscrosscurrencyinterestrateswapsandinterestrateswapsofbillionbillionand billionrespectively allderivativeinstrumentsarerecordedonthebalancesheetatfairvaluechangesinthefairvalueofderivativesare recordedeachperiodincurrentearningsorothercomprehensiveincomedependingonwhetherthederivativeis designatedaspartofahedgetransactionandifsothetypeofhedgetransaction thedesignationasacashflowhedgeismadeattheentrancedateofthederivativecontractatinceptionallderivatives areexpectedtobehighlyeffectiveforeignexchangecontractsdesignatedascashflowhedgesareaccountedforunder theforwardmethodandallgainslossesassociatedwiththesecontractswillberecognizedintheincomestatementwhen thehedgeditemimpactsearningschangesinthefairvalueofthesederivativesarerecordedinaccumulatedother comprehensiveincomeuntiltheunderlyingtransactionaffectsearningsandarethenreclassifiedtoearningsinthesame accountasthehedgedtransaction gainsandlossesassociatedwithinterestrateswapsandchangesinfairvalueofhedgeddebtattributabletochangesin interestratesarerecordedtointerestexpenseintheperiodinwhichtheyoccurgainsandlossesonnetinvestment hedgeareaccountedthroughthecurrencytranslationaccountwithinaccumulatedothercomprehensiveincomethe portionexcludedfromeffectivenesstestingisrecordedthroughinterestincomeexpenseusingthespotmethodonan ongoingbasisthecompanyassesseswhethereachderivativecontinuestobehighlyeffectiveinoffsettingchangesof hedgeditemsifandwhenaderivativeisnolongerexpectedtobehighlyeffectivehedgeaccountingisdiscontinued duringthefiscalsecondquarterofthecompanydesignateditseurodenominatednotesissuedinmaywith duedatesrangingfromtoasanetinvestmenthedgeofthecompanysinvestmentsincertainofits internationalsubsidiariesthatusetheeuroastheirfunctionalcurrencyinordertoreducethevolatilitycausedbychanges inexchangerates asofdecemberthebalanceofdeferrednetlossonderivativesincludedinaccumulatedothercomprehensive incomewasmillionaftertaxforadditionalinformationseetheconsolidatedstatementsofcomprehensiveincome andnotethecompanyexpectsthatsubstantiallyalloftheamountsrelatedtoforwardforeignexchangecontractswill bereclassifiedintoearningsoverthenextmonthsasaresultoftransactionsthatareexpectedtooccuroverthat periodthemaximumlengthoftimeoverwhichthecompanyishedgingtransactionexposureismonthsexcluding interestratecontractsnetinvestmenthedgesandequitycollarcontractstheamountultimatelyrealizedinearningsmay differasforeignexchangerateschangerealizedgainsandlossesareultimatelydeterminedbyactualexchangeratesat maturityofthederivative johnsonjohnsonannualreport thefollowingtableisasummaryoftheactivityrelatedtoderivativesandhedgesforthefiscalyearsendeddecember anddecember december december costof interest costof interest products rd income income products rd income income dollarsinmillions sales sold expense expense expense sales sold expense expense expense theeffectsoffairvaluenetinvestment andcashflowhedging gainlossonfairvaluehedging relationship interestrateswapscontracts hedgeditems derivativesdesignatedashedging instruments gainlossonnetinvestment hedgingrelationship crosscurrencyinterestrateswaps contracts amountofgainorlossrecognizedin incomeonderivativeamount excludedfromeffectivenesstesting amountofgainorlossrecognizedin aoci gainlossoncashflowhedging relationship forwardforeignexchange contracts amountofgainorlossreclassified fromaociintoincome amountofgainorlossrecognizedin aoci crosscurrencyinterestrateswaps contracts amountofgainorlossreclassified fromaociintoincome amountofgainorlossrecognizedin aoci includesequitycollarcontractstheequitycollarcontractsexpiredindecemberof forthefiscalyearsendeddecemberanddecemberthefollowingamountswererecordedonthe consolidatedbalancesheet cumulativeamountoffairvalue lineitemintheconsolidatedbalance hedgingadjustment sheetinwhichthehedgeditemis includedinthecarrying included carryingamountofthehedgedliability amountofthehedgedliability dollarsinmillions december december december december currentportionoflongtermdebt longtermdebt thefollowingtableistheeffectofderivativesnotdesignatedashedginginstrumentforthefiscalyearsended decemberanddecember locationofgainloss gainloss recognizedinincomeon recognizedin dollarsinmillions derivative incomeonderivative derivativesnotdesignatedashedginginstruments december december foreignexchangecontracts otherincomeexpense johnsonjohnsonannualreportthefollowingtableistheeffectofnetinvestmenthedgesforthefiscalyearsendeddecemberand december gainloss gainloss locationofgainorlossreclassified reclassifiedfrom recognizedin fromaccumulatedothercomprehensive accumulatedoci accumulatedoci incomeintoincome intoincome dollarsinmillions debt otherincomeexpense crosscurrencyinterestrateswaps otherincomeexpense thecompanyadoptedasufinancialinstrumentsrecognitionandmeasurementoffinancialassetsand financialliabilitiesasofthebeginningofthefiscalyearthisasuamendspriorguidancetoclassifyequity investmentswithreadilydeterminablemarketvaluesintodifferentcategoriesthatistradingoravailableforsaleand requireequityinvestmentstobemeasuredatfairvaluewithchangesinfairvaluerecognizedthroughnetearningsthe companymadeacumulativeeffectadjustmenttotheopeningbalanceofretainedearningsuponadoptionofasu whichincreasedretainedearningsbymillionnetoftaxanddecreasedaccumulatedothercomprehensive incomeforpreviouslynetunrealizedgainsfromequityinvestments thecompanyholdsequityinvestmentswithreadilydeterminablefairvaluesandequityinvestmentswithoutreadily determinablefairvaluesthecompanyhaselectedtomeasureequityinvestmentsthatdonothavereadilydeterminable fairvaluesatcostminusimpairmentifanyplusorminuschangesresultingfromobservablepricechangesinorderly transactionsfortheidenticalorasimilarinvestmentofthesameissuer thefollowingtableisasummaryoftheactivityrelatedtoequityinvestmentsasofdecember changesinfairvalue december december reflectedinnet sales noncurrentother dollarsinmillions carryingvalue income purchasesother carryingvalue assets equityinvestmentswithreadily determinablevalue equityinvestmentswithoutreadily determinablevalue recordedinotherincomeexpense otherincludesimpactofcurrency forequityinvestmentswithoutreadilydeterminablemarketvaluesmillionofthechangesinfairvaluereflectedinnet incomeweretheresultofimpairmentsthereweremillionofchangesinfairvaluereflectedinnetincomedueto changesinobservableprices forthefiscalyearsendeddecemberchangesinfairvaluereflectedwithinothercomprehensiveincomedueto previouslyunrealizedgainsonequityinvestmentswithreadilydeterminablefairvaluesnetoftaxwasanetgainof million fairvalueistheexitpricethatwouldbereceivedtosellanassetorpaidtotransferaliabilityfairvalueisamarketbased measurementdeterminedusingassumptionsthatmarketparticipantswoulduseinpricinganassetorliabilitythe authoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedbelowwithlevelhavingthehighestpriorityandlevelhavingthelowest thefairvalueofaderivativefinancialinstrumentieforwardforeignexchangecontractsinterestratecontractsisthe aggregationbycurrencyofallfuturecashflowsdiscountedtoitspresentvalueattheprevailingmarketinterestratesand subsequentlyconvertedtotheusdollaratthecurrentspotforeignexchangeratethecompanydoesnotbelievethat fairvaluesofthesederivativeinstrumentsmateriallydifferfromtheamountsthatcouldberealizeduponsettlementor maturityorthatthechangesinfairvaluewillhaveamaterialeffectonthecompanysresultsofoperationscashflowsor financialpositionthecompanyalsoholdsequityinvestmentswhichareclassifiedaslevelanddebtsecuritieswhich areclassifiedaslevelthecompanydidnothaveanyothersignificantfinancialassetsorliabilitieswhichwouldrequire revisedvaluationsunderthisstandardthatarerecognizedatfairvalue johnsonjohnsonannualreport thefollowingthreelevelsofinputsareusedtomeasurefairvalue levelquotedpricesinactivemarketsforidenticalassetsandliabilities levelsignificantotherobservableinputs levelsignificantunobservableinputs thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofdecemberand decemberwereasfollows dollarsinmillions level level level total total derivativesdesignatedashedginginstruments assets forwardforeignexchangecontracts interestratecontracts total liabilities forwardforeignexchangecontracts interestratecontracts total derivativesnotdesignatedashedginginstruments assets forwardforeignexchangecontracts liabilities forwardforeignexchangecontracts availableforsaleotherinvestments equityinvestments debtsecurities grosstonetderivativereconciliation dollarsinmillions totalgrossassets creditsupportagreementcsa totalnetasset totalgrossliabilities creditsupportagreementcsa totalnetliabilities assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofequityinvestmentsofmillionwhichareclassifiedas level includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingdecemberanddecember respectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingdecemberanddecember respectively includescrosscurrencyinterestrateswapsandinterestrateswaps classifiedasnoncurrentotherassetsthecarryingamountoftheequityinvestmentsweremillionandmillionasof decemberanddecemberrespectively classifiedascashequivalentsandcurrentmarketablesecurities seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnsonjohnsonannualreport borrowings thecomponentsoflongtermdebtareasfollows effective effective dollarsinmillions rate rate debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue zerocouponconvertiblesubordinateddebenturesdue debenturesdue notesdue notesdue notesdue notesdue notesduebeurobeuro notesdue debenturesdue notesdue notesdue notesduemmeurommeuro notesduemmgbpmmgbp notesdue notesdue notesdue notesduemmeurommeuro notesdue notesdue debenturesdue notesdue notesduebeurobeuro notesdue notesdue notesdue debenturesdue notesdue debenturesdue notesdue notesdue notesdue notesdue notesdue subtotal lesscurrentportion totallongtermdebt johnsonjohnsonannualreport weightedaverageeffectiverate translationrateatdecember translationrateatdecember theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninandbillionin fairvalueofthelongtermdebtwasestimatedusingmarketpriceswhichwerecorroboratedbyquotedbrokerpricesand significantotherobservableinputslevel thecompanyhasaccesstosubstantialsourcesoffundsatnumerousbanksworldwideinseptemberthe companysecuredanewdaycreditfacilitytotalcreditavailabletothecompanyapproximatesbillionwhich expiresonseptemberinterestchargedonborrowingsunderthecreditlineagreementsisbasedoneitherbids providedbybankstheprimerateorlondoninterbankofferedratesliborplusapplicablemarginscommitmentfees undertheagreementsarenotmaterial throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionisthecurrentportionofthelongtermdebtandtheremainderprincipallyrepresentslocalborrowingby internationalsubsidiaries throughoutthecompanycontinuedtohaveaccesstoliquiditythroughthecommercialpapermarketshortterm borrowingsandthecurrentportionoflongtermdebtamountedtoapproximatelybillionattheendofofwhich billionwasborrowedunderthecommercialpaperprogrambillionisthecurrentportionofthelongtermdebt andtheremainderprincipallyrepresentslocalborrowingbyinternationalsubsidiaries aggregatematuritiesoflongtermobligationscommencinginare dollarsinmillions income taxes theprovisionfortaxesonincomeconsistsof dollarsinmillions currentlypayable ustaxes ustaxesoninternationaloperations internationaltaxes totalcurrentlypayable deferred ustaxes ustaxesoninternationaloperations internationaltaxes totaldeferred provisionfortaxesonincome johnsonjohnsonannualreportacomparisonofincometaxexpenseattheusstatutoryrateofinandinandtothe companyseffectivetaxrateisasfollows dollarsinmillions us international earningsbeforetaxesonincome taxrates usstatutoryrate internationaloperations researchandorphandrugtaxcredits usstateandlocal usmanufacturingdeduction ustaxoninternationalincome taxbenefitsonsharebasedcompensation ustaxbenefitonassetbusinessdisposals allother tcjaandrelatedimpacts effectiverate forallperiodspresentedthecompanyhassubsidiariesoperatinginpuertoricoundervarioustaxincentivesinternational operationsreflectstheimpactsofoperationsinjurisdictionswithstatutorytaxratesdifferentthantheusparticularlyireland switzerlandandpuertoricowhichisafavorableimpactontheeffectivetaxrateascomparedwiththeusstatutoryratethe amountalsoincludestaxcostrelatedtotherevaluationofdeferredtaxbalancesrelatedtothechangeinthebelgianstatutorytaxrate increasingthetaxprovisionbyapproximately includestheimpactofthegiltitaxtheforeignderivedintangibleincomedeductionandotherforeignincomethatistaxableunder theustaxcode representsimpactofadjustmentstothetcjaprovisionaltaxchargethisalsoincludesanettaxbenefitfromthereductionof adeferredtaxliabilityrelatedtoforeignwithholdingtaxesoriginallyaccruedaspartoftheprovisionalchargethisbenefitreducedthe companyseffectivetaxratebyapproximatelyfurtherdescriptionisincludedbelow includesusstateandlocaltaxesprovisionallyrecordedasparttcjaprovisionalchargewhichwasapproximatelyofthetotal effectivetaxrate ondecembertheunitedstatesenactedintolawnewustaxlegislationthetaxcutsandjobsacttcja thislawincludedprovisionsforacomprehensiveoverhaulofthecorporateincometaxcodeincludingareductionofthe statutorycorporatetaxratefromtoeffectiveonjanuarythislegislationalsoeliminatedorreduced certaincorporateincometaxdeductionsaswellasintroducednewprovisionsthattaxedcertainforeignincomenot previouslytaxedbytheunitedstatesthetcjaalsoincludedaprovisionforataxonallpreviouslyundistributedearnings ofuscompanieslocatedinforeignjurisdictionsundistributedearningsintheformofcashandcashequivalentswere taxedatarateofandallotherearningsaretaxedatarateofthistaxispayableoveryearsandwillnot accrueinterestandthesepaymentsbeganinandwillcontinuethroughtheremainingbalanceattheendof thefiscalyearwasapproximatelybillion indecemberthesecprovidedregulatoryguidanceforaccountingoftheimpactsofthetcjareferredtoassab undertheguidanceinsabtheincometaxeffectswhichtheaccountingunderascisincompleteare reportedasaprovisionalamountbasedonareasonableestimatethereasonableestimateissubjecttoadjustmentduring ameasurementperiodnottoexceedoneyearuntiltheaccountingiscompletetheestimateisalsosubjecttothe finalizationofmanagementsanalysisrelatedtocertainmatterssuchasdevelopinginterpretationsoftheprovisionofthe tcjachangestocertainestimatesandamountsrelatedtotheearningsandprofitsofcertainsubsidiariesandthefilingof taxreturns inthefourthquarterofthecompanyrecordedaprovisionaltaxcostofapproximatelybillionwhichconsisted primarilyofthefollowingcomponents abillionchargeonpreviouslyundistributedforeignearningsasofdecember johnsonjohnsonannualreport abilliondeferredtaxliabilityforforeignlocalandwithholdingtaxesoffsetbyabilliondeferredtaxassetfor usforeigntaxcreditsforrepatriationofsubstantiallyallthoseearnings abilliontaxbenefitrelatingtotheremeasurementofusdeferredtaxassetsandliabilitiesandtheimpactofthe tcjaonunrecognizedtaxbenefits abillionchargeforusstateandlocaltaxesontherepatriationoftheseforeignearnings duringthefourthquarterofthecompanycompleteditsfullassessmentandfinalizedtheaccountingfortheimpact oftcjathecompanyrecordednetadjustmentstotheabovecomponentsoftheprovisionalchargeofapproximately billiontheserevisionswerebasedonupdatedestimatesandadditionalanalysisbymanagementaswellasapplying interpretativeguidanceissuedbytheusdepartmentoftreasurytothefactsandcircumstancesthatexistedasofthe tcjaenactmentdatethischargewasprimarilyrelatedtoadditionaldeferredtaxliabilitiesforforeignlocaland withholdingtaxesfortheremainingbalanceofundistributedforeignearningsasofdecemberthatwerenot providedforintheprovisionalchargeinthefourthquarterof thetcjaalsoincludesprovisionsforataxonglobalintangiblelowtaxedincomegiltigiltiisdescribedasthe excessofausshareholderstotalnetforeignincomeoveradeemedreturnontangibleassetsasprovidedbythetcja injanuarythefasbissuedguidancethatallowscompaniestoelectasanaccountingpolicywhethertorecordthe taxeffectsofgiltiintheperiodthetaxliabilityisgeneratedieperiodcostorprovidefordeferredtaxassetsand liabilitiesrelatedtobasisdifferencesthatexistandareexpectedtoeffecttheamountofgiltiinclusioninfutureyears uponreversaliedeferredmethodthroughthethirdfiscalquarterofthecompanyhadprovisionallyelectedto treatgiltiasaperiodexpenseuponfurtheranalysisofthisnewtaxprovisionthecompanyhaselectedtoaccountfor giltiunderthedeferredmethodthedeferredtaxamountsrecordedarebasedontheevaluationoftemporary differencesthatareexpectedtoreverseasgiltiisincurredasaresultofthiselectionthecompanyrecordedadeferred taxcostrelatedtogiltiofapproximatelybillioninthefourthfiscalquarterofrelatedtofactsand circumstancesthatexistedonthedateoftcjaenactment asaresultofthegiltideferredtaxchargeandtheotheradjustmentstotheprovisionalamountthecompanyrecordeda totalofbillionofadjustmentstotheprovisionalchargeincreasingthecompanysannualeffectivetaxrateby approximately duringthecompanyreorganizedtheownershipstructureofcertainforeignsubsidiarieswhichresultedina reductionofcertainforeignwithholdingtaxesthatithadrecognizedaspartoftheprovisionaltcjataxchargeinthefourth quarteroffollowingthecompletionofthisrestructuringinthefourthquarterandasaresultofclarificationby swisstaxauthoritiesregardingtheapplicabilityofwithholdingtaxtorepatriationofcertainearningsthecompany reversedadeferredtaxliabilityofbillionandarelateddeferredtaxassetofbillionforusforeigntaxcreditsfor anetdeferredtaxbenefitofbillionasthisrestructuringoccurredafterthetcjaenactmentdatethebenefitisnot consideredanadjustmenttotheprovisionalamountrecordedinundersabthisbenefitwiththesab adjustmentshasbeenreflectedastcjaandrelatedimpactsonthecompanyseffectivetaxratereconciliation asdescribedinnotetotheconsolidatedfinancialstatementsinthecompanyadoptedasuincome taxesintraentitytransfersofassetsotherthaninventorythisstandardrequiresentitiestorecognizedeferredtaxassets andliabilitiesrelatedtotransferofassetsotherthaninventorywithintheconsolidatedentityatthebeginningoffiscal thecompanyrecordedanetadjustmenttodeferredtaxassetsofapproximatelybillioninthefourthquarterof asaresultoftheelectiontorecordgiltionthedeferredmethodthecompanyrecordedagiltideferredtax liabilityofbillionrelatedtotheadoptionprovisionsofasuasanadjustmenttoretainedearnings theeffectivetaxratedecreasedbycomparedtotheeffectivetaxratewasprimarilydrivenbythe approximatelybillionprovisionaltaxchargerecordedinthefourthquarterofandtheimpactofabelgianstatutory taxratechangewhichincreasedtheeffectiveratebyadditionaldriversoftheannualeffectivetaxwere thereductionoftheusstatutorycorporatetaxrateincludingtheeffectsoftaxelectionswhichresultedinthe accelerationofcertaindeductionsintothetaxreturntheimpactoftheseaccelerateddeductionsdecreasedthe annualeffectivetaxratebyapproximately theimpactoftheadjustmentstotheprovisionaltcjachargeincludingbothsabadjustmentsandthe internalrestructuringdecreasedtheeffectivetaxratebyapproximately giltitaxwhichincreasedtheannualeffectivetaxratebyapproximatelywhichexcludestheimpactofthesab adjustmentfortheadoptionofthedeferredmethodforgilti taxbenefitsreceivedfromstockbasedcompensationduringfiscalandreducedtheeffectivetaxrateby andrespectively johnsonjohnsonannualreport inthefourthquarterofthecompanycompletedthedivestitureofitslifescanbusinessnotewhich increasedthecompanyannualeffectivetaxratebyapproximately moreincomeinhighertaxjurisdictionsrelativetolowertaxjurisdictionsascomparedto theeffectivetaxrateincreasedbyascomparedtoprimarilydrivenbytheenactmentofthetcjain theusindecembertheenactmentofthetcjaresultedinaprovisionaltaxchargeinthefourthquarterof ofapproximatelybillionorapproximatelypercentagepointincreasetotheeffectivetaxrate theremainderoftheincreaseinthetaxrateforwasrelatedtotheremeasurementofthecompanysdeferredtax assetsinbelgiumasaresultofchangesinthebelgianstatutorycorporatetaxrateenactedindecemberoffsetby ataxbenefitfortheclosureofthecompanysanimasinsulinpumpbusiness temporarydifferencesandcarryforwardsforandwereasfollows deferredtax deferredtax dollarsinmillions asset liability asset liability employeerelatedobligations stockbasedcompensation depreciationamortization nondeductibleintangibles internationalrdcapitalizedfortax reservesliabilities incomereportedfortaxpurposes netoperatinglosscarryforwardinternational undistributedforeignearnings globalintangiblelowtaxedincome miscellaneousinternational miscellaneousus totaldeferredincometaxes thecompanyhaswhollyownedinternationalsubsidiariesthathavecumulativenetlossesthecompanybelievesthatitis morelikelythannotthatthesesubsidiarieswillgeneratefuturetaxableincomesufficienttoutilizethesedeferredtaxassets thefollowingtablesummarizestheactivityrelatedtounrecognizedtaxbenefits dollarsinmillions beginningofyear increasesrelatedtocurrentyeartaxpositions increasesrelatedtopriorperiodtaxpositions decreasesrelatedtopriorperiodtaxpositions settlements lapseofstatuteoflimitations endofyear inmillionofthisdecreaseisrelatedtothetcja theunrecognizedtaxbenefitsofbillionatdecemberifrecognizedwouldaffectthecompanysannual effectivetaxratethecompanyconductsbusinessandfilestaxreturnsinnumerouscountriesandcurrentlyhastaxaudits inprogresswithanumberoftaxauthoritiestheirshascompleteditsauditforthetaxyearsthroughandis currentlyauditingthetaxyearsthecompanycurrentlyexpectscompletionofthisauditduringfinal conclusionofthetaxauditmayresultinanoutcomethatisdifferentthanthecompanysestimatesandmayresultina materialimpactonthecompanyscurrentandfutureoperatingresultsorcashflowsintheperiodthattheauditis concludedinothermajorjurisdictionswherethecompanyconductsbusinesstheyearsthatremainopentotaxauditgo johnsonjohnsonannualreport backtotheyearthecompanybelievesitispossiblethatauditsmaybecompletedbytaxauthoritiesinsome jurisdictionsoverthenexttwelvemonthshoweverthecompanyisnotabletoprovideareasonablyreliableestimateof thetimingofanyotherfuturetaxpaymentsrelatingtouncertaintaxpositions thecompanyclassifiesliabilitiesforunrecognizedtaxbenefitsandrelatedinterestandpenaltiesaslongtermliabilities interestexpenseandpenaltiesrelatedtounrecognizedtaxbenefitsareclassifiedasincometaxexpensethecompany recognizedaftertaxinterestexpenseofmillionmillionandmillioninandrespectivelythe totalamountofaccruedinterestwasmillionandmillioninandrespectively employee related obligations attheendofandemployeerelatedobligationsrecordedontheconsolidatedbalancesheetswere dollarsinmillions pensionbenefits postretirementbenefits postemploymentbenefits deferredcompensation totalemployeeobligations lesscurrentbenefitspayable employeerelatedobligationsnoncurrent prepaidemployeerelatedobligationsofmillionandmillionforandrespectivelyareincludedin otherassetsontheconsolidatedbalancesheets pensions benefit plans thecompanysponsorsvariousretirementandpensionplansincludingdefinedbenefitdefinedcontributionand terminationindemnityplanswhichcovermostemployeesworldwidethecompanyalsoprovidespostretirement benefitsprimarilyhealthcaretoalleligibleusretiredemployeesandtheirdependents manyinternationalemployeesarecoveredbygovernmentsponsoredprogramsandthecosttothecompanyisnot significant retirementplanbenefitsforemployeeshiredbeforejanuaryareprimarilybasedontheemployeescompensation duringthelastthreetofiveyearsbeforeretirementandthenumberofyearsofserviceinthecompanyannounced thattheusdefinedbenefitplanwasamendedtoadoptanewbenefitformulaeffectiveforemployeeshiredonorafter januarythebenefitsarecalculatedusinganewformulabasedonemployeecompensationovertotalyearsof service internationalsubsidiarieshaveplansunderwhichfundsaredepositedwithtrusteesannuitiesarepurchasedundergroup contractsorreservesareprovided thecompanydoesnottypicallyfundretireehealthcarebenefitsinadvancebutmaydosoatitsdiscretionthecompany alsohastherighttomodifytheseplansinthefuture inandthecompanyuseddecemberanddecemberrespectivelyasthemeasurement dateforallusandinternationalretirementandotherbenefitplans johnsonjohnsonannualreportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforand includethefollowingcomponents retirementplans otherbenefitplans dollarsinmillions servicecost interestcost expectedreturnonplanassets amortizationofpriorservicecostcredit recognizedactuariallosses curtailmentsandsettlements netperiodicbenefitcost inaspertheadoptionofasutheservicecostcomponentofnetperiodicbenefitcostwaspresentedin thesamelineitemsontheconsolidatedstatementofearningswhereotheremployeecompensationcostsarereported allothercomponentsofnetperiodicbenefitcostarepresentedaspartofotherincomeexpensenetonthe consolidatedstatementofearnings amountsexpectedtoberecognizedinnetperiodicbenefitcostinthecomingyearforthecompanysdefinedbenefit retirementplansandotherpostretirementplans dollarsinmillions amortizationofnettransitionobligation amortizationofnetactuariallosses amortizationofpriorservicecredit unrecognizedgainsandlossesfortheuspensionplansareamortizedovertheaverageremainingfutureserviceforeach planforplanswithnoactiveemployeestheyareamortizedovertheaveragelifeexpectancytheamortizationofgains andlossesfortheotherusbenefitplansisdeterminedbyusingacorridorofthegreaterofthemarketvalueof assetsortheaccumulatedpostretirementbenefitobligationtotalunamortizedgainsandlossesinexcessofthecorridor areamortizedovertheaverageremainingfutureservice priorservicecostsbenefitsfortheuspensionplansareamortizedovertheaverageremainingfutureserviceofplan participantsatthetimeoftheplanamendmentpriorservicecostbenefitfortheotherusbenefitplansisamortizedover theaverageremainingservicetofulleligibilityageofplanparticipantsatthetimeoftheplanamendment thefollowingtablerepresentstheweightedaverageactuarialassumptions retirementplans otherbenefitplans worldwidebenefitplans netperiodicbenefitcost servicecostdiscountrate interestcostdiscountrate rateofincreaseincompensationlevels expectedlongtermrateofreturnonplanassets benefitobligation discountrate rateofincreaseincompensationlevels thecompanysdiscountratesaredeterminedbyconsideringcurrentyieldcurvesrepresentinghighqualitylongterm fixedincomeinstrumentstheresultingdiscountratesareconsistentwiththedurationofplanliabilitiesinthefiscalyear thecompanychangeditsmethodologyindeterminingserviceandinterestcostfromthesingleweightedaverage discountrateapproachtodurationspecificspotratesalongthatyieldcurvetotheplansliabilitycashflowswhich managementhasconcludedisamorepreciseestimatepriortothischangeinmethodologythecompanymeasured johnsonjohnsonannualreport serviceandinterestcostsutilizingasingleweightedaveragediscountratederivedfromtheyieldcurveusedtomeasure theplanobligationsthecompanyhasaccountedforthischangeasachangeinaccountingestimateandaccordingly hasaccountedforitonaprospectivebasisthischangedoesnotimpactthebenefitobligationanddidnothavea materialimpacttothefullyearresults theexpectedratesofreturnonplanassetassumptionsrepresentthecompanysassessmentoflongtermreturnson diversifiedinvestmentportfoliosgloballytheassessmentisdeterminedusingprojectionsfromexternalfinancialsources longtermhistoricalaveragesactualreturnsbyassetclassandthevariousassetclassallocationsbymarket thefollowingtabledisplaystheassumedhealthcarecosttrendratesforallindividuals healthcareplans healthcarecosttrendrateassumedfornextyear ratetowhichthecosttrendrateisassumedtodeclineultimatetrend yeartheratereachestheultimatetrendrate aonepercentagepointchangeinassumedhealthcarecosttrendrateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillions pointincrease pointdecrease healthcareplans totalinterestandservicecost postretirementbenefitobligation johnsonjohnsonannualreportthefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearend andforthecompanysdefinedbenefitretirementplansandotherpostretirementplans otherbenefit retirementplans plans dollarsinmillions changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontributions amendments actuarialgainslosses divestituresacquisitions curtailmentssettlementsrestructuring benefitspaidfromplan effectofexchangerates projectedbenefitobligationendofyear changeinplanassets planassetsatfairvaluebeginningofyear actualreturnonplanassets companycontributions planparticipantcontributions settlements divestituresacquisitions benefitspaidfromplanassets effectofexchangerates planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowing noncurrentassets currentliabilities noncurrentliabilities totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistof thefollowing netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffects accumulatedbenefitobligationsendofyear johnsonjohnsonannualreport otherbenefit retirementplans plans dollarsinmillions amountsrecognizedinnetperiodicbenefitcostandothercomprehensive income netperiodicbenefitcost netactuarialgainloss amortizationofnetactuarialloss priorservicecostcredit amortizationofpriorservicecostcredit effectofexchangerates totallossincomerecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactof internationalplansarefundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhen deemedappropriatetomeetthelongtermobligationsoftheplansforcertainplansfundingisnotacommonpracticeas fundingprovidesnoeconomicbenefitconsequentlythecompanyhasseveralpensionplansthatarenotfunded inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively thefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansand internationalfundedandunfundedpensionplansatdecemberanddecemberrespectively usplans internationalplans qualifiedplans nonqualifiedplans fundedplans unfundedplans dollarsinmillions planassets projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojected benefitobligationandplanassetsofbillionbillionandbillionrespectivelyattheendofand billionbillionandbillionrespectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplans dollarsinmillions projectedfuturebenefitpayments retirementplans otherbenefitplans thefollowingtabledisplaystheprojectedfutureminimumcontributionstotheunfundedretirementplanstheseamounts donotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillions projectedfuturecontributions eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationand investmentofthepensionplansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboard johnsonjohnsonannualreportconsidersfactorsincludinglocalpensionrulesandregulationslocaltaxregulationsavailabilityofinvestmentvehicles separateaccountscommingledaccountsinsurancefundsetcfundedstatusoftheplansratioofactivestoretirees durationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityoflocalmarketsandliquidityofbase currencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobeongoingplans permittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefunds thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareas follows percentof target planassets allocation worldwideretirementplans equitysecurities debtsecurities totalplanassets determinationoffairvalueofplanassets theplanhasanestablishedandwelldocumentedprocessfordeterminingfairvaluesfairvalueisbaseduponquoted marketpriceswhereavailableiflistedpricesorquotesarenotavailablefairvalueisbaseduponmodelsthatprimarily useasinputsmarketbasedorindependentlysourcedmarketparametersincludingyieldcurvesinterestratesvolatilities equityordebtpricesforeignexchangeratesandcreditcurves whiletheplanbelievesitsvaluationmethodsareappropriateandconsistentwithothermarketparticipantstheuseof differentmethodologiesorassumptionstodeterminethefairvalueofcertainfinancialinstrumentscouldresultinadifferent estimateoffairvalueatthereportingdate valuationhierarchy theauthoritativeliteratureestablishesathreelevelhierarchytoprioritizetheinputsusedinmeasuringfairvaluethelevels withinthehierarchyaredescribedinthetablebelowwithlevelhavingthehighestpriorityandlevelhavingthelowest afinancialinstrumentscategorizationwithinthevaluationhierarchyisbaseduponthelowestlevelofinputthatis significanttothefairvaluemeasurement followingisadescriptionofthevaluationmethodologiesusedfortheinvestmentsmeasuredatfairvalue shortterminvestmentfundscashandquotedshortterminstrumentsarevaluedattheclosingpriceortheamount heldondepositbythecustodianbankotherinvestmentsarethroughinvestmentvehiclesvaluedusingthenetasset valuenavprovidedbytheadministratorofthefundthenavisbasedonthevalueoftheunderlyingassetsowned bythefundminusitsliabilitiesandthendividedbythenumberofsharesoutstandingthenavisaquotedpriceina marketthatisnotactiveandclassifiedaslevel governmentandagencysecuritiesalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedon themajormarketonwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarket theinvestmentsareclassifiedwithinlevelofthevaluationhierarchyifquotedmarketpricesarenotavailableforthe specificsecuritythenfairvaluesareestimatedbyusingpricingmodelsquotedpricesofsecuritieswithsimilar characteristicsordiscountedcashflowswhenquotedmarketpricesforasecurityarenotavailableinanactivemarket theyareclassifiedaslevel debtinstrumentsalimitednumberoftheseinvestmentsarevaluedattheclosingpricereportedonthemajormarket onwhichtheindividualsecuritiesaretradedwherequotedpricesareavailableinanactivemarkettheinvestmentsare classifiedaslevelifquotedmarketpricesarenotavailableforthespecificsecuritythenfairvaluesareestimatedby usingpricingmodelsquotedpricesofsecuritieswithsimilarcharacteristicsordiscountedcashflowsandareclassified aslevelleveldebtinstrumentsarepricedbasedonunobservableinputs equitysecuritiesequitysecuritiesarevaluedattheclosingpricereportedonthemajormarketonwhichtheindividual securitiesaretradedsubstantiallyallcommonstockisclassifiedwithinlevelofthevaluationhierarchy johnsonjohnsonannualreport commingledfundstheseinvestmentvehiclesarevaluedusingthenavprovidedbythefundadministratorthenav isbasedonthevalueoftheunderlyingassetsownedbythefundminusitsliabilitiesandthendividedbythenumberof sharesoutstandingassetsinthelevelcategoryhaveaquotedmarketprice insurancecontractstheinstrumentsareissuedbyinsurancecompaniesthefairvalueisbasedonnegotiatedvalue andtheunderlyinginvestmentsheldinseparateaccountportfoliosaswellasconsideringthecreditworthinessofthe issuertheunderlyinginvestmentsaregovernmentassetbackedandfixedincomesecuritiesingeneralinsurance contractsareclassifiedaslevelastherearenoquotedpricesnorotherobservableinputsforpricing otherassetsotherassetsarerepresentedprimarilybylimitedpartnershipsandrealestateinvestmentsaswellas commercialloansandcommercialmortgagesthatarenotclassifiedascorporatedebtotherassetsthatareexchange listedandactivelytradedareclassifiedaslevelwhileinactivelytradedassetsareclassifiedaslevel thefollowingtablesetsforththeretirementplansinvestmentsmeasuredatfairvalueasofdecemberand december quotedprices significant inactive significant investments marketsfor observable unobservable measuredat identicalassets inputs inputsa netasset level level level value totalassets dollarsinmillions shortterminvestmentfunds governmentandagencysecurities debtinstruments equitysecurities commingledfunds insurancecontracts otherassets investmentsatfairvalue theactivityforthelevelassetsisnotsignificantforallyearspresented thecompanysotherbenefitplansareunfundedexceptforuscommingledfundslevelofmillionand millionandusshortterminvestmentfundslevelofmillionandmillionatdecemberand decemberrespectively thefairvalueofjohnsonjohnsoncommonstockdirectlyheldinplanassetswasmillionoftotalplan assetsatdecemberandmillionoftotalplanassetsatdecember savings plan thecompanyhasvoluntaryksavingsplansdesignedtoenhancetheexistingretirementprogramscoveringeligible employeesthecompanymatchesapercentageofeachemployeescontributionsconsistentwiththeprovisionsofthe planforwhichhesheiseligibletotalcompanymatchingcontributionstotheplansweremillionmillionand millioninandrespectively johnsonjohnsonannualreport capital treasury stock changesintreasurystockwere treasurystock amountsinmillionsexcepttreasurystocksharesinthousands shares amount balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatjanuary employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember employeecompensationandstockoptionplans repurchaseofcommonstock balanceatdecember aggregatesharesofcommonstockissuedwereapproximatelysharesattheendofand cashdividendspaidwerepershareincomparedwithdividendsofpershareinandper sharein ondecemberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstocktherepurchase programhasnotimelimitandmaybesuspendedforperiodsordiscontinuedatanytimeanysharesacquiredwillbe availableforgeneralcorporatepurposesthecompanyintendstofinancethesharerepurchaseprogramthroughavailable cashasofdecemberbillionhasbeenrepurchasedundertheprogram onoctoberthecompanyannouncedthatitsboardofdirectorsapprovedasharerepurchaseprogram authorizingthecompanytopurchaseuptobillionofthecompanyssharesofcommonstockthisshare repurchaseprogramwascompletedasofjuly accumulated comprehensive income loss componentsofothercomprehensiveincomelossconsistofthefollowing total gainloss accumulated foreign gainloss employee currency benefit derivatives comprehensive dollarsinmillions translation securities plans hedges incomeloss january netchanges january netchanges december cumulativeadjustmenttoretainedearnings netchanges december seenotetoconsolidatedfinancialstatementsforadditionaldetailsontheadoptionofasu amountsinaccumulatedothercomprehensiveincomearepresentednetoftherelatedtaximpactforeigncurrency translationisnotadjustedforincometaxeswhereitrelatestopermanentinvestmentsininternationalsubsidiariesfor additionaldetailsoncomprehensiveincomeseetheconsolidatedstatementsofcomprehensiveincome johnsonjohnsonannualreport detailsonreclassificationsoutofaccumulatedothercomprehensiveincome gainlossonsecuritiesreclassificationsreleasedtootherincomeexpensenet employeebenefitplansreclassificationsareincludedinnetperiodicbenefitcostseenoteforadditional details gainlossonderivativeshedgesreclassificationstoearningsarerecordedinthesameaccountasthe hedgedtransactionseenoteforadditionaldetails international currency translation fortranslationofitssubsidiariesoperatinginnonusdollarcurrenciesthecompanyhasdeterminedthatthelocal currenciesofitsinternationalsubsidiariesarethefunctionalcurrenciesexceptthoseinhighlyinflationaryeconomieswhich aredefinedasthosewhichhavehadcompoundcumulativeratesofinflationoformoreduringthepastthreeyears orwhereasubstantialportionofitscashflowsarenotinthelocalcurrencybeginninginthefiscalthirdquarterof thecompanyaccountedforoperationsinargentinaashighlyinflationaryforthemajorityofthecompanyssubsidiaries thelocalcurrencyisthefunctionalcurrency inconsolidatinginternationalsubsidiariesbalancesheetcurrencyeffectsarerecordedasacomponentofaccumulated othercomprehensiveincomethisequityaccountincludestheresultsoftranslatingcertainbalancesheetassetsand liabilitiesatcurrentexchangeratesandsomeaccountsathistoricalratesexceptforthoselocatedinhighlyinflationary economiesthetranslationofbalancesheetaccountsforhighlyinflationaryeconomiesarereflectedintheoperating results arollforwardofthechangesduringandforforeigncurrencytranslationadjustmentsisincludedin note netcurrencytransactiongainsandlossesincludedinotherincomeexpensewerelossesofmillionmillion andmillioninandrespectively earnings per share thefollowingisareconciliationofbasicnetearningspersharetodilutednetearningspershareforthefiscalyearsended decemberdecemberandjanuary inmillionsexceptpershareamounts basicnetearningspershare averagesharesoutstandingbasic potentialsharesexercisableunderstockoptionplans lesssharesrepurchasedundertreasurystockmethod convertibledebtshares adjustedaveragesharesoutstandingdiluted dilutednetearningspershare thedilutednetearningspersharecalculationincludedthedilutiveeffectofconvertibledebtthatisoffsetbytherelated reductionininterestexpenseofmillionaftertaxforandandmillionfor thedilutednetearningspersharecalculationforandincludedallsharesrelatedtostockoptionsas theexercisepriceofalloptionswaslessthantheaveragemarketvalueofthecompanysstock rental expense lease commitments rentalsofspacevehiclesmanufacturingequipmentandofficeanddataprocessingequipmentunderoperatingleases wereapproximatelymillionmillionandmillioninandrespectively johnsonjohnsonannualreporttheapproximateminimumrentalpaymentsrequiredunderoperatingleasesthathaveinitialorremainingnoncancelable leasetermsinexcessofoneyearatdecemberare dollarsinmillions total commitmentsundercapitalleasesarenotsignificant common stock stock option plans stock compensation agreements atdecemberthecompanyhadstockbasedcompensationplansthesharesoutstandingareforcontracts underthecompanyslongtermincentiveplanandthelongtermincentiveplanthelongterm incentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewereunderthe longtermincentiveplanunderthelongtermincentiveplanthecompanymayissueuptomillion sharesofcommonstockplusanysharescanceledexpiredforfeitedornotissuedfromthelongtermincentive plansubsequenttoaprilsharesavailableforfuturegrantsunderthelongtermincentiveplanwere millionattheendof thecompensationcostthathasbeenchargedagainstincomefortheseplanswasmillionmillionand millionforandrespectivelythetotalincometaxbenefitrecognizedintheincomestatementfor sharebasedcompensationcostswasmillionmillionandmillionforand respectivelyanadditionaltaxbenefitofmillionwasrecognizedinduetotheadoptionofanewaccounting standardforthereportingofadditionaltaxbenefitsonsharebasedcompensationthetotalunrecognizedcompensation costwasmillionmillionandmillionforandrespectivelytheweightedaverage periodforthiscosttoberecognizedwasyearsyearsandyearsforandrespectively sharebasedcompensationcostscapitalizedaspartofinventorywereinsignificantinallperiods thecompanysettlesemployeebenefitequityissuanceswithtreasurysharestreasurysharesarereplenishedthroughout theyearforthenumberofsharesusedtosettleemployeebenefitequityissuances stockoptions stockoptionsexpireyearsfromthedateofgrantandvestoverserviceperiodsthatrangefrommonthstoyearsall optionsaregrantedattheaverageofthehighandlowpricesofthecompanyscommonstockonthenewyorkstock exchangeonthedateofgrant thefairvalueofeachoptionawardwasestimatedonthedateofgrantusingtheblackscholesoptionvaluationmodel thatusestheassumptionsnotedinthefollowingtableforandgrantsexpectedvolatilityrepresentsa blendedrateofyearweeklyhistoricaloverallvolatilityrateandaweekaverageimpliedvolatilityratebasedon atthemoneytradedjohnsonjohnsonoptionswithalifeofyearsforallgrantshistoricaldataisusedtodetermine theexpectedlifeoftheoptiontheriskfreeratewasbasedontheustreasuryyieldcurveineffectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasandinandrespectivelythe fairvaluewasestimatedbasedontheweightedaverageassumptionsof riskfreerate expectedvolatility expectedlifeinyears expecteddividendyield johnsonjohnsonannualreport asummaryofoptionactivityundertheplanasofdecemberdecemberandjanuaryand changesduringtheyearsendingonthosedatesispresentedbelow aggregate intrinsic weighted value outstanding average dollarsin sharesinthousands shares exerciseprice millions sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatjanuary optionsgranted optionsexercised optionscanceledforfeited sharesatdecember optionsgranted optionsexercised optionscanceledforfeited sharesatdecember thetotalintrinsicvalueofoptionsexercisedwasmillionmillionandmillioninand respectively thefollowingtablesummarizesstockoptionsoutstandingandexercisableatdecember sharesinthousands outstanding exercisable average average average exercise exercise exercisepricerange options life price options price averagecontractualliferemaininginyears stockoptionsoutstandingatdecemberandjanuarywereandanaveragelifeofyearsand andanaveragelifeofyearsrespectivelystockoptionsexercisableatdecemberandjanuary wereatanaveragepriceofandatanaveragepriceofrespectively restrictedshareunitsandperformance shareunits thecompanygrantsrestrictedshareunitswhichvestoverserviceperiodsthatrangefrommonthstoyearsthe companyalsograntsperformanceshareunitswhicharepaidinsharesofjohnsonjohnsoncommonstockafterthe endofathreeyearperformanceperiodwhetheranyperformanceshareunitsvestandtheamountthatdoesvestistied tothecompletionofserviceperiodsthatrangefrommonthstoyearsandtheachievementoverathreeyearperiod ofthreeequallyweightedgoalsthatdirectlyalignwithorhelpdrivelongtermtotalshareholderreturnoperationalsales adjustedoperationalearningspershareandrelativetotalshareholderreturnthenumberofsharesactuallyearnedatthe endofthethreeyearperiodwillvarybasedonlyonactualperformancefromtoofthetargetnumberof performanceshareunitsgrantedinthefourthquarterofthecompanymodifiedtherestrictedshareunitsthatare scheduledtovestbetweenjanuaryandmarchthismodificationguaranteedaminimumaggregate johnsonjohnsonannualreportvaluebelowthemarketvalueofthetotalexpectedpayoutamountforallawardsexpectedtovestduringthisperiodthe amountthatwascommittedwasnotmaterialtothecompanysoverallfinancialposition asummaryoftherestrictedshareunitsandperformanceshareunitsactivityundertheplansasofdecemberis presentedbelow outstanding outstanding restricted performance sharesinthousands shareunits shareunits sharesatdecember granted issued canceledforfeitedadjusted sharesatdecember theaveragefairvalueoftherestrictedshareunitsgrantedwasandinand respectivelyusingthefairmarketvalueatthedateofgrantthefairvalueofrestrictedshareunitswasdiscountedfor dividendswhicharenotpaidontherestrictedshareunitsduringthevestingperiodthefairvalueofrestrictedshareunits issuedwasmillionmillionandmillioninandrespectively theweightedaveragefairvalueoftheperformanceshareunitsgrantedwasandin andcalculatedusingtheweightedaveragefairmarketvalueforeachofthethreecomponentgoalsatthe dateofgrant thefairvaluesforthesalesandearningspersharegoalsofeachperformanceshareunitwereestimatedonthedateof grantusingthefairmarketvalueofthesharesatthetimeoftheawarddiscountedfordividendswhicharenotpaidonthe performanceshareunitsduringthevestingperiodthefairvaluefortherelativetotalshareholderreturngoalofeach performanceshareunitwasestimatedonthedateofgrantusingthemontecarlovaluationmodelthefairvalueof performanceshareunitsissuedwasmillionmillionandmillioninand respectively johnsonjohnsonannualreport segments business geographic areas salestocustomers change dollarsinmillions vs vs consumer babycare us international worldwide beauty us international worldwide oralcare us international worldwide otc us international worldwide womenshealth us international worldwide woundcareother us international worldwide totalconsumer us international worldwide pharmaceutical immunology us international worldwide remicade us usexports international worldwide simponisimponiaria us international johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs worldwide stelara us international worldwide tremfaya us international worldwide otherimmunology us international worldwide infectiousdiseases us international worldwide edurantrilpivirine us international worldwide prezistaprezcobixrezolstasymtuza us international worldwide otherinfectiousdiseases us international worldwide neuroscience us international worldwide concertamethylphenidate us international worldwide invegasustennaxeplioninvegatrinza trevicta us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs risperdalconsta us international worldwide otherneuroscience us international worldwide oncology us international worldwide darzalex us international worldwide imbruvica us international worldwide velcade us international worldwide zytigaabirateroneacetate us international worldwide otheroncology us international worldwide pulmonaryhypertension us international worldwide opsumit us international worldwide tracleer us international johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs worldwide uptravi us international worldwide us international worldwide cardiovascularmetabolismother us international worldwide xarelto us international worldwide invokanainvokamet us international worldwide procriteprex us international worldwide us international worldwide totalpharmaceutical us international worldwide medicaldevices diabetescare us international worldwide diagnostics us international worldwide johnsonjohnsonannualreport salestocustomers change dollarsinmillions vs vs interventionalsolutions us international worldwide orthopaedics us international worldwide hips us international worldwide knees us international worldwide trauma us international worldwide spineother us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide specialty us international worldwide johnsonjohnsonannualreportsalestocustomers change dollarsinmillions vs vs vision us international worldwide contactlensesother us international worldwide surgical us international worldwide totalmedicaldevices us international worldwide worldwide us international worldwide percentagegreaterthanornotmeaningful incomebeforetax identifiableassets dollarsinmillions consumer pharmaceutical medicaldevices total lessexpensenotallocatedtosegments generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillions consumer pharmaceutical medicaldevices segmentstotal generalcorporate worldwidetotal johnsonjohnsonannualreport salestocustomers longlivedassets dollarsinmillions unitedstates europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedassets worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperates exportsalesarenotsignificantinthecompanyhadthreewholesalersdistributingproductsforallthreesegments thatrepresentedapproximatelyandofthetotalconsolidatedrevenuesinthecompanyhad twowholesalersdistributingproductsforallthreesegmentsthatrepresentedapproximatelyandofthetotal consolidatedrevenuesinthecompanyhadtwowholesalersdistributingproductsforallthreesegmentsthat representedapproximatelyandofthetotalconsolidatedrevenues amountsnotallocatedtosegmentsincludeinterestincomeexpenseandgeneralcorporateincomeexpense generalcorporateincludescashcashequivalentsandmarketablesecurities theconsumersegmentincludesagainofbillionfromthedivestitureofnizoralandlitigationexpenseofbillionthe pharmaceuticalsegmentincludesaninprocessresearchanddevelopmentchargeofbillionrelatedtothealiosandxo assetsandthecorrespondingxocontingentliabilityreversalofbillionactelionacquisitionrelatedcostsofbillion unrealizedlossonsecuritiesofbillionandagainofbillionfromthedivestitureofcertainnonstrategicpharmaceutical productsthemedicaldevicessegmentincludesnetlitigationexpenseofbillionarestructuringrelatedchargeofbillion amoacquisitionrelatedcostsofbillionandagainofbillionfromthedivestitureofthelifescanbusinessinthefiscal fourthquarter thepharmaceuticalsegmentincludesbillionforactelionacquisitionrelatedcostsaninprocessresearchanddevelopment expenseofbillionandlitigationexpenseofbillionthemedicaldevicessegmentincludeslitigationexpenseofbillion arestructuringrelatedchargeofbillionanassetimpairmentofbillionprimarilyrelatedtotheinsulinpumpbusinessand billionforamoacquisitionrelatedcoststhemedicaldevicessegmentincludesagainofbillionfromthedivestitureof codmanneurosurgerytheconsumersegmentincludesagainofbillionfromthedivestitureofcompeed includesnetlitigationexpenseofbillionandarestructuringrelatedchargeofbillioninthemedicaldevicessegmentthe pharmaceuticalsegmentincludesapositiveadjustmentofbilliontopreviousreserveestimatesandgainsfromthedivestitures ofthecontrolledsubstancerawmaterialandactivepharmaceuticalingredientapibusinessandcertainanestheticproductsin europe longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyand intangibleassetsandgoodwillnetforandofandrespectively johnsonjohnsonannualreport selected quarterly financial data unaudited selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow dollarsinmillionsexceptpershare first second third fourth first second third fourth data quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomers consumer pharmaceutical medicaldevices totalsales grossprofit earningsbeforeprovisionfortaxeson income netearningsloss basicnetearningslosspershare dilutednetearningslosspershare thefirstquarterofincludesanactelionacquisitionrelatedcostofmillionaftertaxmillionbeforetaxanda restructuringrelatedchargeofmillionaftertaxmillionbeforetax thesecondquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxandarestructuring relatedchargeofmillionaftertaxmillionbeforetax thethirdquarterofincludesaninprocessresearchanddevelopmentexpenseofmillionaftertaxmillion beforetaxrelatedtothealiosandxoassetsandthecorrespondingxocontingentliabilityreversalofmillionafterand beforetaxarestructuringrelatedchargeofmillionaftertaxmillionbeforetaxandamillionbenefitaftertaxfrom theimpactoftaxlegislation thefourthquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxarestructuringrelated chargeofmillionaftertaxmillionbeforetaxandamillionbenefitaftertaxfromtheimpactoftaxlegislation thefirstquarterofincludesarestructuringchargeofmillionaftertaxmillionbeforetaxandanamoacquisition relatedcostofmillionaftertaxmillionbeforetax thesecondquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisition relatedcostsofmillionaftertaxmillionbeforetaxarestructuringchargeofmillionaftertaxmillion beforetaxandanassetimpairmentchargeofmillionaftertaxmillionbeforetax thethirdquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisitionrelated costsofmillionaftertaxmillionbeforetaxandarestructuringchargeofmillionaftertaxmillionbeforetax thefourthquarterofincludesalitigationexpenseofmillionaftertaxmillionbeforetaxactelionacquisitionrelated costsofmillionaftertaxmillionbeforetaxarestructuringchargeofmillionaftertaxmillionbeforetaxan inprocessresearchanddevelopmentexpenseofmillionaftertaxmillionbeforetaxandanaftertaxbenefitof millionrelatedtotheinsulinpumpbusinessadditionallythefourthquarterofincludesaprovisionalchargeof billionforrecentlyenactedtaxlegislation johnsonjohnsonannualreport business combinations divestitures certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedzarbeesincaprivatelyheldcompanythatisaleaderinnaturallybased consumerhealthcareproductsmedicalenterprisesdistributionllcaprivatelyheldhealthcaretechnologyfirmfocused onsurgicalprocedureinnovationbenevirbiopharmincbeneviraprivatelyheldbiopharmaceuticalcompany specializinginthedevelopmentofoncolyticimmunotherapiesandorthotaxyaprivatelyhelddeveloperofsoftware enabledsurgerytechnologiesincludingadifferentiatedroboticassistedsurgerysolution theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill onoctoberthecompanyenteredintoanagreementtoacquirecizholdingscoltdajapanesecompany focusedonthemarketingdevelopmentanddistributionofabroadrangeofdermocosmeticcosmeticandskincare productsforatotalpurchasepriceofapproximatelybillionwhichequatestoapproximatelybillionusingthe exchangerateofjapaneseyentoeachusdollaronjanuarytheacquisitionwascompletedon januarythroughaseriesoftransactionsthatincludedanallcashtenderoffertoacquirethepubliclyheldshares notalreadyheldbythecompanyforpershareuponcompletionofthetenderofferandtherelatedtransactions thecompanyacquiredoftheoutstandingsharesthecompanyplanstoacquiretheremainingsharesthatwerenot tenderedinthetenderofferthroughashareconsolidationunderjapaneselawduringthefirsthalfofandtake appropriateactionstodelistfromthetokyostockexchangetheacquisitionwillincludetherangeofbrandscomprising drcilabolabolaboandgenomerlineofskincareproductsthecompanyexpectstotreatthistransactionasa businesscombinationandwillincludeitintheconsumersegment onfebruarythecompanyenteredintoadefinitiveagreementtoacquireaurishealthincforapproximately billionincashadditionalcontingentpaymentsofuptobillionintheaggregatemaybepayableupon reachingcertainpredeterminedmilestonesaurishealthisaprivatelyhelddeveloperofrobotictechnologiesinitially focusedinlungcancerwithanfdaclearedplatformcurrentlyusedinbronchoscopicdiagnosticandtherapeutic procedurestheclosingissubjecttoantitrustclearanceandothercustomaryclosingconditionsthetransactionis expectedtoclosebytheendofthesecondquarterofthecompanyexpectstotreatthistransactionasabusiness combinationandwillincludeitinthemedicaldevicessegment duringcertainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedactelionltdanestablishedleadingfranchiseofdifferentiatedinnovative productsforpulmonaryarterialhypertensionpahabbottmedicalopticsamoawhollyownedsubsidiaryofabbott laboratorieswhichincludedophthalmicproductsrelatedtocataractsurgerylaserrefractivesurgeryandconsumereye healthneuravilimitedaprivatelyheldmedicaldevicecompanythatdevelopsandmarketsmedicaldevicesfor neurointerventionaltherapytearscienceincamanufacturerofproductsdedicatedtotreatingmeibomiangland dysfunctionsightboxincaprivatelyheldcompanythatdevelopedasubscriptionvisioncareservicethatconnects consumerswitheyecareprofessionalsandasupplyofcontactlensestoraxmedicalincaprivatelyheldmedicaldevice companythatmanufacturesandmarketsthelinxrefluxmanagementsystemforthesurgicaltreatmentof gastroesophagealrefluxdiseaseandmegadynemedicalproductsincaprivatelyheldmedicaldevicecompanythat developsmanufacturesandmarketselectrosurgicaltools theexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwillofthisamountapproximately billionhasbeenidentifiedasthevalueofiprdprimarilyassociatedwiththeacquisitionofactelionltdthevalue oftheiprdwascalculatedusingcashflowprojectionsdiscountedfortheinherentriskintheprojects duringthecompanycompletedtheacquisitionofactelionltdthroughanallcashtenderofferinswitzerlandfor pershareamountingtobillionnetofcashacquiredaspartofthetransactionimmediatelypriortothe completionoftheacquisitionactelionspunoutitsdrugdiscoveryoperationsandearlystageclinicaldevelopmentassets intoanewlycreatedswissbiopharmaceuticalcompanyidorsialtdthesharesofidorsiaarelistedonthesixswiss exchangesixinthecompanyheldofthesharesofidorsiaandhadrightstoanadditionalofidorsia equitythroughaconvertibleloanwithaprincipalamountofapproximatelybillionasaresultofidorsiaraising johnsonjohnsonannualreportadditionalcapitalinjulythecompanycurrentlyholdsofthesharesofidorsiaandhasrightstoanadditional ofidorsiaequitythroughaconvertibleloanwithaprincipalamountofapproximatelybilliontheconvertible loanmaybeconvertedintoidorsiasharesasfollowsiuptoanaggregateshareholdingofofidorsiasharesasa resultofcertainshareholdersholdingmorethanoftheissuedidorsiasharesandiiuptothebalanceofthe remainingamountwithinbusinessdaysofthematuritydateoftheconvertibleloanwhichhasayeartermorif idorsiaundergoesachangeofcontroltransactiontheinvestmentinidorsiawasrecordedasacostmethodinvestmentin otherassetsinthecompanysconsolidatedbalancesheetthecompanyalsoexercisedtheoptionacquiredon actaproductwithinidorsiabeingdevelopedforresistanthypertensioncurrentlyinphaseofclinical developmentthecompanyhasalsoenteredintoanagreementtoprovideidorsiawithaswissfrancdenominatedcredit facilityofapproximatelymillionasofdecemberidorsiahasnotmadeanydrawdownsunderthecredit facilityactelionhasenteredintoatransitionalservicesagreementwithidorsiaactelionhasestablishedaleading franchiseofdifferentiatedinnovativeproductsforpulmonaryarterialhypertensionpahthatarehighlycomplementaryto theexistingportfolioofthecompanytheadditionofactelionsspecialtyinmarketmedicinesandlatestageproductsis consistentwiththecompanyseffortstogrowinattractiveandcomplementarytherapeuticareasandservepatientswith seriousillnessesandsignificantunmetmedicalneed duringthefiscalsecondquarterofthecompanyfinalizedthepurchasepriceallocationtotheindividualassets acquiredandliabilitiesassumedusingtheacquisitionmethodthefollowingtablepresentstheamountsrecognizedfor assetsacquiredandliabilitiesassumedasoftheacquisitiondatewithadjustmentsmadethroughthesecondquarterof dollarsinmillions cashcashequivalents inventory accountsreceivable othercurrentassets propertyplantandequipment goodwill intangibleassets deferredtaxes othernoncurrentassets totalassetsacquired currentliabilities deferredtaxes othernoncurrentliabilities totalliabilitiesassumed netassetsacquired includesadjustmentofmilliontowriteuptheacquiredinventorytoitsestimatedfairvalue theadjustmentsmadesincethedateofacquisitionwerebilliontothedeferredtaxesandbilliontothecurrent liabilitieswiththeoffsettogoodwilltheassetsacquiredarerecordedinthepharmaceuticalsegmenttheacquisitionof actelionresultedinapproximatelybillionofgoodwillthegoodwillisprimarilyattributabletosynergiesexpectedto arisefromtheacquisitionthegoodwillisnotexpectedtobedeductiblefortaxpurposes johnsonjohnsonannualreport thepurchasepriceallocationtotheidentifiableintangibleassetsisasfollows dollarsinmillions intangibleassetswithdefinitelives patentsandtrademarks totalamortizableintangibles inprocessresearchanddevelopment totalintangibleassets includesbillionrelatedtovalchloroneoftheacquiredproductswhichwasdivestedinthefiscalsecondquarterof thepatentsandtrademarksacquiredarecomprisedofdevelopedtechnologywithaweightedaveragelifeofyearsand wasprimarilybasedonthepatentlifeofthemarketedproductstheintangibleassetswithdefiniteliveswereassigned assetlivesrangingfromtoyearstheinprocessresearchanddevelopmentintangibleassetswerevaluedfor technologyprogramsforunapprovedproducts thevalueoftheiprdwascalculatedusingprobabilityadjustedcashflowprojectionsdiscountedfortheriskinherentin suchprojectsthediscountrateappliedwas theacquisitionwasaccountedforusingtheacquisitionmethodandaccordinglytheresultsofoperationsofactelion werereportedinthecompanysfinancialstatementsbeginningonjunethedateofacquisitionfortheyear endeddecembertotalsalesandanetlossforactelionfromthedateofacquisitionwerebillionand billionrespectively thefollowingtableprovidesproformaresultsofoperationsforthefiscalyearendeddecemberandjanuary asifactelionhadbeenacquiredasofjanuarytheproformaresultsincludetheeffectofcertainpurchase accountingadjustmentssuchastheestimatedchangesindepreciationandamortizationexpenseontheacquiredtangible andintangibleassetshoweverproformaresultsdonotincludeanyanticipatedcostsavingsorothereffectsofthe plannedintegrationofactelionaccordinglysuchamountsarenotnecessarilyindicativeoftheresultsiftheacquisition hadoccurredonthedatesindicatedorwhichmayoccurinthefuture unauditedproformaconsolidatedresults dollarsinmillionsexceptpersharedata netsales netearnings dilutednetearningspercommonshare thecompanyrecordedactelionacquisitionrelatedcostsbeforetaxofapproximatelybillionandbillionin andrespectivelywhichwasrecordedinotherincomeexpenseandcostofproductssold duringthecompanyacquiredabbottmedicalopticsamoawhollyownedsubsidiaryofabbottlaboratoriesfor billionnetofcashacquiredtheacquisitionincludedophthalmicproductsrelatedtocataractsurgerylaser refractivesurgeryandconsumereyehealththenetpurchasepricewasprimarilyrecordedasamortizableintangible assetsforbillionandgoodwillforbilliontheweightedaveragelifeoftotalamortizableintangiblesthemajority beingcustomerrelationshipsisapproximatelyyearsthegoodwillisprimarilyattributabletosynergiesexpectedto arisefromthebusinessacquisitionandisnotdeductiblefortaxpurposestheintangibleassetsandgoodwillamountsare basedonthefinalpurchasepriceallocationtheassetsacquiredwererecordedinthemedicaldevicessegment certainbusinesseswereacquiredforbillionincashandbillionofliabilitiesassumedduringthese acquisitionswereaccountedforusingtheacquisitionmethodandaccordinglyresultsofoperationshavebeenincluded inthefinancialstatementsfromtheirrespectivedatesofacquisition theacquisitionsprimarilyincludedvogueinternationalllcaprivatelyheldcompanyfocusedonthemarketing developmentanddistributionofsaloninfluencedandnatureinspiredhaircareandotherpersonalproductsneuwave medicalincaprivatelyheldmedicaldevicecompanythatmanufacturesandmarketsminimallyinvasivesofttissue microwaveablationsystemsneostratacompanyincagloballeaderindermocosmeticsandtheglobalrightsforthe commercializationofrhinocortallergysprayoutsidetheunitedstates johnsonjohnsonannualreporttheexcessofpurchasepriceovertheestimatedfairvalueoftangibleassetsacquiredamountedtobillionandhas beenassignedtoidentifiableintangibleassetswithanyresidualrecordedtogoodwill thenetpurchasepriceforvogueinternationalllcofbillionwasprimarilyrecordedasamortizableintangibleassets forbillionandgoodwillforbilliontheweightedaveragelifeforthebillionoftotalamortizableintangiblesis approximatelyyearsthetrademarkassetvaluesweredeterminedtohavedefinitelivesrangingfromtoyears withthemajoritybeingyearsthegoodwillisprimarilyattributabletosynergiesexpectedtoarisefromthebusiness acquisitionandisexpectedtobedeductiblefortaxpurposestheassetsacquiredwererecordedintheconsumer segment inthecompanycompletedtheacquisitionofsynthesincforapurchasepriceofbillionincashandstock inconnectionwiththeacquisitionofsynthesincthecompanyenteredintotwoacceleratedsharerepurchaseasr agreementsinthecompanysettledtheremainingliabilitiesundertheasragreementswhilethecompany believesthatthetransactionsundereachasragreementandaseriesofrelatedinternaltransactionswereconsummated inataxefficientmannerinaccordancewithapplicablelawitispossiblethattheinternalrevenueservicecouldassert oneormorecontrarypositionstochallengethetransactionsfromataxperspectiveifchallengedanamountuptothe totalpurchasepriceforthesynthessharescouldbetreatedassubjecttoapplicableustaxatapproximatelythe statutoryratetothecompanyplusinterest withtheexceptionoftheactelionltdacquisitionsupplementalproformainformationforandin accordancewithusgaapstandardsrelatedtobusinesscombinationsandgoodwillandotherintangibleassetsisnot providedastheimpactoftheaforementionedacquisitionsdidnothaveamaterialeffectonthecompanysresultsof operationscashflowsorfinancialposition duringthecompanydivestedthelifescanincbusinessforapproximatelybillionandretainedcertainnet liabilitiesotherdivestituresinincludednizoralrocandcertainnonstrategicpharmaceuticalproductsin thepretaxgainsonthedivestitureswereapproximatelybillionadditionallyinthecompanyaccepted thebindingofferfromfortivecorporationtoacquireitsadvancedsterilizationproductsaspbusinessforapproximately billionsubjecttocustomaryadjustmentsthetransactionisexpectedtocloseinasofdecember theassetsheldforsaleontheconsolidatedbalancesheetwerebillionofinventorybillionofpropertyplant andequipmentandbillionofgoodwillthecompanywillretaincertainnetreceivablesofapproximatelybillion associatedwiththeaspbusiness inthecompanyacceptedabindingoffertoformastrategiccollaborationwithjabilinconeoftheworldsleading manufacturingservicesprovidersforhealthcareproductsandtechnologyproductsthecompanyisexpandingayear relationshipwithjabiltoproducearangeofproductswithintheethiconendosurgeryanddepuysynthesbusinesses thistransactionincludesthetransferofemployeesandmanufacturingsitesasofdecembertheassetsheldfor saleontheconsolidatedbalancesheetwerebillionofinventoryandbillionofpropertyplantandequipment netforadditionaldetailsontheglobalsupplychainrestructuringseenotetotheconsolidatedfinancialstatements duringthecompanydivestituresprimarilyincludedthecodmanneurosurgerybusinesstointegralifesciences holdingscorporationandthedivestitureofcompeedtohrapharmainthepretaxgainsonthedivestitures wereapproximatelybillion duringthecompanydivestituresincludedthecontrolledsubstancerawmaterialandactivepharmaceutical ingredientapibusinesscertainanestheticproductsineuropeandcertainnonstrategicconsumerbrandsinthe pretaxgainsonthedivestitureswereapproximatelybillion legal proceedings johnsonjohnsonandcertainofitssubsidiariesareinvolvedinvariouslawsuitsandclaimsregardingproductliability intellectualpropertycommercialsupplierindemnificationandothermattersgovernmentalinvestigationsandotherlegal proceedingsthatarisefromtimetotimeintheordinarycourseoftheirbusiness thecompanyrecordsaccrualsforlosscontingenciesassociatedwiththeselegalmatterswhenitisprobablethata liabilitywillbeincurredandtheamountofthelosscanbereasonablyestimatedasofdecemberthecompany hasdeterminedthattheliabilitiesassociatedwithcertainlitigationmattersareprobableandcanbereasonablyestimated thecompanyhasaccruedforthesemattersandwillcontinuetomonitoreachrelatedlegalissueandadjustaccrualsas mightbewarrantedbasedonnewinformationandfurtherdevelopmentsinaccordancewithascforthese andotherlitigationandregulatorymattersdiscussedbelowforwhichalossisprobableorreasonablypossiblethe companyisunabletoestimatethepossiblelossorrangeoflossbeyondtheamountsalreadyaccruedamountsaccrued johnsonjohnsonannualreport forlegalcontingenciesoftenresultfromacomplexseriesofjudgmentsaboutfutureeventsanduncertaintiesthatrely heavilyonestimatesandassumptionstheabilitytomakesuchestimatesandjudgmentscanbeaffectedbyvarious factorsincludingwhetherdamagessoughtintheproceedingsareunsubstantiatedorindeterminatescientificandlegal discoveryhasnotcommencedorisnotcompleteproceedingsareinearlystagesmatterspresentlegaluncertainties therearesignificantfactsindisputeortherearenumerouspartiesinvolved inthecompanysopinionbasedonitsexaminationofthesemattersitsexperiencetodateanddiscussionswithcounsel theultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthecompanysbalancesheetisnotexpectedto haveamaterialadverseeffectonthecompanysfinancialpositionhowevertheresolutionoforincreaseinaccrualsfor oneormoreofthesemattersinanyreportingperiodmayhaveamaterialadverseeffectonthecompanysresultsof operationsandcashflowsforthatperiod productliability johnsonjohnsonandcertainofitssubsidiariesareinvolvedinnumerousproductliabilityclaimsandlawsuitsinvolving multipleproductsclaimantsinthesecasesseeksubstantialcompensatoryandwhereavailablepunitivedamageswhile thecompanybelievesithassubstantialdefensesitisnotfeasibletopredicttheultimateoutcomeoflitigationthe companyhasestablishedaccrualsforproductliabilityclaimsandlawsuitsincompliancewithascbasedon currentlyavailableinformationwhichinsomecasesmaybelimitedthecompanyaccruesanestimateofthelegal defensecostsneededtodefendeachmatterwhenthosecostsareprobableandcanbereasonablyestimatedforcertain ofthesemattersthecompanyhasaccruedadditionalamountssuchasestimatedcostsassociatedwithsettlements damagesandotherlossestotheextentadverseverdictshavebeenrenderedagainstthecompanythecompanydoes notrecordanaccrualuntilalossisdeterminedtobeprobableandcanbereasonablyestimatedproductliabilityaccruals canrepresentprojectedproductliabilityforthousandsofclaimsaroundtheworldeachindifferentlitigationenvironments andwithdifferentfactpatternschangestotheaccrualsmayberequiredinthefutureasadditionalinformationbecomes available themostsignificantofthesecasesincludethedepuyasrxlacetabularsystemanddepuyasrhipresurfacing systemthepinnacleacetabularcupsystempelvicmeshesrisperdalxareltobodypowderscontaining talcprimarilyjohnsonsbabypowderinvokanaandethiconphysiomeshflexiblecompositemeshasof decemberintheunitedstatestherewereapproximatelyplaintiffswithdirectclaimsinpendinglawsuits regardinginjuriesallegedlyduetothedepuyasrxlacetabularsystemanddepuyasrhipresurfacingsystem withrespecttothepinnacleacetabularcupsystemwithrespecttopelvicmesheswith respecttorisperdalwithrespecttoxareltowithrespecttobodypowderscontainingtalc withrespecttoinvokanaandwithrespecttoethiconphysiomeshflexiblecompositemesh inaugustdepuyorthopaedicsincdepuyannouncedaworldwidevoluntaryrecallofitsasrxlacetabular systemanddepuyasrhipresurfacingsystemusedinhipreplacementsurgeryclaimsforpersonalinjuryhavebeen madeagainstdepuyandjohnsonjohnsonthenumberofpendinglawsuitsisexpectedtofluctuateascertainlawsuits aresettledordismissedandadditionallawsuitsarefiledcasesfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictofohiolitigationhas alsobeenfiledincountriesoutsideoftheunitedstatesprimarilyintheunitedkingdomcanadaaustraliaireland germanyanditalyinnovemberdepuyreachedanagreementwithacourtappointedcommitteeoflawyers representingasrhipsystemplaintiffstoestablishaprogramtosettleclaimswitheligibleasrhippatientsintheunited stateswhohadsurgerytoreplacetheirasrhipsknownasrevisionsurgeryasofaugustdepuyreached additionalagreementsinfebruaryandmarchwhichfurtherextendedthesettlementprogramtoincludeasr hippatientswhohadrevisionsurgeriesafteraugustandpriortofebruarythissettlementprogram hasresolvedmorethanclaimsthereforebringingtoresolutionsignificantasrhiplitigationactivityintheunited stateshoweverlawsuitsintheunitedstatesremainandthesettlementprogramdoesnotaddresslitigationoutsideof theunitedstatesinaustraliaaclassactionsettlementwasreachedthatresolvedtheclaimsofthemajorityofasrhip patientsinthatcountryincanadathecompanyhasreachedagreementstosettletwopendingclassactionswhichhave beenapprovedbythequbecsuperiorcourtandthesupremecourtofbritishcolumbiathebritishcolumbiaorderis currentlythesubjectofanappealthecompanycontinuestoreceiveinformationwithrespecttopotentialadditionalcosts associatedwiththisrecallonaworldwidebasisthecompanyhasestablishedaccrualsforthecostsassociatedwiththe unitedstatessettlementprogramanddepuyasrhiprelatedproductliabilitylitigation claimsforpersonalinjuryhavealsobeenmadeagainstdepuyorthopaedicsincandjohnsonjohnsoncollectively depuyrelatingtothepinnacleacetabularcupsystemusedinhipreplacementsurgerythenumberofpending productliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwithrespecttopotential johnsonjohnsonannualreportcostsandtheanticipatednumberofcasescasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasa multidistrictlitigationintheunitedstatesdistrictcourtforthenortherndistrictoftexaslitigationhasalsobeenfiledin somestatecourtsandincountriesoutsideoftheunitedstatesseveraladverseverdictshavebeenrenderedagainst depuyoneofwhichwasreversedonappealandremandedforretrialthesecondremainsunderappealandthethirdis pendingdecisiononposttrialmotionsinthedistrictcourtthecompanyhasestablishedanaccrualforproductliability litigationassociatedwiththepinnacleacetabularcupsystemthecompanyisnegotiatingsettlementsofthese casesandtherelatedcostsarereflectedinthecompanysaccruals claimsforpersonalinjuryhavebeenmadeagainstethiconincethiconandjohnsonjohnsonarisingoutofethicons pelvicmeshdevicesusedtotreatstressurinaryincontinenceandpelvicorganprolapsethecompanycontinuesto receiveinformationwithrespecttopotentialcostsandadditionalcasescasesfiledinfederalcourtsintheunitedstates havebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthesoutherndistrictofwest virginiathecompanyhassettledorotherwiseresolvedamajorityoftheunitedstatescasesandthecostsassociated withthesesettlementsarereflectedinthecompanysaccrualsinadditionclassactionsandindividualpersonalinjury casesorclaimshavebeencommencedinvariouscountriesoutsideoftheunitedstatesincludingclaimsandcasesinthe unitedkingdomthenetherlandsandbelgiumandclassactionsinisraelaustraliaandcanadaseekingdamagesfor allegedinjuryresultingfromethiconspelvicmeshdevicesinaustraliaatrialofclassactionissueshasbeencompleted andthepartiesareawaitingadecisionthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconspelvicmeshproducts followingajuneworldwidemarketwithdrawalofethiconphysiomeshflexiblecompositemeshclaimsfor personalinjuryhavebeenmadeagainstethiconincandjohnsonjohnsonallegingpersonalinjuryarisingoutoftheuse ofthisherniameshdevicecasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamultidistrict litigationmdlintheunitedstatesdistrictcourtforthenortherndistrictofgeorgiaamulticountylitigationmclhas alsobeenformedinnewjerseystatecourtandassignedtoatlanticcountyforcasespendinginnewjerseyproduct liabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotentialcostsand theanticipatednumberofcasesthecompanyhasestablishedaccrualswithrespecttoproductliabilitylitigation associatedwithethiconphysiomeshflexiblecompositemesh claimsforpersonalinjuryhavebeenmadeagainstjanssenpharmaceuticalsincandjohnsonjohnsonarisingoutofthe useofrisperdalindicatedforthetreatmentofschizophreniaacutemanicormixedepisodesassociatedwithbipolari disorderandirritabilityassociatedwithautismandrelatedcompoundslawsuitshavebeenprimarilyfiledinstatecourtsin pennsylvaniacaliforniaandmissouriotheractionsarependinginvariouscourtsintheunitedstatesandcanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassettledorotherwiseresolvedmanyoftheunitedstates casesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccruals claimsforpersonalinjuryarisingoutoftheuseofxareltoanoralanticoagulanthavebeenmadeagainstjanssen pharmaceuticalsincjpijohnsonjohnsonandjpiscollaborationpartnerforxareltobayeragandcertainofits affiliatesthenumberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceive informationwithrespecttopotentialcostsandtheanticipatednumberofcasescasesfiledinfederalcourtsintheunited stateshavebeenorganizedasamultidistrictlitigationintheunitedstatesdistrictcourtfortheeasterndistrictof louisianainadditioncaseshavebeenfiledinstatecourtsacrosstheunitedstatesmanyofthesecaseshavebeen consolidatedintoastatemasstortlitigationinphiladelphiapennsylvaniaandtherearecoordinatedproceedingsin delawarecaliforniaandmissouriclassactionlawsuitsalsohavebeenfiledincanadathecompanyhasestablishedan accrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithxarelto personalinjuryclaimsallegingthattalccausescancerhavebeenmadeagainstjohnsonjohnsonconsumerincand johnsonjohnsonarisingoutoftheuseofbodypowderscontainingtalcprimarilyjohnsonsbabypowderthe numberofpendingproductliabilitylawsuitscontinuestoincreaseandthecompanycontinuestoreceiveinformationwith respecttopotentialcostsandtheanticipatednumberofcaseslawsuitshavebeenprimarilyfiledinstatecourtsin missourinewjerseyandcaliforniacasesfiledinfederalcourtsintheunitedstateshavebeenorganizedasamulti districtlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseythecompanyhassuccessfullydefended anumberofthesecasesbuttherehavebeenverdictsagainstthecompanyincludingaverdictinjulyof billionthecompanybelievesthatithasstronggroundsonappealtooverturntheseverdictsthecompanyhas establishedanaccrualfordefensecostsonlyinconnectionwithproductliabilitylitigationassociatedwithbodypowders containingtalc infebruaryasecuritiesclassactionlawsuitwasfiledagainstjohnsonjohnsonandcertainnamedofficersinthe unitedstatesdistrictcourtforthedistrictofnewjerseyallegingthatjohnsonjohnsonviolatedthefederalsecurities johnsonjohnsonannualreport lawsbyfailingtoadequatelydisclosetheallegedasbestoscontaminationinbodypowderscontainingtalcprimarily johnsonsbabypowderandthatpurchasersofjohnsonjohnsonssharessufferedlossesasaresultplaintiffsare seekingdamagesinoctoberashareholderderivativelawsuitwasfiledagainstjohnsonjohnsonasthenominal defendantanditscurrentdirectorsasdefendantsintheunitedstatesdistrictcourtforthedistrictofnewjerseyalleging abreachoffiduciarydutiesrelatedtotheallegedasbestoscontaminationinbodypowderscontainingtalcprimarily johnsonsbabypowderandthatjohnsonjohnsonhassuffereddamagesasaresultofthosealleged breachesplaintiffisseekingdamagesandanorderforthecompanytoreformitsinternalpoliciesandproceduresin januarytwoerisaclassactionlawsuitswerefiledbyparticipantsinthejohnsonjohnsonsavingsplanagainst johnsonjohnsonitspensionandbenefitscommitteeandcertainnamedofficersintheunitedstatesdistrictcourtfor thedistrictofnewjerseyallegingthatthedefendantsbreachedtheirfiduciarydutiesbyofferingjohnsonjohnson stockasajohnsonjohnsonsavingsplaninvestmentoptionwhenitwasimprudenttodosobecauseoffailuresto discloseallegedasbestoscontaminationinbodypowderscontainingtalcprimarilyjohnsonsbabypowderplaintiffs areseekingdamagesandinjunctivereliefeachofthesematterswillbeadjudicatedinconjunctionwiththemultidistrict litigationreferencedinthepriorparagraphinadditionthecompanyhasreceivedpreliminaryinquiriesandsubpoenasto producedocumentsregardingthesemattersfromsenatormurrayamemberofthesenatecommitteeonhealth educationlaborandpensionsthedepartmentofjusticeandthesecuritiesandexchangecommissionthecompanyis cooperatingwiththesegovernmentinquiriesandwillbeproducingdocumentsinresponse claimsforpersonalinjuryhavebeenmadeagainstanumberofjohnsonjohnsoncompaniesincludingjanssen pharmaceuticalsincandjohnsonjohnsonarisingoutoftheuseofinvokanaaprescriptionmedicationindicated toimproveglycemiccontrolinadultswithtypediabeteslawsuitsfiledinfederalcourtsintheunitedstateshavebeen organizedasamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofnewjerseycaseshavealso beenfiledinstatecourtsinpennsylvaniacaliforniaandnewjerseyclassactionlawsuitshavebeenfiledincanada productliabilitylawsuitscontinuetobefiledandthecompanycontinuestoreceiveinformationwithrespecttopotential costsandtheanticipatednumberofcasesthecompanyhassettledorotherwiseresolvedmanyofthecasesandclaims intheunitedstatesandthecostsassociatedwiththesesettlementsarereflectedinthecompanysaccruals intellectualproperty certainsubsidiariesofjohnsonjohnsonaresubjectfromtimetotimetolegalproceedingsandclaimsrelatedto patenttrademarkandotherintellectualpropertymattersarisingoutoftheirbusinessesmanyofthesemattersinvolve challengestothecoverageandorvalidityofthepatentsonvariousproductsandallegationsthatcertainofthecompanys productsinfringethepatentsofthirdpartiesalthoughthesesubsidiariesbelievethattheyhavesubstantialdefensesto thesechallengesandallegationswithrespecttoallsignificantpatentstherecanbenoassuranceastotheoutcomeof thesemattersalossinanyofthesecasescouldadverselyaffecttheabilityofthesesubsidiariestoselltheirproducts resultinlossofsalesduetolossofmarketexclusivityrequirethepaymentofpastdamagesandfutureroyaltiesandmay resultinanoncashimpairmentchargeforanyassociatedintangibleassetthemostsignificantofthesemattersare describedbelow medicaldevices injunerembrandtvisiontechnologieslprembrandtfiledapatentinfringementlawsuitagainstjohnson johnsonvisioncareincjjvciintheunitedstatesdistrictcourtfortheeasterndistrictoftexasallegingthatjjvcis manufactureandsaleofitsacuvueadvanceandacuvueoasyshydrogelcontactlensesinfringed rembrandtsunitedstatespatentnoandseekingmonetaryreliefthecasewastransferredtotheunited statesdistrictcourtforthemiddledistrictoffloridawhereatrialinmayresultedinaverdictofnoninfringement thatwassubsequentlyupheldonappealinjulyrembrandtsoughtanewtrialbasedonallegednewevidence whichthedistrictcourtdeniedinaprilthecourtofappealsoverturnedthatrulingandremandedthecasetothe districtcourtforanewtrialanewtrialwasheldinaugustandthejuryreturnedaverdictofnoninfringementin favorofjjvcirembrandthasappealedtheverdicttotheunitedstatescourtofappealsforthefederalcircuitcafc infebruarythecafcaffirmedthejudgmentinfavorofjjvci inmarchmedinolltdmedinolfiledapatentinfringementlawsuitagainstcordiscorporationcordisand johnsonjohnsonintheunitedstatesdistrictcourtforthesoutherndistrictofnewyorkallegingthatcordisssalesof thecypherandcypherselectstentsmadeintheunitedstatessincewillfullyinfringedfourofmedinols patentsdirectedtothegeometryofarticulatedstentsmedinolisseekingdamagesandattorneysfeesalthough johnsonjohnsonhassincesoldcordisithasretainedliabilityforthiscaseaftertrialinjanuarythedistrictcourt dismissedthecasefindingmedinolunreasonablydelayedbringingitsclaimsthelachesdefenseinseptember johnsonjohnsonannualreportthedistrictcourtdeniedamotionbymedinoltovacatethejudgmentandgrantitanewtrialmedinolappealedthe decisiontotheunitedstatescourtofappealsforthefederalcircuitinmarchtheunitedstatessupremecourt heldthatthelachesdefenseisnotavailableinpatentcasesinapriltheunitedstatescourtofappealsforthe federalcircuitremandedthecasebacktothedistrictcourttoreconsidermedinolsmotionforanewtrialandbriefingin thedistrictcourtwascompletedinjune innovembermedideallcmedideafiledapatentinfringementlawsuitagainstdepuyorthopaedicsincinthe unitedstatesdistrictcourtforthenortherndistrictofillinoisalleginginfringementbytheattunekneesystemin aprilmedideafiledanamendedcomplaintaddingdepuysynthesproductsincanddepuysynthessalesincas nameddefendantsmedideaallegesinfringementofunitedstatespatentnos andrelatingtoposteriorstabilizedkneesystemsspecificallymedideaallegesthatthe sofcamtmcontactfeatureoftheattuneposteriorstabilizedkneeproductsinfringesthepatentsinsuitmedideais seekingmonetarydamagesandinjunctivereliefinjunethecasewastransferredtotheunitedstatesdistrictcourtfor thedistrictofmassachusettsaclaimconstructionhearingwasheldinoctoberandaclaimconstructionorderwas issuedinnovemberindecembermedideastipulatedtononinfringementoftheandpatents basedonthedistrictcourtsclaimconstructionandreservingitsrighttoappealthatconstructionleavingonlythepatent atissuebeforethedistrictcourtinjanuarythedistrictcourtstayedthecasependingadecisionintheinterpartes reviewproceedingonthepatentseebelowindecemberdepuysynthesproductsincfiledapetitionforinter partesreviewwiththeunitedstatespatentandtrademarkofficeusptoseekingtoinvalidatethetwoclaimsofthe patentassertedinthedistrictcourtlitigationandinjunetheusptoinstitutedreviewofthoseclaimsahearing trialisscheduledformarchandadecisionintheproceedingisduebyjune indecemberethiconendosurgeryincandethiconendosurgeryllcnowknownasethiconllcsued covidienincintheunitedstatesdistrictcourtforthedistrictofmassachusettsseekingadeclarationthatunitedstates patentnosthepatentandthepatentareeither invalidornotinfringedbyethiconsensealxlargejawtissuesealerproductinaprilcovidienlpcovidien salesllcandcovidienagcollectivelycovidienansweredandcounterclaimeddenyingtheallegationsasserting willfulinfringementofthepatentthepatentandunitedstatespatentnosthepatent thepatentandandseekingdamagesandaninjunctioncovidienfiledamotion forpreliminaryinjunctionwhichwasdeniedinoctoberthepartieshaveenteredjointstipulationssuchthatonlythe patentthepatentandthepatentremainindisputetrialisscheduledtobegininseptember innovemberboardofregentstheuniversityoftexassystemandtissuegeninccollectivelyutfiledalawsuit intheunitedstatesdistrictcourtforthewesterndistrictoftexasagainstethiconincandethiconusllcallegingthe manufactureandsaleofvicrylplusantibacterialsuturesmonocrylplusantibacterialsuturespdsplus antibacterialsuturesstratafixposantibacterialsuturesandstratafixmonocrylplusantibacterial suturesinfringeplaintiffsunitedstatespatentnosanddirectedtoimplantablepolymerdrug releasingbiodegradablefiberscontainingatherapeuticagentutisseekingdamagesandaninjunctionindecember ethiconfiledpetitionswiththeusptoseekinginterpartesreviewiprofbothassertedpatentsthosepetitions havebeenstayedbytheusptopendingadecisionbytheuscourtofappealsforthefederalcircuitinanunrelated case pharmaceutical inaprilmorphosysagagermanbiotechcompanyfiledapatentinfringementlawsuitagainstjanssenbiotech incjbigenmabusincandgenmabascollectivelygenmabintheunitedstatesdistrictcourtforthedistrictof delawaremorphosysallegedthatjbismanufactureandsaleofdarzalexdaratumumabwillfullyinfringed morphosysunitedstatespatentnosandmorphosyssoughtmoneydamagesjbi licensespatentsandthecommercialrightstodarzalexfromgenmabinjanuarythedistrictcourtgranted summaryjudgmentinjbiandgenmabsfavorinvalidatingtheassertedclaimsofthepatentsinsuitandthepartiesfileda jointstipulationofdismissaloftheaction inaugustsandozltdandhexalagcollectivelysandozfiledalawsuitintheenglishhighcourtagainstgd searlellcapfizercompanysearleandjanssensciencesirelanducjsiallegingthatsearlessupplementary protectioncertificatespcgbspcwhichisexclusivelylicensedtojsiisinvalidandshouldberevoked janssencilaglimitedsellsprezistadarunavirintheunitedkingdompursuanttothislicenseinoctober searleandjsicounterclaimedagainstsandozforthreatenedinfringementofthespcbasedonstatementsofitsplansto launchgenericdarunavirintheunitedkingdomsandozadmittedthatitsgenericdarunavirproductwouldinfringethe johnsonjohnsonannualreport spcifitisfoundvalidsearleandjsiareseekinganorderenjoiningsandozfrommarketingitsgenericdarunavirbefore theexpirationofthespcfollowingatrialinaprilthecourtenteredadecisionholdingthatthespcisvalidand grantingafinalinjunctionsandozhasappealedthecourtsdecisionandtheinjunctionisstayedpendingtheappealin januarythecourtreferredtheissueonappealtothecourtofjusticefortheeuropeanunioncjeuandstayedthe proceedingspendingthecjeusrulingontheissue inaprilacertapharmabvastrazenecaukltdandastrazenecapharmaceuticalslpfiledapatentinfringement lawsuitintheunitedstatesdistrictcourtforthedistrictofdelawareagainstpharmacylicsllcandabbvieinc collectivelyabbvieallegingthatthemanufactureandsaleofimbruvicainfringesuspatentno janssenbiotechincwhichcommercializesimbruvicajointlywithabbvieintervenedintheactioninnovember atrialisscheduledtobegininjanuary remicaderelatedcases inaugustcelltrionhealthcarecoltdandcelltrioninccollectivelycelltrionfiledanapplicationwiththeunited statesfoodanddrugadministrationfdaforapprovaltomakeandsellitsowninfliximabbiosimilarinmarch janssenbiotechincjbifiledalawsuitintheunitedstatesdistrictcourtforthedistrictofmassachusettsagainst celltrionandhospirahealthcarecorporationhospirawhichhasexclusivemarketingrightsforcelltrionsinfliximab biosimilarintheunitedstatesseekingamongotherthingsadeclaratoryjudgmentthattheirbiosimilarproductinfringesor potentiallyinfringesseveraljbipatentsincludingunitedstatespatentnorelatingtoremicadeinfliximab thepatentandunitedstatespatentnothepatentdirectedtothecellculturemediausedtomake celltrionsbiosimilarinaugustthedistrictcourtgrantedbothcelltrionsandhospirasmotionsforsummary judgmentofinvalidityofthepatentjbiappealedthosedecisionstotheunitedstatescourtofappealsforthefederal circuitinjanuarythefederalcircuitdismissedtheappealasmootbasedonitsaffirmanceofadecisionbythe usptospatenttrialandappealboardaffirminginvalidityofthepatent injunejbifiledtwoadditionalpatentinfringementlawsuitsassertingthepatentoneagainstcelltrionand hospiraintheunitedstatesdistrictcourtforthedistrictofmassachusettsandtheotheragainsthyclonelaboratories incthemanufacturerofthecellculturemediathatcelltrionusestomakeitsbiosimilarproductintheunitedstates districtcourtforthedistrictofutahonjulythedistrictcourtgrantedcelltrionsmotionforsummaryjudgment ofnoninfringementandenteredanorderdismissingthelawsuitagainstcelltrionandhospirajbiappealedtothe unitedstatescourtofappealsforthefederalcircuitthelitigationagainsthycloneinutahisstayedpendingthe outcomeofthemassachusettsactions thefdaapprovedthefirstinfliximabbiosimilarforsaleintheunitedstatesinandanumberofsuchproductshave beenlaunched litigationagainstfilersofabbreviatednewdrugapplicationsandas thefollowingsummarizeslawsuitspendingagainstgenericcompaniesthathavefiledabbreviatednewdrugapplications andaswiththefdaorundertakensimilarregulatoryprocessesoutsideoftheunitedstatesseekingtomarketgeneric formsofproductssoldbyvarioussubsidiariesofjohnsonjohnsonpriortoexpirationoftheapplicablepatentscovering thoseproductstheseandastypicallyincludeallegationsofnoninfringementandinvalidityoftheapplicablepatentsin theeventthesubsidiariesarenotsuccessfulinanactionortheautomaticstatutorystayoftheandasexpiresbeforethe unitedstatesdistrictcourtrulingsareobtainedthethirdpartycompaniesinvolvedwouldhavetheabilityuponapproval ofthefdatointroducegenericversionsoftheirproductstothemarketresultinginthepotentialforsubstantialmarket shareandrevenuelossesfortheapplicableproductsandwhichmayresultinanoncashimpairmentchargeinany associatedintangibleassetinadditionfromtimetotimesubsidiariesmaysettlethesetypesofactionsandsuch settlementscaninvolvetheintroductionofgenericversionsoftheproductsatissuetothemarketpriortotheexpirationof therelevantpatentstheinterpartesreviewiprprocesswiththeunitedstatespatentandtrademarkofficeuspto createdundertheamericainventsactisalsobeingusedattimesbygenericcompaniesinconjunctionwithandas andlawsuitstochallengetheapplicablepatents zytiga injulyjanssenbiotechincjanssenoncologyincandjanssenresearchdevelopmentllccollectively janssenandbtginternationalltdbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstanumberofgenericcompaniesandcertainoftheiraffiliatesandorsupplierswhofiled andasseekingapprovaltomarketagenericversionofzytigamgbeforetheexpirationofunitedstatespatent nothepatentthegenericcompaniesincludeamnealpharmaceuticalsllcand johnsonjohnsonannualreportamnealpharmaceuticalsofnewyorkllccollectivelyamnealapotexincandapotexcorpcollectivelyapotex citronpharmallccitrondrreddyslaboratoriesltdanddrreddyslaboratoriesinccollectivelydrreddys mylanpharmaceuticalsincandmylaninccollectivelymylanparpharmaceuticalsincandparpharmaceutical companiesinccollectivelyparsunpharmaceuticalindustriesltdandsunpharmaceuticalsindustriesinc collectivelysuntevapharmaceuticalsusainctevawockhardtbioagwockhardtusallcandwockhardt ltdcollectivelywockhardtwestwardpharmaceuticalcorpwestwardandhikmapharmaceuticalsllchikma janssenandbtgalsoinitiatedpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnew jerseyagainstamerigenpharmaceuticalslimitedamerigeninmayandglenmarkpharmaceuticalsincglenmarkin juneeachofwhomfiledanandaseekingapprovaltomarketitsgenericversionofzytigabeforetheexpirationof thepatenttheselawsuitshavebeenconsolidatedwiththelawsuitfiledinjuly inaugustjanssenandbtgfiledanadditionaljurisdictionalprotectivelawsuitagainstthemylandefendantsinthe unitedstatesdistrictcourtforthenortherndistrictofwestvirginiawhichhasbeenstayed inaugustjanssenandbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofnewjerseyagainsttevawhofiledanandaseekingapprovaltomarketagenericversionofzytigamgbefore theexpirationofthepatentthislawsuithasbeenconsolidatedwiththelawsuitfiledinjuly infebruaryjanssenandbtgfiledapatentinfringementlawsuitagainstmsnpharmaceuticalsincandmsn laboratoriesprivatelimitedcollectivelymsninunitedstatesdistrictcourtforthedistrictofnewjerseybasedonits andaseekingapprovalforagenericversionofzytigapriortotheexpirationofthepatent innovemberjanssenandbtginitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofnewjerseyagainstqilupharmaceuticalcoltdandqilupharmainccollectivelyqiluwhofiledananda seekingapprovaltomarketagenericversionofzytigabeforetheexpirationofthepatent indecemberjanssenandbtgenteredintoasettlementagreementwithglenmarkinjanuaryjanssen dismisseditslawsuitagainstsunafteritwithdrewitsandainapriljanssenandbtgenteredintoasettlement agreementwithapotex inoctobertheunitedstatesdistrictcourtforthedistrictofnewjerseyissuedarulinginvalidatingallasserted claimsofthepatentthecourtheldthatthepatentclaimswouldbeinfringedifthepatentwerevalidjanssen appealedthecourtsdecision innovembertheunitedstatescourtofappealsforthefederalcircuitdeniedjanssensrequestforaninjunction pendingappealasaresultseveralgenericversionsofzytigahaveenteredthemarketjanssenhasappealedthe decisionoftheunitedstatesdistrictcourtforthedistrictofnewjerseyandtheoralargumentontheappealis scheduledformarch thelawsuitsagainstmsnandqiluremainpendinginthedistrictcourtsineachoftheselawsuitsjanssenisseekingan orderenjoiningthedefendantsfrommarketingtheirgenericversionsofzytigabeforetheexpirationofthepatent severalgenericcompaniesincludingamerigenargentumpharmaceuticalsllcargentummylanwockhardtactavis amnealdrreddyssuntevawestwardandhikmafiledpetitionsforinterpartesreviewiprwiththeuspto seekingtoinvalidatethepatentinjanuarytheusptoissueddecisionsfindingthepatentclaims unpatentableandjanssenrequestedrehearingindecembertheusptodeniedjanssensrequestforrehearingof theiprdecisionsjanssenfiledanappealwhichwasconsolidatedwiththeabovementionedappealofthedecisionof theunitedstatesdistrictcourtforthedistrictofnewjersey inoctoberjanssenincandjanssenoncologyinccollectivelyjansseninitiatedtwonoticesofapplication undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedtevaand theministerofhealthincanadainresponsetotevasfilingabbreviatednewdrugsubmissionsandsandseeking approvaltomarketgenericversionsofzytigamgandzytigamgbeforetheexpirationofcanadianpatent noinjunethepartiesenteredintoasettlementagreement innovemberjansseninitiatedanoticeofapplicationundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexincapotexandtheministerofhealthincanadainresponsetoapotexsfiling ofanabbreviatednewdrugsubmissionandsseekingapprovaltomarketagenericversionofzytigabeforethe expirationofcanadianpatentnothefederalcourtofcanadascheduledthefinalhearingforapril janssenisseekinganorderprohibitingtheministerofhealthfromissuinganoticeofcompliancewithrespectto apotexsandsbeforetheexpirationofjanssenspatent johnsonjohnsonannualreport injanuaryjansseninitiatedanoticeofapplicationundersectionofthepatentedmedicinesnoticeof complianceregulationsagainstapotexandtheministerofhealthincanadainresponsetoapotexsfilingofan abbreviatednewdrugsubmissionandsseekingapprovaltomarketafilmcoatedgenericversionofzytigabefore theexpirationofcanadianpatentnojanssenisseekinganorderprohibitingtheministerofhealthfrom issuinganoticeofcompliancewithrespecttoapotexsandsbeforetheexpirationofjanssenspatent xarelto beginninginoctoberjanssenpharmaceuticalsincjpiandbayerpharmaagandbayerintellectualproperty gmbhcollectivelybayerfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelaware againstanumberofgenericcompanieswhofiledandasseekingapprovaltomarketgenericversionsofxarelto beforeexpirationofbayersunitedstatespatentnosandrelatingtoxareltojpiis theexclusivesublicenseeoftheassertedpatentsthefollowinggenericcompaniesarenameddefendantsaurobindo pharmalimitedandaurobindopharmausainccollectivelyaurobindobreckenridgepharmaceuticalinc breckenridgeinvagenpharmaceuticalsincinvagenmicrolabsusaincandmicrolabsltdcollectivelymicro mylanpharmaceuticalsincmylanprinstonpharmaceuticalsincsigmapharmlaboratoriesllcsigmapharmtorrent pharmaceuticalslimitedandtorrentpharmainccollectivelytorrenttrialconcludedinaprilinjulythe districtcourtenteredjudgmentagainstmylanandsigmapharmholdingthattheassertedcompoundpatentisvalidand infringedinseptemberthedistrictcourtenteredjudgmentagainsttheremainingdefendantsnoneofthe defendantsappealedthejudgment beginninginapriljpiandbayerintellectualpropertygmbhandbayeragcollectivelybayeragfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgeneric companieswhofiledandasseekingapprovaltomarketgenericversionsofxareltobeforeexpirationofbayerags unitedstatespatentnorelatingtoxareltojpiistheexclusivesublicenseeoftheassertedpatent thefollowinggenericcompaniesarenameddefendantsalembicpharmaceuticalslimitedalembicglobalholdingsa andalembicpharmaceuticalsincalembicaurobindobreckenridgeinvagenlupinlimitedandlupin pharmaceuticalsinccollectivelylupinmicromylansigmapharmtaropharmaceuticalindustriesltdandtaro pharmaceuticalsusainccollectivelytaroandtorrentlupincounterclaimedfordeclaratoryjudgmentof noninfringementandinvalidityofunitedstatespatentnobutlupindismisseditscounterclaimsafteritwas providedacovenantnottosueonthatpatentaurobindotarotorrentmicrobreckenridgeinvagensigmapharm lupinandalembichaveagreedtohavetheircasesstayedandtobeboundbytheoutcomeofanyfinaljudgment renderedagainstanyoftheotherdefendantsthecaseshavebeenconsolidatedfordiscoveryandtrialandare currentlysetfortrialinapril indecemberjpiandbayeragfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrict ofdelawareagainsttevapharmaceuticalsusaincandtevapharmaceuticalindustriesltdcollectivelytevawhofiled anandaseekingapprovaltomarketagenericversionofxareltobeforeexpirationofbayeragspatent ineachoftheselawsuitsjpiisseekinganorderenjoiningthedefendantsfrommarketingtheirgenericversionsof xareltobeforetheexpirationoftherelevantpatents inmaymylanfiledapetitionforinterpartesreviewwiththeusptoseekingtoinvalidatethepatentin decembertheusptoissuedadecisiondenyinginstitutionofmylanspetitionforinterpartesreview prezista inmayjanssenproductslpandjanssensciencesirelanduccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainstdrreddyslaboratoriesinc drreddyslaboratoriesltdlauruslabsltdandpharmaqinccollectivelydrlwhofiledanandaseekingapproval tomarketgenericversionsofprezistabeforetheexpirationofunitedstatespatentnosand trialisscheduledtobegininmay indecemberjansseninitiatedapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstamnealpharmaceuticalsllcamnealpharmaceuticalscompanygmbhamnealpharmaceuticalsof newyorkllcamnealpharmaceuticalspvtltdandrakspharmapvtltdcollectivelyamnealwhofiledananda seekingapprovaltomarketgenericversionsofprezistabeforetheexpirationofunitedstatespatentnos ineachoftheselawsuitsjanssenisseekinganorderenjoiningthedefendantsfrommarketingitsgenericversionsof prezistabeforetheexpirationoftherelevantpatents johnsonjohnsonannualreportinvokanainvokamet beginninginjulyjanssenpharmaceuticalsincjanssenresearchdevelopmentllccilaggmbhinternational andjanssenpharmaceuticanvcollectivelyjanssenandmitsubishitanabepharmacorporationmtpcfiledpatent infringementlawsuitsintheunitedstatesdistrictcourtforthedistrictofnewjerseytheunitedstatesdistrictcourtfor thedistrictofcoloradoandtheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgeneric companieswhofiledandasseekingapprovaltomarketgenericversionsofinvokanaandorinvokametbefore expirationofmtpcsunitedstatespatentnosandorrelatingtoinvokanaandinvokamet janssenistheexclusivelicenseeoftheassertedpatentsthefollowinggenericcompaniesarenameddefendantsapotex incandapotexcorpapotexaurobindopharmausaincaurobindomacleodspharmaceuticalsltdandmacleods pharmausaincinvagenpharmaceuticalsincinvagenprinstonpharmaceuticalsincdrreddyslaboratoriesinc anddrreddyslaboratoriesltdheterousaincheterolabslimitedunitvandheterolabslimitedmsn laboratoriesprivateltdandmsnpharmaceuticalsinclauruslabsltdindocoremediesltdzyduspharmaceuticals usainczydussandozincsandoztevapharmaceuticalsusaincandlupinltdandlupinpharmaceuticals inc beginninginjulyjanssenandmtpcfiledpatentinfringementlawsuitsintheunitedstatesdistrictcourtforthe districtofnewjerseyandtheunitedstatesdistrictcourtforthedistrictofcoloradoagainstsandozandinvagenwho filedandasseekingapprovaltomarketgenericversionsofinvokanaandorinvokametbeforeexpirationof mtpcsunitedstatespatentnothepatentrelatingtoinvokanaandinvokametandagainst zyduswhofiledandasseekingapprovaltomarketgenericversionsofinvokanaandinvokametbeforeexpiration ofthepatentmtpcsunitedstatespatentnorelatingtoinvokanaandinvokametandmtpcs unitedstatespatentnorelatingtoinvokametandagainstaurobindowhofiledanandaseeking approvaltomarketagenericversionofinvokanabeforeexpirationofthepatentandthepatentrelatingto invokana janssenistheexclusivelicenseeoftheassertedpatentsinoctoberthecoloradolawsuitsagainstsandozwere dismissedindecemberthedelawarelawsuitsagainstapotexandtevaweredismissed inapriljanssenandmtpcfiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthedistrictof newjerseyagainstprinstonwhofiledanandaseekingapprovaltomarketagenericversionofinvokanabefore expirationofthepatentrelatingtoinvokana ineachoftheselawsuitsjanssenandmtpcareseekinganorderenjoiningthedefendantsfrommarketingtheirgeneric versionsofinvokanaandorinvokametbeforetheexpirationoftherelevantpatents opsumit injanuaryactelionpharmaceuticalsltdactelioninitiatedapatentinfringementlawsuitintheunitedstates districtcourtforthedistrictofnewjerseyagainstzyduspharmaceuticalsusainczydusandamneal pharmaceuticalsllcamnealeachofwhomfiledanandaseekingapprovaltomarketagenericversionofopsumit beforetheexpirationofunitedstatespatentnointhelawsuitactelionisseekinganorderenjoiningzydus andamnealfrommarketinggenericversionsofopsumitbeforetheexpirationofthepatentindecemberthe districtcourtenteredanorderwhereinoneofthedefendantsamnealstipulatedtoinfringementtrialisscheduledto commenceinoctober invegasustenna injanuaryjanssenpharmaceuticanvandjanssenpharmaceuticalsinccollectivelyjansseninitiatedapatent infringementlawsuitintheunitedstatesdistrictcourtforthedistrictofnewjerseyagainsttevapharmaceuticalsusa inctevawhofiledanandaseekingapprovaltomarketagenericversionofinvegasustennabeforethe expirationofunitedstatespatentnointhelawsuitjanssenisseekinganorderenjoiningtevafrom marketingagenericversionofinvegasustennabeforetheexpirationofthepatent infebruaryjanssenincandjanssenpharmaceuticanvcollectivelyjansseninitiatedanoticesofapplication undersectionofthepatentedmedicinesnoticeofcomplianceregulationsagainsttevacanadalimitedtevaand theministerofhealthinresponsetotevasfilingofanabbreviatednewdrugsubmissionandsseekingapprovalto marketagenericversionofinvegasustennabeforetheexpirationofcanadianpatentnosand janssenisseekinganorderprohibitingtheministerofhealthfromissuinganoticeofcompliancewith respecttotevasandsbeforetheexpirationofthesepatentsthefinalhearingisscheduledtobegininseptember johnsonjohnsonannualreport imbruvica beginninginjanuarypharmacyclicsllcpharmacyclicsandjanssenbiotechincjbifiledpatentinfringement lawsuitsintheunitedstatesdistrictcourtforthedistrictofdelawareagainstanumberofgenericcompanieswhofiled andasseekingapprovaltomarketgenericversionsofimbruvicabeforeexpirationofpharmacyclicsunitedstates patentnos andorrelatingtoimbruvicajbiistheexclusivelicenseeoftheassertedpatentsthefollowing genericcompaniesarenameddefendantsciplalimitedandciplausaincciplafreseniuskabiusallcfresenius kabiusaincandfreseniuskabioncologylimitedfreseniuskabisandozincandlekpharmaceuticalsdd sandozshilpamedicarelimitedshilpasunpharmaglobalfzeandsunpharmaceuticalindustrieslimitedsun tevapharmaceuticalsusainctevaandzydusworldwidedmccandcadilahealthcarelimitedzydustrialis scheduledtobegininoctober inoctoberpharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstsunassertingnewlyissuedunitedstatespatentno ineachofthelawsuitspharmacyclicsandjbiareseekinganorderenjoiningthedefendantsfrommarketinggeneric versionsofimbruvicabeforetheexpirationoftherelevantpatents injanuarypharmacyclicsandjbiamendedtheircomplaintsagainstfreseniuskabizydustevaandsandozto furtherallegeinfringementofuspatentnosand injanuarypharmacyclicsandjbifiledapatentinfringementlawsuitintheunitedstatesdistrictcourtforthe districtofdelawareagainstzyduswhofiledanandaseekingapprovaltomarketagenericversionofimbruvica mgbeforetheexpirationofuspatentnos governmentproceedings likeothercompaniesinthepharmaceuticalandmedicaldevicesindustriesjohnsonjohnsonandcertainofits subsidiariesaresubjecttoextensiveregulationbynationalstateandlocalgovernmentagenciesintheunitedstatesand othercountriesinwhichtheyoperateasaresultinteractionwithgovernmentagenciesisongoingthemostsignificant litigationbroughtbyandinvestigationsconductedbygovernmentagenciesarelistedbelowitispossiblethatcriminal chargesandsubstantialfinesandorcivilpenaltiesordamagescouldresultfromgovernmentinvestigationsorlitigation averagewholesalepriceawplitigation johnsonjohnsonandseveralofitspharmaceuticalsubsidiariesthejjawpdefendantsalongwithnumerousother pharmaceuticalcompanieswerenamedasdefendantsinaseriesoflawsuitsinstateandfederalcourtsinvolving allegationsthatthepricingandmarketingofcertainpharmaceuticalproductsamountedtofraudulentandotherwise actionableconductbecauseamongotherthingsthecompaniesallegedlyreportedaninflatedaveragewholesaleprice awpforthedrugsatissuepayorsallegedthattheyusedthoseawpsincalculatingproviderreimbursementlevelsthe plaintiffsinthesecasesincludedthreeclassesofprivatepersonsorentitiesthatpaidforanyportionofthepurchaseof thedrugsatissuebasedonawpandstategovernmententitiesthatmademedicaidpaymentsforthedrugsatissue basedonawpmanyofthesecasesbothfederalactionsandstateactionsremovedtofederalcourtwereconsolidated forpretrialpurposesinamultidistrictlitigationintheunitedstatesdistrictcourtforthedistrictofmassachusettswhere allclaimsagainstthejjawpdefendantswereultimatelydismissedthejjawpdefendantsalsoprevailedinacase broughtbythecommonwealthofpennsylvaniaotherawpcaseshavebeenresolvedthroughcourtorderorsettlement twocasesremainpendinginacasebroughtbyillinoistrialhasbeenscheduledformarchinnewjerseya putativeclassactionbaseduponawpallegationsispendingagainstcentocorincandorthobiotechincbothnow janssenbiotechincjohnsonjohnsonandalzacorporation opioidslitigation beginninginandcontinuingtothepresentjohnsonjohnsonandjanssenpharmaceuticalsincjpialongwith otherpharmaceuticalcompanieshavebeennamedinmorethanlawsuitsbroughtbycertainstateandlocal governmentsrelatedtothemarketingofopioidsincludingduragesicnucyntaandnucyntaertodate complaintsagainstpharmaceuticalcompaniesincludingjohnsonjohnsonandjpihavebeenfiledinstatecourtbythe johnsonjohnsonannualreportstateattorneysgeneralinarkansasfloridakentuckylouisianamississippimissourinewhampshirenewjerseynew mexicoohiooklahomaandsouthdakotacomplaintsagainstthemanufacturersalsohavebeenfiledinstateorfederalcourt bycitycountyandlocalgovernmentagenciesinthefollowingstatesalabamaarkansascaliforniaconnecticutflorida georgiaillinoiskentuckylouisianamainemarylandmassachusettsmississippimissourinevadanewhampshirenew jerseynewmexiconewyorknorthcarolinaohiooklahomaoregonpennsylvaniarhodeislandsouthcarolinasouth dakotatennesseetexasutahvirginiawashingtonwestvirginiaandwisconsinthegovernmentofpuertoricofiledsuit insuperiorcourtofsanjuaninadditiontheprovinceofbritishcolumbiafiledsuitincanadatheseactionsallegeavariety ofclaimsrelatedtoopioidsmarketingpracticesincludingfalseadvertisingunfaircompetitionpublicnuisanceconsumerfraud violationsdeceptiveactsandpracticesfalseclaimsandunjustenrichmentthesuitsgenerallyseekpenaltiesandorinjunctive andmonetaryreliefandinsomeofthesuitstheplaintiffsareseekingjointandseveralliabilityamongthedefendantsthese casesareinearlystagesoflitigationinoctoberjohnsonjohnsonandjpiwerebothservedwithamotionto consolidatependingmattersintoafederalmultidistrictlitigationmdlinthesoutherndistrictofohioin decemberthemdlwasapprovedinthenortherndistrictofohioandthereareovercasesthathavebeen transferredtothemdl johnsonjohnsonjpiandotherpharmaceuticalcompanieshavealsoreceivedsubpoenasorrequestsforinformation relatedtoopioidsmarketingpracticesfromthefollowingstateattorneysgeneralalaskaindianamontananew hampshiresouthcarolinatennesseetexasandwashingtoninseptemberjohnsonjohnsonandjpiwere contactedbythetexasandcoloradoattorneygeneralsofficesonbehalfofapproximatelystatesregardingamulti stateattorneygeneralinvestigationthemultistatecoalitionservedjohnsonjohnsonandjpiwithsubpoenasaspartof theinvestigationjohnsonjohnsonandjpihavealsoreceivedrequestsforinformationfromtherankingminoritymember oftheunitedstatessenatecommitteeonhomelandsecurityandgovernmentalaffairsregardingthesalesmarketing andeducationalstrategiesrelatedtothepromotionofopioidsuse inaugustdepuyorthopaedicsincdepuyincnowknownasdepuysynthesincandjohnsonjohnson servicesinccollectivelydepuyreceivedaninformalrequestfromtheunitedstatesattorneysofficeforthedistrictof massachusettsandthecivildivisionoftheunitedstatesdepartmentofjusticetheunitedstatesfortheproductionof materialsrelatingtothedepuyasrxlhipdeviceinjulytheunitedstatesnotifiedtheunitedstatesdistrict courtforthedistrictofmassachusettsthatithaddeclinedtointerveneinaquitamcasefiledpursuanttothefalse claimsactagainstthecompaniesinfebruarythedistrictcourtgrantedthecompaniesmotiontodismisswith prejudiceunsealedthequitamcomplaintanddeniedthequitamrelatorsrequestforleavetofileafurtheramended complaintthequitamrelatorsappealedthecasetotheunitedstatescourtofappealsforthefirstcircuitinjuly thefirstcircuitaffirmedthedistrictcourtsdismissalinpartreversedinpartandaffirmedthedecisiontodenythe relatorsrequesttofileathirdamendedcomplainttherelatorsremainingclaimsarenowpendingbeforethedistrictcourt andfactdiscoveryiscurrentlyscheduledtocloseinseptemberadditionallydepuyfiledapetitionforcertiorariwith theunitedstatessupremecourtseekingreviewofthefirstcircuitsdecisionthesupremecourtdeniedthepetitionin april sinceoctoberagroupofstateattorneysgeneralhaveissuedcivilinvestigativedemandsrelatingtothe developmentsalesandmarketingofseveralofdepuyorthopaedicsincshipproductsinjulytheoregon departmentofjusticewhichwasinvestigatingthesemattersindependentlyoftheotherstatesannouncedasettlementof itsasrxlhipdeviceinvestigationwiththestateoforegonindecemberthecompanytheremainingstates andthedistrictofcolumbiaagreedtosettlealloftheinvestigationsandonjanuarythestatesandthe companyfiledconsentjudgmentsresolvingthematter inoctoberjohnsonjohnsonwascontactedbythecaliforniaattorneygeneralsofficeregardingamultistate attorneygeneralinvestigationofthemarketingofsurgicalmeshproductsforherniaandurogynecologicalpurposesby johnsonjohnsonssubsidiaryethiconincethiconjohnsonjohnsonandethiconhavesinceenteredintoaseries oftollingagreementswiththestatesandthedistrictofcolumbiaparticipatinginthemultistateinvestigationandhave respondedtocivilinvestigativedemandsservedbycertainoftheparticipatingstatesthestatesareseekingmonetary andinjunctivereliefinmaycaliforniaandwashingtonfiledcivilcomplaintsagainstjohnsonjohnsonethiconand ethiconusllcallegingviolationsoftheirconsumerprotectionstatutessimilarcomplaintswerefiledagainstthe companiesbykentuckyinaugustandbymississippiinoctoberjohnsonjohnsonandethiconhave enteredintoanewtollingagreementwiththeremainingstatesandthedistrictofcolumbia indecembertherakosinctherakosformerlyasubsidiaryofjohnsonjohnsonandpartoftheorthoclinical diagnosticsincocdfranchisereceivedaletterfromthecivildivisionoftheunitedstatesattorneysofficeforthe johnsonjohnsonannualreport easterndistrictofpennsylvaniainformingtherakosthattheunitedstatesattorneysofficewasinvestigatingthesales andmarketingofuvadexmethoxsalenandtheuvarxtsandcellexsystemsduringtheperiodtothepresent theunitedstatesattorneysofficerequestedthatocdandjohnsonjohnsonpreservedocumentsthatcouldrelateto theinvestigationtherakoswassubsequentlyacquiredbyanaffiliateofgorescapitalpartnersiiilpinjanuary andocdwasdivestedinjunefollowingthedivestitureofocdjohnsonjohnsonretainsocdsportionofany liabilitythatmayresultfromtheinvestigationforactivitythatoccurredpriortothesaleoftherakosinmarchand marchtheunitedstatesattorneysofficerequestedthatjohnsonjohnsonproducecertaindocumentsand johnsonjohnsoniscooperatingwiththoserequests injunethemississippiattorneygeneralfiledacomplaintinchancerycourtofthefirstjudicialdistrictofhinds countymississippiagainstjohnsonjohnsonandjohnsonjohnsonconsumercompaniesincnowknownas johnsonjohnsonconsumerincjjcithecomplaintallegesthatdefendantsfailedtodiscloseallegedhealthrisks associatedwithfemaleconsumersuseoftalccontainedinjohnsonsbabypowderandjohnsonsshowerto showeraproductdivestedinandseeksinjunctiveandmonetaryrelieftrialisstayedpendinginterlocutoryappeal ofadenialofjjcismotionforsummaryjudgment inmarchjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstates attorneysofficeforthesoutherndistrictofnewyorkrelatedtojpiscontractualrelationshipswithpharmacybenefit managersovertheperiodfromjanuarytothepresentwithregardtocertainofjpispharmaceuticalproductsthe demandwasissuedinconnectionwithaninvestigationunderthefalseclaimsact injanuaryjanssenpharmaceuticalsincjpireceivedacivilinvestigativedemandfromtheunitedstates departmentofjusticerelatingtoallegationsconcerningthesalesandmarketingpracticesofolysioindecember johnsonjohnsonandjpiwereservedwithawhistleblowerlawsuitfiledintheunitedstatesdistrictcourtforthe centraldistrictofcaliforniaallegingtheofflabelpromotionofolysioandadditionalproductsincludingnucynta xareltolevaquinandremicadeatthistimethefederalandstategovernmentshavedeclinedtointervene andthelawsuitwhichisrelatedtothecivilinvestigativedemandisbeingprosecutedbyaformercompanyemployee theunitedstatesdistrictcourtforthecentraldistrictofcaliforniadismissedtheclaiminaprilinmaythe relatorfiledanoticeofappealtotheunitedstatescourtofappealsfortheninthcircuit innovemberasecondwhistleblowerlawsuitwasunsealedintheunitedstatesdistrictcourtforthecentral districtofcaliforniathelawsuitissubstantiallysimilartothelawsuitunderappealbutisbroughtinthenameofthe originalrelatorthefederalandstategovernmentshavedeclinedtointerveneinthesecondsuitatthistime infebruaryjohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekingtheproductionofrecordspertainingtopaymentstoanyccharitableorganizationthat providesfinancialassistancetomedicarepatientsmultiplepharmaceuticalcompanieshavepubliclyreportedreceiptof subpoenasandongoinginquiriessimilartothisoneandtheonedescribedbelowthegovernmenthasrepresentedthatit willnotbepursuingactionagainstthecompanyinthismatter actelionpharmaceuticalsusincactelionusreceivedasubpoenainmaywithfollowuprequestsfor documentsfromtheunitedstatesattorneysofficeforthedistrictofmassachusettsthesubpoenaseekstheproduction ofrecordspertainingtoactelionuspaymentstoccharitableorganizationsthatprovidefinancialassistanceto medicarepatientsindecemberthecompanyandtheunitedstatesdepartmentofjusticeagreedtoasettlement inthismatter inmarchjanssenbiotechincreceivedacivilinvestigativedemandfromtheunitedstatesdepartmentofjustice regardingafalseclaimsactinvestigationconcerningmanagementandadvisoryservicesprovidedtorheumatologyand gastroenterologypracticesthatpurchasedremicadeorsimponiaria inaprilandseptemberjohnsonjohnsonreceivedsubpoenasfromtheunitedstatesattorneyforthedistrictof massachusettsseekingdocumentsbroadlyrelatingtopharmaceuticalcopaymentsupportprogramsfordarzalex olysioremicadesimponistelaraandzytigathesubpoenasalsoseekdocumentsrelatingtoaverage manufacturerpriceandbestpricereportingtothecenterformedicareandmedicaidservicesrelatedtothoseproducts aswellasrebatepaymentstostatemedicaidagencies injunejohnsonjohnsonreceivedasubpoenafromtheunitedstatesattorneysofficeforthedistrictof massachusettsseekinginformationregardingpracticespertainingtothesterilizationofdepuysynthesincspinal implantsatthreehospitalsinbostonaswellasinteractionsofemployeesofcompanysubsidiarieswithphysiciansat thesehospitalsjohnsonjohnsonanddepuysynthesinchaveproduceddocumentsinresponsetothesubpoenaand arefullycooperatingwiththegovernmentsinvestigation johnsonjohnsonannualreportinjulyadvancedsterilizationproductsaspreceivedacivilinvestigativedemandfromtheunitedstates departmentofjusticeregardingafalseclaimsactinvestigationconcerningthepricingqualitymarketingandpromotion ofevotechecrtyvekpeelpouchesorsterradcyclesurebiologicalindicators injulythepublicprosecutionserviceinriodejaneiroandrepresentativesfromthebrazilianantitrustauthority cadeinspectedtheofficesofmorethancompaniesincludingjohnsonjohnsondobrasilindstriaecomrciode produtosparasadeltdatheauthoritiesappeartobeinvestigatingallegationsofpossibleanticompetitivebehaviorand possibleimproperpaymentsinthemedicaldeviceindustrytheunitedstatesdepartmentofjusticeandtheunited statessecuritiesandexchangecommissionhavemadeadditionalpreliminaryinquiriesabouttheinspectioninbraziland johnsonjohnsondobrasilindstriaecomrciodeprodutosparasadeltdaiscooperatingwiththoserequests fromtimetotimethecompanyhasreceivedrequestsfromavarietyofunitedstatescongressionalcommitteesto produceinformationrelevanttoongoingcongressionalinquiriesitisthepolicyofjohnsonjohnsontocooperatewith theseinquiriesbyproducingtherequestedinformation generallitigation inaprilaputativeclassactionwasfiledagainstjohnsonjohnsonjohnsonjohnsonsalesandlogistics companyllcandmcneilppcincnowknownasjohnsonjohnsonconsumerincinnewjerseysuperiorcourt camdencountyonbehalfofpersonswhoresideinthestateofnewjerseywhopurchasedvariousmcneil overthecounterproductsfromdecemberthroughthepresentthecomplaintallegesviolationsofthenewjersey consumerfraudactfollowingthegrantofamotiontodismissandthefilingofanamendedcomplaintinmaythe courtdeniedamotiontodismisstheamendedcomplaintindecemberasettlementwasreachedandthematter hasbeendismissed inmaytwopurportedclassactionswerefiledinfederalcourtoneintheunitedstatesdistrictcourtforthecentral districtofcaliforniaandoneintheunitedstatesdistrictcourtforthesoutherndistrictofillinoisagainstjohnson johnsonandjohnsonjohnsonconsumercompaniesincnowknownasjohnsonjohnsonconsumerincjjci allegingviolationsofstateconsumerfraudstatutesbasedonnondisclosureofallegedhealthrisksassociatedwithtalc containedinjohnsonsbabypowderandjohnsonsshowertoshoweraproductnolongersoldbyjjciboth casesseekinjunctivereliefandmonetarydamagesneitherincludesaclaimforpersonalinjuriesinoctoberboth casesweretransferredtotheunitedstatesdistrictcourtforthedistrictcourtofnewjerseyaspartofanewlycreated federalmultidistrictlitigationinjulythedistrictcourtgrantedjohnsonjohnsonsandjjcismotiontodismiss oneofthecasesinseptembertheunitedstatescourtofappealsforthethirdcircuitaffirmedthisdismissalin septembertheplaintiffinthesecondcasevoluntarilydismissedtheircomplaintinmarchtheplaintiffinthe secondcaserefiledinillinoisstatecourt inaugustunitedstatescustomsandborderprotectionuscbpissuedapenaltynoticeagainstjanssenortho llcjanssenorthoassessingpenaltiesfortheallegedimproperclassificationofdarunavirethanolatetheactive pharmaceuticalingredientinprezistainconnectionwithitsimportationintotheunitedstatesinoctober janssenorthosubmittedapetitionforreliefinresponsetothepenaltynoticeinmayuscbpissuedan amendedpenaltynoticeassessingsubstantialpenaltiesandjanssenorthofiledapetitionforreliefinjuly inmarchandapriloverputativeclassactioncomplaintswerefiledbycontactlenspatientsinanumberofcourts aroundtheunitedstatesagainstjohnsonjohnsonvisioncareincjjvciandothercontactlensmanufacturers distributorsandretailersallegingverticalandhorizontalconspiraciestofixtheretailpricesofcontactlensesthe complaintsallegethatthemanufacturersreachedagreementswitheachotherandcertaindistributorsandretailers concerningthepricesatwhichsomecontactlensescouldbesoldtoconsumerstheplaintiffsareseekingdamagesand injunctivereliefalloftheclassactioncasesweretransferredtotheunitedstatesdistrictcourtforthemiddledistrictof floridainjunetheplaintiffsfiledaconsolidatedclassactioncomplaintinnovemberinjunethe districtcourtdeniedmotionstodismissfiledbyjjvciandotherdefendantsdiscoveryisongoinginmarchthe plaintiffsfiledamotionforclasscertificationthedistrictcourtheldahearingonthemotionforclasscertificationinaugust indecemberthedistrictcourtgrantedtheplaintiffsmotionforclasscertification inaugusttwothirdpartypayorsfiledapurportedclassactionintheunitedstatesdistrictcourtfortheeastern districtoflouisianaagainstjanssenresearchdevelopmentllcjanssenorthollcjanssenpharmaceuticalsinc orthomcneiljanssenpharmaceuticalsincandjohnsonjohnsonaswellascertainbayerentitiesallegingthatthe defendantsimproperlymarketedandpromotedxareltoassaferandmoreeffectivethanlessexpensivealternative medicationswhilefailingtofullydiscloseitsrisksthecomplaintseeksdamages johnsonjohnsonannualreport inmaylonzasalesaglonzafiledarequestforarbitrationwiththelondoncourtofinternationalarbitration againstjanssenresearchdevelopmentllcjanssenrdlonzaallegesthatjanssenrdbreacheda agreementbetweenthepartiesbysublicensingcertainlonzatechnologyusedinthemanufactureofdaratumumab withoutlonzasconsentlonzaseeksmonetarydamagesthearbitrationhearingwasheldinseptemberpost hearingbriefingiscompleteandthepartiesareawaitingadecision inmayapurportedclassactionwasfiledintheunitedstatesdistrictcourtforthewesterndistrictofwashingtonagainst lifescanincjohnsonjohnsonotherdiabetesteststripmanufacturersandcertainpharmacybenefitmanagerspbmsthe complaintallegesthatconsumerspaidinflatedpricesforglucosemonitorteststripsasaconsequenceofundisclosedrebatesand otherincentivespaidbymanufacturerstopbmsthecomplaintincludesricoerisaandstateconsumerprotectionclaimsthe complaintseeksequitablereliefanddamagesinnovemberthecasewasorderedtransferredtounitedstatesdistrict courtforthedistrictofnewjerseythelifescanbusinesswasdivestedinoctoberandjohnsonjohnsonretainedliability thatmayresultfromtheseclaimspriortotheclosingofthedivestiture inseptemberpfizerincpfizerfiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotechinc collectivelyjansseninunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniapfizerallegesthatjanssen hasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaintseeksdamagesand injunctiverelief beginninginseptembermultiplepurportedclassactionswerefiledagainstjohnsonjohnsonandjanssen biotechinccollectivelyjanssenallegingthatjanssensremicadecontractingstrategiesviolatedfederalandstate antitrustandconsumerlawsandseekingdamagesandinjunctivereliefinnovemberthecaseswereconsolidated forpretrialpurposesinunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniaasinreremicadeantitrust litigation injunewalgreencoandkrogercofiledanantitrustcomplaintagainstjohnsonjohnsonandjanssenbiotech inccollectivelyjanssenintheunitedstatesdistrictcourtfortheeasterndistrictofpennsylvaniathecomplaint allegesthatjanssenhasviolatedfederalantitrustlawsthroughitscontractingstrategiesforremicadethecomplaint seeksdamagesandinjunctiverelief inoctobercertainunitedstatesservicemembersandtheirfamiliesbroughtacomplaintagainstanumberof pharmaceuticalandmedicaldevicescompaniesincludingjohnsonjohnsonandcertainofitssubsidiariesallegingthat thedefendantsviolatedtheunitedstatesantiterrorismactthecomplaintallegesthatthedefendantsprovidedfunding forterroristorganizationsthroughtheirsalespracticespursuanttopharmaceuticalandmedicaldevicecontractswiththe iraqiministryofhealth andoverhealthcareincandoverfiledalanhamactcaseagainstjohnsonjohnsonconsumerincinaprilinthe unitedstatesdistrictcourtforthedistrictofmassachusettsandoverassertsthattheclaimnotmadewithnatural rubberlatexoncoachsportswrapbandaidbrandsecureflexwrapandbandaidbrandhurt freewrapisfalseandoverseeksactualdamagesandprejudgmentinterestthereondisgorgementofprofitstreble damagesattorneysfeesandinjunctivereliefindecemberthepartiesenteredintoasettlementagreement inoctobertwoseparateputativeclassactionswerefiledagainstactelionpharmaceuticalltdactelion pharmaceuticalsusincandactelionclinicalresearchinccollectivelyactelioninunitedstatesdistrictcourtforthe districtofmarylandandunitedstatesdistrictcourtforthedistrictofcolumbiathecomplaintsallegethatactelion violatedstateandfederalantitrustandunfaircompetitionlawsbyallegedlyrefusingtosupplygenericpharmaceutical manufacturerswithsamplesoftracleertracleerissubjecttoariskevaluationandmitigationstrategywhich imposesrestrictionsondistributionoftheproductinjanuarytheplaintiffsdismissedthedistrictofcolumbiacase andfiledaconsolidatedcomplaintinfederalcourtinmaryland indecemberjanssenbiotechincjanssenoncologyincjanssenresearchdevelopmentllcandjohnson johnsoncollectivelyjanssenwereservedwithaquitamcomplaintfiledonbehalfoftheunitedstatesstatesand thedistrictofcolumbiathecomplaintwhichwasfiledindecemberinunitedstatesdistrictcourtforthenorthern districtofcaliforniaallegesthatjanssenviolatedthefederalfalseclaimsactandstatelawwhenprovidingpricing informationforzytigatothegovernmentinconnectionwithdirectgovernmentsalesandgovernmentfundeddrug reimbursementprogramsatthistimethefederalandstategovernmentshavedeclinedtointervene johnsonjohnsonoritssubsidiariesarealsopartiestoanumberofproceedingsbroughtunderthecomprehensive environmentalresponsecompensationandliabilityactcommonlyknownassuperfundandcomparablestatelocalor foreignlawsinwhichtheprimaryreliefsoughtisthecostofpastandorfutureremediation johnsonjohnsonannualreport restructuring inthefirstquarterofthecompanyannouncedrestructuringactionsinitsmedicaldevicessegmenttobetterserve theneedsofpatientsandcustomersintodaysevolvinghealthcaremarketplacethecompanyhasundertakenactionsto strengthenitsgotomarketmodelacceleratethepaceofinnovationfurtherprioritizekeyplatformsandgeographiesand streamlineoperationswhilemaintaininghighqualitystandards inthecompanyrecordedapretaxchargeofmillionofwhichmillionwasincludedincostofproducts soldandmillionwasincludedinotherincomeexpensetotalprojectcostsofbillionhavebeenrecorded sincetherestructuringhasbeenannouncedthisrestructuringprogramwascompletedinthefiscalfourthquarterof onaprilthecompanyannouncedplanstoimplementaseriesofactionsacrossitsglobalsupplychainthat areintendedtofocusresourcesandincreaseinvestmentsinthecriticalcapabilitiestechnologiesandsolutionsnecessary tomanufactureandsupplyitsproductportfolioenhanceagilityanddrivegrowththeglobalsupplychainactionswill includeexpandingtheuseofstrategiccollaborationsandbolsteringinitiativestoreducecomplexityimprovecost competitivenessenhancecapabilitiesandoptimizethesupplychainnetworkforadditionaldetailsontheglobalsupply chainrestructuringstrategiccollaborationsseenotetotheconsolidatedfinancialstatementsinthecompany recordedapretaxchargeofmillionofwhichmillionwasincludedincostofproductssoldandmillion wasincludedinotherincomeexpenseseethefollowingtableforadditionaldetailsontherestructuringprograms intotalthecompanyexpectstheglobalsupplychainactionstogenerateapproximatelybilliontobillionin annualpretaxcostsavingsthatwillbesubstantiallydeliveredbythecompanyexpectstorecordpretax restructuringchargesofapproximatelybilliontobillionoverthetoyearperiodofthisactivitythesecosts areassociatedwithnetworkoptimizationsexitcostsandaccelerateddepreciationandamortization thefollowingtablesummarizestheseverancechargesandtheassociatedspendingundertheseinitiativesthroughthe fiscalyearended dollarsinmillions severance assetwriteoffs total reservebalancejanuary activity reservebalancejanuary activity reservebalancedecember currentyearactivity charges cashpayments settlednoncash reservebalancedecember cashoutlaysforseveranceareexpectedtobesubstantiallypaidoutoverthenextyearsinaccordancewiththecompanysplans andlocallaws otherincludesprojectexpensesuchassalariesforemployeessupportingtheinitiativeandconsultingexpenses althoughthemedicaldevicesrestructuringprogramwascompletedinthecompanyexpectsthatseverance chargeswillcontinuebeyondthatdatethecompanycontinuouslyreevaluatesitsseverancereservesrelatedto restructuringandthetimingofpaymentshasextendedduetotheplannedreleaseofassociatesregardingseverallonger termprojectsthecompanybelievesthattheexistingseverancereservesaresufficienttocovertheglobalsupplychain plansgiventheperiodoverwhichtheactionswilltakeplacethecompanywillcontinuetoassessandmakeadjustments asnecessaryifadditionalamountsbecomeprobableandestimableapproximatelyindividualsreceivedseparation paymentssincetheserestructuringannouncements johnsonjohnsonannualreport report independent registered public accounting firm totheboardofdirectorsandshareholdersofjohnsonjohnson opinionsonthefinancialstatementsandinternalcontroloverfinancialreporting wehaveauditedtheaccompanyingconsolidatedbalancesheetsofjohnsonjohnsonanditssubsidiariesthe companyasofdecemberanddecemberandtherelatedconsolidatedstatementsofearningsof comprehensiveincomeofequityandofcashflowsforeachofthethreeyearsintheperiodendeddecember includingtherelatednotescollectivelyreferredtoastheconsolidatedfinancialstatementswealsohaveauditedthe companysinternalcontroloverfinancialreportingasofdecemberbasedoncriteriaestablishedininternal controlintegratedframeworkissuedbythecommitteeofsponsoringorganizationsofthetreadway commissioncoso inouropiniontheconsolidatedfinancialstatementsreferredtoabovepresentfairlyinallmaterialrespectsthefinancial positionofthecompanyasofdecemberanddecemberandtheresultsofitsoperationsanditscash flowsforeachofthethreeyearsintheperiodendeddecemberinconformitywithaccountingprinciples generallyacceptedintheunitedstatesofamericaalsoinouropinionthecompanymaintainedinallmaterialrespects effectiveinternalcontroloverfinancialreportingasofdecemberbasedoncriteriaestablishedininternal controlintegratedframeworkissuedbythecoso basisforopinions thecompanysmanagementisresponsiblefortheseconsolidatedfinancialstatementsformaintainingeffectiveinternal controloverfinancialreportingandforitsassessmentoftheeffectivenessofinternalcontroloverfinancialreporting includedintheaccompanyingmanagementsreportoninternalcontroloverfinancialreportingourresponsibilityisto expressopinionsonthecompanysconsolidatedfinancialstatementsandonthecompanysinternalcontroloverfinancial reportingbasedonourauditsweareapublicaccountingfirmregisteredwiththepubliccompanyaccountingoversight boardunitedstatespcaobandarerequiredtobeindependentwithrespecttothecompanyinaccordancewiththe usfederalsecuritieslawsandtheapplicablerulesandregulationsofthesecuritiesandexchangecommissionandthe pcaob weconductedourauditsinaccordancewiththestandardsofthepcaobthosestandardsrequirethatweplanand performtheauditstoobtainreasonableassuranceaboutwhethertheconsolidatedfinancialstatementsarefreeofmaterial misstatementwhetherduetoerrororfraudandwhethereffectiveinternalcontroloverfinancialreportingwasmaintained inallmaterialrespects ourauditsoftheconsolidatedfinancialstatementsincludedperformingprocedurestoassesstherisksofmaterial misstatementoftheconsolidatedfinancialstatementswhetherduetoerrororfraudandperformingproceduresthat respondtothoseriskssuchproceduresincludedexaminingonatestbasisevidenceregardingtheamountsand disclosuresintheconsolidatedfinancialstatementsourauditsalsoincludedevaluatingtheaccountingprinciplesused andsignificantestimatesmadebymanagementaswellasevaluatingtheoverallpresentationoftheconsolidatedfinancial statementsourauditofinternalcontroloverfinancialreportingincludedobtaininganunderstandingofinternalcontrol overfinancialreportingassessingtheriskthatamaterialweaknessexistsandtestingandevaluatingthedesignand operatingeffectivenessofinternalcontrolbasedontheassessedriskourauditsalsoincludedperformingsuchother proceduresasweconsiderednecessaryinthecircumstanceswebelievethatourauditsprovideareasonablebasisfor ouropinions definitionandlimitationsofinternalcontroloverfinancialreporting acompanysinternalcontroloverfinancialreportingisaprocessdesignedtoprovidereasonableassuranceregardingthe reliabilityoffinancialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewith generallyacceptedaccountingprinciplesacompanysinternalcontroloverfinancialreportingincludesthosepoliciesand proceduresthatipertaintothemaintenanceofrecordsthatinreasonabledetailaccuratelyandfairlyreflectthe transactionsanddispositionsoftheassetsofthecompanyiiprovidereasonableassurancethattransactionsare recordedasnecessarytopermitpreparationoffinancialstatementsinaccordancewithgenerallyacceptedaccounting johnsonjohnsonannualreportprinciplesandthatreceiptsandexpendituresofthecompanyarebeingmadeonlyinaccordancewithauthorizationsof managementanddirectorsofthecompanyandiiiprovidereasonableassuranceregardingpreventionortimelydetection ofunauthorizedacquisitionuseordispositionofthecompanysassetsthatcouldhaveamaterialeffectonthefinancial statements becauseofitsinherentlimitationsinternalcontroloverfinancialreportingmaynotpreventordetectmisstatementsalso projectionsofanyevaluationofeffectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequate becauseofchangesinconditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate spricewaterhousecoopersllp florhamparknewjersey february wehaveservedasthecompanysauditorsinceatleastwehavenotbeenabletodeterminethespecificyearwe beganservingasauditorofthecompany johnsonjohnsonannualreport managements report internal control financial reporting undersectionofthesarbanesoxleyactofmanagementisrequiredtoassesstheeffectivenessofthe companysinternalcontroloverfinancialreportingasoftheendofeachfiscalyearandreportbasedonthatassessment whetherthecompanysinternalcontroloverfinancialreportingiseffective managementofthecompanyisresponsibleforestablishingandmaintainingadequateinternalcontroloverfinancial reportingthecompanysinternalcontroloverfinancialreportingisdesignedtoprovidereasonableassuranceastothe reliabilityofthecompanysfinancialreportingandthepreparationofexternalfinancialstatementsinaccordancewith generallyacceptedaccountingprinciples internalcontrolsoverfinancialreportingnomatterhowwelldesignedhaveinherentlimitationsthereforeinternalcontrol overfinancialreportingdeterminedtobeeffectivecanprovideonlyreasonableassurancewithrespecttofinancial statementpreparationandmaynotpreventordetectallmisstatementsmoreoverprojectionsofanyevaluationof effectivenesstofutureperiodsaresubjecttotheriskthatcontrolsmaybecomeinadequatebecauseofchangesin conditionsorthatthedegreeofcompliancewiththepoliciesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessofthecompanysinternalcontroloverfinancialreportingas ofdecemberinmakingthisassessmentthecompanyusedthecriteriaestablishedbythecommitteeof sponsoringorganizationsofthetreadwaycommissioncosoininternalcontrolintegratedframework thesecriteriaareintheareasofcontrolenvironmentriskassessmentcontrolactivitiesinformationandcommunication andmonitoringthecompanysassessmentincludedextensivedocumentingevaluatingandtestingthedesignand operatingeffectivenessofitsinternalcontrolsoverfinancialreporting basedonthecompanysprocessesandassessmentasdescribedabovemanagementhasconcludedthatasof decemberthecompanysinternalcontroloverfinancialreportingwaseffective theeffectivenessofthecompanysinternalcontroloverfinancialreportingasofdecemberhasbeenauditedby pricewaterhousecoopersllpanindependentregisteredpublicaccountingfirmasstatedintheirreportwhichappears herein salexgorsky sjosephjwolk alexgorsky josephjwolk chairmanboardofdirectors executivevicepresident chiefexecutiveofficer chieffinancialofficer johnsonjohnsonannualreportshareholder return performance graphs setforthbelowarelinegraphscomparingthecumulativetotalshareholderreturnonthecompanyscommonstockfor periodsoffiveyearsandtenyearsendingdecemberagainstthecumulativetotalreturnofthestandard poorsstockindexthestandardpoorspharmaceuticalindexandthestandardpoorshealthcareequipment indexthegraphsandtablesassumethatwasinvestedondecemberanddecemberineachof thecompanyscommonstockthestandardpoorsstockindexthestandardpoorspharmaceuticalindexand thestandardpoorshealthcareequipmentindexandthatalldividendswerereinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceucidcal index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sphealthcareequipmentindex johnsonjohnsonannualreport item changes disagreements accountants accounting financial disclosure notapplicable item controls procedures disclosurecontrolsandproceduresattheendoftheperiodcoveredbythisreportthecompanyevaluatedthe effectivenessofthedesignandoperationofitsdisclosurecontrolsandproceduresthecompanysdisclosurecontrols andproceduresaredesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatit filesorsubmitsundertheexchangeactisrecordedprocessedsummarizedandreportedwithinthetimeperiods specifiedinthesecsrulesandformsdisclosurecontrolsandproceduresincludewithoutlimitationcontrolsand proceduresdesignedtoensurethatinformationrequiredtobedisclosedbythecompanyinthereportsthatitfilesor submitsundertheexchangeactisaccumulatedandcommunicatedtothecompanysmanagementincludingitsprincipal executiveandprincipalfinancialofficersorpersonsperformingsimilarfunctionsasappropriatetoallowtimelydecisions regardingrequireddisclosurealexgorskychairmanandchiefexecutiveofficerandjosephjwolkexecutivevice presidentchieffinancialofficerreviewedandparticipatedinthisevaluationbasedonthisevaluationmessrsgorsky andwolkconcludedthatasoftheendoftheperiodcoveredbythisreportthecompanysdisclosurecontrolsand procedureswereeffective reportsoninternalcontroloverfinancialreportingtheinformationcalledforbythisitemisincorporatedhereinby referencetomanagementsreportoninternalcontroloverfinancialreportingandtheattestationregardinginternal controlsoverfinancialreportingincludedinthereportofindependentregisteredpublicaccountingfirmincludedin itemofthisreport changesininternalcontroloverfinancialreportingduringthefiscalquarterendeddecembertherewereno changesinthecompanysinternalcontroloverfinancialreportingidentifiedinconnectionwiththeevaluationrequired underrulesaanddundertheexchangeactthathavemateriallyaffectedorarereasonablylikelyto materiallyaffectthecompanysinternalcontroloverfinancialreporting thecompanyisimplementingamultiyearenterprisewideinitiativetointegratesimplifyandstandardizeprocessesand systemsforthehumanresourcesinformationtechnologyprocurementsupplychainandfinancefunctionstheseare enhancementstosupportthegrowthofthecompanysfinancialsharedservicecapabilitiesandstandardizefinancial systemsthisinitiativeisnotinresponsetoanyidentifieddeficiencyorweaknessinthecompanysinternalcontrolover financialreportinginresponsetothisinitiativethecompanyhasandwillcontinuetoalignandstreamlinethedesignand operationofitsfinancialcontrolenvironment item b information notapplicable johnsonjohnsonannualreportpart iii item directors executive officers corporate governance theinformationcalledforbythisitemisincorporatedhereinbyreferencetothediscussionoftheauditcommitteeunder thecaptionitemelectionofdirectorsboardcommitteesandthematerialunderthecaptionsitemelectionof directorsandstockownershipandsectioncompliancesectionabeneficialownershipreporting complianceintheproxystatementandthematerialunderthecaptionexecutiveofficersoftheregistrantinpartiof thisreport thecompanyscodeofbusinessconductwhichcoversallemployeesincludingthechiefexecutiveofficerchief financialofficerandcontrollermeetstherequirementsofthesecrulespromulgatedundersectionofthe sarbanesoxleyactofthecodeofbusinessconductisavailableonthecompanyswebsiteatwwwjnjcom codeofbusinessconductandcopiesareavailabletoshareholderswithoutchargeuponwrittenrequesttothesecretary atthecompanysprincipalexecutiveofficesanysubstantiveamendmenttothecodeofbusinessconductoranywaiver ofthecodegrantedtothechiefexecutiveofficerthechieffinancialofficerorthecontrollerwillbepostedonthe companyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysandretainedonthewebsiteforatleastone year inadditionthecompanyhasadoptedacodeofbusinessconductethicsformembersoftheboardofdirectorsand executiveofficersthecodeofbusinessconductethicsformembersoftheboardofdirectorsandexecutiveofficers isavailableonthecompanyswebsiteatwwwinvestorjnjcomgovboardconductcfmandcopiesareavailableto shareholderswithoutchargeuponwrittenrequesttothesecretaryatthecompanysprincipalexecutiveofficesany substantiveamendmenttothecodeoranywaiverofthecodegrantedtoanymemberoftheboardofdirectorsorany executiveofficerwillbepostedonthecompanyswebsiteatwwwinvestorjnjcomgovcfmwithinfivebusinessdaysand retainedonthewebsiteforatleastoneyear item executive compensation theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorcompensationanditemcompensationcommitteereportcompensation discussionandanalysisandexecutivecompensationtablesintheproxystatement thematerialincorporatedhereinbyreferencetothematerialunderthecaptioncompensationcommitteereportinthe proxystatementshallbedeemedfurnishedandnotfiledinthisreportandshallnotbedeemedincorporatedby referenceintoanyfilingunderthesecuritiesactofasamendedorthesecuritiesexchangeactofas amendedasaresultofthisfurnishingexcepttotheextentthatthecompanyspecificallyincorporatesitbyreference item security ownership certain beneficial owners management related stockholder matters theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitemstock ownershipandsectioncomplianceintheproxystatementandnotecommonstockstockoptionplansand stockcompensationagreementsofthenotestoconsolidatedfinancialstatementsinitemofthisreport johnsonjohnsonannualreport equity compensation plan information thefollowingtableprovidescertaininformationasofdecemberconcerningthesharesofthecompanys commonstockthatmaybeissuedunderexistingequitycompensationplans numberof securitiesto beissuedupon weightedaverage numberofsecurities exerciseof exercisepriceof remainingavailablefor outstanding outstanding futureissuanceunderequity plancategory optionsandrights optionsandrights compensationplans equitycompensationplansapprovedbysecurity holders equitycompensationplansnotapprovedbysecurity holders total includedinthiscategoryarethefollowingequitycompensationplanswhichhavebeenapprovedbythecompanysshareholders longtermincentiveplanandlongtermincentiveplan thiscolumnexcludessharesreflectedunderthecolumnnumberofsecuritiestobeissueduponexerciseofoutstandingoptions andrights thelongtermincentiveplanexpiredaprilalloptionsandrestrictedsharesgrantedsubsequenttothatdatewere underthelongtermincentiveplan item certain relationships related transactions director independence theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionsitem electionofdirectorsdirectorindependenceandrelatedpersontransactionsintheproxystatement item principal accountant fees services theinformationcalledforbythisitemisincorporatedhereinbyreferencetothematerialunderthecaptionitem ratificationofappointmentofindependentregisteredpublicaccountingfirmintheproxystatement johnsonjohnsonannualreportpart iv item exhibits financial statement schedules thefollowingdocumentsarefiledaspartofthisreport financialstatements consolidatedbalancesheetsatendoffiscalyearsand consolidatedstatementsofearningsforfiscalyearsand consolidatedstatementsofcomprehensiveincomeforfiscalyearsand consolidatedstatementsofequityforfiscalyearsand consolidatedstatementsofcashflowsforfiscalyearsand notestoconsolidatedfinancialstatements reportofindependentregisteredpublicaccountingfirm allschedulesareomittedbecausetheyarenotapplicableortherequiredinformationisincludedinthefinancial statementsornotes exhibitsrequiredtobefiledbyitemlofregulationsk theinformationcalledforbythisitemisincorporatedhereinbyreferencetotheexhibitindexinthisreport item summary registrantsmayvoluntarilyincludeasummaryofinformationrequiredbyformkunderthisitemthecompanyhas electednottoincludesuchsummaryinformation johnsonjohnsonannualreport signatures pursuanttotherequirementsofsectionofthesecuritiesexchangeactoftheregistranthasdulycausedthis reporttobesignedonitsbehalfbytheundersignedthereuntodulyauthorized datefebruary johnsonjohnson registrant sagorsky agorskychairmanboardofdirectors andchiefexecutiveofficer pursuanttotherequirementsofthesecuritiesexchangeactofthisreporthasbeensignedbelowbythefollowing personsonbehalfoftheregistrantandinthecapacitiesandonthedatesindicated signature title date sagorsky chairmanboardofdirectors february agorsky chiefexecutiveofficer principalexecutiveofficer sjjwolk chieffinancialofficer february jjwolk principalfinancialofficer srakapusta controllerandchiefaccountingofficer february rakapusta principalaccountingofficer smcbeckerle director february mcbeckerle sdsdavis director february dsdavis sieldavis director february ieldavis sjadoudna director february jadoudna smbmcclellan director february mbmcclellan sammulcahy director february ammulcahy swdperez director february wdperez scprince director february cprince saewashington director february aewashington srawilliams director february rawilliams johnsonjohnsonannualreportexhibit index regsk exhibittable itemno descriptionofexhibit restatedcertificateofincorporationeffectivefebruaryincorporatedhereinbyreferencetoexhibitiofthe registrantsformkannualreportforthefiscalyearendedjanuary ii bylawsofthecompanyasamendedeffectivejanuaryincorporatedhereinbyreferencetoexhibitthe registrantsformkcurrentreportfiledjanuary upontherequestofthesecuritiesandexchangecommissiontheregistrantwillfurnishacopyofallinstrumentsdefiningthe rightsofholdersoflongtermdebtoftheregistrant longtermincentiveplanincorporatedhereinbyreferencetoexhibitoftheregistrantssregistrationstatement filedwiththecommissiononmayfileno b formofstockoptioncertificateunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibitof theregistrantsformkcurrentreportfiledjanuary c longtermincentiveplanincorporatedhereinbyreferencetoappendixaoftheregistrantsproxystatementfiledwith thecommissiononmarch formofstockoptioncertificaterestrictedshareunitcertificateandperformanceshareunitcertificateunderthe longtermincentiveplanincorporatedhereinbyreferencetoexhibitsandoftheregistrantsformq quarterlyreportfiledmay e globalnonqualifiedstockoptionawardagreementglobalrestrictedshareunitawardagreementandglobalperformance shareunitawardagreementunderthelongtermincentiveplanincorporatedhereinbyreferencetoexhibits andoftheregistrantsformqquarterlyreportfiledmay f johnsonjohnsonexecutiveincentiveplanasamendedincorporatedhereinbyreferencetoexhibitfoftheregistrants formkannualreportforthefiscalyearendeddecember g domesticdeferredcompensationcertificateofextracompensationplanincorporatedhereinbyreferencetoexhibitg oftheregistrantsformkannualreportfortheyearendeddecember h amendmentstothecertificateofextracompensationplaneffectiveasofjanuaryincorporatedhereinbyreferenceto exhibitjoftheregistrantsformkannualreportfortheyearendeddecember certificatesoflongtermperformanceplanincorporatedhereinbyreferencetoexhibitoftheregistrantsform qquarterlyreportforthequarterendedseptember j amendedandrestateddeferredfeeplanfordirectorsamendedasofjanuaryincorporatedhereinbyreference toexhibitkoftheregistrantsformkannualreportforthefiscalyearendedjanuary k thejohnsonjohnsonexecutiveincomedeferralplanamendedandrestatedeffectivejanuaryincorporated hereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterendedseptember l excesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreferencetoexhibitjoftheregistrants formkannualreportforthefiscalyearendeddecember amendmentstothejohnsonjohnsonexcesssavingsplaneffectiveasofjanuaryincorporatedhereinbyreference toexhibitpoftheregistrantsformkannualreportforthefiscalyearendeddecember n excessbenefitplansupplementalretirementplanincorporatedhereinbyreferencetoexhibithoftheregistrantsform kannualreportforthefiscalyearendedjanuary amendmentstotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitroftheregistrantsformkannualreportforthefiscalyearended december p amendmenttotheexcessbenefitplanofjohnsonjohnsonandaffiliatedcompanieseffectiveasofjanuary incorporatedhereinbyreferencetoexhibitqoftheregistrantsformkannualreportforthefiscalyearended december q executivelifeplanagreementincorporatedhereinbyreferencetoexhibitioftheregistrantsformkannualreport forthefiscalyearendedjanuary r executivelifeplanagreementclosureletterincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedmarch employmentagreementfordrpaulusstoffelsincorporatedhereinbyreferencetoexhibitoftheregistrantsformq quarterlyreportforthequarterendedseptember summaryofemploymentarrangementsforsandraepetersonincorporatedhereinbyreferencetoexhibittofthe registrantsformkannualreportfortheyearendeddecember johnsonjohnsonannualreport u severancepayplanofjohnsonjohnsonandusaffiliatedcompaniesamendedandrestatedasofoctober incorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreportforthequarterended september v firstamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitoftheregistrantsformqquarterlyreport forthequarterendedjune w secondamendmenttotheseverancepayplanofjohnsonjohnsonandusaffiliatedcompaniesasamendedandrestated effectiveoctoberincorporatedhereinbyreferencetoexhibitxoftheregistrantsformkannualreportfor thefiscalyearendedjanuary subsidiariesfiledwiththisdocument consentofindependentregisteredpublicaccountingfirmfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfiledwiththisdocument certificationofchiefexecutiveofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument certificationofchieffinancialofficerpursuanttosectionofthesarbanesoxleyactfurnishedwiththisdocument xbrlextensiblebusinessreportinglanguagethefollowingmaterialsfromthisreportforthefiscalyearendeddecember formattedinextensivebusinessreportinglanguagexbrliconsolidatedbalancesheetsiiconsolidated statementsofearningsiiiconsolidatedstatementsofcomprehensiveincomeivconsolidatedstatementsofequity vconsolidatedstatementsofcashflowsandvinotestotheconsolidatedfinancialstatements managementcontractorcompensatoryplan paperfiling acopyofanyoftheexhibitslistedabovewillbeprovidedwithoutchargetoanyshareholdersubmittingawrittenrequest specifyingthedesiredexhibitstothesecretaryattheprincipalexecutiveofficesofthecompanypursuanttoitem biiiaofregulationskthecompanyhasnotfiledasexhibitstothisformkcertainlongtermdebt instrumentsincludingindenturesunderwhichthetotalamountofsecuritiesauthorizeddoesnotexceedofthetotal assetsofthecompanyanditssubsidiariesonaconsolidatedbasisthecompanyherebyagreestofurnishacopyofany suchinstrumenttothesecuponrequest thefollowingexhibitsindicatedasbeingfiledwiththisdocumentareomittedfromtheprintedversionofthis annualreport exhibit exhibit johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact ialexgorskycertifythat ihavereviewedthisannualreportonformkforthefiscalyearendeddecemberthereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting salexgorsky alexgorsky chiefexecutiveofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact ijosephjwolkcertifythat ihavereviewedthisannualreportonformkforthefiscalyearendeddecemberthereportof johnsonjohnsonthecompany basedonmyknowledgethisreportdoesnotcontainanyuntruestatementofamaterialfactoromittostatea materialfactnecessarytomakethestatementsmadeinlightofthecircumstancesunderwhichsuchstatementswere madenotmisleadingwithrespecttotheperiodcoveredbythisreport basedonmyknowledgethefinancialstatementsandotherfinancialinformationincludedinthisreportfairly presentinallmaterialrespectsthefinancialconditionresultsofoperationsandcashflowsofthecompanyasofand fortheperiodspresentedinthisreport thecompanysothercertifyingofficersandiareresponsibleforestablishingandmaintainingdisclosurecontrols andproceduresasdefinedinexchangeactrulesaeanddeandinternalcontroloverfinancial reportingasdefinedinexchangeactrulesafanddfforthecompanyandhave adesignedsuchdisclosurecontrolsandproceduresorcausedsuchdisclosurecontrolsandprocedures tobedesignedunderoursupervisiontoensurethatmaterialinformationrelatingtothecompanyincludingits consolidatedsubsidiariesismadeknowntousbyotherswithinthoseentitiesparticularlyduringtheperiodin whichthisreportisbeingprepared bdesignedsuchinternalcontroloverfinancialreportingorcausedsuchinternalcontroloverfinancial reportingtobedesignedunderoursupervisiontoprovidereasonableassuranceregardingthereliabilityof financialreportingandthepreparationoffinancialstatementsforexternalpurposesinaccordancewithgenerally acceptedaccountingprinciples cevaluatedtheeffectivenessofthecompanysdisclosurecontrolsandproceduresandpresentedinthis reportourconclusionsabouttheeffectivenessofthedisclosurecontrolsandproceduresasoftheendofthe periodcoveredbythisreportbasedonsuchevaluationand ddisclosedinthisreportanychangeinthecompanysinternalcontroloverfinancialreportingthat occurredduringthecompanysmostrecentfiscalquarterthecompanysfourthfiscalquarterinthecaseofan annualreportthathasmateriallyaffectedorisreasonablylikelytomateriallyaffectthecompanysinternalcontrol overfinancialreportingand thecompanysothercertifyingofficersandihavedisclosedbasedonourmostrecentevaluationofinternal controloverfinancialreportingtothecompanysauditorsandtheauditcommitteeofthecompanysboardof directorsorpersonsperformingtheequivalentfunctions aallsignificantdeficienciesandmaterialweaknessesinthedesignoroperationofinternalcontrolover financialreportingwhicharereasonablylikelytoadverselyaffectthecompanysabilitytorecordprocess summarizeandreportfinancialinformationand banyfraudwhetherornotmaterialthatinvolvesmanagementorotheremployeeswhohaveasignificant roleinthecompanysinternalcontroloverfinancialreporting sjosephjwolk josephjwolk chieffinancialofficer datefebruary johnsonjohnsonannualreportexhibit certificationofchiefexecutiveofficer pursuanttosectionofthesarbanesoxleyact theundersignedalexgorskythechiefexecutiveofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendeddecemberthereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany salexgorsky alexgorsky chiefexecutiveofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportexhibit certificationofchieffinancialofficer pursuanttosectionofthesarbanesoxleyact theundersignedjosephjwolkthechieffinancialofficerofjohnsonjohnsonanewjerseycorporationthe companypursuanttouscasadoptedpursuanttosectionofthesarbanesoxleyactof herebycertifiesthattothebestofmyknowledge thecompanysannualreportonformkforthefiscalyearendeddecemberthereportfully complieswiththerequirementsofsectionaofthesecuritiesexchangeactofand theinformationcontainedinthereportfairlypresentsinallmaterialrespectsthefinancialconditionand resultsofoperationsofthecompany sjosephjwolk josephjwolk chieffinancialofficer datedfebruary thiscertificationisbeingfurnishedtothesecwiththisreportonformkpursuanttosectionofthe sarbanesoxleyactofandshallnotexcepttotheextentrequiredbysuchactbedeemedfiledbythecompany forpurposesofsectionofthesecuritiesexchangeactofasamendedorotherwisesubjecttotheliabilityof thatsection johnsonjohnsonannualreportthispageintentionallyleftblankthispageintentionallyleftblankthispageintentionallyleftblankreconciliationofnongaapfinancialmeasures twelvemonths incr dollarsinmillionsexceptpersharedata decr earningsbeforeprovisionfortaxesonincomeasreported intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment diabetesassetimpairment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecurities impactoftaxlegislation earningsbeforeprovisionfortaxesonincomeasadjusted netearningsasreported nm intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment diabetesassetimpairment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecurities impactoftaxlegislation netearningsasadjusted dilutednetearningspershareasreported nm intangibleassetamortizationexpense litigationexpensenet actelionacquisitionrelatedcost restructuringother inprocessresearchanddevelopment amoacquisitionrelatedcost contingentliabilityreversal unrealizedlossonsecurities impactoftaxlegislation dilutednetearningspershareasadjusted operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rates impactofcurrencyatforeigncurrencyexchangerates operationaldilutednetearningspershareasadjustedatforeigncurrencyexchange rates includesmillionrecordedincostofproductssoldandmillionrecordedinotherincomeexpenseinand millionrecordedincostofproductssoldandmillionrecordedinotherincomeexpensein includesforeigncurrencytranslation nmnotmeaningful johnsonjohnsonannualreportthecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsandnetearningspersharedilutedon anadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestorsamongother thingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodin variousperiodsthesemeasuresmayexcludesuchitemsasintangibleassetamortizationexpensesignificantcosts associatedwithacquisitionsrestructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificant accountingortaxmattersthesespecialitemsmaybehighlyvariabledifficulttopredictandofasizethatsometimeshas substantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagementusesthesemeasures internallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocating resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovision fortaxesonincomenetearningsandnetearningspersharedilutedpreparedinaccordancewithgaapadjusted earningsbeforeprovisionfortaxesonincomeadjustednetearningsandadjustednetearningspersharedilutedmaynot becomparablewiththecalculationofsimilarmeasuresforothercompaniesthelimitationsofusingthesenongaap financialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchasintangibleassetamortizationexpensetheeffectsofanacquisition restructuringlitigationandchangesinapplicablelawsandregulationsincludingsignificantaccountingortaxmattersand donotprovideacomparableviewofthecompanysperformancetoothercompaniesinthehealthcareindustryinvestors shouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiortomeasuresof financialperformancepreparedinaccordancewithgaap thetablesbelowareprovidedtoreconcilecertainnongaapfinancialdisclosuresinthechairmansletter dollarsinmillions netcashflowsfromoperatingactivities additionstopropertyplantandequipment freecashflow operationalgrowth incr medicaldevices decr worldwideasreported impactofacquisitionsdivestitures worldwideoperationalgrowthexcludingacquisitionsdivestitures operationalsalesgrowthexcludingthenetimpactofacquisitionsanddivestituresisanongaapfinancialmeasure investorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfororsuperiorto measuresoffinancialperformancepreparedinaccordancewithgaapduetothevariablenatureofacquisitionsand divestituresandtheimpacttheymayhaveontheanalysisofunderlyingbusinessperformanceandtrends managementbelievesthatprovidingthismeasureenhancesaninvestorsunderstandingofthecompanys performanceandmayassistintheevaluationofongoingbusinessoperationsperiodoverperiodthisnongaap financialmeasureispresentedtopermitinvestorstomorefullyunderstandhowmanagementassessesthe performanceofthecompanyincludingforinternalevaluationoftheperformanceofthecompanysbusinessesand planningandforecastingforfutureperiodstheuseofthisnongaapfinancialmeasureasaperformancemeasureis limitedinthatitprovidesaviewofthecompanysresultsofoperationswithoutincludingalleventsduringaperiodand maynotprovideacomparableviewofthecompanysperformancetothatofothercompaniesinthehealthcare industry johnsonjohnsonannualreportboard directors senior management alexgorsky alexgorsky chairmanboardofdirectors chiefexecutiveofficer chairmanexecutivecommittee marycbeckerle chiefexecutiveofficerhuntsmancancerinstitute joaquinduato attheuniversityofutah vicechairmanexecutivecommittee distinguishedprofessorofbiology collegeofscienceuniversityofutah paulusstoffels vicechairmanexecutivecommitteechiefscientificofficer dscottdavis formerchairmanandchiefexecutiveofficer petermfasolo unitedparcelserviceinc executivevicepresidentchiefhumanresourcesofficer ianeldavis ronaldakapusta chairmanrollsroyceholdingsplc corporatecontrollerchiefaccountingofficer formerchairmanandworldwidemanagingdirector ashleymcevoy mckinseycompany executivevicepresidentworldwidechairman jenniferadoudna medicaldevices professorofchemistryprofessorofbiochemistry thibautmongon molecularbiology executivevicepresidentworldwidechairmanconsumer likashingchancellorsprofessorinbiomedical andhealthuniversityofcaliforniaberkeley michellerryan treasurer markbmcclellan directordukerobertjmargolismd michaelesneed centerforhealthpolicy executivevicepresidentglobalcorporateaffairs chiefcommunicationsofficer annemmulcahy formerchairmanandchiefexecutiveofficer thomasjspellmaniii xeroxcorporation corporatesecretaryassistantgeneralcounsel williamdperez jennifertaubert retiredpresidentandchiefexecutiveofficer executivevicepresidentworldwidechairman wmwrigleyjrcompany pharmaceuticals charlesprince michaelhullmann retiredchairmanandchiefexecutiveofficer executivevicepresidentgeneralcounsel citigroupinc kathrynewengel aeugenewashington executivevicepresidentchiefglobalsupplychainofficer dukeuniversityschancellorforhealthaffairs presidentandchiefexecutiveofficer josephjwolk dukeuniversityhealthsystem executivevicepresidentchieffinancialofficer ronaldawilliams memberexecutivecommittee formerchairmanandchiefexecutiveofficer aetnainc johnsonjohnsonannualreportprincipaloffice stocklisting johnsonjohnsononline onejohnsonjohnsonplaza johnsonjohnsoncommonstock ourwebsitewwwjnjcom newbrunswicknewjersey listedonnewyorkstockexchange stocksymboljnj httpwwwjnjcommediacenter annualmeetingofshareholders shareholderrelationscontact thursdayapril thomasjspellmaniii wwwfacebookcomjnj corporatesecretary ameasterndoorsopentomeetingat wwwtwittercomjnjnews wwwtwittercomjnjcares hyattregencynewbrunswick investorrelationscontact twoalbanystreet christopherdelorefice newbrunswicknewjersey wwwyoutubecomjnj vicepresidentinvestorrelations allshareholdersasoftherecorddateof februaryareinvitedtoattend httpwwwlinkedincomcompany johnsonjohnson aformalnoticeofannualmeeting investorrelationswebsite proxystatementandproxyhavebeen wwwinvestorjnjcom thejohnsonjohnsonyearin madeavailabletoshareholders stocktransferagentandregistrar reviewisavailableonourwebsiteat annualreportonformkand questionsregardingstockholdings httpswwwjnjcomyearinreview proxystatement certificatereplacementtransferdividends theinformationonthesewebsitesshould johnsonjohnsonsannualreportonformk andaddresschangesshouldbedirectedto notbedeemedtobepartofthisannual forthefiscalyearendeddecemberis ourstocktransferagentandregistrarat report includedinthisannualreportinitsentiretywith computersharetrustcompanyna theexceptionofcertainexhibitstheformk pobox completewithallofitsexhibitsisavailableonour louisvilleky websiteatwwwinvestorjnjcomseccfmandthe overnightmail secswebsiteatwwwsecgov computersharetrustcompanyna shareholdersmayalsoobtaincopiesofthe souththstreetsuite exhibitsourannualreporton louisvilleky formkandourproxystatement withoutchargeuponwrittenrequesttothe shareholderwebsite officeofthecorporatesecretaryatour wwwcomputersharecominvestor principalofficeaddressorbycalling dividendreinvestmentplan theplanallowsforfullorpartialdividend electronicdeliverynotification reinvestmentandadditionalweeklycash theproxystatementandourannual investmentsuptoperyearin reportareavailableonourwebsite johnsonjohnsoncommonstockwithout wwwinvestorjnjcomgov pershareorservicechargesonstock c annualmeetingmaterialscfmshareholderswho purchasesifyouareinterestedin receivepapercopiesofourproxystatementand participatingintheplanandneedan annualreportbymailcanelecttoreceiveinstead enrollmentformandormoreinformation anemailmessagewithalinktothosedocuments pleasecalltheplanadministrator thejohnsonjohnsonannualreport ontheinternetregisteredshareholdersmay computersharetrustcompanynaat containsmanyofthevaluabletrademarks enrollinelectronicdeliveryat andtradenamesownedandusedbythe wwwcomputersharenacomgreenbeneficial outsidetheusoraccessonlineat johnsonjohnsonfamilyofcompaniesin shareholderswhoholdsharesofjohnson wwwcomputersharecominvestor theunitedstatesandinternationallyto johnsoncommonstockthroughabankbrokeror distinguishproductsandservicesof otherholderofrecordgenerallycanenrollfor hearingimpaired outstandingquality electronicdeliveryatenrollicsdeliverycomjnj shareholderswhohaveinquiriesregarding johnsonjohnson stockrelatedmatterscancommunicate directlywithcomputersharetrustcompany naviaatelecommunicationsdevicetdd thetelephonenumberforthisserviceis outsidetheuswe blend heart science ingenuity profoundly change trajectory health humanity